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PREFACE. 
The terms osteoporosis and osteopaenia will be used interchangeably in order to 
avoid confusion. The literature abounds with reports of osteoporosis in rheumatoid 
arthritis (RA). However, close scrutiny shows that several questions remain un-
answered. It is not clear whether the osteopaenia of RA is due to a generalised de-
fect in collagen synthesis or a result of excessive bone resorption. The main reason 
for this continuing controversy appears to be related to inadequate control for age 
and the menopause in the subjects studied. Since the exact mechanisms for age-re-
lated (Type II) and post-menopausal (Type I) idiopathic osteoporosis are not known, 
it is clear that any attempts at separating these effects from the additional multi-fac-
torial basis of bone loss in RA could only add to the confusion. The analysis is com-
pounded by the fact that many of the kinetic markers of bone metabolism may be-
have as acute phase reactants in RA, making their evaluation difficult in the absence 
of information about disease activity, physical activity, drug therapy and nutritional 
status. The age-related prevalence of RA adds to the difficulties in evaluating an ade-
quate sample of young patients. For all these reasons, it would seem appropriate to 
embark on a systematic analysis of the factors possibly related to bone loss in RA. 
The ideal group of patients would be young and premenopausal. This creates a fur-
ther technical difficulty in that current evidence suggests that RA patients in this age 
group rarely show significant differences in bone mass when compared with normal 
subjects. Several reasons could possibly explain this. They include the lack of a de-
finition of osteoporosis; insensitivity of the Vernier caliper technique in detecting 
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small changes over time; predominantly cortical bone loss, usually at the metacar-
pals; and limited availability of the sophisticated nuclear techniques. Costs can also 
be prohibitive. South Africa is a vast country with a population of several million sub-
jects. The most sophisticated method of bone mass measurement available is the 
single photon absorptiometer. In Cape Town, where this study was undertaken, the 
only objective measure of bone mass is radiogrammetry. Despite its limitations, 
radiogrammetry has great potential value as a measure of radiological events in the 
hands of patients with RA, where the greatest damage from the disease is generally 
seen. Osteoporosis is usually the earliest radiological feature (apart from soft-tissue 
swelling - which is usually clinically apparent). The need for a quantitative measure 
of early radiological change has been highlighted in a number of recent editorials. 
Unfortunately, the Vernier caliper technique of radiogrammetry is poorly reproduc-
ible, between different observers and the same observer at different times. The 
method is tedious and subject to a number of potential sources of error. The earlier 
innovations of computer-assisted techniques has done relatively little to improve the 
technical speed of the procedure, and the error has remained unchanged. Reports of 
single photon absorptiometry have been unable to show significant correlations with 
disease activity in young subjects (small samples). The same can be said about studies 
using neutron activation analysis. Dual photon absorptiometry measures trabecular 
bone and its application to measurements in the hand and wrist is encouraging. It is 
against this background that I undertook to study a group of 100 young subjects with 
RA who were premenopausal and independently ambulant. They were to be com-
pared with 100 young normal subjects. Exact age and sex matching was considered 
inappropriate since statistically significant changes have been generally difficult to 
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detect in this age group. Males usually have a higher bone mass, and RA is generally 
a disease of females, so the groups were marginally matched for these important fac-
tors. The protocol was designed to evaluate as many of the confounding variables as 
possible, in the limited scope of a cross-sectional analysis. A computer-assisted tech-
nique using a digitiser interfaced with a personal computer was designed and evalu-
ated. Patients with systemic lupus erythematosus were included in the analysis, pro-
vided they fulfilled the selection criteria for age, menopause and disability. Bone 
mass in SLE has not been previously systematically studied and the frequent use of 
corticosteroid therapy in these patients makes them an ideal group for comparison 
with RA. The fact that the diseases are pathogenetically and clinically similar streng-
thens their possible role in adding to the knowledge regarding the mechanism of os-
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ABSTRACT. 
The literature is replete with reports of osteoporosis in rheumatoid arthritis, but the 
mechanism of bone loss remains obscure. This is probably due to the overlap with 
bone loss of aging and the menopause, whose exact mechanisms are also poorly 
understood. Against this background, a study was designed to evaluate generalised 
bone loss in young, premenopausal (if female), patients with rheumatoid arthritis. 
The protocol was designed to record demographic data, as well as information per-
taining to the disease. Cortical bone mass was measured at the metacarpals and left 
femur, using an automated, computer-controlled technique. Trabecular bone was 
evaluated at the left femur (Singh index) as well as at the 3rd lumbar vertebra (Sa-
ville index). Bone kinetics were studied by the measurement of urinary excretion of 
calcium, phosphate and hydroxy-praline (resorption) and serum alkaline phospha-
tase (formation). Disease activity was measured clinically and with laboratory in-
dices. Physical activity was indirectly measured by quantitating the disability, using 
the Keitel function test as well as a modified health assessment questionnaire 
(HAQ). The radiograph of the right wrist was scored by the Larsen index. The carpo-
metacarpal ratio was also calculated from the radiograph. Numerous statistical tech-
niques were applied in the analysis of the data. Healthy volunteers were used as con-
trols. Patients with SLE were also studied, in order to compare the 2 inflammatory 
diseases. Patients with RA had generalised cortical bone loss (metacarpal and femur) 
(p < 0.001). Trabecular bone measurements were not significantly different from nor-
mals, using the crude radiographic techniques. Duration of disease was the most im-
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.. 
portant clinical determinant of this bone loss. The relative contributions of disease 
activity and lack of physical activity to the loss of bone could not be adequately separ-
ated using conventional statistical techniques. Corticosteroid therapy did not pro-
mote metacarpal bone loss in these subjects, but may have contributed to thinning of 
the femoral cortex. Nonsteroidal anti-inflammatory drugs and disease modifying 
agents did not seem to influence the extent of the bone loss. Nutritional status and 
skinfold thickness did not correlate with bone mass. Dietary factors played no role in 
the genesis of bone loss, but may have had some effect on disease activity. Metacar-
pal measurements showed a sensitivity of 80% and specificity of 85% in discriminat-
ing between osteopaenic and normopaenic groups with RA. Osteopaenia could not 
be adequately predicted in the absence of metacarpal measurements. Metacarpal 
bone loss in RA was due to endosteal resorption, while in SLE it was due to perios-
teal resorption. The semi-automatic technique for measurement of metacarpal bone 
mass showed good reproducibility among 5 observers and at 2 different centres. The 
pathogenesis of bone loss in RA was multifactorial, the largest contribution probably 
coming from a humoral factor in the circulation, closely related to disease activity. 
Ionised calcium was elevated in 55% of RA patients, but only 5% of SLE patients. 
Serum PTH levels were normal in 99% of the RA subjects. Elevations in alkaline 
phosphatase. (25%) probably reflected disease activity rather than increased bone 
formation. Factor analysis of 27 variables showed that disease activity was central to 
the development of OP in RA. CS therapy tended to be used in the presence of ac-
tive disease. Disability was not an important determinant of bone loss in RA, but may 
be a useful measure of activity of the disease. This study did not evaluate the rela-
tionships with sex hormonal status or vitamin D metabolism. Future research should 
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aim at cohort analysis at 2 different periods, in order to improve our understanding 
of the pathogenesis of bone loss in RA. 
INTRODUCTION. 
A BRIEF OVERVIEW. 
Over the last 20 years, more has been written about osteoporosis (OP) in 
rheumatoid arthritis (RA), than any other extra-articular manifestation of the dis-
ease. In the last few years, this has been related to the development of more 
refined, reproducible and accurate non-invasive techniques for the in-vivo 
measurement of bone mass (Johnston 1982). When used in patients with RA, 
these support the concept that generalised OP is a frequent feature of the disease 
(McConkey 1965). More recently, Sambrook et al (1987) have shown with dual 
photon absorptiometry (DP A), that RA patients have similar bone mass to nor-
mal post-menopausal subjects. Juxta-articular OP is a well recognised manifesta-
tion of RA and is one of the radiological criteria in the American Rheumatism 
Association (ARA) criteria for classification of RA (Ropes et al 1958). Its exact 
definition is not clear, but Larsen (1977) seems to compare it with the bone den-
sity at the metacarpal midshaft. 
Controversy revolves around the mechanism for the localised and generalised 
bone loss in RA The importance of defining predicting factors has recently been 
reviewed (Sambrook et al 1987). It is generally agreed that in RA several import-
ant associated features, confounders, may contribute significantly to the loss of 
bone mass. Among these, the most strongly implicated is immobilisation, but dis-
ease activity, nutrition, drug therapy, menopausal status and age also make a con-
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tribution. Some work (Kennedy et al 1976; 1979) has shown that hypercalcaemic 
serum from patients with RA induces bone resorption in vitro. Prostaglandins 
(PG) E2 and F2 are implicated. It has recently also been suggested (Ralston et al 
1986) that interleukin 2 may have an effect of stimulating osteoclast activating f ac-
tor ( OAF), to cause bone resorption in these patients, as in patients with certain 
malignant diseases. 
Osteopaenia is defined radiologically and osteoporosis, histologically. Osteo-
paenia is the radiological impression of bone loss, and the osteoporotic syndrome 
is the association of osteopaenia and structural bone failure (fracture). Barnett 
and Nordin (1960), separate the definition of osteoporosis into simple and accel-
erated depending on whether the apparent density of representative bone is nor-
mal or low, after correction for age and sex, respectively. Bone is osteoporotic 
when its apparent density falls below the young normal lower limit. This depends 
on objective measurement. The author favours Barnett and Nordin's concept, 
despite its inherent weakness of including some patients with osteomalacia (OM). 
The terms osteoporosis and osteopaenia will henceforth be used interchangeably 
in order to avoid confusion. The mechanisms of post-menopausal OP are not 
known. 
There are various ways of diagnosing osteopaenia, but it is usually done by 
radiography (Genant et al 1988a). Pathogenetic mechanisms other than normal 
aging need to be sought only when dealing with accelerated OP. The clinical syn-
drome characterised by vertebral and/or femoral neck fractures represents a late 
stage in the diagnosis. In order for treatment to be effective, it is imperative that 
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the diagnosis is made at a much earlier stage, using the numerous new non-inva-
sive techniques which have been developed (Cameron and Sorensen 1963; Came-
ron et al 1968; Mazess 1987; Recker 1982). 
Single photon absorptiometry (SPA) (Wahner et al 1977; Nicoll et al 1987a; 
Gupta et al 1984 ), neutron activation analysis (NAA) (Kennedy et al 1982; Eastell 
et al 1983; Tothill et al 1986; Nicoll et al 1987b ), whole body retention (WBR) of 
calcium (Kennedy et al 1982) and Tc-99m labeled phosphates (Fogelman et al 
1978; Holmes 1978), quantitative computed tomography (QC-T) scanning (Ge-
nant et al 1982; Genant 1988) and dual photon absorptiometry (DP A) (Schaadt 
and Bohr 1982; Smith et al 1983; Tothill et al 1983; Nuti et al 1988; Mazess et al 
1988) studies are largely limited to highly specialised centres and are useful for 
serial evaluations. Mazess (1983) suggested that DPA and/or QC-T scanning 
would become the non-invasive standards for evaluating metabolic bone disease 
(MED). Smith et al (1983) compared different energy sources for DPA and found 
that 241 Am and 137 Cs could be used as practical alternatives to 153 Gd. In South 
Africa, there are very few single photon absorptiometers and no dual photon ab-
sorptiometry apparatus at the moment. Radiogrammetry remains the only objec-
tive method for non-invasive evaluation of OP in the western Cape. 
In RA, measurement of bone mass in the hands has potential for the evalu-
ation of disease progression. However, hand deformities may influence the repro-
ducibility of the measurement, making changes difficult to interpret. Nicoll et al 
(1987a) designed an apparatus to apply the technique of SPA (with its established 
potential for precision and low radiation dosage and its simple nucleonic require-
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men ts) to the measurement of hand bone mineral. They found that hand 
measurement was not unduly influenced by a 3 cm limit proximal to the ulna sty-
loid. Errors introduced in the result by repositioning the marker band are incor-
porated in the precision measurement. Hutton et al (1988), reported the use of 
DP A of the hand in evaluating early RA They concluded that this was a poten-
tially useful objective measure of bony change in RA. 
Bone biopsy remains the most important diagnostic investigation for gener-
alised OP. Malluche et al (1982a & b ), using more recent techniques, have im-
proved its quantitative use. It remains the most critical marker of bone turnover, 
which is essential if one is to relate reduced bone mass to Frost's (1963, 1973a, 
1973b, 1979), concept of coupling between formation and resorption as a dy-
namic, controlled process. It is the only way to exclude OM. However, it is limited 
by its invasive nature. 
Only when expressed in morphological terms, does coupling and uncoupling 
become sufficiently concrete to be amenable to further analysis. The piecemeal 
character of the lamellar bone turnover implies the activation, in specific loca-
tion, of new sites of bone resorption or formation. This relates to separate aspects 
of the precursor cells' activities : first, discrete location and number of these acti-
vities (activation frequency) and second, their subsequent local rate and duration. 
While little is known about the activation of these sites, several agents have been 
implicated in the onset and maintenance of local osteoclast proliferation (Avioli 
1987). Similar recently identified factors, usually a byproduct of bone matrix de-
gradation, have been implicated in the onset and maintenance of osteoblast pro-
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liferation, and have been proposed as a coupling factor (Raisz and Kream 1983; 
Raisz 1988). 
Jaworski (1984), in a comprehensive review of the concept of coupling and 
uncoupling, remarked that the ultimate reduction of bone physiology and patho-
logy to its molecular biology is unavoidable and a necessary condition for further 
progress in this field. This descent to the ultimate should be balanced by the 
awareness of the integrating mechanisms so obvious in the making and mainten-
ance of the skeleton. This means that direct inferences and applications from the 
molecular level to the normal or diseased whole skeleton, without taking into ac-
count the hierarchy of its intermediate levels of organisation, may fail to enhance 
understanding. 
Raisz (1988) presented a comprehensive overview of the local and systemic 
factors in the pathogenesis of osteoporosis. He re-iterated the difficulties in de-
finition and diagnosis. He also emphasised the difficulties in predicting subjects 
who were likely to develop fractures. The potential local regulators of bone meta-
bolism have only begun to be identified. He introduces Eriksen's (1986) concept 
of the regulation of the normal sequence of bone remodeling and the possible pa-
thologic alterations in that sequence. The first step is activation. Inactive bone 
surfaces are covered by lining cells, possibly of osteoblastic lineage, which can re-
spond to bone resorbing hormones. The next step is bone resorption , which in-
volves replication of osteoclast progenitors and their differentiation, migration 
and fusion into mature osteoclasts under the control of both local and systemic 
hormones. Once the osteoclasts have resorbed most of the mineral and matrix, 
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there is a reversal phase during which macrophages may appear on the resorbing 
surface. The next stage of the remodeling cycle is the formation phase, in which 
the osteoblasts replace resorbed bone. A number of factors influence the extent 
and rapidity of the replacement. The systemic hormones (growth hormone, gluco-
corticoids, thyroid hormones, insulin and oestrogen) as well as local substances 
(PG E2, IL-1, interferon alpha, insulin-like growth factor and transforming 
growth factor beta) exert their effect through the calcium regulating hormones to 
produce resorption or formation. 
Although it is generally accepted that osteoclasts (OC) are the cells respon-
sible for bone resorption, Rodan and Martin (1981) presented interesting evi-
dence to support their hypothesis that osteoblasts may have a pivotal role in the 
hormonal regulation of bone resorption. It is clear that these cells have an intri-
cate communications network which regulates the coupling process in favour of 
bone formation up to a certain critical stage when the balance is disturbed in fa-
vour of resorption. Relatively little is known about the factors controlling this im-
portant change in skeletal dynamics. 
Adams (1981) pointed out that there was no evidence that the persons with 
the least amount of bone at the start of adult life are those destined to lose the 
most bone with advancing age. None the less, they could form the group likely to 
develop structural failure of the skeleton in old age. Persons with low bone mass 
seem to manifest the OP syndrome earlier than those with better mass; females 
have lower bone mass than males and they develop OP more readily. Solomon 
(1979), showed results which differ from those of Stewart et al (1972), in that 
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Caucasians, despite higher bone mass than blacks in South Africa, developed far 
more complications of the osteoporotic syndrome with age, especially females. 
Studies of bone mass in osteoporotic patients who develop fractures (Aitken 
1984b) emphasised the concept of a numeric definition of OP. This is the only 
way to identify at risk subjects, in whom prophylactic therapy may be a feasible 
option. Mazess (1987) in an editorial, questioned the practice of defining OP nu-
merically, since most of the attributable risk of hip fracture occurs in subjects 
with the lowest 10% of femoral neck density (90% specificity), whereas most of 
the attributable risk of crush fracture occurs in the lowest 30% of spine density 
(70% specificity). He pointed out that public health attention needs to be di-
rected toward these low-density minorities to be cost-effective. 
Peck (1987) provides a perspective of the medical and social implications of 
osteoporosis. About 1.5 million fractures, usually of the spine, wrist and hip, are 
attributable to OP in the USA annually, at a total cost of $7 to $10 billion. The 
prevalence of OP in the USA is 20 million. Over 200,000 hip fractures each year 
are attributable to OP, and hip fracture is a dominant cause of morbidity, mor-
tality and cost to society. He re-iterated the importance of a reduction in bone 
mass as a risk factor and drew attention to the importance of early diagnosis. The 
local and systemic factors responsible for bone resorption were also reviewed in 
this paper. Similar costs are incurred in Finland annually (Simonen 1986). 
In the same issue, Lindsay (1987) reviewed the non-invasive techniques for 
measuring bone mass. He emphasised the need for screening, but pointed out 
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that the current techniques (SPA, DPA and C-T scanning) were not cost-effec-
tive. This is in agreement with the recommendations of Hall et al (1987). Radio-
grammetry is still recommended by the FDA for drug trials, and the precision of 
the technique is comparable to that of SPA and DPA (Dequeker 1972; 1982). Al-
though low bone mass is a risk factor for fracture, it does not predict fracture for 
an individual patient. 
A number of factors are implicated in the risk for fracture. Low bone mass 
seems to be the common denominator. Other important risk factors include fe-
male sex, caffeine intake, Caucasian race and a susceptibility to falling (Cum-
mings 1985; Cummings et al 1985). 
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CORTICAL BONE. 
The development of new non-invasive methods for determining whole bone 
mass and total body calcium have not only simplified the process, but have also 
considerably improved the sensitivity of these measurements (Wahner et al, 
1984a and 1984b ). These generally use radioactive absorptive and retention tech-
niques and are technically highly sophisticated. Since these are financially avail-
able only at specialised centres interested in MBD research, the more easily ob-
tained radiogrammetric methods continue to be the most practical method of 
determining bone mass. The other advantage of radiological methods is that dif-
ferential evaluation of the skeleton is possible at little extra cost or inconveni-
ence, allowing simultaneous assessment of cortical bone and trabecular bone in 
the same patient. Different radiological scoring methods have been devised to 
enable researchers to quantitate bone mass. The methods generally in use include 
single photon absorptiometry and radiogrammetry. Dual photon techniques, 
QCT scanning and neutron activation analysis are available for research only. 
They are not currently recommended for screening. 
RADIOGRAMMETRY. 
Barnett and Nordin (1960), reported a method for objective measurement of 
the cortical bone at the 2nd metacarpal midshaft of either hand and the midshaft 
of the femur, as well as a measurement of the biconcavity of the third lumbar ver-
tebra as a measure of trabecular bone. The metacarpal index (MI) was calculated 
as the ratio of the thickness of the cortex in the shaft of the metacarpal ( d) to the 
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total width of the bone (D) { MI = d/D }. Their study was unable to demonstrate 
any correlation between peripheral and spinal scores, suggesting to them that 
there may be 2 types of OP - spinal and peripheral. Only the hand scores were 
found to fall with age in normal subjects. They concluded that their method may 
prove useful in the routine screening of suspected cases until a satisfactory 
method of measuring vertebral density could be evolved. This study was carefully 
conducted and has served as the basis of a number of subsequent studies, aimed 
at improving the sensitivity of the method. 
Meema and Meema (1969), questioned the relationship between porosity and 
cortical thickness, suggesting that measurements of cortical thickness may not re-
flect reduced mineral density, if such a disparity should exist. Using SPA and 
radiogrammetry at the distal radius, they showed that cortical thickness measure-
ments were not sufficiently sensitive for determining the degree of osteopaenia, 
since they failed in the diagnosis of bone mineral loss which frequently mani-
fested itself as intracortical porosity. 
Exton-Smith et al (1969a), tested this hypothesis by comparing the ash content 
of the left third proximal phalanx with the measurement on X-Ray, in 29 selected 
patients. They calculated a third index - the cortical area index (CAI), for correla-
tions with dry ash weight of bone. Comparing various calculations of bone mass, 
they found a significant correlation only with the CAI (r= 0.85). They concluded 
that no special advantage was obtained by dividing cortical thickness by external 
diameter. They showed that estimates of the cross-sectional area of the cortex 
made from X-Rays were directly related to chemical measurements of ash con-
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tent. Moreover, this calculation was based on the same simple measurements of 
the hand X-Ray that were used to estimate cortical thickness. 
Albright et al (1941) and later Albright (1947), described the clinical syn-
drome of OP which is almost physiological after the menopause. Albright and 
Reifenstein (1948) described the syndrome of metabolic bone disease in patients 
with hyperparathyroidism. Newton-John and Morgan (1968), supported the con-
cept that the clinical syndrome of OP could result solely from the loss of bone 
with age. Exton-Smith et al (1969a), further suggested that variations in skeletal 
size invalidated comparisons between the bones of different individuals. They 
found that the product of length and external shaft diameter (DX L), correlated 
with cortical area (r = 0.86). They concluded that the dimensionless ratio, cortical 
area/ surface area [CNSA = (D2 - d2) / D x L]), minimised the effect of differen-
ces in skeletal size between men and women. 
Horsman and Simpson (1975), pointed out that in those longitudinal mor-
phometric studies which had used the 2nd metacarpal index, the results had thus 
far been severely limited by measurement error. They developed a simple 
method involving morphometric measurements on radiographs of the diephysis 
of the metacarpals of both hands, (the six metacarpal hand score) (M6HS), by 
which sequential changes in bone geometry, and by implication bone mass, may 
be observed. Their method was simply implemented, requiring only conventional 
diagnostic X-Ray facilities and relatively inexpensive measuring calipers. They 
concluded that the method had a precision comparable to that of SP A. 
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Two disadvantages of the above method were the subjectivity and tedious na-
ture of the measurement procedure, both of which may be eliminated by the de-
velopment of an automated measurement system. These authors expressed the 
opinion that such objectivity would only be achieved at the expense of simplicity. 
The application of the technique to normal premenopausal females showed that 
within the limits of measurement error and group size, premenopausal women on 
the whole neither gained nor lost bone from the endosteal surface. 
Dequeker (1976), observed that the multiplicity of metacarpal indices pro-
posed suggested that none had been really satisfactory. The difficulty of differen-
tiating pathological from physiological bone loss is linked to the large variability 
of bone mass within one age group. This variability in bone mass is almost con-
stant and not influenced by age or sex. 
He suggested that the cortical area ( CA = D2 - d2 ) was the most suited to be 
grouped according to outer diameter (periosteal bone). Normal values have to be 
obtained for each population separately. X-Ray determination of periosteal and 
endosteal surface changes in long bones in different populations or in the same 
population over a period of time provides information on skeletal dynamics. As 
both processes may represent responses to different mechanical and chemical 
stimuli, they have to be considered separately in studies of OP. 
Horsman et al (1977), described a semi-automated technique for measuring 
the diameters at the midshaft, using a computer-controlled morphometer. This 
device has replaced the Vernier calipers. The error remained the same, and the 
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midpoint was still determined manually prior to measurement. They showed that 
the medullary width increases with age after the menopause, reaching a plateau 
in some patients. Total width also increases, suggesting that this may be the rea-
son for the subsequent decrease in cortical thinning. The combined cortical width 
decreases progressively as well. These authors proposed that OP results from the 
inability to increase total width and arrest resorption, particularly in the absence 
of a protective effect from oestrogens. 
Fredensborg and Nilsson (1977), introduced a further index, the femoral cor-
tical index, as a guide to the selection of persons likely to develop fractures of the 
femoral neck. Cortical thickness was measured immediately proximal to the 
lesser trochanter. The measure of the thickness of the medial cortex was divided 
by the width of the femoral neck in its most narrow part. The ratio was referred to 
as the cortical index of the femoral neck. There was no right / left difference. The 
index did not significantly decrease with age, but it was significantly decreased in 
individuals with fracture of the upper end of the femur. They concluded that the 
cortex of the femoral neck was probably not a useful variable for morphometric 
valuation of bone mass. However, it may have some use in predicting the risk of 
femoral neck fracture from routine films of the hips. These authors did not simul-
taneously measure the metacarpal indices in their patients. 
Aitken (1984a), introduced further formulae for calculations of bone mass 
using measurements at the 2nd metacarpal. These derived values provide differ-
ent expressions of the same data and all have their uses. He pointed out that all 
the calculations assume that the metacarpal at its midpoint is a perfect hollow cy-
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linder and that this assumption is quite erroneous. Other expressions have been 
derived to relate the physical and chemical properties of bone. Hence with the 
knowledge of the gravimetric density of bone (2.0 g.ml-1) one can calculate the 
whole bone density (WBD), whole bone ash (WBA) and the whole bone calcium 
(WBCa). 
The use of a digitiser in radiogrammetry was first undertaken by Evans et al 
(1978). They performed measurements on X-Ray pictures projected on a paper 
with a twelvefold enlargement by an overhead projector. They introduced the 
concept of corrected cortical area, which was a correction of the CA to a mean 
total area (TA) of 782 mm
2
. They believed that measurement of the metacarpals 
in this manner had several advantages over other metacarpal measurements. It 
expresses a defined area and does not make the assumption that the bone is tubu-
lar. However, a further error variable is introduced in the magnification process. 
Buckland-Wright (1983 a & b; 1986) extended the concept in its application 
to microfocal radiological diagnosis in RA. This involves the use of the microfo-
cal X-Ray unit, characterised by an extremely small X-Ray source overcoming 
many of the limitations of the conventional units. This X-Ray unit produces pro-
jection radiographs at high magnification ( x 10 or more), obtained by placing the 
object close to the X-Ray source and the film at some distance away. It provides 
high resolution and penumbra! blurring is minimal. However, the method is more 
useful in the detection of erosions than in the measurement of bone mass. 
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REPRODUCIBILITY OF THE RADIOGRAMMETRY METHOD. 
One important drawback of the radiogrammetry method is that errors are in-
troduced at both the observer level and the level of the radiology. Horsman and 
Simpson (1975) pointed out that only the total error is usually measurable. Each 
of these errors is a compounded error consisting of sub-errors at each level. With 
respect to measurement, the observer error is related to the recording of one's 
measurements as well as the subsequent calculation of bone mass. Such calcula-
tions are computerised in equipment using photon absorptiometry. 
Several of the above authors (Barnett and Nordin 1960; Saville 1967; Hors-
man and Simpson 1975; Dequeker 1976), who have performed inter- and intra-
observer analyses of variance, have found it imperative that the same observer 
perform all the measurements, due to the coefficient of variation ( cv) of 2% -
18%, using Vernier calipers. It seems that this is the major limitation of the radio-
grammetric method. Also, when applied to interpretation of therapeutic efficacy, 
bias is unavoidable if the observer knows what therapy is being given to the pa-
tient, particularly if the same observer is involved in both the clinical and radio-
logical evaluation. 
Double-blind studies are limited by the expertise required in doing radio-
grammetry on a number of X-Rays to improve reproducibility. This usually 
means that the same observer is involved in both the clinical and radiological 
evaluation. Computer-assisted methods of bone measurement have the added ad-
vantage of removing this important subjective element which contributes to the 
total error. 
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Dequeker (1976) and Exton-Smith et al (1969a), drew attention to several ad-
ditional limits of the radiogrammetry approach. It had failed to give information 
on the bone status at an individual level due to the large variability in each sex-
age group even when it was corrected for skeletal size. On an individual and 
short-term basis the static radiographic picture does not necessarily coincide with 
direct measurements of bone dynamics. 
Those who have reported findings of radiogrammetry have not been consist-
ent in their methods for testing reproducibility. Barnett and Nordin (1960) stu-
died measurement error by randomly selecting ten sets of X-Rays (normal and 
abnormal) measured by nine independent radiologists, who had been briefly in-
structed in the technique of measurement. Saville (1967) found a cv of 7%. How-
ever, inter- and intra-observer differences of 0.02 mm were statistically signifi-
cant. Adams et al (1969) compared measurements of 3 observers, measuring cor-
tical width at the midshaft in 86 X-Rays on 2 occasions. The coefficient of vari-
ation ( cv = SD/mean x 100) was 8 - 11 %. The standard deviation of 0.2-0.3 mm 
between observers was statistically significant. Naor et al (1972) randomly se-
lected 10 of 806 X-Rays which were read on 2 occasions. They also measured the 
two cortices separately, rather than calculating it as the difference between outer 
and inner diameters (D-d). The SD was accurate to within 0.037 mm. The intra-
and inter-observer differences were statistically significant. 
Bloom (1980) measured various bone sites and compared the reproducibility. 
He found a cv of 13.9 - 17.4 % at the metacarpals. However, at the humerus, the 
cv was reduced to 9.1 %, suggesting that the wider diameters were probably more 
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reproducible. Horsman and Simpson (1975), who report on serial measurements 
of the six metacarpal hand score (M6HS) defined the midpoints of the metacar-
pals on the first set of X-Rays and superimposed subsequent pictures on this orig-
inal, as a marker of the point for measuring inner and outer diameters. The addi-
tional potential sources of error introduced by this method make it relatively un-
suitable, although Horsman suggested that the reproducibility was improved. 
They later described a semi-automated technique, which probably reduced the 
mathematical error but did little to improve the errors of measurement. 
Dequeker (1976), used 2 sets of X-Rays and measured a reference metacarpal. 
The study showed that it is possible to obtain a coefficient of variation of 1.9%, 
which is comparable with that reported with the use of DP A (Sambrook et al 
1987). This is the only report of such a low cv using this technique. The inter-ob-
server differences remained statistically significant. 
The mean measuring error of 8% for cortical thickness with calipers suggests 
that an interval of many years is necessary to find a longitudinal difference in a 
normal aging individual with certainty. Another limitation of the radiogrammetry 
method is the occurrence of local disorders of bone as occur after fractures and 
RA. There may also be a permeative type of cortical bone loss which may be ap-
parent on observation, but which affects the cortical measurements only slightly 
eg thyrotoxicosis. 
The most serious limitation of radiogrammetry is that it does not measure 
trabecular bone. Nevertheless, as observed by Dequeker (1976), the measure-
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ment of cortical bone certainly has added to the knowledge of changes in bone 
mass in aging and disease. 
Aitken (1984a), pointed out that the errors with the caliper method have led 
to radiogrammetry methods being labelled a guestimate of bone mass. The inter-
observer differences are unacceptable and it is again strongly recommended that 
a single observer perform the test. The method is tedious and in consecutive X-
Rays, Horsman and Simpson (1975) have superimposed X-Rays rather than re-
peat the measurements of the midpoints of the shafts of the metacarpals. The ad-
ditional errors introduced by this method leave much to be desired, even though 
they claim that this would not be the case. 
A preset mould of a metacarpal bone embedded in wax or similar substance 
could serve as a fixed object against which comparisons are made between X-
Rays and between observers. Using this latter method, it would be possible to de-
sign a study which would allow simple evaluation of inter-observer differences as 
well as inter-centre differences; where more than one hospital is involved in the 
recruitment of patients and controls. The M6HS and 2nd metacarpal index, as 
well as some sites of the skeleton using SP A, essentially measure cortical bone. 
The 6 metacarpal index has not been previously evaluated in patients with RA, al-
though one group have devised a score using 3 metacarpals of the right hand only 
(Virtama et al 1968). 
Aitken (1984a), warns in his book that irregularities on the endosteal outline 
often lead to indecision as to where exactly the cortex ends and the medullary 
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cavity begins. The investigator must adopt a set of rules which he follows slavishly 
to help with measurement strategy. 
TRABECULAR BONE. 
Among the methods used for measuring OP in trabecular bone, bone biopsy 
is probably the most sensitive, followed by DPA, NAA, WBR of calcium, QC-T 
scanning and SP A. Magnetic resonance imaging has not been applied to the study 
of 9P and it is not known whether the fat-rich marrow of osteoporotic patients is 
demonstrable by this technique. It has been used successfully in the measurement 
of localised OP at the femur and is the most useful method for the diagnosis of 
avascular necrosis of the femoral head. Mazess (1982) provided a useful back-
ground to the non-invasive methods for quantitating trabecular bone. 
Lost mineral in bone is replaced by marrow fat. A 50% increase in marrow fat 
will appear as a 25% bone loss to single energy quantitative spinal C-T; a 12% 
bone loss with Compton scattering; a 7% loss to dual energy QC-T; and a 3% loss 
to DPA (Cohn 1982). OP is detected on radiographs of the lumbar spine when 
30-50% of the bone mass has been lost, making this a late diagnostic feature. 
HANDAND WRIST. 
The presence of juxta-articular OP is sometimes regarded as evidence of 
trabecular bone involvement. Studies using SP A (Mazess 1979) consider the 
proximal radius as trabecular bone while the junction of the lower and middle 
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third of the shaft represents cortical bone. Dequeker (1972), however, regards all 
measurements at the radius as cortical measures. The most reliable method of 
trabecular bone measurement is DP A at the hip or vertebra, with reported coeffi-
cients of variation of 1.5-2% (Sambrook et al 1987). 
FEMUR. 
Singh et al (1972), showed that an index based on the changes in the trabecu-
lar pattern of the upper end of the femur could distinguish between persons with 
and persons without spinal crush fractures. The method is based on the fact that, 
as trabecular bone loss occurs, those trabeculae that are subjected to less mech-
anical stress are lost first. The radiological femoral trabecular pattern was charac-
terised by a 7 - point scale -- grade 7 (normal) to grade 1 (severe osteopaenia). 
The grading correlated well (r = 0.81) with the histologic grading of trabecular 
bone in iliac crest biopsy specimens of the same patients. In a detailed methodo-
logic description, the same authors (1973), outlined some difficulties which may 
occur. Occasionally, radiographs showing transitional stage between one grade 
and the next may be difficult to grade. Where there was an actual difference of 
one grade between the left and right hips, the higher grade was arbitrarily used. 
Other conditions which might interfere with the trabecular pattern grading are 
arthritic conditions of the hip and abnormalities of the neck-shaft angle. They 
emphasised that, unless the radiograph is taken with the hips in 15° internal rota-
tion, accurate grading was not possible. They concluded that persons with a femo-
ral trabecular pattern index of grade 4 or lower have a pathologic degree of bone 
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loss and have a higher risk of fracture. They recommend that consideration 
should be given to prophylactic treatment of individuals with a skeletal grade of 4 
or less, even if they do not have spinal or femoral neck fractures. Metacarpal 
bone measurements were not performed in the same patients, so it is not clear if 
the patients with a low Singh index also had less metacarpal bone. One would ex-
pect this to be the case, since vertebral fracture incidence has been correlated 
with decreased metacarpal bone mass (Barnett and Nordin 1960; Aitken 1984). 
Dequeker et al (1974) confirmed the clinical value of the Singh index in evalua-
ting asymptomatic spinal OP and femoral neck fracture. 
VERTEBRAE. 
Jensen and Tougaard (1981), evaluated a simple X-Ray method for monitor-
ing the progress of OP. The method for measuring vertebral height is a three-
stage process. The method is valid for the body heights of the sixth thoracic to the 
fifth lumbar vertebrae in all patients with a scoliosis of less than 15°. It took them 
about 15 minutes to measure the vertebral heights of one patient. They found the 
mean vertebral body height to be lower in OP subjects than in normal controls. 
They concluded that the ability of the method to register changes in vertebral 
body heights even when no fracture had occurred, made it valuable for monitor-
ing the progress of OP. The method has not been applied in RA. The Saville 
index (Saville 1967), has been generally used in RA. It is a grading of the 3rd lum-
bar vertebra according to the trabecular and cortical pattern. Grades 1 and 2 are 
normal, while grades 3 and 4 are osteopaenic and associated with fracture. Verti-
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cal trabeculations remain until the latest stage. Kovarik et al (1981), showed that 
poor consensus can be achieved when 3 different radiologists interpret routine X-
Rays of the spine for the diagnosis of osteoporosis. Reading of the Singh index 
was associated with a learning effect. The lumbar spine index, Singh index and 
photon absorptiometry were unable to differentiate males who had crush verte-
bral fractures from those who did not. In females, however, these semi-quantita-
tive methods were able to discriminate significantly, irrespective of age in de-
cades. They concluded that the lumbar spine index is a subordinate test for the di-
agnosis of senile OP. 
The method used by an investigator is largely determined by the facilities 
available at the institution performing the study. Also, non-invasive methods are 
preferred by both the investigators and subjects. Aitken (1984a), reminds us that 
the accuracy and reproducibility of histomorphometry for assessing bone mass 
(bone biopsy), even with the most sophisticated methods available, is inferior to 
that of radiographic morphometry, in the hands of some workers. Bergaoui et al 
(1987) showed significant correlations between cortical thickness and iliac crest 
biopsy at the humerus and radius, but not at the second metacarpal. This dif-
ference is possibly due to the fact that the larger bones have a higher content of 
trabecular bone, but may also relate to the greater variation in measurement at 
the second metacarpal, as shown by Bloom (1980). 
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RELEVANCE OF RADIOGRAMMETRY. 
Differential changes in the axial and peripheral skeleton correlate with each 
other in RA, as shown by Saville (1967) and Reid et al (1982). Bjelle and Nilsson 
(1970), showed changes in the metacarpals, but were unable to demonstrate 
changes in the femoral cortex and lumbar spine of RA subjects. Peripheral 
changes predominate in RA, so that the major contribution of objective measure-
ment would relate to the quantification of juxta-articular OP. 
In postmenopausal females, it seems that trabecular loss proceeds at half the 
rate of cortical loss (Riggs et al 1981), and trabecular loss is clinically more signi-
ficant in its relation to the vertebral crush syndrome. Each of the presently avail-
able methods used to determine the nature and degree of changes in skeletal me-
tabolism has significant limitations. However, numerous studies have shown stat-
istically significant correlations between the different methods at the different 
sites in postmenopausal OP (Cohn 1982). Age-related changes can also be dem-
onstrated by radiogrammetry of the metacarpals in normal subjects (Smith et al 
1969; Solomon 1979; Meyers 1982). 
Radiographic techniques can be applied to the whole skeleton, but they lack 
the sensitivity required for quantifying levels of change associated with the devel-
opment of pathological conditions. Radiogrammetry, with quantitation of cortical 
thickness of the appendicular skeleton, is useful but not always indicative of the 
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status of the axial skeleton. Photon absorptiometric techniques, although highly 
quantitative and precise, provide information on only a localised portion of the 
appendicular or trabecular skeleton. 
Finally, total body calcium measurements by NAA permit the direct in vivo 
measurement of total calcium content of the body, and hence skeletal mass, with 
a high degree of precision. 
Cohn et al (1978), commented that metacarpal measurements were insensi-
tive to small decreases in bone mass since cortical thinning usually denoted an ad-
vanced stage of generalised OP. They suggested that total body calcium measure-
ments were probably the most accurate technique for measuring the absolute and 
relative loss of bone mass. Mazess (1979), concluded that suitably normalised 
(standardised) measurements of peripheral bones could give discrimination bet-
ter than that of unnormalised total body measurements and equal to that of un-
normalised spine measures. Horsman et al (1983) showed that total body calcium 
could be estimated from peripheral bone measurements. Kovarik et al (1981) 
pointed out several limitations of the semi-quantitative methods for measuring 
bone mass, but concluded that they have definite clinical relevance. 
Aitken (1973) showed a surprisingly good correlation (r = 0.7) between verte-
bral medullary WBD and metacarpal mineral content in 13 female cadavera. In 
1974, Aitken et al showed that there are also statistically significant correlations 
between in vitro measurements at the metacarpal and the distal femur, distal 
radius and distal midshaft. The radiation dosage to the patient's hands, derived 
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from direct output measurements made with an electrometer and ionisation 
chamber, is about 40 mrem. The time spent by the patient in the X-Ray room is 
less than 1 minute, and the technician time involved in estimating the M6HS will 
be about 10 minutes. This is highly suitable for epidemiologic studies. 
Despite the difficulties with the use of radiogrammetry, Horsman et al (1977) 
were able to show significant sequential changes in bone mass in postmenopausal 
females receiving oestrogen replacement or calcium therapy. They devised a 
computer-assisted technique for radiogrammetry, but were unable to demon-
strate a significant reduction in the total error compared with Vernier calipers. 
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BONE LOSS IN RHEUMATOID ARTHRITIS. 
The literature is replete with studies of OP in RA. Guyatt et al (1984), pointed 
out that several factors contribute a conj ounding bias to any study of this nature. 
The effects of age, menopausal status, polypharmacy, immobilisation, diet, ma-
labsorption of calcium, bone resorption stimulating factors, corticosteroid ( CS) 
and second line drugs on bone metabolism are difficult to separate from those of 
disease activity as a composite parameter. It is, therefore, not surprising that in 
1988 there is still no resolution of the conflict between those who think osteoporosis 
is due to a calcium drain and those who think it has primarily to do with collagen, 
Wright (1965). Since the pathogenesis of primary OP is not known (Kruse and 
Kuhlencordt 1980), overlapping factors need to be excluded if meaningful con-
clusions are to be derived from studies on RA subjects. 
LITERATURE REVIEW. 
Among the earliest studies of OP in RA is a report by Mcconkey et al (1965). 
They studied 102 females of mean age 58.4 years and duration of RA 11.8 years. 
Skin transparency was subjectively assessed as being transparent, opaque or 
doubtful. Vertebral OP was also subjectively graded at the thoracic and lumbar 
spine according to vertical trabeculation, fractures of the end plates and bicon-
cavity of the vertebral bodies. They reported a 38% incidence of OP, and in those 
patients who also had transparent skin the incidence was as high as 76%. They 
concluded that OP is probably not one disease but an accompaniment of a num-
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ber of disorders with different causes; one type associated with transparent skin. 
They suggested that when OP is accompanied by transparent skin a disorder of 
connective tissue underlies both phenomena. 
The prevalence of op· in relation to CS therapy was not significantly different 
between treated and untreated patients. Although the findings in this study are 
significant, the pathogenetic inferences about the disease are difficult to separate 
from those of age. Also, no mention was made of the menopausal status of the 
patients. Finally, the subjective assessments of OP and skin transparency should 
have been evaluated in relation to observer differences. Guyatt et al (1984) argue 
that the small daily dose is scarcely sufficient to have an effect on the physiology 
of bone. 
The role of physical activity in the genesis of OP in RA was questioned in the 
same year. Castillo et al (1965), studied hand radiographs from 153 unselected 
patients with RA. Cystic erosions and OP were subjectively graded as being mild, 
moderate or severe. They reported a significant inverse relation between cystic 
changes and OP in the hands (x2 = 44.3;p < 0.001). A significant positive correla-
tion was found between cystic erosions and physical activity, while OP correlated 
inversely with physical activity. They concluded that, because the men in their 
group dominated the cystic group and females dominated the osteopaenic group, 
the cystic changes were due to increases in intra-articular pressures related to 
tasks performed with the hands. 
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Several difficulties are encountered in the interpretation of this data. The 
authors did not present the age or menopausal status of their patients, no tests of 
hand strength were carried out between the groups, physical activity was inferred 
from Steinbrocker's classification (1949) of functional disability only, and the 
methods of evaluating OP and cystic erosions were not analysed for observer dif-
ferences. This study added little to the understanding of the pathogenesis of OP 
in RA. 
Probably the most significant contribution to some of our understanding of 
OP in RA was made by Saville (1967). They studied 164 patients (128 female, 36 
male), measuring the cortical thickness of the left radius just below the tuberos-
ity, using the method of Meema and Meema (1969). Spinal porosity at the lumbar 
spine was graded from 0-4 according to strict criteria. The inter-observer correla-
tion for spinal porosity grading was 0.69, while that of measurement of the radial 
cortex was 0.95. The intra-observer difference was 0.2 mm., but this was highly 
significant and suggested that this technique was unsuitable for paired measure-
ments in individuals radiographed at different times. They recommended that, in 
a clinical study, the radiographs should be measured by one observer. 
They found that the tendency for cortical thickness to diminish as grade of 
spinal porosity increases, was highly significant both for men suffering from RA 
and for women. This finding supports the suggestion that there is a surprisingly 
good correlation between clinical assessment of radiographic bone density and 
mineral measurements from autopsy material. They concluded that these 2 
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simple clinical techniques are suitable for assessing differences in bone density 
between groups of individuals. 
Later, Saville and Kharmosh (1967) evaluated the influence of age, sex and 
CS therapy on OP in the same group of 164 patients with RA. They found that in 
women taking CS, cortical thickness remained the same in treated and untreated 
groups until the 6th decade; after which time there was a decrease in both groups, 
the decrease being greater in treated females. 
In men taking CS, there was a decrease in cortical thickness in both groups 
during the 6th decade; tending to rise again in both groups in subsequent de-
cades. They concluded that age greater than 50 years had a more profound effect 
on bone mass than CS therapy. This study included 45 patients younger than 30 
years of age. Adding all the males and females less than 50 years of age failed to 
show a relationship between CS therapy and OP. They suggested that the insuffi-
ciency of cases of OP among the younger age group is thus a natural one, and makes 
it necessary to combine mild, moderate and severe grades in order to compare men 
and women under 50 years with respect to treatment with steroids. 
The study confirmed an inverse relation between porosity and functional 
ability. They concluded that while small doses of CS had been shown to play a 
role in the development of OP, age, sex and physical disability were more import-
ant. They also suggested that CS may have a protective effect on cortical bone in 
younger women! The only defect in this study was the small number of patients 
under 50 years of age and the small daily dose of CS. 
INTRODUCTION 30 
The following year, Virtama et al (1968), studied OP in 33 patients with RA. 
The study group consisted of 7 males and 26 females, the ages of whom are not 
indicated. They introduced the osteoporosis index (OI), which is the mean corti-
cal index of the 2nd, 3rd and 4th proximal phalanges or metacarpals of the right 
hand only. They studied their patients at 2 intervals, 4 years apart. Measurements 
were not simultaneously carried out on the left hand. They found that the fall in 
OI was more rapid in the old age groups than in the young ones. 
Duration of disease had no influence. There was a parallel between destruc-
tive changes and OP. No correlation was found with rheumatoid factor (RF) titre, 
but those with a higher erythrocyte sedimentation rate (ESR) seemed to have a 
lower bone mass. Power of grip showed a high correlation with bone mass at the 
proximal phalanx of the right hand, but none with the metacarpals. According to 
this study, quantitative estimation of the mineral content of bones in RA seemed not 
to be as important as suggested. Even if it has a great theoretical interest, such simple 
tests as grip strength and radiographs reflected the degree and development of the 
disease giving an appropriate basis to therapeutic measures. CS therapy for more 
than 1 year did not increase the pace of demineralisation of the hand bones. The 
flaws in this study include the lack of an assessment of physical activity, omission 
of the age of the patients in the report and the measurement of grip strength only 
at the end of the study. It is, therefore, difficult to comment on the significance of 
this study in relation to the pathogenesis of the bone loss reported. 
Bjelle et al (1970), quantitated the bone mass in 37 female patients with RA 
using several different methods, and attempted to define the role of CS therapy 
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in producing OP. Radiogrammetry measurements were performed at the lower 
radius, right 2nd metacarpal and midshaft of the femur. Photon densitometry was 
done at the distal end of the femur using the method of Nilsson (1966) and the 
lumbar spine was graded according to the recommendations of Saville (1967). 
They found that, overall, there was a decrease in bone mineral content 
(BMC), CA, and cortical width at the femur in RA patients compared with age-
matched normals. Spinal OP occurred no more frequently than in controls. In CS 
treated patients, the values of bone mass were significantly lower in the upper 
limb, but the differences were of doubtful significance in the lower limb and lum-
bar spine. The duration of disease could not be shown to influence any of the par-
ameters of bone mass. Duration could also not explain the difference between 
CS-treated and non-treated patients. They concluded that RA produced OP and 
that CS therapy contributed to this loss. However, the lack of effect on the skele-
ton of the lower limb probably reflected the effects of weight-bearing and activity 
in the patients who could and did walk. 
A detailed review of OP in RA was presented by Duncan (1972). He dis-
cussed normal bone physiology, illustrating the close relationship between osteo-
blasts, osteoclasts and synoviocytes. He makes a strong case for a vascular basis to 
OP, quoting angiographic studies (from their unit), which showed increased vas-
cularity in areas close to bone erosions. He observed that no clear relationship 
existed between bone mass and tendency to fracture, suggesting that there may be 
an inhibitor to repair which is the predominant factor. He considered that the 
evidence for steroid bone loss was substantial, but that the mechanism for this 
INTRODUCTION 32 
loss was not known. Finally, he recommended that the prevention of bone loss 
was extremely important, since the evidence showed that bone lost after the 
menopause was essentially irreplaceable. 
Kennedy et al (1974), studied 420 patients with RA; 295 females, of whom 109 
were on CS therapy and 26 were under 45 years of age. The onset of menopause 
in the females was 45.2 years. The 2nd metacarpal index (MI) was measured with 
Vernier calipers. Under 45 years of age, there was no statistical difference be-
tween the groups taking CS and those who were not. In males over 45 years, MI 
was inversely related to duration of disease. With respect to CS therapy, the MI 
was significantly lower in females irrespective of age, while in males this only 
reached significance after the age of 55 years. The findings of this study are signi-
ficant, but the interpretation is hampered by the small number of patients under 
45 years of age, absence of trabecular bone measurements, the mean age of the 
study groups being over 50 years and the absence of data regarding physical activ-
ity. 
The above authors later corrected some of the defects in their study by repor-
ting the findings of the femoral index (FI) and clavicular cortical thickness 
(CCT), in the same patients (1975). They found the CCT to be lower in all patient 
groups, but this difference reached significance only in males between 55 and 65 
years of age. They reported a good correlation between MI and FI, and also that 
bone mass was lower at both the metacarpal and femur than at the clavicle. They 
concluded that RA caused generalised OP. The majority of their patients were 
menopausal and the functional ability was not indicated. 
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An abstract of a histological study presented by Muirden (1976) at an Austra-
lian meeting is quoted by several authors. The area of bone adjacent to articular 
cartilage and the synovial reflection was studied in 15 patients with RA. In 5 pa-
tients tetracycline labelling was performed, and in 2 patients a double label was 
given. Even in early disease, where there was no macroscopic evidence of cartil-
age or bone damage, a marked cellular reaction in the periosteum deep to the sy-
novial layer was noted. Vascular changes were prominent. Absorption of bone 
was active around numerous osteoclasts along the periosteal surface of bone. 
These areas were detached from synovial and sub-synovial granulation tissue. 
More surprisingly, osteoclastic and osteoblastic reactions were seen on the mar-
row surface of trabeculae. Tetracycline was deposited here, indicating active re-
modeling and repair of bone side by side with destruction. 
The findings conflicted with the popular concept of eroding rheumatoid gra-
nulation tissue as the sole primary event in the periarticular bone lesion. A spec-
trum of change was also apparent at the pannus-cartilage junction where eroding 
cells may or may not be separated by a layer of fibrous tissue. He concluded that 
vascular changes, leading to ischaemia and dilatation of vessels resulting in acti-
vation of osteoclasts and bone absorption, were likely to be important factors. He 
remarked that the pathological resemblance in extreme cases to Paget's disease 
may have therapeutic implications. This was the first histological evidence of ac-
tive bone loss in RA. However, the ages and physical abilities of the patients were 
omitted, so that it is difficult to establish the roles of age, menopause and immo-
bilisation in the genesis of the changes described. 
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Robinson et al (1975), evaluated the possibility of prostaglandin (PG) stimu-
lated bone resorption as the possible mechanism for bone destruction in RA. Sy-
novia from 2 patients with classical RA were incubated in a culture medium 
which was assayed for purified PG E2. Bone resorption stimulating (BRS) activity 
was evaluated using an ether extract of the medium incubated with mouse cal-
varia. Separate experiments were performed in the presence of Indomethacin 
(PG E2 inhibitor) and Colchicine (PG E2 stimulant). They found that RA syno-
vial culture contained tenfold higher concentrations of PG E2 than normal syno-
vial culture and concluded that this was the basis for the BRS activity in RA syno-
vial cultures. They confirmed that Indomethacin inhibits BRS while Colchicine 
stimulates BRS. 
They remarked that the extraction of BRS activity by ether was significant. 
Parathormone (PTH) and osteoclast activating factor ( OAF) are not extractable 
by organic solvents, so that they are unlikely to have been responsible for the 
BRS activity seen here. They concluded that PG E2 was the bone resorbing factor 
in RA and suggested that their findings supported a retarding role for non steroi-
dal anti-inflammatory drugs (NSAID). The numbers are also too small for 
meaningful conclusions. 
These authors had omitted the age, menopausal status and functional ability 
of their patients. Since the mechanisms of menopausal and immobilisation OP in-
clude an unidentified resorption stimulating factor in some instances, these facts 
need to be known in order to place the above findings in perspective. 
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Kennedy et al (1976), presented a conflicting report on the bone resorbing ac-
tivity in the sera of patients with RA. They studied 2 groups of RA patients 
divided on the basis of the level of the ionised calcium so that there were 8 nor-
mocalcaemic and 6 hypercalcaemic patients. These sera and a group of normal 
sera were then incubated with rat calvaria labelled with Ca45. BRS activity was 
measured as the ratio between Ca 45 released by treated and control numbers of 
the bone pair (test/control Ca45 ratio). They found that the hypercalcaemic group 
of patients had a significantly higher ratio than those who were normocalcaemic. 
The BRS activity was found to be equivalent to 0.5 U/ml. of PTH. This was in-
hibited by the addition of calcitonin, suggesting that the resorption was a cell-
mediated phenomenon. These authors discounted the suggestion that the BRS 
activity is PG E2 mediated because it is so easily degraded. 
They postulated that OAF was likely to cause the erosion in RA and sug-
gested that the idea was supported by Muirden's findings (1976). They remarked 
on the therapeutic implications of the inhibitory effect shown by calcitonin. This 
study is marred severely by the omissions of similar well-intentioned attempts at 
deducing the pathogenesis of bone resorption in RA : they did not indicate the 
age, menopausal status and functional status of the patients in the study. 
The role of CS therapy in the genesis of OP in RA is further addressed in a 
study by Mueller (1976), comparing RA patients with a group of patients with as-
thma. Bone mass was measured at the distal and midshaft radius using single 
photon absorptiometry (SP A). It was found that females with RA treated with CS 
showed severe and dramatic demineralisation while patients with asthma showed 
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no detectable bone mineral loss whether or not CS had been used in the therapy. 
The loss in RA was equally severe at distal and midshaft radius, suggesting similar 
rates of cortical and trabecular loss. They concluded that RA had a unique cata-
bolic effect on the skeleton. They further suggested the alternative hypothesis, 
that asthma or its treatment protects against bone loss. The author omitted to re-
port the age, menopausal status or functional status of the patients, so the results 
are difficult to interpret. 
Trabecul~ bone mass measurement has been facilitated by the introduction 
of total body neutron activation analysis (NAA). Zanzi et al (1976), compared 
bone mineral content (BMC) using a Norland analyser and NAA for measuring 
total body calcium (TBCa). Nineteen patients with RA, 12 of whom were on CS 
therapy equivalent to 13 mg for a mean of 3.7 years, were studied. There was a 
highly significant correlation between TBCa and BMC in the total population 
under study. Significantly lower values were found only in postmenopausal fe-
males taking CS therapy. This study confirmed the positive correlation between 
cortical and trabecular bone changes in RA, and emphasised the need for further 
studies on larger numbers of premenopausal patients. 
Kennedy et al (1977), presented a further review of the literature, dealing at 
great length with the evidence that RA causes generalised OP through a BRS fac-
tor. They questioned the role of the menopause in the genesis of this bone loss. 
No substantial contribution to our understanding of the pathogenesis of OP in 
RA was provided in this paper. 
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One of the first studies to evaluate the effect of therapy in modifying the OP 
of RA was presented by Hahn and Hahn (1976). They interpreted the evidence to 
be strongly in support of CS-induced bone loss in children and in females over 
the age of 50 years. They found that patients with RA treated with non-steroid 
drugs who had stage 3-4 disease, had significantly less forearm bone mass (using 
SP A), than did patients with stage 1-2 disease. Vitamin D and calcium supple-
ments did not increase the BMC in these patients. They concluded that patients 
with rheumatic diseases were subject to the same genetic, environmental, and 
age-sex related determinants of OP that affect the general population as a whole. 
They are much more prone to an accelerated development of severe OP as a 
result of decrease in the level of physical activity, disease-related alterations in 
Vit D metabolism, and toxic side-effects of the agents required to control their 
disease. The authors emphasised that the most effective means of managing 
skeletal complications in rheumatic disease patients was early detection and 
prevention. 
Hancock et al (1978), reported an absorptiometry study using SPA at the 
lower end of the femur. The findings were then correlated with disease activity, 
body weight, knee circumference and mobility, among other things. Forty-two pa-
tients with RA ( of whom 16 were under 50 years of age), were compared with 27 
patients who had osteoarthritis (OA). They found the bone mass in both patient 
groups to be lower than a control group of 554 normal subjects. This finding con-
flicted with the general concept that OA is associated with increased bone mass. 
This study also found a positive relationship between muscle weight and bone 
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mass. Albumen also correlated with bone mass, suggesting a causal link between 
these 2 variables. They concluded that the only significant finding from this study 
was the negative correlation between muscle function and bone mass. The num-
bers of subjects in this study were extremely small, and the effects of aging are 
difficult to separate entirely. This study supports the concept that studies of OP in 
RA should be restricted to subjects who are functionally independent. 
Kennedy et al (1979), presented yet another comprehensive review on the im-
plications of hypercalcaemia in RA and the investigation of its causes. They re-
ported on the ionised calcium in a random group of 50 patients with RA. Twenty-
three ( 46%) had elevated corrected total serum calcium and 8 (16%) had elev-
ated ionised calcium. The average age was 51.6 years. No patients had elevated 
levels of PTH, despite biochemical evidence of PTH-like activity. They also 
found a significant correlation between the erosion score and the metacarpal 
index. They suggested that this indicated similar events at the joint margin and 
the midshaft of the metacarpal. They also suggested that the MI provided a rea-
sonably simple guide to the extent of bone damage occurring in the hands of the 
rheumatoid patient. No correlation was found between hypercalcaemia and dis-
ease activity. Urinary D-glucaric acid (GLA-protein) levels were elevated. 
They concluded that hypercalcaemia was a not uncommon feature of RA and 
that BRS activity was responsible for this state. Calcitonin and hydrocortisone 
(both of which block in vitro resorption), may have therapeutic roles in prevent-
ing or diminishing this loss. Again, omission of age and menopausal status con-
fuse the interpretation of these important findings. 
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In a study involving a larger sample, Scott et al (1981) contradicted the above 
findings of hypercalcaemia in RA. Three groups were studied, consisting of : 
a) 201 ambulant outpatients with RA (mean age 52.3 years); 
b) 
c) 
155 in-patients with non-rheumatic diseases (mean age 59.2 years); and, 
38 inpatients with RA (mean age 57 years). 
There were 2 control groups; one of 4490 healthy subjects and another of 
2609 inpatients at a general hospital. Patients with any possible associated cause 
of altered calcium metabolism were excluded. Disease activity was assessed by 
the early morning stiffness (EMS), Ritchie articular index (RAI), Hb, ESR, CRP, 
and haptoglobin. 
They found that calcium levels were lower in RA patients as well as hospital 
inpatients, compared with healthy controls. Inpatients with RA had lower calcium 
levels than all the other groups in this study. There were no significant differences 
between RA inpatients using vitamin D and calcium supplements, and those who 
were not. RA outpatients on CS therapy had levels which were lower than nor-
mal, but higher than those not on CS therapy. This study emphasises the need for 
controls to be matched for the presence or absence of disease. The contradictory 
findings are difficult to interpret in relation to the pathogenesis of bone loss in 
RA. The role of age and menopause are not addressed by the authors. 
Osteomalacia always needs to be considered as a cause of bone loss in RA. 
Bird et al (1982) compared serum 25-0H vitamin D concentrations in RA and 
OA, and found no significant differences. They were unable to show any correla-
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tions between 25-0H D concentrations and duration of arthritis or the articular 
index in the RA group. 
Buchanan et al (1982), in a review of some metabolic effects of arthritis, con-
sidered OP to be one of the commonest systemic complications of RA. They 
commented on the association of hypergastrinaemia and hypercalcaemia in some 
patients with RA. It is not clear whether the bone resorbing substance is gastrin 
or whether it has similar radio-immunological properties. They supported the 
concept of chemical stimulated bone resorption in RA. 
Reid et al (1982), reported on the effects of disease activity and CS therapy on 
TBCa measurement in RA. 63 patients with RA (mean age 34 years), comprising 
of 4 groups divided on the basis of menopausal status and CS therapy, were com-
pared with normal controls matched for age, sex and menopausal status. Total 
body calcium (TBCa) was not correlated with any single measure of disease activ-
ity. However, when a composite index of an articular index (AI), EMS, ESR, 
functional class (FC) and rheumatoid factor (RF) was evaluated, a weak inverse 
relationship was found. In patients receiving steroids, TBCa was closely corre-
lated with mean daily dose but not with mean duration of treatment or with total 
cumulative dose. They concluded that the finding of reduced TBCa in non-steroid 
treated patients strongly suggested that the reduction in bone mass is an integral 
feature of the disease. They interpreted the significant correlation with CS therapy 
to favour an implication of this drug in the pathogenesis. 
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They also drew attention to the need for epidemiological studies into fracture 
incidence in order to establish the pathological basis of bone loss in RA. Despite 
the methodological care taken in this study, several important associated factors 
needed to be controlled. This study confirmed the body of circumstantial evi-
dence that RA causes OP. However, the pathogenesis of this loss had not been 
adequately evaluated in this study. 
Steven et al (1982), added to the controversy in a report of whole body reten-
tion (WBR) of diphosphonate in RA. WBR of diphosphonate (the most accurate 
measure of skeletal metabolic activity), was measured in 3 groups of rheumatic dis-
ease patients (29 RA; 10 OA; 9 AS) and age and sex-matched normal controls. 
This study showed significantly increased uptake in RA patients compared with 
OA patients only. The major component of this RA group consisted of inpatients 
and patients on CS therapy. The difference between steroid and non-steroid pa-
tients was highly significant. All patients had normal PTH levels and no correla-
tion was found with ionised calcium (Ca2 +) levels. 
A negative correlation was found with disease duration but not disease activ-
ity. The significance of these findings is not clear, since the ages of the patients 
were not stated and the physical activity had not been evaluated at all. Despite 
this, they concluded that the elevated WBR levels seen in RA patients taking corti-
costeroids are unlikely to be the result of synovial inflammation and may reflect a 
non-specific effect. 
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Rajapakse et al (1983), using Tc-99m as a measure of WBR, studied 21 pa-
tients with RA (mean age 51 years). They excluded patients with renal disease, 
CS therapy and biochemical evidence of MBD. In addition to WBR, urinary hy-
droxy proline (OH-P), ESR and radiological grades of RA were also recorded. 
WBR and urinary excretion of OH-P were both higher in RA patients than in 
controls. WBR correlated with OH-P excretion, AI and global assessment of ac-
tivity, but not with ESR, radiological grading or disease duration. 
Inpatients and outpatients had similar results, suggesting to the authors that 
mobility played an insignificant role in the genesis of the bone losing state in RA. 
No further assessment of physical activity is provided and in-vitro studies of bone 
were not done. The conclusion that OH-P excretion may be a useful measure of 
disease activity in RA supports the finding by Mbuyi et al (1982), that glycosami-
noglycans (GAG) and OH-P excretion is increased in RA. 
Earlier research seems to have concentrated on the negative effects of rheu-
matoid disease and CS therapy on bone mass. It is reasonable to assume that dis-
ease modifying drugs such as gold sodium thiomalate (Myocrisin), triethyl phos-
phate gold (Ridaura/Auranofin), D - Penicillamine, Chloroquine and Sulphasala-
zine should have a positive effect on bone mass. The earliest study, by Schorn 
(1983), looked at 2nd metacarpal bone mass in 172 RA patients, of whom 42 were 
on penicillamine and 17 on ridaura (mean age 46 years for males and 50 years for 
females). Radiographs were measured 3 years apart. The 2nd metacarpal area 
index fell in RA patients irrespective of CS therapy. 
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Patients on Ridaura showed a fall despite 12 months of therapy. The penicil-
lamine group was most interesting; over a 3 year period the area index fell from 
62.2 to 58.2, whereas in the year that they were continuously on penicillamine 
therapy, the area index increased from 58.2 to 63.5 (p < 0.01). This is surprising, 
since penicillamine, which is thought to work by inhibiting collagen cross linking 
and synthesis would be expected to hasten OP by suppressing collagen matura-
tion in bone. The author concluded that RA is associated with progressive loss of 
bone mineral content, irrespective of disease duration. 
He also believes that the reversal of bone loss in the penicillamine group was 
the result of improved hand function due to a reduction in joint swelling and sy-
novitis. The findings of this study suggested that penicillamine probably had more 
anti-rheumatoid activity than oral gold. The importance of these findings is 
marred by the absence of tests of hand function in the patients at the times of 
bone mass measurement, but the finding with respect to penicillamine therapy 
was very interesting and worthy of more intensive investigation. 
Fam et al (1983), in a review of stress fractures in RA, presented their experi-
ence with 4 patients (mean age 61.5 years). All presented with pain in the lower 
limbs and all showed diffuse osteopaenia. They found that stress fractures re-
sulted from muscular activity rather than from direct impact. A number of factors 
contributed to the insufficiency fractures in RA, including generalised OP, angu-
lar joint deformities and increased activity following reconstructive surgery. 
Three patients had been on CS therapy and one was found to have osteomalacia 
(OM) on histology. They believed that stress fractures may be missed early on, 
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and the role of scanning was emphasised. Healing of RA stress fractures pro-
ceeded normally. 
Wordsworth et al (1984), in a report of MBD among inpatients with RA, stu-
died 25 consecutive RA patients admitted to their hospital (age range 50-70 
years). Fourteen had been on less than 10 mg/day CS therapy. The evaluation in-
cluded dietary assessment of calcium and vitamin D intake, sunlight exposure and 
articular index (AI). The spinal OP score was calculated by summing the total 
number of wedge fractures ( = 1), and crush fractures ( = 2) in the thoracolumbar 
spine. Bone biopsy at the iliac crest was done on all patients. Plasma and urine 
biochemistry were measured before and after 50,000 IU of vit. D daily. Seven pa-
tients (5 on CS therapy) had sustained pathological fractures in the preceding 5 
years. Radiological evidence of OP was present in 14 of the 25. Spinal OP tended 
to increase with age and CS therapy and the scores were also higher in those who 
sustained limb fractures. The 10 patients who showed histological evidence of OP 
also had the highest spinal score. Dietary levels of vit. D and calcium were below 
required levels and 10 patients had low excretion of D-xylose. There was a close 
correlation between X-Ray and histology, and CS therapy appeared to be a po-
tent association with limb fractures. No cases of OM were found in this study. 
Hajiroussou et al (1984), studied 32 consecutive outpatients with RA (mean 
age 59.4 years), to see the effects of oral prednisone (5mg daily) on the axial and 
appendicular skeleton. These were matched with 31 RA patients who had never 
r~ceived CS therapy (mean age 58.5 years). Radiogrammetry was measured at the 
right 2nd metacarpal and the lower femur, while the spine was subjectively 
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graded according to the trabecular pattern at the vertebrae. The difference be-
tween treated and untreated patients was not statistically significant, and the 
authors concluded that the risk of developing OP should perhaps not be con-
sidered a definite contra-indication to low-dose CS therapy. In female patients, 
the central skeleton appeared to be more sensitive than the peripheral skeleton 
to the effects of CS therapy. 
Ng et al (1984), evaluated bone biopsy specimens from 45 RA and 41 QA pa-
tients (average age 55 years), who came to total hip replacement (THR). De-
tailed biochemical analysis and a detailed dietary history were also obtained. 
Trabecular bone volume (TBV) resorption surface were significantly lower in RA 
females than normal females, and lower in OA males than in normal males. His-
tological OP was judged to be more common among patients thought to have skin 
transparency. There was a significant reduction in mean PTH in RA males com-
pared with OA. No patients had definite hypercalcaemia. No cases of OM were 
found in this study. The overall prevalence of OP was 27%. 
Katz et al (1984), studied the pathogenesis of OP in RA using in-vitro effects 
of copper (cu2+) on PG mediated bone resorption. They found that the inhibi-
tory effect of Cu2+ was greater than that of indomethacin alone, suggesting that 
copper may have more than one locus of action. In a similar experiment, PTH 
mediated bone resorption was unaffected by the addition of Cu2+ to the system. 
They concluded that Cu2 + not only impeded the action of exogenous PG on 
bone, but may also inhibit resorption mediated by lysosomal enzymes or other as 
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yet undefined mechanisms. Cu2+ may uncouple the resorptive response to PG, 
but its exact mechanism of action cannot be deduced from these experiments. 
Tannebaum (1984), in a review of the literature on the pathogenesis of OP in 
rheumatology practice, concluded that prolonged immobility and disease dura-
tion were important factors. CS therapy could be expected to hasten the process 
due to a direct effect of decreasing osteoblast function, as well as an indirect re-
duction in calcium absorption from the intestine. Elevated PTH levels resulted, 
followed by bone resorption. The author also states that there is evidence that 
supplemental calcium and vitamin D may be beneficial in retarding this process, 
but does not indicate the source of his reference. PTH levels were not measured, 
and no reference was made to the lack of studies showing elevated PTH levels in 
patients with RA. 
Reid et al (1984a), studied NAA in RA and found a 5.3% loss in men and 
6.8% loss in females with RA not on CS therapy. They also found a correlation 
with disease activity and disease duration. When patients on CS therapy were 
added to the analysis, it seemed that loss of bone was exaggerated early and then 
equilibrated with the normal rate. Patients with polymyalgia rheumatica (PMR), 
showed no loss in bone mass, suggesting that RA patients may be more sensitive 
to CS therapy. They observed that calcium and vitamin D did not increase bone 
mass in the longterm, fluoride is contra-indicated in RA and trials of anabolic ste-
roids in the treatment of bone loss in RA are in progress. They concluded that a 
mild degree of generalised OP occurred in RA, but the loss was significantly in-
creased when CS therapy (6.25 mg daily) was given. The age and functional status 
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of the patients were not described, making these results difficult to interpret with 
respect to pathogenesis of bone loss in RA. 
Reid et al (1984b) also studied bone mass in nodal primary generalised osteo 
arthritis (OA) using NAA. They were unable to confirm the earlier suggestions 
(Foss et al 1972; Roh et al 1974) that patients with OA had an increased bone 
mass. 
The effects of calcium and vitamin D treatment on bone mass were further 
studied by Dykman et al (1984), using SPA measurements. Measurements were 
done at metaphyseal (MM) and diephyseal (DM) sites. Serum PTH, 1,25 OH-D 
and 25 D cholecalciferol were measured. Radiographs of the hands, femur and 
spine were assessed for fracture and all patients had iliac crest bone biopsy. The 
study included 30 ambulant patients with rheumatic diseases who were on more 
than 5 mg. CS for longer than 6 months. Twenty-three completed the study, of 
whom 12 had RA, 8 had SLE, one had scleroderma, one had seronegative RA 
and one had mixed connective tissue disease (MCTD). The results showed an 
overall mild but insignificant increase in bone mass at both areas in treated and 
placebo groups. They concluded that vitamin D and calcium supplementation did 
not increase appendicular bone mass in RA, nor did it reduce the fracture in-
cidence to any significant extent. Since the age range and functional status of the 
patients were not indicated, these results need to be interpreted with great cau-
tion. 
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In a population-based study of fractures after RA, Hooyman et al (1984) 
found that aging, reduced ambulation and relative weight were significant predic-
tors of proximal femur fracture occurrence. Age and relative weight were inde-
pendent predictors of risk for pelvic fractures, while aging was the only significant 
variable in the final proportional hazards models for proximal humerus, distal 
forearm and vertebral fractures. They concluded that a causal relation between 
RA and fracture incidence was unlikely. They also proposed that it was not 
necessary to invoke a generalised inhibiting factor in the genesis of bone loss in 
RA. 
Bone biopsy remains the most critical investigation in understanding the 
mechanisms of bone turnover in RA. Ishikawa et al (1984), reported on light 
microscopy and electron microscopy changes in 7 patients with RA. Although 
light microscopy showed that bone resorption was mediated by macrophages and 
osteoclasts, electron microscopy suggested phagocytosis by macrophages. Osteo-
clasts contained vacuolated material. Osteoblasts were also seen, suggesting that 
repair and resorption co-existed. Resorption exceeded formation, but the greater 
the resorption, the greater the formation. They concluded that multiple factors 
contributed to the pathogenesis of OP in RA. No information was provided on 
the age and functional status of their patients. 
Dykman et al (1985), further analysed the factors associated with glucocorti-
coid induced osteopaenia in rheumatic diseases. They previously reported their 
findings of reduced MM and DM in OP, using SPA They pointed out that in CS-
induced OP the MM falls to a greater extent than the DM, so that the DM:MM 
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ratio rises. This trend was found by multivariate analysis to be independent of 
age. Increased ratios, similar to age older than 50 years and menopause, were as-
sociated with a higher incidence of fractures. There were 82 patients with RA and 
41 with SLE. They concluded that longterm CS therapy had a cumulative effect, 
occurred in all patient groups, was as common in males as females, and resulted 
in fractures in patients older than 50 years who were post-menopausal and had 
had large cumulative doses of this drug. 
The influence of the menopausal state on the effect of CS therapy was further 
questioned in a study by Als · et al (1985a). 97 patients were categorised into 4 
groups based on steroid use and menopausal status. Bone mineral content 
(BMC) was measured using SP A and total b~dy bone mineral (TBBM) using 
DP A measurements. They found that RA males treated with CS had lower 
TBBM than normal controls and RA patients on penicillamine. RA females had 
lower TBBM than normal irrespective of CS or penicillamine therapy. On the 
other hand, BMC was lower in all the RA patients compared with normal con-
trols. In premenopausal RA females, both TBBM and BMC were significantly 
lower in patients receiving CS therapy. In postmenopausal females, however, 
there was no detectable difference due to treatment. The results in premenopau-
sal females suggested that CS therapy caused bone loss in RA. The findings with 
respect to post-menopausal females receiving CS therapy are difficult to under-
stand from the data provided. 
Sambrook et al (1985a), in a 3-part study on 17 patients with RA of recent 
onset, evaluated bone turnover in early disease ( average age 54 years; duration 3 
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years). They found that although RA patients had a trend towards lower indices 
of bone formation and higher indices of resorption, these differences were not 
statistically significant. Measures of disease activity did not correlate with any 
index of bone formation. Physical activity was quantitated using the Framingham 
activity index, but the finding of reduced muscle mass in this sample did not allow 
this effect to be totally excluded. Osteocalcin, a measure of bone formation, was 
reduced in these patients. 
They concluded in this first part, that no skeletal abnormalities could be 
found in patients with RA of recent onset. These findings seemed to support the 
idea that the effects of disease duration are more likely to be due to aging than 
prolonged disease. The effects of age and menopausal status are not addressed. 
In a 2nd paper (1985b ), the same authors report on serial measurements of 
bone density in the distal radius, mid-shaft of radius and lumbar spine. At the dis-
tal radius, some patients showed a rapid fall in a stepwise fashion. Joint count and 
CRP correlated with bone loss at the lumbar spine, but not at the radial mid-
shaft. The annual loss was calculated to be 2.5%. They concluded that predomi-
nantly local factors were responsible for bone loss in early disease. They postu-
lated that fluctuation in disease activity may have contributed to the stepwise loss 
at the distal radius. 
Calcium absorption in RA was studied by the same group of authors (1985c) 
on the same 17 patients as above. They found no significant differences in mean 
values of serum calcium and plasma creatinine compared with controls. Frac-
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tional absorption of calcium was significantly reduced in the patients, but did not 
correlate with any index of disease activity. Levels of calcitriol were significantly 
increased in patients with RA. There was no significant difference in calcium in-
take between RA patients and controls. They suggested that the impaired calcium 
absorption in these patients may have been due to either a vasculitis or Sjogren's 
syndrome, or even secondary to NSAID's. They concluded that impaired calcium 
absorption would increase the risk of OP in RA. 
Reid et al (1985), in a further analysis of the effects of CS therapy in RA, com-
pared 39 RA patients receiving CS therapy (25 low dose; 14 high dose), with 41 
patients who had asthma and 12 who had PMR. Longitudinal bone studies were 
also available on 57 RA patients (30 on regular CS therapy) and 19 patients with 
OA over 18 months. They found that the mean measured TBCa in the low dose 
CS group was slightly but significantly lower than predicted. TBCa was not corre-
lated with duration of therapy or total dose taken. There was, however, a strong 
correlation between the mean daily dose of prednisolone and TBCa in the RA 
patients. The RA patients treated with moderate doses of CS had significantly 
less TBCa than all the other groups. In the longitudinal study, the patients treated 
with CS did not appear to lose any bone, while those patients who did not receive 
CS had a marked loss. 
Patients receiving moderate doses of CS had significantly lower bone mass 
than those receiving low dose CS, suggesting a bone loss threshold slightly in ex-
cess of 5mg daily. Patients with RA receiving CS therapy lost more bone than pa-
tients with asthma or PMR, and the longitudinal studies supported the concept 
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that CS-induced bone loss occurred early in the course of the disease. The age 
and functional class, which may have been important confounders, are not indi-
cated for the study groups. 
Als et al (1985b ), studied the role of disease duration and functional impair-
ment in determining bone loss in RA in 105 patients using SP A measurements. 
The mean age was 57.2 years, and the group comprised of 29 patients receiving 
myocrisin, 61 receiving penicillamine and 15 receiving either cytotoxics, chloro-
quine or NSAID's only. They found that patients whose disease had been present 
longer than 8 years had a significantly lower functional ability than those with 
duration 0-3 years. Functional class 2,3 and 4 had significantly lower bone mass 
than functional class 1, measured by SP A. Duration of disease for 4 years or more 
was associated with a significantly lower BMC than with duration less than 4 
years. A functional impairment corresponding to FC 1 or duration of RA less 
than 3 years implied less than 10% reduction in BMC compared with normal. If 
the FC changed to 2 or the disease was present longer than 4 years, the BMC 
could be as low as 85%. Progression from FC 2 to 3 or duration from less than 3 
years to greater than 8 years did not seem to have any substantial effect on the 
BMC. 
The data in this study did not clarify which of the two, functional class or dura-
tion of disease, carries the principal load on bone mass. They concluded that a 
high degree of functional impairment implied a low BMC. The greatest loss oc-
curred in the first 3 years. Also, the effect of a long duration was simply one of ad-
ding more years of disability. The major importance of this study was that CS-
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treated patients were excluded. No comments were made regarding the effects of 
disease modifying drugs on bone mass. 
D'Angelo et al (1985), in another study of the effects of CS therapy on bone 
mineral metabolism, studied 41 patients with a mean age of 54.5 years. The mean 
Ca2+ was at the lower normal limit. Mean alkaline phosphatase (AP) was at the 
upper limit of normal, but was much higher in CS-treated patients. Prolonged, 
high-dose CS therapy was associated with higher fasting creatinine/calcium ratios. 
Urinary phosphate was lower in CS-treated patients. PTH was within normal 
limits. Urinary OH-P levels were higher in patients not treated with CS. BMC 
was reduced in all patients. 
The significant reduction in BMC of patients who had never received CS ther-
apy suggested to the authors that the bone loss was disease-mediated. CS dosage 
of 10 mg was considered to be a critical level above which a significant decrement 
of BMC may occur in RA patients. Calcitonin levels were at the lower normal 
level in all cases. The authors suggested that this was due to a reduction in syn-
thesis or release of calcitonin in RA. The calcitonin deficiency was not corrected 
by CS therapy. This study did not adequately evaluate the effects of immobility 
and the results were confounded by the average age of the patients. 
Shimuzu et al (1985), using histomorphometric studies on 12 patients with RA 
and 6 with OA, found almost equal total bone volume (TBV) in both groups of 
patients. In the RA group, percentage active osteoid was increased and inactive 
osteoid decreased. RA patients showed a significant increase in resorption com-
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pared with formation. They concluded that periarticular OP was chemically medi-
ated. The age and physical activity of the patients are not indicated by the auth-
ors, making the results difficult to interpret with respect to pathogenesis. 
Fogelman (1986), remarked in an editorial that despite abundant evidence 
showing that RA patients lose bone at an accelerated rate, the reason for the 
bone loss was not established. In the same edition Gevers et al (1986), reported 
on a study of osteocalcin in 56 patients with classical or definite RA. They found a 
significant increase in osteocalcin level in RA. Alkaline phosphatase (AP) activity 
was also increased in the RA patients. The significant correlation with osteocalcin 
indicated that the AP arises from bone and was further evidence that bone turn-
over was increased in RA. There was also a good correlation of osteocalcin with 
OH-Proline, implying that there is also a link between osteocalcin, bone resorp-
tion and disease activity. They concluded that overall bone turnover was in-
creased in RA and that serum osteocalcin appeared to be a useful investigation of 
bone metabolism in this disease. The interpretation of AP levels is confounded by 
the fact that the liver is a potential source of AP as an acute phase reactant in RA. 
Isoenzymes are crucial to accurate interpretation. The level of gamma glutamyl 
transferase ( GGT) may provide additional support for liver origin of this enzyme 
in some instances. 
Reid (1986), using TBCa measurements at 18 month follow up of their earlier 
cases, found that bone loss occurred to the same extent in patients using 5.1 - 10 
mg/day of CS as in patients using NSAID's or penicillamine. No significant loss 
occurred in females using less than 5 mg/day. This finding was interesting, and 
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suggested that CS therapy might limit the degree of local bone damage at periar-
ticular sites by reducing disease activity. They hypothesised that CS could induce 
bone loss early in the course of therapy, perhaps at an axial site, and thereafter 
prevent destructive bone loss at appendicular bone sites. Longitudinal studies are 
needed to test this hypothesis. This report reflects a change in this group's ideas 
about the effects of CS therapy on bone loss in RA. 
Pitt et al (1986), used an isotope (methylene diphosphonate) to study the me-
tabolic activity of erosions by scanning the joints of 10 patients with RA. They 
were unable to confirm that erosions always showed increased uptake of isotope. 
They also found that erosions could appear within 12 months without any preced-
ing bone isotope changes. An additional feature emerging from this study was the 
well known difficulty in clearly defining criteria for erosions which would satisfy a 
number of observers. Internal consistency was high, but cross observer reproduci-
bility was much lower. Metabolic activity of erosions was not compared with bone 
mass in this study. 
Ekenstam et al (1986), reported their finding of reduced osteocalcin levels in 
serum from 36 patients with classical or definite RA. This finding contradicted 
the increased levels reported by other workers (Gevers 1986). They found that all 
patients with RA had significantly lower mean values for serum osteocalcin than 
a group of age matched patients with ankylosing spondylitis. 
The effects of therapy were interesting. Penicillamine and chloroquine caused 
the levels to rise significantly over a nine month period, while CS caused the le-
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vels to fall even lower. Withdrawal of CS therapy was accompanied by a rise in le-
vels. NSAID's had no effect on osteocalcin levels. This study found no correlation 
between serum osteocalcin and duration or activity of the disease defined by ESR 
and acute phase reactants. They offered several interesting explanations for their 
observation of lowered osteocalcin levels, but concluded that it was premature to 
define the possible value of osteocalcin as a marker of the deleterious effects of 
CS on the skeleton. 
Bijlsma et al (1986) studied the effects of methylprednisolone pulse (MP) 
therapy on bone metabolism in RA. Twenty patients (19 female) with a mean age 
of 60.6 years and mean duration of disease of 14 years were studied. Subjects 
were given lG MP infusions. They concluded that changes in bone metabolism 
during MP therapy were only minor and transient. They suggested that the sus-
tained fall in OH-Praline levels in the urine at 3 days after the last MP infusion, 
may reflect a fall in juxta-articular bone resorption, and that the effects of CS on 
bone differed with duration and dosage of therapy. Since the mean age of the pa-
tients exceeded 55 years and the mean duration of disease was 14 years, it is 
possible that the bone mass of the subjects in this study had stabilised by the time 
of the study. 
Verstraeten and Dequeker (1986) reported on the effects of low dose CS on 
vertebral and peripheral bone mineral content and fracture incidence in post-
menopausal patients with RA. BMC was measured by SP A at the radius and by 
DPA at the lumbar vertebra. In the control group, BMC at the radius was signifi-
cantly correlated with BMC at the vertebra, while in the RA group this correla-
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tion was found only in the CS treated group. The percentage of patients in the CS 
treated group who sustained fractures was greater than the percentage in the non-
CS treated group. They concluded that RA did not alter the BMC in the spine, 
but that CS even in low dose affected the spine and fracture incidence. They pos-
tulated that this effect of CS in postmenopausal females was due to suppression 
of the hypothalamic-pituitary axis, resulting in smaller amounts of androstene-
dione from the adrenal for conversion to oestradiol in the subcutaneous fat. It is 
difficult to explain the apparent discrepancy between vertebral BMC and fracture 
incidence when a case control study was made in the RA group with comparable 
disease duration. 
Sambrook et al (1986), in a study of 84 patients with RA (mean age 56 years), 
compared a group receiving CS (n=40) with a group (n=44) not receiving CS 
therapy. Bone mineral density (BMD, g,'cm2) in the lumbar spine and femoral 
neck was measured with a dual photon absorptiometer (DP A). They concluded 
that low dose oral CS do not result in significant axial bone loss in RA. They also 
commented that fear of inducing osteoporosis should not influence the decision 
to use these agents. 
Kaplan (1987), in an editorial, discusses the possible chemical mechanisms for 
bone resorption in Rheumatic diseases. The responses are largely dependent 
upon the interaction of bradykinin with cellular receptors. Two types of receptors 
have been defined thus far, B2 and Bl. The most ubiquitous is the B2 receptor, 
which is stimulated by lysyl-bradykinin as well as by bradykinin. The Bl receptor 
is stimulated by desArg9-bradykinin to a greater degree than by the above-men-
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tioned kinins. It appears to be inducible in some tissues as a result of an inflam-
matory response. 
Lerner et al (1987) present evidence that desArg9-bradykinin and bradykinin 
are capable of stimulating bone mineral mobilisation and matrix degradation that 
is dependant upon interaction with osteoclasts. This suggests that kinins activate 
the osteoclast and that the reaction is dependent upon endogenous prostaglandin 
production. 
Avioli (1987) summarised the current knowledge regarding the possible basis 
of osteopaenia in RA. He suggests that the mast cell may prove to be pivotal in 
inducing both the periarticular and generalised osteopaenia. In addition, IL-1 (in-
terleukin 1) may have a local regulating effect on bone resorption through its ac-
tion on macrocyte - monocyte interaction. 
The evidence for generalised bone loss in RA is strengthened by a report 
from Sambrook et al (1987). They reported DPA measurements in the lumbar 
spine and femoral neck in 111 patients with classical RA. The study showed a sig-
nificant correlation between bone mass and physical activity, as measured by the 
Framingham index (Kannel et al 1979), with a predictive value of 18.5%. A signi-
ficant correlation was also found with markers of disease activity. Corticosteroid 
therapy was not significantly correlated with bone mass and spinal fractures were 
not increased in patients receiving such therapy. Age and menopausal status were 
not considered to have any significant added effect in RA. Smoking and alcohol 
were also not significant factors in this study. Although parity was not a significant 
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predictor of lumbar BMD, they felt that multiparity may have had a protective ef-
fect in RA. 
Mellish et al (1987), studied bone biopsies in 48 patients with definite or 
classical RA. The mean trabecular bone volume volume was significantly reduced 
in females aged 34 - 50 years, but not in males in the same age group. Older pa-
tients of both sexes were similar to the controls. The mean trabecular plate thick-
ness was significantly reduced in all the females, but not the males. The mean 
trabecular plate density and separation showed no age related change in either 
male or female patients. They conclude that the basis for increased fracture in 
RA is most likely to be trabecular thinning. 
In 1988, Alwan et al provided further evidence for bone resorbing activity in 
the synovial fluid of patients with RA and destructive OA. Using the mouse cal-
varial system, they showed that synovial fluid from destructive OA and RA pa-
tients had significantly higher resorptive capabilities than fluid from simple OA 
and pyrophosphate arthropathy. These effects were shown to be largely due to 
IL-1 activity. However, other undetermined factors were also responsible, since 
IL-1 activity was higher in RA subjects, while bone resorptive activity was greater 
in patients with destructive OA. The bone resorbing activity was reduced by dia-
lysis of the fluid. 
Cooper et al (1988) reported on alterations in appendicular skeletal mass in 
patients with rheumatoid, psoriatic and osteoarthropathy. 50 patients were stu-
died using SP A at the distal forearm. Distal forearm BMC was reduced in pa-
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tients with RA and psoriasis and increased in those with OA. The increase in 
bone mass in patients with OA was confined to those with isolated large joint dis-
ease and was not found in those with primary generalised OA. 
Ralston et al (1988) reported a high prevalence of unrecognised OM in 31 
hospital patients with RA. The study was conducted in Glasgow. All affected pa-
tients were elderly women who had a poor diet and were virtually housebound. 
Additional risk factors in 2 patients were partial gastrectomy and occult coeliac 
disease. Biochemical screening was of limited value in differential diagnosis. Di-
agnosis was based on iliac crest biopsy. 
Compston et al (1988) using quantitative computed tomography in 88 pa-
tients, presented further evidence for vertebral bone loss in RA, especially in 
younger subjects. They were unable to demonstrate any relationship with nutri-
tional status, disease duration or disability index. The prevalence of OP was 7%, 
as defined by a bone mass greater than 2SD below the normal mean. 
In summary, several studies of OP in RA have been reported over the years. 
Table 1 shows that the majority of these otherwise well constructed studies are 
severely limited by the difficulty in differentiating age related changes from those 
due to disease. It is surprising to find that the more recent studies (1985 / 1986) 
also failed to control for this most important risk factor in the pathogenesis of 
bone loss. A study of the age range with respect to the mean suggests larger num-
bers of older subjects. 
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Table 1.Summary of earlier studies of OP in RA, showing the year, sample size 
and age ranges of each. Where the range was not available, the mean age is shown. 
Authors Year Sample Size Mean Age/ Range 
Control RA Control RA 
McConkey et al 1965 102 40-78 
Saville 1967 92 164 21-76 20-70 
Virtama et al 1968 33 25-65 
Bjelle et al 1970 74 37 40-70 20-65 
Kennedy et al 1974 629 420 26-75 26-75 
Kennedy et al 1975 221 307 21-79 25-78 
Scott et al 1981 155 201 59.2 52.3 
Reid et al 1982 40 63 54 54 
Rajapaksi et al 1983 21 51 
Schorn 1983 172 46 
Ng et al 1984 41 45 58 59 
Sambrook et al 1985 19 17 55.4 
Als et al 1985 105 53 
D' Angelo et al 1985 41 54 
Verstraeten et al 1986 43 104 58.6 59.2 
Bijlsma et al 1986 20 36-77 
Sambrook et al 1986 84 56.1 
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DIFFERENTIAL SKELETAL CHANGES IN RA. 
Bjelle and Nilsson (1970), in a study of patients with RA, showed that changes 
in the hands were not necessarily associated with vertebral changes. This study 
suggested that possibly two types of bone loss occur in RA. However, it is also 
possible that changes in the vertebrae were not detectable because of the insensi-
tivity of the visual method in detecting changes in trabecular bone mass. This 
finding was in contrast to the earlier finding by Saville (1967), who found a tend-
ency for cortical thickness to decrease as spinal porosity increased. Kennedy et al 
(1975), found a good correlation between the metacarpal cortical index and the 
femoral cortical index. They also found that bone mass in their patients with RA 
was lower at the metacarpal and femur than at the clavicle. Zanzi et al (1976), 
comparing total body calcium using NAA with bone mineral content using SP A, 
found a good correlation between the methods. These findings suggest that RA is 
a cause of generalised bone loss, similar to the loss reported in diseases such as 
hyperparathyroidism and the humeral mediated bone loss of malignancy reported 
by Ralston et al (1986). However, it is possible that changes in the hands are far in 
excess of changes in other areas in patients with RA. Reid et al (1982), in a study 
reporting measurement of TBCa, speculate that the reduced TBCa seen in RA is 
attributable to the disproportionate bone-losing effect of RA in the hands. 
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RADIOLOGICAL ASSESSMENT OF RA. 
Radiography provides an important method for evaluating RA. A variety of 
evaluation systems, practically all based on conventional radiography, have been 
used in clinical and epidemiological studies of RA. Radiological changes in RA 
may be reported in descriptive form, which is used routinely to give an overall 
view of the status of a joint or of a patient. For scientific purposes, however, this 
is insufficient and some form of staging or scoring is required to permit numerical 
analysis of the degree of joint destruction. 
A radiological evaluation, suitable for both clinical trials and routine follow-
up of patients during treatment of RA, should fulfill the following criteria: 
1. It should be objective, reproducible and accurate. 
2. The changes recorded should be relevant to the long-term progression 
of the arthritic process and should be independent of acute exacerba-
tions. 
3. The degree of severity of joint destruction assessed by the radiological 
method, should correspond ( as closely as possible) to the clinical status 
of the joint. 
4. It should be possible to record changes in separate parameters (for 
example erosion and joint space narrowing) as well as the overall result 
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of these parameters in a single joint, a group of joints, or in the patient 
as a whole. 
5. The method should be based on standard projections of plain films for 
use in multi-centre studies. 
LITERATURE REVIEW. 
STANDARD 
The most widely used radiological classification of RA was presented by 
Steinbrocker and colleagues in 1949, who proposed a standardised evaluation 
based on four stages. Although used for several decades, this system had obvious 
disadvantages. The staging depended on the worst affected joint. Several patho-
logical changes may develop between examinations, without qualifying the joint 
for progression from one stage to the next. This meant that the sensitivity of the 
system was low. The vague descriptions qualifying for each stage also meant low 
reproducibility. Although stages 1-3 corresponded with chronic progression of 
the disease and roughly with the clinical status, stage 4 did not. Ankylosis (stage 
4) may reflect a reparative process in arthritis. Sievers (1965) and Larsen (1973), 
confirmed poor reproducibility using this method. Of the above ideal criteria, 
therefore, only number 5 was fulfilled by this system. 
In 1963, Kellgren et al published an Atlas of Standard Radiographs of Arthritis 
with reference films, representing stages 2-4 as defined by Steinbrocker (1949), 
for the hand, wrist, forefoot and cervical spine. Similar objections are raised with 
respect to the second, third and fourth ideal criteria referred to above. 
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In 1971, Sharp et al designed a scoring system for erosion and joint space nar-
rowing in the hand and wrist. This system fulfilled most of the above criteria, but 
included only 2 of the parameters which constitute arthritic change and was 
limited to the hand and wrist. 
Larsen (1973; 1974) and later Larsen et al (1977), presented a 6-graded sys-
tem based on standard reference films, describing all the large joints as well as 
the hand and foot. Although this system has been widely accepted in clinical re-
search, it does have some disadvantages. De Carvalho et al (1981), concluded that 
the Larsen system fails to detect progression of joint changes over short observa-
tion periods. It is clear, therefore, that radiological evaluation in RA is subject to 
differences related to different observers as well as the interval between observa-
tions. Larsen et al (1983) compared radiological changes with auranofin and 
myocrisin and showed sensitivity of the method. 
Brook and Corbett (1977) studied the radiographic changes in early rheuma-
toid disease. They found changes in the feet more commonly than in the hands. 
Erosions preceded joint space narrowing. In 71.3%, changes occurred within 2 
years of the onset of disease. They graded OP of the hands subjectively as absent, 
definite or severe. 77.6% of those with definite OP developed diagnostic ero-
sions. In 8 patients with severe OP, progression was rapid. They concluded that 
frequent X-Ray examinations in the first 2 years after presentation were required 
if we are to identify patients at risk for serious joint damage. The study suggests 
that OP may be a useful predictor of severe disease. These features are import-
INTRODUCTION 66 
ant, since the radiographs were measured by a single observer who followed the 
patients prospectively. 
De Carvalho et al (1980), addressed the question of the joints which could be 
grouped in the radiological evaluation. They found that the wrist and carpus 
could be regarded as a single unit, as well as the 2nd to 5th MCP, PIP, DIP joint 
of the hands and feet. De Carvalho (1981), in a prospective evaluation of 188 pa-
tients, found that the Larsen index was unable to express progression in up to 
42%. He concluded that for shorter periods of observation a more detailed sys-
tem of evaluation was required. 
Mewa et al (1983), evaluating observer differences in detecting erosions in 
radiographs of RA, compared 3 radiographic views (postero-anterior (PA); Nor-
gaard 1965 and Brewerton 1967) of the hands. They found that the observer 
agreement was uniformly poor with all views and the number of erosions de-
tected was similar in all 3 views, though slightly lower in the Norgaard view. They 
concluded that no advantage could be demonstrated in choosing the Brewerton 
or Norgaard views over the standard PA view for detecting erosions at the MCP 
joints. 
Gofton (1983), in an editorial on the problems associated with the measure-
ment of radiologic progression of disease in RA, pointed out (amongst other 
things) that no study had compared the sensitivity of scoring methods on the same 
sets of films. Practically, one is faced with the problem of determining if a small 
difference in the appearance of an erosion is due to advance of disease, to dif-
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ference in contrast between 2 films or to minor differences in projection. Film 
quality is of greatest importance in this comparison. 
Iannuzzi et al (1983), in an exhaustive review of the literature reporting the ef-
fects of drug therapy on radiological changes in RA, emphasised the many meth-
odologic flaws in such reports. These related to the small number of observers 
evaluating X-Rays, randomisation of treatment groups, duration of follow-up, 
sample size and radiological techniques. They also commented on the lack of 
correlation between clinical responses ( as judged by signs and symptoms of dis-
ease activity) and radiographic changes. It is possible that some of the disparity 
was due to the lack of sensitivity of the radiological method in assessing progres-
sion or improvement in RA. Genant (1983) provided further guidelines on the as-
sessment of radiographic changes in RA. 
Buckland-Wright (1983a & b; 1985; 1986), recognising the limitations of con-
ventional diagnostic radiology, reported on the development of microfocal radio-
graphy as a more accurate means of quantifying disease activity. In a detailed 
presentation of the technique, its limitations and advantages, the author con-
cluded that microfocal radiography provided a precise method of qualitative and 
quantitative assessment of changes in bone structure and was a technique which 
could be applied in the evaluation of the effectiveness of disease-modifying drugs. 
Scott et al (1985), in a re-evaluation of the methods of radiological assessment 
of RA, concluded that there was good correlation between the Larsen system 
(1977) and Sharp's scoring system (1971), using joint space narrowing, erosions, 
INTRODUCTION 68 
and loss of allignment in the evaluation. This was an important study since it com-
pared the different methods on the same set of radiographs. They found good re-
producibility between observers. In addition, joint space narrowing correlated 
with erosive change. They also pointed out that cartilage loss rather than erosive 
change may be of critical importance and that the relationship required further 
investigation. 
Sharp (1985), in a discussion of X-Ray analysis of outcome in RA, concluded 
that radiological evaluation of outcome was an attractive method of representing 
disease at a given time and measuring its progression. He expressed the opinion 
that a better understanding of how to measure radiological progression, including 
defining the sensitivity of measurement and the reproducibility of detecting 
change, could be expected to make possible wider and more successful use of 
radiological evaluation in future. 
Sharp et al (1985a), in a carefully conducted study, clarified a number of mis-
conceptions introduced by earlier studies. Four different radiological methods for 
assessing RA were used by 13 observers on X-Rays from the same 49 patients 
with classical or definite RA. Intra-observer variance was assessed by single ob-
servers reading the same films 2 or 3 times without knowing the prior readings. 
Repeated radiographs of the same patients were studied in sequence. They found 
that 2 observers, reading the same films on multiple occasions, were quite con-
sistent in scoring abnormalities; absolute scores of multiple observers, using the 
same or different methods, were quite divergent; correlation coefficients between 
total scores of multiple observers were 0.85 in approximately 2 of 3 comparisons; 
INTRODUCTION 69 
individual observer rankings of films agreed within 10% of the median rank of all 
observers in 2 of 3 instances; there was agreement on progression of disease in 
approximately 92% of sequential film comparisons when the difference between 
the films was 15 units of standardised score; and, no statistically significant dif-
ferences were detected between different methods or different observers. 
Pullar and Capell (1985), in an editorial on the influence of treatment on radi-
ological progression of RA, emphasised the need for more sensitive radiological 
techniques in detecting change with therapy. They recommended that other 
avenues be looked at. Radiogrammetry measurement of bone mass is an attrac-
tive alternative, but the Vernier caliper technique is limited by similar unaccept-
able observer differences. 
Sharp et al (1985b) provided a useful approach to the scoring of hand X-Rays, 
particularly with respect to the number of joints to be included in the radiological 
evaluation of RA. 
Scott (1986), presenting an analysis of the long term progression of joint dam-
age in RA, re-iterates the relative importance of cartilage loss, which can be diffi-
cult to separate from erosive change using Larsen's grading technique. The 
relative importance of cartilage loss is further reflected in changes of the carpo-
metacarpal ratio, as referred to by Trentham and Masi (1976). 
Fries et al (1986), extending some of the earlier points made by Sharp (1985), 
conducted a randomised controlled trial of the assessment of radiological pro-
gression in RA. A number of important conclusions emerged. Erosions and joint 
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space narrowing contribute different information, and both should be evaluated 
separately. There is little difference between global erosion estimates and 
weighted erosion counting. The use of trained, experienced readers is critically 
important to the identification of disease progression. Evaluating either a more 
comprehensive or a more selective number of joints makes little difference in 
either reliability or validity. Averaging the scores of 3 or more readers greatly in-
creases the reliability of progression scores. Films should be read in pairs rather 
than separately. With optimal reading techniques, the required number of pa-
tients in a study could be greatly reduced; such reading techniques could reduce 
costs by at least one-half and could achieve high study power with reasonable 
numbers of patients. 
Kaye et al (1987) reported a technique of measuring joint space narrowing 
(JSN), erosion and malalignment at specific sites in the hand and wrist. Using this 
schema, a total score is derived for the right and left hands respectively. They 
concluded that bony ankylosis in RA was often associated with longer duration 
and greater severity of disease. 
In one of the few studies relating clinical changes to radiological scores, Fuchs 
et al (1988) showed that joint scores for limitation of motion and deformity were 
strongly correlated with the total scores derived with the technique of Kaye et al 
(1987). The correlations with joint swelling scores were much lower. Radiological 
scores were not correlated at all with joint count tenderness scores, using a modi-
fied Ritchie index. This raises important issues related to the design of drug trials 
INTRODUCTION 71 
evaluating disease modifying drugs. It also supports the idea that adequate evalu-
ation of function may serve a useful purpose in the monitoring of disease activity. 
In addition to the monitoring of therapy and or disease progression, radio-
graphs in RA have been used in diagnosis. Symmetry of involvement is con-
sidered characteristic of RA, However, Halla et al (1986), in a systematic roent-
genographic study of small joint involvement in RA, found that absolute sym-
metry was the exception rather than the rule. Unilateral involvement ( complete 
asymmetry) was more common than previously found. DIP joint involvement was 
found in 16%. There was no significant right handed predominance of erosions. 
Although Burns and Calin (1983) found that erosions and global symmetry were 
strongly correlated with seropositivity in a blinded study, this study was unable to 
confirm the finding. 
In a comprehensive review of radiological assessments of outcome in RA, 
Dawes (1988) re-iterated the methodological difficulties. He concluded that the 
advent of new technology should improve our knowledge further and may estab-
lish imaging of joints as the assessment of choice in inflammatory joint disease. 
Even now the use of an established scoring method, appropriate radiographic 
technique, careful timing of films and appropriate study groups should allow a 
better judgment of therapeutic effects and assessment of disease outcome by 
radio graphs. 
The question of frequency of radiological evaluation and the differentiation 
between erosion score and damage score is addressed in a paper by Larsen and 
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Thoen (1987). They concluded that disease duration was a critical feature for 
therapeutic studies. They suggested that patients with disease duration less than 
36 months only were suitable for therapeutic trials of RA and that the follow-up 
time should be at least 18 months if radiological assessment is used. 
Young et al (1988), reported a very interesting study of a prognostic index for 
erosive changes in the hands, feet and cervical spine of patients with early RA. 
Clinical, laboratory and radiological changes were evaluated over a 3 year inter-
val. The strongest association with the presence of peripheral radiological dam-
age was the rheumatoid factor. Subluxation of the cervical spine was associated 
only with HLA Dw 2 and HLA B27. Discriminant function analysis predicted the 
development of erosive damage in 79% (RA latex titre, SCAT, Hb and platelet 
count). Radiological outcome in the cervical spine was successfully predicted in 
82% using HLA Dw2, HLA B27 and age at onset of disease. They concluded that 
the best predictors of erosive disease were standard laboratory features measured 
at onset, but that more powerful discriminant factors are needed if these are to 
influence clinical practice. 
Mottonen (1988) evaluated the factors which predict erosiveness and the de-
velopment of new erosions in RA. He found that the feet were more useful than 
the hands; that joint swelling was a better predictor than tenderness; that the 
ESR was more closely related to progression than the CRP; and there was equal 
progression in seropositive and seronegative disease. 
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Resorptive arthropathy may occur in 5% of patients with RA (Mody and 
Meyers 1988). The mechanisms are not known, but vascular defects have been 
suggested. There are very few reports of the association with RA and no reports 
of the markers of metabolic bone disease in this situation. The study of Mody and 
Meyers (1988) report the lack of any association with serology or subcutaneous 
nodules. Ionised calcium, calcium excretion and PTH levels were not measured. 
It is clear that this sub-group of patients with RA suffer a unique uncoupling of 
the metabolic process in bone. They need to be more carefully evaluated as a 
source of information regarding bone loss in RA. 
The need for an objective measure of bone loss in the hands of RA patients 
has been discussed. Hutton et al (1988) recently reported the use of DPA of the 
hand in early RA. They concluded that the technique may be superior to conven-
tional radiography in the evaluation of early disease. However, the expense of the 




Trentham and Masi (1976) introduced the carpo-metacarpal ratio (CMR) as a 
measure of radiological progression at the wrist in RA. The ratio was determined 
by dividing the right carpal length by the right third metacarpal length. The longi-
tudinal length of the carpus was measured from two distinct points on plain films 
of the wrist and hand, ie, the distance from the dense volar-ulnar margin of the 
distal radius to the base of the third metacarpal bone at its cortical midpoint. This 
carpal length was divided by the greatest length of the third metacarpal bone to 
determine the CMR. All measurements were carried out to the nearest mil-
limeter and the ratio was quickly derived using a hand calculator. The CMR was 
found to be independent of age, and did not correlate with degree of mineralisa-
tion, osteoarthritis or handedness. 
The ratio was abnormally low in 19% of male RA patients without erosions 
and in all with multiple erosions and deformity. Similar trends were seen in RA 
females. All increases from a pre-erosive to an erosive stage showed a fall in the 
CMR. The fall in the ratio with progressing RA appears to be explained by its 
ability to detect degrees of cartilage loss and bone compaction at the radio-lu-
nate, lunate-capitate, and capitate-third metacarpal articulations. 
They concluded that the ratio may prove to be more sensitive than conven-
tional radiologic procedures in detecting progression of disease in some patients. 
It may have particular value in longitudinal studies of RA patients in setting long-
term drug evaluations, by providing data suitable for objective analysis. The ratio 
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is proposed as an adjunct to careful, experienced, radiographic description, which 
is undoubtedly of great diagnostic value. 
Alarcon and Koopman (1985), using both cross-sectional and longitudinal ap-
proaches, validated the CMR initially described by Trentham and Masi (1976). 
They found that the CMR clearly distinguishes between early and advanced dis-
ease. They suggested that the changes in CMR reflect progressive loss of cartilage 
and/or bone mass, although it is not possible to distinguish these two processes. 
Their finding that the ratio could be determined rapidly, offers a clear advantage 
over the more cumbersome and time-consuming methods of Larsen et al (1977) 
and Sharp et al (1971) and Sharp (1983). These authors concluded that the CMR 
is a useful, reproducible and simple measurement of disease progression in RA. 
The relationship between bone loss at the metacarpals and loss of carpal 
length has not been evaluated in normal aging, or in patients with RA. Similarly, 
no information is available regarding the relationship between the femoral bone 
and CMR. One might expect that inflammatory arthritides such as RA and SLE 
would show a similar effect on bone and cartilage loss. These relationships need 
to be evaluated in longitudinal and cross-sectional studies. 
Dawes (1988) provided a comprehensive review of the methods used for as-
sessing radiological outcome in RA. He also provides useful insights to the rela-
tionships between function and radiological change, differentiation between in-
flammatory and mechanical progression and measuring the effects of treatment 
on radiological progression. He concluded that the use of an established scoring 
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method, appropriate radiographic technique, careful timing of films and appro-
priate study groups should allow a better judgment of therapeutic effects and as-
sessment of disease outcome by radiographs. 
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FACTORS CONTRIBUTING TO OP IN RA. 
AGE, SEX and MENOPAUSAL STATUS. 
Age, sex and menopausal status make vital contributions to the development 
of OP in the non-arthritic population. Numerous reports have confirmed the ob-
servation of age-related bone loss, which seems to be accelerated in the meno-
pausal female ( Cohn et al 1978; Saville & Kharmosh 1967). It is also known that 
males have a higher bone mass than females (Garn 1967a). Idiopathic juvenile os-
teoporosis is a rare condition (Evans 1983), which seems to differ from osteogen-
esis imperfecta. The mechanisms of age-related bone loss are poorly understood, 
but the pathogenesis is likely to be multifactorial. Physiological changes in the 
metabolism of parathormone (PTH) may be important (Parsons 1979). 
Evans et al (1983) reviewed the syndrome of juvenile OP, which introduces 
the possible lower limit of adult-based studies as 18 years of age. In addition, epi-
demiological studies show that bone loss occurs slightly later in males, and the 
rate of loss is slower. Newton-John and Morgan (1968), confirmed the observa-
tion by Albright et al (1941) that the clinical syndrome of OP can result solely 
from the bone loss of age, which usually commences around the age of 35-40 
years. In males, the calculated loss is 4.5% per decade, while in females this loss is 
10% per decade, as found by Newton-John and Morgan (1968; 1970). Bone loss is 
rarely detectable by standard techniques before the age of 45 years. It can be as-
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sumed that these physiological effects are operative in the aging patient irrespec-
tive of whether or not disease is present. 
Marcus et al (1983) have shown that trabecular bone volume of iliac crest de-
creases in women across the span of reproductive life. The predicted annual loss 
of bone represents a change of 0.04%-0.08% total bone volume (TBV), and the 
cumulative effect over 30 years might amount to a loss of 25% of original trabe-
cular bone volume before the age of menopause is reached. If loss of bone were 
to continue at this same rate, even without a menopausal acceleration, 50% of 
original bone mass would be lost by age 80, half of which would have occurred 
before the menopause. 
Trabecular bone is lost prior to the withdrawal of oestrogen which accom-
panies the menopause, suggesting that oestrogen withdrawal is not the only rea-
son for the accelerated loss in postmenopausal women. Factors operating during 
adolescence or earlier may have an important bearing on skeletal integrity in 
later life. 
Garn et al (1967a & b) suggested that the best natural protection against the 
sequelae of bone loss was a large skeletal mass at maturity. Newton-John and 
Morgan (1968) and Stewart et al (1972) make a similar claim regarding the pat-
tern of bone loss with aging. Seeman et al (1988) studied the effect of early meno-
pause on bone mass in normal women and patients with osteoporosis. They con-
cluded that patients with OP have lower bone mass, which is independent of the 
INTRODUCTION 79 
age at menopause. The risk of early menopause is probably related to the dura-
tion of exposure to minimal trauma at low bone mass. 
The effect of aging on bone mass has been demonstrated with the use of 
radiogrammetry (Barnett and Nordin 1960; Exton-Smith et al 1969; Smith et al 
1969), single and dual photon absorptiometry, NAA and whole body retention 
(WBR) studies (Avioli 1984a & b ). Similar effects of aging have been shown in 
RA, emphasising the need for studies in large groups of young subjects. Poor con-
trol for this important factor severely reduces the interpretation of statements re-
garding pathogenesis. The importance of age (Saville and Kharmosh 1967) and 
menopausal status (van Soesbergen et al 1986) in the OP of RA are well recog-
nised. 
Earlier studies in RA have compared individuals whose mean age is in excess 
of 50 years. They have assumed the suggestion by Saville and Kharmosh (1967), 
that the natural selection of the disease results inf ewer young people being eligible 
for study. There is clearly a need for a carefully conducted study of subjects in 
whom age-related effects present no confusion in interpreting the results. 
Osteopaenia needs to be detected long before the clinical syndrome manifests 
itself in the form of vertebral and femoral neck fractures. Therapeutic measures 
will only be effective in the prevention the clinical syndrome if started at the age 
of peak bone mass. 
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PHYSICAL ACTMTY. 
Numerous studies have shown that immobilisation causes OP. Paraplegic pa-
tients have been shown by Wright et al (1965), using osteodensitometric tech-
niques, to start losing bone mass within 6 months of paralysis. The loss is accel-
erated over the next two years and then slows down to a plateau by 4 years. Simi-
larly, Jenkins and Cochran (1969) have demonstrated localised OP in the hume-
rus of an arm immobilised in a plaster cast (POP) for a fracture. In this situation, 
bone loss begins as early as 3 weeks after the application of the cast. In addition, 
the bone loss of immobilisation, although generalised, tends to be rather patchy. 
Peacock and Francis (1982) have compared this with the patchy OP of Sudeck 
dystrophy. 
Although loss of bone with reduced mobility has been easily demonstrated, 
the reverse is more difficult to prove scientifically. 
Donaldson (1933; 1935) long ago showed that physical activity increases bone 
mass in animals. The difficulty lies in defining the degree of physical activity 
necessary to stimulate bone formation. An additional difficulty lies in finding a 
suitably sensitive method of measurement to detect these changes, as shown in 
the study by Aloia et al (1978). The important question in a rheumatoid popula-
tion is also one of comparability between an ambulant normal population and a 
group of ambulant patients who have the additional burden of joint pain, swelling 
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and stiffness to contend with. There is no clear definition as to the degree of 
physical inactivity necessary to produce a critical imbalance of coupling. 
Three theories have been proposed to explain the possible effects of muscle 
activity on bone. The first is a neural effect on bone; the second suggests that vas-
cular and blood flow changes are associated with physical activity; and the third 
relates it to mechanical stress and strain resulting from weight bearing and 
muscle tension. 
Dalen and Olsson (1974) concluded that it was impossible to obtain a rapid 
increase in the amount of bone mineral in the skeleton of healthy normal male 
subjects by physical training. Aloia et al (1978), explained the failure to demon-
strate an increase in bone mass in 9 postmenopausal females with exercise, by 
suggesting that SP A is either insensitive at detecting the changes or that the ap-
pendicular skeleton does not reflect changes in the whole skeleton. Nilsson and 
Westlin (1971) showed that top rank athletes had significantly denser femora 
than non-athletes. White et al (1984), investigating the effects of exercise on the 
bones of postmenopausal women, found that walking and aerobic dancing caused 
a significant increase in bone width and cross sectional moment of inertia com-
pared with a program of no physical activity. Krolner et al (1983) also recom-
mended physical exercise as a prophylaxis against involutional vertebral bone 
loss. 
Johnell and Nilsson (1984) evaluating the factors associated with OP in per-
imenopausal females, found that late menarche and early menopause were asso-
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dated with lower bone mineral content while the life-style parameters such as 
smoking and physical activity were not. 
Dalsky et al (1988), in a study of weight-bearing exercise training and lumbar 
bone mineral content (DP A) in postmenopausal women, showed significant in-
creases above baseline. These were maintained with continued training in older, 
postmenopausal women. With reduced weight-bearing exercise, bone mass 
reverted to baseline levels. Further studies are needed to determine the thre-
shold exercise prescription that will produce significant increase in bone mass. 
In a comprehensive review of the literature, Falch (1982) points out the vari-
ous difficulties in these studies. The relationship with aging must always be con-
sidered. They conclude that immobilisation osteopaenia is largely reversible 
when mobilisation is re-instituted. They also express the opinion that it is uncer-
tain whether physical activity can increase maximal bone mass or limit the bone 
loss due to aging. This is contrary to the findings in astronauts, whose bone mass 
rarely returns to normal over a prolonged period, even with exercise. 
In an editorial, Burry (1987) pointed out that exercise does not usually accel-
erate arthritis. Recently, there has been renewed interest in the association be-
tween physical activity and disease activity in RA. Nordemar (1976; 1981a; 
1981b ), Ekblom et al (1974; 1975) and Lyndberg et al (1988) have all shown 
beneficial effects of exercise in patients with RA Beals et al (1985), in a measure-
ment of exercise tolerance in patients with RA and OA, showed that there were 
no statistically significant differences between the groups, although both groups 
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were significantly weaker than controls. Strenuous ergometer exercise did not 
exacerbate joint symptoms in these patients. The effects of exercise on bone mass 
in patients with RA are not known. These relationships are worthy of more care-
ful evaluation. 
In RA, functional assessment is probably the closest indirect measure of 
physical activity. Disability in RA is difficult to quantify, and detailed evaluation 
of physical activity is required when evaluating its possible effects on bone mass. 
The development of disability in RA is a progressive phenomenon which is in-
fluenced by numerous related and unrelated factors (Sherrer 1986). 
The methods for functional assessment in RA have been extensively reviewed 
by Liang and Jette (1981), and are essentially designed as a measure of outcome. 
The oldest is the method of Steinbrocker (1949). 
Burton and Wright (1983) outlined the difficulties in designing a functional 
index. They concluded that the measures of function currently available were in-
clined to be too lengthy, too complex or suffered from cross-cultural difficulties. 
They suggested that it may be better to move away from seeking a general func-
tional index and concentrate on the needs of particular groups of patients. 
Helewa et al (1982) described an independent measurement of functional ca-
pacity in RA based on the Mc Master Study of Medical Care Utilisation. The 
questionnaire is completed within a mean of 18 minutes and is reproducible be-
tween 2 observers. Meenan (1982) provided a conceptual background and dis-
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cussed the measurement properties of the AIMS ( arthritis impact measurement 
scales) approach to health status assessment. 
The Keitel functional test (1972) (KFf), is an observed measure of function 
in distal and proximal joints throughout the body. It consists of 24 standardised 
tasks performed by the individual and rated by trained observers. The test can be 
performed in 10-15 minutes and does not require special props. The Keitel in-
strument demonstrates high inter- observer agreement (r = 0.85), and Eberl et al 
(1976) demonstrated good test-retest ability ( coefficient of generalisability 
=0.96). 
Lee et al (1973), described a functional status instrument based on self-report 
data. This ordinal index measures whether an activity is performed and the de-
gree of difficulty perceived in performing the activity. The Lee instrument pro-
duces statistically significant correlations with walking time (r = 0.47), grip 
strength (r = 0.57), and the Ritchie Articular Index (RAJ) for joint tenderness 
(r = 0.62). The Lee index demonstrated significant changes in RA patients who 
had undergone total hip surgery, but not in patients on a drug study. Whether this 
lack of difference was due to the ineffectiveness of the drug or the instrument's 
lack of precision is not known. 
Badley et al (1984), argued that critics of the methods of assessment of func-
tion had been obsessed with evaluating reproducibility, to the virtual neglect of 
validity or biological significance. They derived a mobility score for activities of 
daily living using a standardised questionnaire of 24 activities selected from the 
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41 recommended in the Health Assessment Questionnaire of the World Health 
Organisation. 
Convery et al (1977), described an almost perfect relationship between their 
method (based on a detailed questionnaire) and the ARA functional classifica-
tion. However, there is no appropriate score for each class. They concluded that it 
is difficult to relate the ARA classes to overall function. These measures of dis-
ability are more relevant to a rheumatoid population than a physical activity index 
such as the Framingham index (Kannel 1979), which is highly subjective and 
poorly reproducible. 
Durham et al (1985) compiled the MDR index of function in RA which com-
prised of a ten item list of activities which were considered most essential to inde-
pendence in modern, western, urban living. They concluded that their index ful-
filled the urgent need for a functional index which was easy and economical to 
apply and which was reliable and valid. The method needs to be tested in drug 
trials before valid conclusions can be drawn about its sensitivity in detecting 
change with time. Thompson (1987) reviewing the various techniques for evalua-
ting functional outcome in RA concluded that the modified Stanford HAQ is 
suitable for evaluating function in RA. However, there is a need for long-term 
studies of changes in HAQ scores in normal and arthritic populations. 
Nicassio et al (1985) drew attention to the psychological contribution to 
learned disability in RA. They pointed out that the learned helplessness model 
described by Miller et al (1979) and Garber et al (1980) appears to have signifi-
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cant relevance to the analysis of the relation between psychological variables and 
health outcomes in RA. They developed the Arthritis Helplessness Index (AHI), 
which is a fifteen item scale to assess patients' perceptions of helplessness in cop-
ing with arthritis. It is a measure of perceived helplessness and not a measure of 
actual helplessness. 
The measure is correlated with self-reported cognitive, affective, and behavio-
ral dimensions of RA and with changes in health status. Therefore, the AHI may 
be helpful in the clinical evaluation and screening of patients who may benefit 
from psychosocial interventions that would complement their medical regimens. 
Yelin et al (1980), document the high probability of work loss among patients 
with RA Sixty percent of their sample was disabled at the time of study, which 
was an average of 10 years after onset of disease. They were unable to show any 
positive effects on work of the drug, medical or surgical therapies which respond-
ents received perhaps outlining the importance of learned helplessness in the dis-
ability of RA. 
Fries (1983a), in a comprehensive review on the assessment of disability, 
points out that in RA, disability cannot be considered apart from other dimen-
sions such as mortality, pain, iatrogenic problems and economic impact. He rec-
ommended the use of the more reliable and more valid instruments such as self-
administered patient questionnaires. 
The evaluation of sexual activity is a useful indirect measure of physical activ-
ity. Brown et al (1987), in an evaluation of the impact of RA on patients daily 
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lives, found that sexual difficulties were present in 40% of their subjects. Al-
though the reasons are numerous, disease activity may play a vital role. A recent 
editorial ( Cohen 1987) highlights this issue in RA subjects. 
Although most of these indices revolve around the ease of performance of ac-
tivities of daily living, none of them consider the patient's attitude to sexual activ-
ity. Psychological factors often contribute, but impairment of physical function or 
activity of disease may make a significant contribution to poor sexual perfor-
mance. 
Despite the clear clinical impression that functional disability may bear a rela-
tionship with diseases activity, there have been surprisingly few reports of corre-
lations between functional class and the RAJ or Lansbury systemic index. Since 
functional disability (KFf) may be more reproducibly measured than the RAI 
(Eberl et al 1976), it is important that this relationship be more carefully evalu-
ated (Thompson 1980). 
The relationship between functional impairment and disease activity requires 
careful evaluation. Kirwan and Reeback (1986) developed the modified HAQ 
and found a significant correlation with disease activity. Bombardier et al (1986) 
showed that the KFf improved with auranofin therapy. Recently, Thompson et al 
(1987) derived a computer-based articular index which showed significant corre-
lation with the CRP. They also found that findings in a restricted set of joints 
were equivalent to those in a more complete set. However, the system appears 
complicated and difficult to administer. Eberhardt et al (1988) reported a method 
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of functional assessment for early RA, but did not evaluate the relationship with 
disease activity. Thompton et al (1988) compared 28 articular indices to detect an 
induced flare of joint inflammation, but the report was based on a short-term 
evaluation only. They were able to detect a flare with moderate accuracy if ten-
derness and swelling of joints were simultaneously present. When a weighting for 
joint size was included, these were the most sensitive indices. 
SEROLOGY. 
The rheumatoid factor (RF) differentiates the polyarticular syndrome due to 
RA from that of conditions like psoriasis and Reiter's disease. Serological tests 
for RA are based on the determination of the sheep cell agglutination test and 
the latex fixation test. These are capable of determining immunoglobulin (lg) G, 
lg M and lg A RF. In practice, only the lg M RF tends to be evaluated. The ARA 
criteria (Ropes et al 1959; Arnett et al 1988) regard a test as significant if it is 
present in less than 5% of a normal population. Others have defined seropositiv-
ity on the basis of a latex greater than 320 (Alarcon et al 1982). The exact role of 
RF in the pathogenesis of the disease is not clear, but numerous studies have 
demonstrated that seropositive patients have more severe disease (Duthie et al 
1964; Cats et al 1970; Feigenbaum et al 1979). In an analysis of therapeutic inter-
vention based on a case-controlled comparison of seronegative and seropositive 
disease, Reilly et al (1988) concluded that seronegative disease in females may be 
INTRODUCTION 89 
as severe as seropositive disease in a referral-centre population and should be 
treated with similar vigor. Similar conclusions were reached by Tuomi et al (1988) 
in an eight-year longitudinal study. 
Calin and Marks (1981) present a very strong argument against the diagnosis 
of seronegative RA, an recommend that such patients be labelled as undifferen-
tiated seronegative arthritis. Masi and Feigenbaum (1983) conclude that seronega-
tive RA is a valid clinical diagnosis. They point out that for research purposes it is 
important to segregate patients according to the presence or absence of RF, ero-
sions, HLA DR4 or other notable immunologic or clinical variants. In a later edi-
torial, Masi (1988) warns that criteria for seronegative RA may be premature and 
that the 1987 revised ARA criteria (Arnett et al 1988) need to be evaluated. 
There is also the possibility that RF is an epiphenomenon which has little to do 
with disease progression (Levinson and Martin 1988). 
BIOCHEMISTRY OF METABOLIC BONE DISEASE. 
' Nordin (1978) reviewed the diagnostic procedures in disorders of calcium me-
tabolism He outlines the investigations which are mandatory. Jowsey (1977), in a 
textbook on bone metabolism, expanded on some of the practical precautions 
and theoretical background to these measurements. 
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The first step is to obtain plasma and urine from the patient in the fasting 
state. Blood measurements are calcium, phosphate, creatinine, alkaline phospha-
tase, blood urea, electrolytes and bone GLA-protein. If the facilities are avail-
able, blood should be taken for measuring ionised calcium, PTH, calcitonin, 25-
hydroxy cholecalciferol (25-0HD3) and other vitamin D metabolites. Urine 
measurements are calcium, phosphate, creatinine and OH-proline. Urine can be 
collected over 2 hours or 24 hours and findings can be related to creatinine clear-
ance. 
Alkaline phosphatase and GLA measure bone formation, while urinary OH-
Proline, calcium and phosphorous excretion are a measure of bone resorption. It 
is a general observation that resorption always precedes formation (Frost 1963). 
The methods for evaluating MBD have several drawbacks when applied to a 
population of patients with RA. Mbuyi et al (1982), showed that urinary excretion 
of OH-Proline was higher in RA patients with higher grades of disease activity, 
probably due to the greater tissue destruction and inflammatory response. Ken-
nedy et al (1979) found elevated levels of total calcium in some RA patients with 
normal levels of PTH. 
Scott et al (1981), reported hypocalcaemia in their patients with RA. They did 
not measure PTH. D'Angelo et al (1985) found all biochemical variables in RA 
patients to be within normal limits, although ionised calcium levels were at the 
lower limit, AP was at the upper limit and PTH was at the upper borderline. Sam-
brook et al (1985a & b ), found a trend for RA patients to have lower indices of 
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bone formation and higher indices of bone resorption, but the differences were 
not statistically significant. Obviously, some controversy exists in this regard. 
Bird et al (1982) were unable to demonstrate differences in 25-0H vitamin D 
concentrations in RA patients compared with age-matched patients with osteo-
arthritis (OA). Schnitzler and Solomon (1984) found osteomalacia (OM) in 
11.25% of white South African females beyond 60 years of age who presented 
with femoral neck fractures (FNF). They postulated that this was due to reduced 
sun exposure, but no dietary or treatment history was available in those patients. 
No similar study has been reported on RA patients in South Africa. 
Alkaline phosphatase (AP) may arise in bone and liver, so that measurement 
of isoenzymes is critical. Concomitant rises in gamma glutamyl transpeptidase 
( GGT) usually imply liver disease, which is not infrequent in RA (Roberts and 
Coblyn 1983). Elevations in AP may also be part of the acute phase response, so 
that it has limited value as a marker of bone metabolism in RA 
Gevers et al (1986), found a significantly increased osteocalcin (GLA) level in 
RA. This finding suggested that bone loss in RA is unlikely to be due to an abso-
lute decrease in bone formation. They also found a good correlation of osteocal-
cin with fasting urinary OH-Praline and mucopolysaccharide excretion, sugges-
ting that there is also a link between osteocalcin, bone resorption and disease ac-
tivity in RA. Butler et al (1988) found increased levels of osteocalcin in men and 
postmenopausal females with RA who had reduced BMC measured by SPA in 
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the distal forearm. This suggests that bone formation is normal or accelerated, 
but the role of osteocalcin in the acute phase response is not known. 
Ekenstam et al (1986), compared serum osteocalcin levels in patients with RA 
and other inflammatory arthritides with those in controls matched for age, sex 
and factors influencing osteocalcin. The acute effects on serum osteocalcin due to 
CS therapy and NSAID's was studied, and serial measurements were performed 
in a number of RA patients receiving remission inducing drugs (RID's). Contrary 
to the findings of Gevers (1986), they found that osteocalcin was reduced in 
males and females with RA or other of the inflammatory arthritides. Acutely, CS 
therapy lowered the levels further, while NSAID's had no effect. In the longitudi-
nal study, RID's caused a gradual rise in the levels of osteocalcin. No correlation 
was demonstrated with biochemical markers of disease activity in RA. 
Verstraeten and Dequeker (1986), found that total calcium levels in active 
RA normalised when adjusted for albumin, when compared with age, sex and 
menopausal age-matched controls. Serum phosphorous and alkaline phosphatase 
were elevated in the RA subjects. Urinary OH-P was elevated, but calcium excre-
tion was normal. PTH levels were normal. They concluded that active RA was as-




Clinical evaluation of disease activity in RA is based on subjective, semi - ob-
jective and objective variables which form the basis of weighted scales (Wright 
1983). The systemic nature of the disease demands that any index of disease activ-
ity comprise of features related to the local effects of joint inflammation ( early 
morning stiffness, night pain, articular index, number of warm or swollen joints, 
grip strength, functional status), as well as the systemic effects of inflammation 
(hours to onset of fatigue, anaemia, elevated ESR, CRP and plasma viscosity, and 
reduced SH-groups) (Lansbury 1958; Wright et al 1985). Pain is a useful feature 
of disease activity in RA. Its objective measurement has been considerably im-
proved by the visual analogue scales (VAS) recommended by Huskisson (1974; 
1982) and Dixon (1981). However, psychological factors may contribute signifi-
cantly to the perception of pain. Parker et al (1988) draw attention to these re-
lated psychosocial problems, which may need to be treated separately in the pain 
management strategy in RA. Anderson et al (1987) reported the validity of a be-
havioral observation method for the objective assessment of RA pain. Callahan et 
al reported a pain scale based on activities of daily living (ADL) and a VAS. Scott 
and Huskisson (1979) showed differences in the reporting of pain when vertical 
and horizontal VAS were compared. 
The number of warm and swollen joints also reflect inflammation. This sub-
jective evaluation is improved when taken in conjunction with isotope studies 
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(1982). Pinals et al (1981) developed preliminary criteria for clinical remission in 
RA. They considered night pain to be an additional feature of active disease in 
RA and emphasised the importance of the duration of early morning stiffness 
(EMS) as a symptom of disease activity. The mechanisms of EMS in RA are not 
clearly understood (Magder et al 1986). However, they did not evaluate func-
tional impairment in any detail. 
Wright et al (1985) introduced the concept of the patient model system, where 
the patient serves as his/her own control. Seven clinical and six biochemical vari-
ables were evaluated, including CRP, PV, SH-groups and serum histidine levels. 
The model is extremely useful for research on the effects of disease modifying 
agents in RA. 
A number of studies (Eberl et al 1976; Hart and Huskisson 1972; Joyce et al 
1983; Kirwan et al 1983a & b) have demonstrated clinicians' inconsistencies when 
evaluating disease activity. Kirwan et al (1988) further showed that analysis of 
clinical judgment helps to improve agreement in the assessment of RA. In RA, it 
is pertinent to ask what are we measuring ? Is disease activity a measure of process 
or outcome? Should we measure short-term or long-term effects of the disease? 




Laboratory tests are subject to misinterpretation, variation with age and sex 
(Shearn et al 1986), smoking (Larkin et al 1984) and fasting (Palmblad et al 1977). 
Chlud (1986) reviewed the limitations of the ESR as a measure of inflammation. 
However, he concluded that - in its standardised form - it is still a valid method 
for objective assessment of RA inflammatory activity, provided it is carried out 
within 4 hours of obtaining the sample. He points out that the acute phase pro-
teins (APP) are not more valid in reflecting disease activity, prognosis or out-
come. They do, however, reflect possible changes sooner and are less prone to 
disturbances. Kelly et al (1987) found that ESR correlated with clinical parame-
ters better than did serum or plasma viscosity. Mielke et al (1985) also showed 
the ESR to be the best indicator of inflammatory activity in RA. Rowe et al 
(1987) compared CRP levels in the synovial fluid (SF) and in the serum of pa-
tients with RA, OA and psoriatic arthropathy. They found that SF CRP levels 
were significantly reduced compared with serum levels. Changes in SF CRP re-
flected closely changes in serum CRP. They conclude that possible consumption 
of CRP in the SF may be playing an important part in the inflammatory process in 
RA. Van der Heidje et al (1988), in a review of the literature of prognostic fea-
tures on the final outcome of RA, conclude that female sex and a positive RF are 
variables indicating a poor prognosis. Long-standing increased ESR and CRP 
values, decreased Hb, or the appearance of subcutaneous nodules are indicators 
of a less favorable clinical course. Other factors are difficult to evaluate due to in-
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complete and heterogeneous study designs. Thompson et al (1987) developed a 
computer-based articular index and related this to the acute phase response. 
They found that findings in a restricted set of joints was equivalent to those in a 
more complete set; that the simultaneous presence of joint tenderness and swell-
ing yielded higher correlation than did either variable alone; and that joint 
weighting for size yielded higher correlations than simple counts. 
Dawes et al (1987) showed that alpha-1-anti-trypsin may behave as an acute 
phase reactant in RA. Pickup et al (1981) demonstrated the value of plasma vis-
cosity (PV) as an index of disease activity in RA. Larkin et al (1984) showed sev-
eral advantages of PV over ESR in RA. Circulating immune complexes (CIC) can 
be measured by various techniques. Westedt et al (1986) showed that CIC con-
taining IgA appear to predict erosive arthritis. Measurement of CIC may add to 
the predictive value of multiple variables. Sukenik et al (1988) showed that serum 
and synovial fluid (SF) levels of serum amyloid A protein correlated significantly 
with CRP levels from these sites. It would seem that little advantage is gained in 
adding yet another biochemical variable to the evaluation of diseases activity. The 
bone resorption states are closely linked to the synergistic action of interleukins 
and growth factors and may be susceptible to control with biological response 
modifiers (Stanshenko et al 1987; Scheinberg 1988). Thompson (1988) puts the 
various laboratory in perspective in a useful review of the literature. 
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RADIOLOGY. 
The radiograph represents destructive effects of the disease which are largely 
irreversible (joint space narrowing, erosions, dislocation and ankylosis). Buck-
land-Wright (1985), using microfocal radiography, suggests that radiographs are 
valuable in monitoring RA disease activity. 
Pullar and Capell (1986) pointed out in an editorial questioning the effect of 
treatment on radiological progression in RA, that inexpensive, time-saving, ob-
jective methods need to be sought to monitor radiological change. Bone metabo-
lism is a dynamic process and could be subject to alterations in disease activity. 
The current methods of bone mass measurement using Vernier calipers are in-
sensitive, tedious and poorly reproducible. 
The above subjective, semi-objective and objective measures of disease activ-
ity are often weighted and summated to comprise a systemic index as described 
by Lansbury (1958). The Lansbury systemic index (LSI) needs to be modified for 
current purposes, since the use of salicylates is being rapidly replaced with newer 
NSAID's. 
Liang et al (1982) provide useful insight into the problems in their review of 
the search for a more perfect mousetrap (health status or quality of life instru-
ment). They conclude that obsession with statistical soundness of instruments 
may cloud the objective of finding measures that are patient orientated and clini-
cally useful. 
The Ritchie articular index (RAI) (1968), based on a record of the graded 
pain response to pressure over selected joints has gained worldwide acceptance 
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as a test of disease activity. However, the reproducibility has recently been ques-
tioned and a modification suggested (Hart et al 1985). They showed that reprodu-
cibility was improved by grading the pain response as present or not, while the 
clinical value was maintained. Lewis et al (1988) reported close agreement within 
and between observers in an evaluation of the RAJ. This was the first study to ad-
dress the question of a significant Ritchie score. They emphasise the importance 
for each centre to determine its own 95% confidence intervals for these import-
ant errors. The need for an all-encompassing articular index of disease activity is 
further outlined in a paper by Klinkhoff et al (1988), who reduced the inter-ob-
server variability by modifying the joint count of the Co-operating clinics of the 
ARA (1965). The value of standardisation in reducing variability is clearly dem-
onstrated. They conclude that such a reduction may allow a reduction in the 
sample size required for RA clinical trials. 
Evaluation of functional impairment as a marker of disease activity needs 
more careful study in RA. Pincus et al (1987) recently showed that such evalu-
ation was able to predict mortality in a group of RA subjects. McGuire and 
Wright (1971), in recommending a statistical approach to indices of disease activ-
ity in RA, found that factor analysis and a maximisation of statistical significance 
were two mathematical techniques which produced clinically significant results. 
Mallya and Mace (1981), found that a multivariate analysis (MVA) seems to pro-
vide a rapid and easy way of producing an index of disease activity (IDA) that 
correlates well with the facets used. Hart and Huskisson (1972) set out an import-
ant series of recommendations regarding measurement in RA. Their recommen-
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dation of a top six include a pain scale; duration of EMS; patient preference; ar-
ticular index and digital joint size. They point out that further work must be di-
rected at reducing the number of tests needed by improving their quality. Radio-
logical changes were not included in these statistical analyses. 
Recently, attention has focused on alternative biochemical measures of dis-
ease activity. Among these, serum sulphydryl groups have been a source of atten-
tion. Lorber et al (1964) and Hall et al (1982) showed that reduced levels are 
characteristic of active RA. Grimaldi (1980) showed the potential for change in 
the levels in a patient treated with cyclophosphamide. Helliwell et al (1984a & b) 
showed that thyroxine binding prealbumen was altered by changes in disease ac-
tivity, making it less useful as a test of nutritional status in RA. Forster and 
McConkey (1986) showed that circulating immune complexes (CIC) reflect dis-
ease activity in a manner analogous to the ESR and CRP. They also found that 
CIC levels fell with high dose CS therapy, but not with doses lower than 20 mg 
daily. 
Reibnegger et al (1986) measured urinary neopterin levels in 106 patients 
with RA and in 45 patients with OA (Neopterin is a marker for activation of cel-
lular immunity). Levels were significantly higher in RA than in OA patients and 
were strongly dependant on stage and activity of RA. Correlations with other la-
boratory parameters were weak. MV A demonstrated that urinary neopterin le-
vels reflected clinical activity better than did other laboratory findings. Thus, 
neopterin determinations might be useful in monitoring RA patients. 
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Berliner et al (1985) reported on the usefulness of the leukergy test in evalua-
ting disease activity in RA. This leucocyte adhesiveness/aggregation (LAA) corre-
lates well with severity in rheumatic patients (Berliner et al 1988). In a sub-
sequent comparison with other laboratory markers such as CRP, albumin, Hb, 
etc, they found the LAA to be the best laboratory variable for the grading of dis-
ease activity. Correct grading was achieved in 63% of the patients with LAA, 
compared with 48% with CRP. They suggest that LAA of the peripheral blood 
during inflammation may be used as a reliable marker of disease activity in RA. 
Spiegel et al (1987) showed that walking time and grip strength measured 
function rather than disease activity over time. They suggested that these be used 
as objective functional measures in studies primarily directed towards changing 
functional ability, but appeared to be poor major outcome measures for trials 
aimed at altering disease activity. 
Hancock et al (1978) were unable to demonstrate a correlation between bone 
mass and disease activity. Reid et al (1982), however, showed a weak inverse rela-
tionship when a composite index of AI, EMS, ESR, FC and rheumatoid factor 
(RF) was evaluated. The observation by Sambrook et al (1985b ), that bone loss in 
RA occurs in a stepwise fashion, supports the concept that these periods of loss 
may represent exacerbations of disease. 
Radiological change in RA is a progressive phenomenon, as is indicated from 
the scoring system of Larsen and Dale (1977). Although this grading system is 
practical and useful in routine analysis, De Carvalho (1981) has shown that it fails 
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to describe the progression in a considerable percent of examinations. Scott et al 
(1985) showed that, although changes in the hands and wrists were unable to pre-
dict large joint disease, significant correlations (r = 0.85, 0.79, 0.74) were found 
between total scores at the PIP, MCP and wrist joints compared with the total 
score in other joints. 
Fletcher and Rowley (1952) and Scott and Bacon (1985), have shown that an 
erosion is an irreversible event with very limited repair observed very rarely. Shi-
pley (1985), in an essay on the natural history of erosions, concluded that it was 
doubtful whether we could regard the natural history of erosions as a single en-
tity. He suggested that, probably, we should think in terms of several different 
potential historical courses and try to distinguish between them at an earlier 
stage. 
In an comprehensive review of clinical and laboratory markers of outcome in 
RA, McKenna (1988) concluded that several parameters of disease activity ap-
pear to remain remarkably constant: grip strength, duration of EMS, ESR, 
haemoglobin, PV and serum histidine all appear to be stable indicators of disease 
activity when compared with the articular index. A suitable articular index would 
be a good indicator of prognosis, particularly if combined with a measure of the 
acute phase response. Larsen (1988) showed that CRP and orosomucoid were the 
most valuable markers for severe RA, since they showed a significant correlation 
with radiographic changes, ADL index and Drug index. They conclude that the 
ESR and RF (SCAT) are not suitable measures of disease activity on their own. 
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The interpretation of reports in the literature is confounded by the overlap 
between measures of activity, severity and outcome. In a series of publications 
(Fries 1983b; Bird et al 1983; Potts et al 1987), recommendations were made for 
the measurement of outcome. Distinction is drawn between process and outcome 
on the basis of potential for change with time. The Stanford health assessment 
questionnaire (HAQ) is currently regarded as the most suitable measure of pa-
tient status in Europe and the UK. Spiegel et al (1988) in an attempt to answer 
the question what are we measuring, undertook to examine self-reported func-
tional measures. They found that mental and physical health perceptions were 
significant predictors for each self-reported functional measure. They concluded 
that the relationships among mental health and self-reported functioning should 
be considered when interpreting studies that use functional status questionnaires. 
The status of patient status measures is reviewed in an excellent editorial by Mee-
nan and Pincus (1987). In a long-term study extending over a period of 20 years, 
Scott et al (1987) pointed out the aggressive nature of RA and its effect on pa-
tients' lives. They question the concept of remission in RA, suggesting that the 
beneficial effects of DMA extend only over a few years and that they do not in-
fluence long-term outcome. These negative conclusions may be related to the late 
introduction of these agents in the group under study. Meyers (1984) addressed 
several several difficulties related to the definition of remission in RA. However, 
remission is proposed as the goal of rheumatic disease therapy (Roth 1982). 
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INFLAMMATION MEDIATED OSTEOPAENIA. 
Erosions occur when the cortex of the bone has been breached. In a review of 
the pathogenesis of the erosion, Kennedy and Lindsay (1977) showed that there 
was conflicting evidence favoring the presence of a resorption stimulating factor. 
Robinson et al (1975) postulated that PG E2 was responsible. Krane (1974), in a 
similar experiment, also showed bone resorptive activity in the sera of patients 
with RA, but concluded that PG E2 was unlikely to be the factor responsible. It is 
important to note that NSAID's (potent inhibitors of prostaglandin synthetase) 
have not been shown to alter significantly the progression of bone involvement. 
However, Khokher and Dandona (1988) showed inhibitory effects of indometh-
acin and salicylate on osteoblast activity in subjects with OA. It seems, therefore, 
that NSAID may inhibit formation without interfering with resorption. 
Pitt et al (1986), in an attempt to study the metabolic activity of erosions in 
RA using the bone seeking isotope methylene diphosphonate, were unable to al-
ways show increased uptake in erosions. Radiological evidence of erosion could 
occur within 12 months, without any preceding bone isotope changes. In many 
cases the presence of a positive scan was associated with healing of an erosion 
rather than radiological deterioration. They also confirmed the well known diffi-
culty in clearly defining criteria for erosions which would satisfy a number of ob-
servers. 
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Perhaps the erosion is a late stage of disease and that the serial measurement 
of osteoporosis accurately and consistently may serve a more useful endpoint for 
analysing the effects of RID's on radiological progression in RA Abendroth et al 
(1988) in a histomorphological and immunological study of the mechanism of 
joint destruction in RA, conclude that autoantibodies to altered membrane struc-
tures of connective tissue cells is the primary development in the pannus. This 
stimulates the proliferation of cells and the transformation of connective tissue, 
bone and cartilage. 
In the studies of OP in RA, there has been no attempt at comparing the total 
Larsen score in the hand and wrist with the 2nd or six metacarpal indices. Cer-
tainly there seems a need for a reproducible method for evaluating Larsen grades 
1 and 2 in the pre-erosive stage (De Carvalho 1981). Kennedy et al (1979), 
showed concordance between erosion score and metacarpal index, suggesting 
that whatever is happening at the joint surface is also being reflected at the mid-
point of the shaft of the metacarpal. 
The pathogenesis of the erosion is not known. In addition to the postulate by 
Kennedy et al (1976), there is the alternative suggestion that erosions represent 
the effects of raised intra-articular pressure, as shown by Castillo et al (1965). The 
erosion may also conceivably be an extension of the juxta-articular OP commonly 
described in RA. Harris (1976), reviewing insights into the pathogenesis of the 
proliferative lesion in RA, concluded that with availability of experimental sys-
tems in which the proliferative response of synovial cells and macrophages to cer-
tain stimuli can be measured, there existed means for establishing conditions es-
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sential for inhibiting part of the proliferative response and repressing some of the 
destructive potential of RA. No such studies seem to have been done. 
Histopathological studies of the synovial-cartilage-bone junctions are ham-
pered by the pluri-potential nature of the osteoblast, osteoclast and macrophage, 
all of which arise from the same stem cell. In an excellent essay on joint and bone 
metabolism, Peacock and Francis (1982), explored these fascinating inter-rela-
tionships. The tissues have a common origin embryologically, they have a similar 
biochemical profile and the various cell types in each tissue have an analogous 
pattern of organisation and inter-communication. Blair et al (1985) showed that 
macrophage mediated bone resorption occurs in an acidic environment 
In an electron microscopic study of the synovial-bone junction in RA, Ishika-
wa et al (1984) concluded that there was a strong likelihood that articular bone 
resorption depends upon the local host response to the macrophage and osteo-
clast in the rheumatoid joint. Bromley and Woolley (1984 a & b) and Crisp et al 
(1984) found mast cells at sites of cartilage erosion in some of their patients. 
Wasserman (1984), reviewing the relationship of the mast cell to inflammation, 
concluded that the mast cell provides a homeostatic function in the joint. Mast 
cells have been reported by Taylor et al (1986) to stimulate angiogenesis, prob-
ably through the release of heparin. This may encourage the spread and over-
growth of invasive rheumatoid pannus tissue. As heparin has also been shown, by 
Sakamoto et al (1975), to stimulate the release of collagenase from cultured bone 
tissue, it might have an important function in regulating proteinase physiology at 
the rheumatoid lesion. 
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The presence of mast cells at sites of cartilage erosion suggests that they can 
regulate the microenvironmental physiology by the production of various vasoac-
tive, chemotactic, spasmogenic, and proteinase-modulating factors in response to 
certain local stimuli. The mast cell product most likely to influence bone remode-
ling is heparin. 
Goldhaber (1965) has shown that heparin can potentiate, while Johnston et al 
(1970) have shown that protamine can inhibit, PTH-mediated bone resorption in 
vitro. PTH has been shown by Crisp et al (1983), to potentiate bone resorption in 
RA. Shiozawa et al (1984) suggested that fibronectin on the surface of articular 
cartilage was responsible for promoting pannus extension. Blauss et al (1985) 
strengthened the arguments favoring inflammation mediated osteopaenia (IMO) 
by demonstrating bone resorption in rats given intra-abdominal injections of in-
flammatory substances. The reaction was associated with bone resorption at distal 
sites. 
Crisp et al (1986) used a quantitative mouse calvarial bone resorption assay to 
investigate the effects of the mast cell products, heparin and histamine, and of 
salmon calcitonin. Amorphous heparin, containing a range of molecular weight 
fractions, inhibited resorption by 15-20% at concentrations of 0.75-5.0 mg/ml. A 
defined heparin species of molecular weight 13,500 inhibited resorption by 14-
28% at 10-5-10-4 mol/1. Histamine inhibited resorption by 19-55% at 10-3-10-2 
mol/1. It was proposed that heparin and histamine depress coupled bone resorp-
tion and formation and may lead to net loss of bone. Salmon calcitonin inhibited 
resorption at concentrations as low as 10 pg/ml. Amorphous (but not defined) he-
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parin blunted calcitonin-induced inhibition of bone resorption and may depress 
osteoclasts. 
Little is known of the properties of the human mast cell heparin released in 
vivo. Mast cell heparin release adjacent to osteoclasts in the rheumatoid joint 
could impair the effect of circulating calcitonin and indirectly stimulate osteoclas-
tic resorption. Even if this indirect catabolic effect of heparin can be confirmed, 
however, it is unlikely to be as important as its primary antianabolic role. 
Taylor et al (1986) found that histamine stimulates PGE production by RA sy-
novial cells and human articular chondrocytes in culture. They propose that the 
mechanism of action is related to H1 receptor activation and subsequent arachi-
donic acid liberation. 
Tan et al (1988) studied the effects of aminobisphosphonate (APD) in the in-
hibition of interleukin-induced bone resorption in mouse calvaria. The positive 
effects cause the authors to conclude that these in vitro observations may have re-
levance to the use of APD in bone and joint diseases in which inflammation and 
bone resorption are prominent. The most likely candidates would probably be 
those diseases associated with arthritis mutilans (severe resorptive arthropathy). 
The metabolic bone events in this interesting clinical situation have not been ade-
quately addressed in the literature. 
Rooney et al (1976) and De Witte et al (1979), have reported elevated levels 
of gastrin in some patients with RA. The source of elevated gastrin in RA is not 
known. Preliminary immunofluorescent studies by Buchanan et al ( 1982) suggest 
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that an as yet unidentified synovial cell may be responsible for gastrin production, 
and that this may reflect disease activity. Yorke et al (1986), confirm these find-
ings. Henriksson et al (1986), also confirming these findings, suggested that dis-
turbances in gastric flora may influence the course of the disease. This is also the 
postulated mechanism of the effect of Salazopyrine in RA. La Montagna et al 
(1987) reported a low incidence of hypergastrinaemia in their patients with RA. 




Several studies have attempted to show a relationship between disease dura-
tion and loss of bone mass. Such a relationship could be expected if one considers 
that aging causes a loss in bone mass. Menopause could also conceivably accel-
erate such loss in RA. In a study of the right 2nd metacarpal, Schorn (1983) found 
a statistically significant reduction in the area index of non-CS treated patients ac-
cording to duration of disease. Reid and Nuki (1984a), using NAA, showed a ne-
gative correlation between disease duration and total body bone mineral 
(TBBM). 
Sambrook et al (1985b ), in an analysis of osteocalcin and urinary OH-praline, 
concluded that no skeletal abnormalities could be found in RA patients with less 
than 3 years of disease. Als et al (1985b ), found that patients with RA longer than 
4 years had lower bone mass than those with a shorter duration of disease. The 
interest of this study was the finding that functional impairment also deteriorated 
with prolonged disease, so that it was difficult to differentiate the respective con-
tribution of disease duration and immobilisation to the bone loss. They concluded 
that in RA, maximum bone loss occurred in the first 3 years. The effect of a long 
duration was simply one of adding more years of disability. 




NON STEROIDALANTI-INFLAMMATORY DRUGS. 
Despite the experimental evidence of the inhibitory effect of NSAID on bone 
resorption (Klaushofer 1988), there is little clinical evidence that these drugs pre-
vent bone loss in RA (Reid 1986; Cooper et al 1988). Klaushofer et al (1988) 
evaluated the biopotency of various NSAID in inhibiting PG mediated bone re-
sorption, in a neonatal mouse calvaria organ culture medium. Diclofenac was the 
most potent, while salicylates showed the least potency. In practice, most patients 
with RA require regular NSAID. Perhaps the osteopaenia of RA would be more 
significant if such agents are not being used. Since studies of OP in RA emanate 
from specialised centres dealing with relatively severe cases, it is unlikely that a 
large enough group of subjects with RA not receiving NSAID would be available 
for study. More recently, however, Khokhler and Dandona (1988) showed that as-
pirin and indomethacin inhibit osteoblast function in vitro. These relationships 
are obviously important and require study, but protocols would be difficult to de-
sign. The role of NSAID in the management of RA is not regarded as disease 
modifying. 
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DISEASE MODIFYING AGENTS. 
Few studies have documented intake of disease modifying agents (DMA's) in 
relation to bone mass. Als et al (1985b ), who compared these regimens, showed 
that penicillamine may off er some protection against loss, myocrisin offers none 
and NSAID's probably have no effect at all. Schorn (1983), showed that penicil-
lamine therapy showed a definite increase in area index over a 3 year period. 
Robinson et al (1975), using in vitro studies, have shown indocid to inhibit PG 
E2 mediated bone resorption, while colchicine stimulates bone resorption in this 
experimental situation. One would expect that a reduction of the inflammatory 
load with Rill's would prevent resorption mediated by interleukin 2 or OAF. 
Also, better disease control could lead to improved function, as suggested by 
Schorn (1983). Penicillamine therapy (Schorn and Mowat 1977) has been shown 
to result in improved bone mass, despite its effect of altered collagen metabolism. 
However, the effect on wound healing was equivalent to that of giving CS therapy 
for 3 years. This finding is significant, since objective measurement of these 
changes using a sensitive device would be a useful means of evaluating radiologi-
cal progression in RA. 
Situnyake (1988) in a comprehensive review of the literature evaluating dis-
ease modifying effects of therapy in RA, concludes that these d~gs are capable 
of altering the disease in the short-term only. Large-dose corticosteroid therapy 
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may influence progression of erosions, but the effects on metacarpal bone mass 
are controversial. 
There is obviously controversy in this area as well, and the role of immobi-
lisation in this situation needs to be more carefully evaluated. Ideally, young sub-
jects need to be studied. Comparisons between groups should enable one to 
evaluate the effects of therapy. Treated and untreated groups should not only be 
compared with one another, but also with normal controls. 
CORTICOSTEROIDS. 
In the clinical situation, there is controversy as to the mechanism whereby CS-
related bone loss is mediated ( Guyatt et al 1984 ). It is not known whether it is the 
total daily dose, total duration or total dose of CS which is important. McConkey 
et al (1965) found that OP was most common in RA patients with transparent 
skin who had received CS therapy. Saville and Kharmosh (1967) concluded that 
age greater than 50 years had a more profound effect on bone mass than CS ther-
apy. They believed that duration of CS therapy was extremely important. They 
also suggested that CS therapy may have a protective role on bone mass in 
women under 45 years of age. Duncan (1972) concluded from a review of the lit-
erature that CS therapy in RA definitely caused OP, but that the mechanism 
whereby this effect was mediated remained unclear. Suda et al (1983) studied the 
effects of hydrocortisone on osteoclasts generated in cat bone marrow cultures, 
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and found that osteoclast numbers and size were reduced. These findings are 
compatible with the suggestion that CS may act directly on osteoclasts, which in 
vivo may result in decreased resorption of bone. However, it is not clear to what 
extent these findings can be extrapolated to the mechanisms in man. Rickers et al 
(1984) concluded that high-dose prednisone therapy has an effect on cortical and 
trabecular bone. 
Kennedy et al (1974) found that CS therapy significantly reduced bone mass 
only in patients over 45 years of age. In males, this loss became statistically signi-
ficant only after the age of 55 years. Mueller (1976), comparing RA patients with 
asthma patients taking CS therapy, found that only patients with RA showed a 
loss of bone mass with such treatment. Hahn and Hahn (1976), concluded that CS 
related OP is more common in children and in women over the age of 50 years. 
Reid et al (1982), found that in RA patients using CS therapy, total body calcium 
was closely correlated with mean daily dose but not with duration of treatment or 
mean cumulative dose. 
Schorn (1983) showed that area index was reduced in RA patients irrespective 
of CS therapy, but comparisons were not made between treated and untreated 
patients. Wordsworth et al (1984), found that spinal OP tended to increase with 
age and CS therapy (less than 10 mg. daily), often leading to pathological frac-
tures. Hajiroussou et al (1984), in a study of prolonged low dose CS therapy in 
RA, found no significant differences when compared with matched patients not 
given CS therapy. They concluded that the risk of developing OP should perhaps 
INTRODUCTION 114 
not be considered a definite contraindication to the use of low-dose CS therapy in 
RA. 
Dykman et al (1984) showed that oral 1,25 dihydroxy-D3 and calcium sup-
plementation did not significantly increase bone mass. These same authors (1985) 
showed subsequently that CS therapy reduces metaphyseal mass (MM) to a 
greater extent than diephyseal mass (DM), causing the DM:MM ratio to increase. 
The implications of this finding are not clear, but seem to point to a specific diag-
nostic pattern of bone loss with CS therapy. 
In a comprehensive essay on determining causation, Guyatt et al (1984), con-
cluded that the evidence that exogenous CS cause clinically important OP was 
weak and unproven. The review of the literature on bone loss in RA showed that 
a similar statement could be made about this association in RA. Byron and 
Mowat (1985), studying the pattern of CS prescribing in their unit, were surprised 
to discover that 24% were receiving CS therapy for articular disease, with a mean 
duration of therapy of 8.3 years. De Deuxchaisnes et al (1986) showed that the 
menopausal state had a synergistic effect on the bone-losing process accompa-
nying low-dose CS therapy. 
Zerwekh et al (1984) studied 34 patients with RA to see the effects of CS 
therapy on vitamin D metabolism. The patients were initiated into a double-blind 
trial that lasted 32 weeks. There were no significant differences between the 
treated (5 mg daily for 24 weeks) and untreated groups in serum levels of vitamin 
D or its metabolites. 
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The suspected effects of prednisone on bone mass have led to the evaluation 
of other forms of corticosteroid. Deflazacort, a oxazolino derivative of predni-
sone, has been compared with prednisone in a number of recent studies. Lo Cas-
cio et al (1984) showed that trabecular bone was lost to a lesser extent with Defla-
zacort than prednisone in 2 groups of subjects matched for age, sex and under-
lying disease. The dose of prednisone or deflazacort is not stated. Gennari et al 
(1984) compared the effects of 20 mg prednisone with that of 30 mg deflazacort 
in 10 patients. They found that both these agents caused an elevation in serum 
PfH levels, but that prednisone had a more profound effect. Reduction in bone 
mass was also less in the deflazacort group. They propose that CS induced bone 
loss is mediated by an elevation in PfH secondary to increased urinary excretion 
of calcium as well as decreased intestinal absorption of calcium. Balsan et al 
(1987) showed a similar effect of deflazacort in the treatment of 9 children re-
quiring varying doses of prednisone. They concluded that these results warrant 
the extension of clinical trials with this new glucocorticoid for the management of 
the acute, active phase of paediatric diseases requiring steroid therapy. 
Bijlsma et al (1988a) re-evaluated the effect of oral calcium and vitamin Don 
CS-induced OP. BMC measurements of the spine were prospectively studied, 
comparing the preventive effect of calcium (500 mg a day) and calcium plus vit-
amin D (4000 IU on alternate days) during long-term treatment (2-161 months). 
40 patients (mean age 45.5 years) with a variety of rheumatic disorders requiring 
more than 10 mg a day of CS were evaluated. They concluded that a small in-
crease in BMC was noted in both groups, but no differences between preventive 
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calcium and calcium plus vitamin D became evident. It was suggested that pa-
tients receiving prednisone should be advised to use supplemental calcium. 
The same authors (1988b) report on the acute changes in calcium and bone 
metabolism during MP pulse therapy (1000 mg alternate daily for 3 doses) in RA. 
The effects could be divided into those which occur within 24 hours and those 
secondary effects arising after 24 hours. The primary effects (24 hrs) include a de-.. 
crease in bone resorption and formation; a decrease in renal excretion of cal-
cium; and an increase in serum 1-25 dihydroxy cholecalciferol. The secondary ef-
fects (after 24 hrs) include a decrease in serum calcium due to the decrease in in-
testinal Ca absorption and the decrease in renal tubular reabsorption of Ca; and 
an increase in serum PTH concentrations. In a previous study it was found that 
these changes normalise within a few days after completion of the CS treatment. 
Despite these warnings about the possible effects of CS therapy in RA, these 
drugs continue to be used in the clinic (Barraclough 1986). Byron and Kirwan 
(1986) reported that 25% of the patients attending their clinic were receiving 
regular systemic CS therapy. Ianuzzi (1987) concluded from a review of the lit-
erature that CS therapy has a definite place in the treatment of RA. They have 
not been proven to be disease modifying, but adequate trials are lacking. In rec-
ognition of this, Byron and Kirwan (1986), questioned the feasibility of a trial to 
see the disease-modifying capabilities of CS therapy. They concluded from a re-
view of the literature that a trial of low-dose CS therapy for the prevention of 
erosion development was feasible and should possibly be undertaken. Buchanan 
et al (1988) showed that reduction of the dose of prednisone from a mean of 3.5 
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mg daily to placebo caused an almost immediate flare in the arthritis. They con-
cluded that homeopathic doses of oral CS are effective in RA. Such doses are un-
likely to interfere with bone resorption. 
HAND EVALUATION. 
SIMPLE HAND FUNCTION 
In a systematic, radiological study, Halla et al (1986), showed that the small 
joints in the hand and wrist are the commonest sites of Rheumatoid involvement. 
In studies of radiological evaluation of progression, Larsen and Dale (1977) have 
shown that these joints contribute to approximately 50% of the total score. It is, 
therefore, incumbent on the researcher to correlate bone changes in the hand 
with changes in hand function and strength. 
Hand function can be evaluated in several ways, each aimed at demonstrating 
some aspect of dysfunction. Since hand function can be impaired by extra-articu-
lar disease as well as articular disease, it is desirable to try to study several com-
ponents in a single test. Grip strength is such a test, since it uses a combination of 
function and strength in the PIP's, MCP's and wrists, respectively. De Choisy 
(1973) introduced the concept of the functional grip, which is measured with the 
Winthrop torquometer. It has an advantage over the sphygmomanometer test be-
cause it measures wrist and arm movement as well as the usual grip strength. 
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The KFf (Keitel 1972) evaluates some aspects of hand function, which can be 
monitored serially. In addition, Clawson et al (1971), devised a test of hand func-
tion using 4 simple procedures performed during a monitored period of time. 
The tests were designed to evaluate the results of hand surgery in RA. 
HAND STRENGTH. 
One would expect that bone mass would correlate with loss of function or 
strength in the hand. Virtama et al (1968), in a study involving 33 patients, found 
that power of grip in the right hand showed a high correlation with bone mass in 
the proximal phalanx but not in the metacarpal. It is important to note that grip 
strength is often a component of systemic indices of disease activity such as the 
Lansbury systemic index (1958). McGuire and Wright (1971), Mallya and Mace 
(1981) and Rhind et al (1980) recommend grip strength as an integral component 
of an index of disease activity in RA, for application in drug trials. These gener-
ally use the sphygmomanometer. 
De Choisy (1973), designed the Winthrop torquometer for measurement of 
functional grip in RA. The torquometer measures both the ability to grip and also 
the ability of the wrist and elbow to rotate. The study showed that there was very 
good and statistically significant correlation between grip strength as measured by 
the conventional sphygmomanometer and functional grip as measured by the tor-
quometer. This study did not measure bone mass in relation to grip strength. 
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Myers et al (1980), evaluated hand grip function using a dynamometer. The 
device was able to relate power and work. The physical features of the device 
(standard clinical inflated cuff bag) offer several advantages over the use of a 
solid-handle torsion dynamometer. Long et al (1970), defined power grip as forc-
ible activities of the fingers and thumb acting against the palm. Flexion, abduc-
tion and adduction of the phalanges are involved in adjusting to the shape of the 
object. All the extrinsic and some intrinsic muscles of the hand are involved in 
normal power grip. 
In a study of bone mass in relation to hand strength, a group of workers (Dick-
son et al 1972) measured forces in individual digits using a cybernometer. They 
were unable to show any relationship between flexion force and 2nd metacarpal 
bone mass (Dickson et al 1973). However, finger extension, adduction and abduc-
tion were not measured. The relationship between bone mass and hand grip was 
also not studied, although the earlier study showed a significant correlation be-
tween grip strength and cybemometer readings. 
Agre et al (1987) evaluated the reproducibility of dynamometer measure-
ments of muscle strength in the upper and lower limbs respectively. They found 
that although the dynamometer was reliable for measuring upper extremity 
muscle groups, it was unreliable for measuring lower extremity muscle groups. 
They outline the need for further work to evaluate muscle strength quantitatively 
in the clinical setting in an accurate, valid and reliable manner. 
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There is a need for a careful evaluation of finger strength in relation to meta-
carpal bone mass. It is very likely that patients with RA lose bone in the hands as 
a result of weakening of grip secondary to inflammatory arthritis. 
NUTRITIONAL STATUS AND DIET. 
In a comprehensive review of current techniques of nutritional assessment, 
Grant et al (1981), suggested that, to aid in nutritional assessment, the body could 
be divided into six compartments, namely, fat; skin and skeleton; extracellular 
mass; plasma protein; visceral protein mass; and skeletal muscle or somatic pro-
tein mass. No anthropometric or biochemical tests are available as a measure of 
bone mass, although inferences can be made from the difference between lean 
body mass and fat mass. The fat component can be measured by a summation of 
triceps and subscapular skinfold thicknesses (SFf's) (Sloan 1967), while the vis-
ceral protein mass is represented in serum albumen, transferrin, prealbumen and 
skin antigen delayed hypersensitivity. 
Skeletal muscle body cell mass is measured by arm muscle circumference 
(Frisancho 1974), creatinine height index and weight. Baker et al (1982) showed 
that general clinical assessment is a reproducible and valid technique for evalua-
ting nutritional status. Measurement of thyroxine binding prealbumen (IBP A) is 
considered by Keyser (1979) to be the most accurate and sensitive biochemical 
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index in the assessment of nutritional status. Serum half-life is 2 days and its body 
pool is quite small. It is best measured by radial immunodiffusion. 
Watters et al (1985), in a study of nutritional assessment by hand grip dynamo-
metry, found that hand grip strength measured this way was reduced in severely 
malnourished males. However, dynamometry correlated very poorly with most 
nutritional tests studied in the same patients. Hand grip strength also fell with in-
creasing age. They suggest that dynamometry is not a substitute for nutritional 
tests but rather another of an already long list of nutritional measurements. The 
poor correlation with these nutritional parameters precludes its use as a single 
test. Blackburn and Thornton (1979) provided valuable guidelines for the nutri-
tional assessment of the hospitalised patient. 
Retinol binding protein (RBP), is the specific protein for vitamin A alcohol 
transport and is linked with prealbumen in a constant molar ratio. The serum 
half-life is only 10 hours, so that acute changes in protein malnutrition are best 
reflected in this measure. 
McConkey et al (1965), in one of the earliest studies of OP in RA, related 
bone mass to skin transparency and found that RA patients who were on corticos-
teroids had transparent skin as well as lower bone mass than their non-treated co-
horts. They postulated that a common defect of collagen metabolism in bone and 
skin was responsible for this association. No relationship could be demonstrated 
between bone mass and skinfold thickness of the dorsum of the hand in this 
study. Few subsequent studies have attempted a similar analysis. 
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Hancock et al (1978), found that osteoporotic RA patients tended to have 
lower serum albumen levels. They offered the suggestion that this may represent 
a defect in bone glycoprotein formation. A recent study by Sambrook et al 
(1985c), in patients with short duration of RA, demonstrated that calcium absorp-
tion was abnormal. The reasons for this are conjectural at present. The patient 
population studied had an average age of 55.4 years. This is significant, since cal-
cium absorption has been shown to be reduced in post-menopausal OP by Bulla-
more et al (1970). Age may have been a significant factor in the pathogenesis of 
the calcium malabsorption in this group of RA patients. 
Lean body mass (LBM) is a measure which excludes the fat component. Will-
more and Behnke (1970) showed that lean body mass can be predicted almost 
equally well from either skin folds, circumferences and diameters, or a combina-
tion of these. The method has been validated by Tcheng and Tipton (1973). None 
of the previous studies of OP in RA have attempted to correlate bone mass with 
anthropomorphic measurements of LBM, although Mcconkey (1965) and Schorn 
and Mowat (1977) were unable to show correlations with SFf at the dorsum of 
the hand. Reid et al (1982), measuring LBM by the retention of potassium, were 
unable to demonstrate a relationship between LBM and bone mass. 
Helliwell et al (1984a) in a study of nutritional status in 50 patients with RA, 
using the anthropometric body mass index and triceps SFf measurements, found 
evidence of malnutrition in 26%. Upper arm circumference was significantly re-
duced in male but not female subjects with RA. Malnourished patients had more 
active disease. They concluded that in RA, severity of disease adversely affects 
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the nutritional status. In another report (1984b ), the same authors show that the 
biochemical markers of disease activity (ESR, CRP, Al antichymotrypsin) 
showed a negative correlation with TBP A as a marker of nutritional status. It may 
behave as a negative acute phase reactant in these patients and is, therefore, a 
poor guide to nutritional status. 
Peacock and Francis (1982), pointed out that vitamin D deficiency was still a 
significant factor in the low bone mass of RA patients in places such as the UK. 
This emphasises the need for biopsy confirmation of OP in patients with radio-
logical evidence of osteopaenia, since this is the only way to differentiate OM 
from OP. The incidence of OM in RA patients in RSA is not known. 
Serum albumin is a useful estimate of visceral protein status (Bistrian et al 
1975). Bistrian et al (1976) have also shown a good correlation between changes 
in serum albumen and changes in upper arm circumference. In addition, it is in-
expensive and easy to determine. Anderson and Wochos (1982), showed that the 
hospital stay was prolonged, and the postoperative complication increased, in 
hospitalised patients who had low serum albumen levels. Low albumen is not di-
rectly involved in the pathogenesis of protein calorie malnutrition, but depression 
of lymphocytes, anergy and reduced antibody responses are restored when al-
bumen levels are repleted. 
The dietary contribution to bone formation is well known. Seftel et al (1966) 
showed that in middle-aged South African Blacks with OP, 69% were scorbutic, 
or had been scorbutic in the past. The reasons for this have been reviewed, iron 
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overload being suggested as the most likely explanation. They pointed out that 
there are at least 3 ways in which iron overload may lead to OP. It might damage 
organs or tissues concerned with bone formation; it might impede calcium ab-
sorption; or it might interfere with the metabolism of ascorbic acid. 
Richman et al (1979) considered diet to be the major reason for the differen-
ces in intracortical bone remodeling seen in three Aboriginal American popula-
tions. It is well known that a high protein diet causes metabolic acidosis which is 
associated with bone loss and hypercalciuria (Saube_rlich 1972; Lemann 1966 Ma-
zess and Mather 1974). On the other hand, Ellis et al (1972) have shown that 
vegetarians demonstrate less cortical bone loss than omnivores, by radiographic 
examination. Investigators have also noted diminished formation of osteoid by os-
teoblasts in protein deficiency, a decrease in the number of osteoblasts, and 
slowed mineralisation (Follis 1957; Ramalingaswami and Deo 1968 and Stewart 
1975). 
Lukert et al (1987) studied the relationship between nutritional factors, cal-
cium regulating hormones and bone density in 3 groups of normal subjects. In 
perimenopausal females, significant correlations were found between bone den-
sity and dietary Ca:P ratio, iPTH and 25 OH D. In elderly women, significant 
correlations were found between change in bone density and initial bone density; 
change in bone density and serum 25 OH D; and serum calcium and age. In el-
derly men, significant correlations were found between serum 25 OH D and die-
tary vit D; iPfH and 25 OH D; and iPTH and serum phosphorous. They con-
cluded that the more adequate the state of vit D nutrition, the lower the serum 
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iPTH in perimenopausal women and elderly men and the less bone loss in elderly 
women. They suggested that the dietary Ca:P ratio may be important in maintain-
ing bone density in perimenopausal women. 
Since dietary intake is a vital aspect of bone metabolism, it is pertinent that 
some measure of dietary analysis be related to bone mass. Several methods of 
dietary evaluation are available, and the sensitivity is obviously improved by the 
degree of detail recorded. Reshef and Epstein (1972), concluded that the Burke-
type interview (1947) is reliable and reproducible. In a review of validations of 
dietary assessment methods, Block (1982), comments that a seven-day record of 
actual intake should give a reasonably accurate measurement. Also, a seven-day 
record is more representative of usual intake than a single day. 
The seven-day record is a standard measure of dietary intake used by the die-
titians at our hospital and consists of a 7-day record of all foods taken orally. 
These records are then analysed in a variety of ways. Socio-economic and other 
factors will obviously influence individual dietary habits. Computer programmes 
have been devised to quantitate the daily intake of calcium, phosphorous and vit-
amin D at the SAMRC in Cape Town. 
Bone turnover can only be fully evaluated if dietary intake is correlated with 
urinary, faecal, blood and bone calcium studies. With respect to RA, dietary fac-
tors may influence bone mass indirectly through modifying disease activity. It is 
interesting to note that Palmblad et al (1977) demonstrated that fasting may re-
duce levels of acute phase reactants, although there is no significant improvement 
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in disease activity. These findings were confirmed by Skoldstam et al (1979; 
1983), and they may be important when considering the relationship between dis-
ease activity, diet and bone mass in RA The effects of dietary manipulation on 
disease activity in RA have been shown in a number of studies (Kremer et al 
1975; Stroud 1983; Uden et al 1983; Magaro et al 1988). 
SMOKING. 
Previous studies have not considered the role of smoking in the pathogenesis 
of the OP in RA. Jensen et al (1985), in a recent study in postmenopausal fe-
males, have shown that smoking reduces the effects of exogenous oestrogens on 
bone mineral metabolism. This may be an area in which prophylactic measures 
may serve a major role in preventing age-related bone loss or postmenopausal 
OP. Larkin et al (1984) have shown that smoking reduces the ESR, but has no ef-
fect on plasma viscosity. This lack of dependence of the plasma viscosity on smok-
ing habits may be advantageous in sequential studies of disease activity in RA. 
The relationship between smoking and bone mass in RA has not been evaluated 
in any of the earlier studies. 
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GENETICS. 
Inheritance could affect the development of OP in 2 ways. Genetic factors 
could influence the amount of bone mass attained at maturity and subjects with 
genetically determined lower bone mass might be more susceptible to develop 
OP after entering the period of age-dependant bone loss. Alternatively, or in con-
junction with the above, genetic factors could influence the rate of bone loss. 
Dykman et al (1985), in a study of factors influencing CS induced osteopaenia, 
remark that although US blacks have a higher bone mass throughout life than 
whites, there is no difference in the fracture rate between the 2 races. In South 
Africa, Dent et al (1976), showed that severe degrees of vertebral deformity were 
commoner in Caucasians than in blacks. Solomon (1979) in a study in Johannes-
burg, showed that bone mass in Blacks was lower than Whites for all ages in the 2 
sexes. He also showed that Caucasians lost bone more rapidly, discounting the 
suggestion by Stewart et al (1972) that a lower bone mass at onset of maturity pre-
cipitates bone loss later in life. However, black patients are subject to the same 
age and presumed steroid related losses, so it would seem that environmental fac-
tors are also important. Mayor (1976) also pointed out the need for differential 
bone mineral standards for Blacks. Wagener and Hough (1987) evaluated meta-
carpal bone mass in 559 White and 582 Coloured subjects aged 10-80 years. They 
showed significant differences between males and females in the 2 groups. Col-
oureds had a lower metacarpal bone mass, underlining the need for normal 
values appropriate to the individual. No previous studies have evaluated the 
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genetic profile which predisposes to the development of OP in the aging, meno-
pausal or rheumatoid populations. 
Smith et al (1973), in a study of 71 juvenile and 80 adult monozygotic (MZ) 
and dizygotic (DZ) twin pairs, found a definite genetic element. However, gene 
transmission is not of the Mendelian type. HLA studies were not performed in 
the groups. The intrapair variance was greater in the dizygotic pairs. Because the 
tendency to OP was greater in the adult twins, they concluded that environmental 
factors were likely to be important. The exact genetic factors for osteoporosis are 
not known. No previous studies of post - menopausal (or other) OP have evalu-
ated the HLA antigens in affected and unaffected subjects. The interpretation of 
genetic factors in RA subjects with OP would be difficult to separate from the 
disease - susceptibility genes. It is possible that the same genetic factors may pre-
dispose subjects to the development of both RA and OP. Prockop (1988) re-
viewed the genetic mechanisms in osteogenesis imperfecta. The genetic defect 
may reside at a number of steps in the intra- and extracellular synthesis of type I 
collagen from procollagen. The primary aetiology of OP might be in minor muta-
tions within genes whose correct expression is required to assemble and maintain 
normal cartilage and associated joint structures. 
In RA, HLA DR4 has been shown to increase the relative risk (rr) (Woodrow 
1986; Sachs and Kirwan 1986; Tiwari and Terasaki 1985). There is also some evi-
dence that this leucocyte antigen may be a marker for more severe disease ( Gran 
et al 1984). The studies are controversial (Silman et al 1988), but this is an area 
that is likely to develop further. Gran and Husby (1987) point to the need for 
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criteria to clearly define the group of seronegative RA, who may have milder dis-
ease and a different genetic predisposition to RA. The immunogenetics of RA 
are adequately reviewed in 2 recent editorials by Woodrow (1988) and Mc Cus-
ker and Singal (1988). Caution is expressed in interpreting HLA data. 
Khan et al (1987) suggest that a significant relationship can be found between 
RA and HLA B27. They found that patients with RA who had the B27 antigen 
were more likely to develop atlanto-axial subluxation. Dahlqvist (1986) showed a 
strong association between B27 and RA in Swedish subjects with RA. It is likely 
that this high prevalence is related to the higher frequency of this gene in the 
general Swedish population. Quite clearly, these relationships need further evalu-
ation, since the genes are not known to be in linkage disequilibrium and the clini-
• cal significance remains obscure. Lanchbury (1988) and Mc Cusker and Singal 
(1988), in comprehensive editorials on the molecular genetics of the HLA-D re-
gion component of inherited susceptibility to RA, reviewed the developments 
over the last ten years. The field is exciting and in a state of flux as new facts 
become available. The past, present and future trends in research are reviewed in 
this very useful essay. 
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SEASONAL VARIATION. 
The seasonal variation of calcium balance has been known for some time 
(Malm 1958; Smith et al 1964; Stamp and Round 1974; Robertson et al 1974). 
Aitken et al (1973) showed that metacarpal bone mass of 38 postmenopausal fe-
males was 3.4% higher in the period May-August than in November-February. 
Krolner (1983a) similarly reported an increase of 1.7% in the lumbar spine bone 
mineral content of 26 normal women during July-September compared with 
January-March. 
Tothill et al (1986), however, were unable to demonstrate any seasonal vari-
ation in TBCa using whole body measurements in patients with rheumatic dis-
eases. They point out that the mechanism for this seasonal variation is not known. 
The differences in their findings may also be related to the fact that they studied a 
different group of subjects. 
CONTROLS. 
The selection of controls for comparison in any study of OP is extremely im-
portant. Scott et al (1981) have shown that not only is bone mass lower in hospi-
talised RA patients but that inpatients with other diseases also had a lower bone 
mass than normal. They also showed that bone mass was lower in RA hospitalised 
patients than it was in RA outpatients. Most studies in the past have used only a 
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single control group for comparison, consisting of normal individuals matched for 
age and sex. The majority of such studies report findings on patients and controls 
whose average age is in excess of 50 years, making it very difficult to separate the 
effects of age-related bone loss in the pathogenesis of the OP in RA (Table 1). In 
a recent critical analysis of CS-associated OP, Guyatt et al (1984) drew attention 
to this and remarked that in the majority of studies the important 'confounders' out-
lined had not been adequately excluded for valid conclusions to be drawn about the 
effects of steroids on bone mineral metabolism. Reid et al (1985) compared RA pa-
tients with patients who had polymyalgia rheumatica (PMR) (n = 19) as well as 
patients with asthma (n = 19). The PMR group is suitable for comparison with 
post-menopausal (elderly) subjects, but not with younger patients suffering from 
RA. Asthmatic subjects generally do not have disability related to joint stiffness 
and deformity, making them relatively unsuitable for comparison with patients 
who have RA. Systemic lupus erythematosus (SLE) appears to be ideal for com-
parison with young RA subjects. Although the arthropathy is generally much 
milder than that of RA (Labowitz et al (1971), it can be deforming in some pa-
tients (Alarcon-Segovia et al 1988). In addition, the inflammatory nature of the 
disease is similar to that of RA (Seitz and Hunstein 1985). Finally, corticosteroid 
therapy is often used in treatment, making this an ideal group for evaluating the 
effects of CS therapy in the 2 diseases. There is no known relationship between 
SLE and hyperparathyroidism (Gordon and Isenberg 1987). Bone mass evalu-
ation in SLE also has some bearing on the aetio-pathogenesis of avascular ne-
crosis (A VN) of the femoral head in this disease (Zizic et al 1985). The mechan-
ism is unknown, but micro-fractures due to OP have been postulated as a patho-
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genetic factor. Lindsay et al (1976) demonstrated the value of bone density 
measurement in predicting the risk of developing A VN following renal transplan-
tation. 
Several reports have compared RA patients with a group of subjects suffering 
from QA (Burr et al 1983). This is obviously undesirable, since QA is generally a 
disease of elderly subjects who may have age-related bone loss prior to the devel-
opment of their disease (Voss and Byers 1972). It is usually characterised radio-
logically by features of bone hypertrophy (Dequeker 1983; Verstraeten et al 
1986). The age-related factors are difficult to separate. Recent evidence suggests 
that some patients with QA have reduced bone mass. 
SEX STEROIDS. 
The effects of the postmenopausal state on bone metabolism are though to be 
largely related to the removal of a protective effect of oestrogens (Lindsay 1978; 
1987; Nordin et al 1970). Hormonal replacement therapy (HRT) is being more 
forcefully recommended for all postmenopausal females (Nordin et al 1979; 1980; 
1985). In RA, there is evidence that oestrogen therapy may have a beneficial ef-
fect on clinical and laboratory manifestations of the disease (Bijlsma, 1987). 
Some improvement during oestrogen treatment was found in 30m walking time, 
Hb concentration, and thrombocytosis. ESR and CRP deteriorated in both these 
periods (of the double blind cross-over study), but less in the oestrogen treated 
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period. Grip strength improved during both periods. The number of swollen 
joints decreased whereas the joint tenderness score increased during the 
oestrogen period. The sample is small and the period of therapy short, but the 
findings are exciting and require further investigation. The effects of pregnancy 
on disease activity in RA are also well established (Ostensen et al 1983). 
The importance of androgens in maintaining bone was demonstrated by the 
finding of OP in men with idiopathic hypogonadotropic hypogonadism (Finkel-
stein et al 1987; Seeman et al 1983). Low levels of androgenic anabolic steroids 
have also been reported in women with RA (Masi et al 1984). Sambrook et al 
(1988) recently reported the relationship between sex hormone status and osteo-
porosis in postmenopausal females with RA. Compared with the controls, post-
menopausal RA patients had significantly reduced levels of oestrone, dehy-
droepiandrosterone sulphate (DHEAS), testosterone and femoral BMD. They 
conclude that reduced DHEAS levels in postmenopausal females with RA may 
increase their risk of osteoporosis. Premenopausal females were not studied, 
again diminishing the potential contribution of an excellent study. Spector et al 
(1988) have also reported low free testosterone levels in RA. 
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STATISTICAL METHODS. 
A basic knowledge of statistical methods is essential to the correct interpreta-
tion of results. Clinical epidemiology introduces statistical concepts such as speci-
ficity, sensitivity and prevalence. Williams (1979), in his book on reasoning with 
statistics, provides excellent guidelines on the application of statistical methods 
and the interpretation of results. 
Research in MBD involves several potential sources for invalidation of re-
sults, as exemplified in the review of the perplexing pathogenetic factors. A fur-
ther source of error is introduced in the selection of a control group, in terms of 
age, sex and physical activity. The probability of disproving the null hypothesis is 
also greatly influenced by the sensitivity of the measuring instrument and the X-
Ray technique. As Horsman et al (1975) have pointed out, it is often impossible 
to separate the components of this total error. 
Virtama and Helela (1968), Adams et al (1969) and Dequeker et al (1972) stu-
died observer error by expressing measurement differences as a percentage of the 
overall mean value. Dequeker (1976), reminds us that the inter-observer error 
also depends partially on the difficulty in defining the exact margins of the corti-
cal layer. It is advisable to define the inner limit of the cortical layer as the border 
of the solid cortical layer without separate trabeculae in the vicinity. These dif-
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ferences provide reason to believe that one observer working according to certain 
defined rules obtains the most reliable results. 
Barnett (1969), in a study of simultaneous pairwise linear structural relation-
ships, provided a series of mathematical equations which have been adapted for 
computerisation. The work in that study was based on the relative merits of 3 or 
mare instruments designed to measure certain aspects of lung function. The 
method is designed for performing triplet comparisons. Analyses of variance and 
paired t-tests are also useful under these circumstances, but they are limited in 
that they do not separate the potential sources of observer error in the same way 
that the method of Barnett (1969) does. 
Where multiple variables are compared in more than two groups, a profes-
sional statistician is often required for guidance on the appropriate tests for re-
gression and factor analyses. Frequency distributions need to be critically evalu-
ated for possible bias and validation of comparisons and correlations. In other in-
stances, non-parametric tests of rank order may need to be applied (Fleiss 1981). 
Consensus analysis (Bull et al 1986) enables one to eliminate less valuable tests 
using the mean of the correlation coefficients (r values) of a group of tests 
relative to a dependant variable. This technique has been usefully applied in 
evaluating 17 independent markers of disease activity in RA. 
Stepwise multiple regression analysis enables one to predict the variation in 
the dependent variable. Cluster analysis provides a means of grouping common 
variables. Discriminant analysis allows the calculation of specificity and sensitivity 
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of a test, using true and false positive and negative results. Pleiss (1981) provides 
useful guidelines on the use of applied probability. The above concepts are also 
explained in some detail. 
The recent introduction of the Receiving Operator Characteristic (ROC) 
curve (Lusted 1972) to clinical statistics (Swets 1979) has provided a major tool in 
detectability (Simpson et al 1973). A ROC curve demonstrates the relationship 
between the true positive ratio (TPR) and the false positive ratio (FPR) as the 
definition of a positive test is varied. ROC curves free us from the constraint of a 
predetermined definition of positivity. Hessel (1979), in an editorial, provides a 
useful perspective on the use of ROC analysis. The application of this statistical 
technique to a personal computer was facilitated by Centor (1985), who intro-
duced a Vzsicalc program for estimating the area under a ROC curve. The area 
under the ROC curve is similar to the Mann-Whitney U test, which is equivalent 
to the Wilcoxon rank-sum test (Hanley 1985). The ROC curve has the advantage 
that the standard error of the area can be calculated, confidence intervals for the 
area can be worked out and tests can be constructed to compare two curves. This 
technique has not been applied to the radiological evaluation of RA. However, 2 
recent reports evaluate these concepts in relation to the osteopaenia of aging, 
comparing TBCa with BMC at the wrist (SP A) and bone density at the spine 
(DPA) (Ott et al 1983; Cohn et al 1986). 
Ott et al (1983), reported that ROC curve analysis showed TBCa to be a bet-
ter discriminant than BMC in determining osteoporosis. The prevalence of OP in 
their sample was 25%. The posttest probability of disease was 90% if the TBCa / 
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TBCa p ratio was less than 0.84. Cohn et al (1986), in a similar study, found that 
TBCa was correctly able to classify 86% of OP subjects, while BMC was correct 
in 31 % compared with 56% using spinal bone density. In a serial study, they were 
able to predict normal individuals at risk for developing OP. The application of 
this statistical technique in Rheumatology was recently reviewed by Lequesne 
(1988), who illustrated the concept with HLA B27 in the diagnosis of ankylosing 
spondylitis. 
Where numerous related variables are considered, factor analysis ( Gorsuch 
1974) may be a useful means of reducing variables by grouping related variables 
into factors. The purpose of using factor analysis is scientific. Usually the aim is to 
summarise the interrelationships among the variables in a concise but accurate 
manner as an aid in conceptualisation. The result is based on principal compo-
nents analysis. 
Graphical methods need to be carefully selected. Useful recommendations 
are provided by Chambers et al (1983). Further developments in the field of sen-
sitivity and specificity include the derivation of likelihood ratios, post-test positiv-
ity and the development of decision-making trees. These are reviewed in a chap-
ter (Fletcher et al 1982) on the interpretation of diagnostic data, which is recom-
mended for reading to all interested in developing and using diagnostic informa-
tion in clinical practice. 
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In the final analysis of the vast literature on this controversial subject, it seems 
that the pathogenesis of the OP in RA is multifactorial. The osteoporotic syndrome 
is most likely to manifest itself in the susceptible individual who develops the 
added problems of immobilisation due to severity of RA. Several other environ-
mental factors such as diet, drug intake, disease activity and smoking may accel-
erate the process in that individual. The role of inflammation mediated osteo-
paenia in the pathogenesis of bone loss in RA needs further investigation. The 
nature of the effects of corticosteroid therapy are not clearly established. 
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NUMERICAL DEFINffiON OF OSTEOPOROSIS. 
Previous studies of OP (Dequeker 1976; Evans et al 1978) had arbitrarily 
defined subjects as osteopaenic if the cortical area was less than two standard de-
viations below the mean for a young normal group of subjects (fracture threshold). 
The earlier studies of OP in RA as well as those looking at bone loss of aging, 
have been unable to demonstrate statistically significant differences in premeno-
pausal subjects using a variety of different techniques. This is probably due to the 
small numbers of premenopausal subjects included in those studies. The numeri-
cal definition of OP is subject to wide variation, dependant on the technique used 
and the characteristics of the control subjects used for comparison. 
CLINICAL SIGNIFICANCE OF OSTEOPOROSIS. 
The financial implications of idiopathic OP have recently been reviewed for 
the USA (Peck 1987). These implications for the OP of RA are not known, but 
would probably be much smaller than this. The most serious complication of OP 
is the development of fractures and a reduced bone mass is the dominant risk fac-
tor, even though the relationship is not strictly linear. The lack of consensus re-
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garding the definition of OP (Mazess 1987) causes great difficulty in the develop-
ment of prophylactic or therapeutic strategies. Carlsson and Nilsson (1980) re-
ported the relationship of bone mass and loosening of the femoral component in 
total hip replacement. They studied 83 patients with OA, so their conclusions may 
not necessarily apply to patients with RA. They were unable to demonstrate a re-
lationship between pre-operative films and subsequent loosening of the femoral 
component of the prosthesis. Haider and Storey (1962) reported a small number 
of RA patients who developed spontaneous fractures. Fam et al (1983) also re-
ported spontaneous fractures in 4 patients with RA, 3 of whom had osteoporosis. 
They drew attention to the importance of considering stress fractures in the dif-
ferential diagnosis in patients with RA presenting with painful lower limbs. 
Hooyman et al (1984) reported arr of 1.5 for developing fractures after RA. Uni-
variate analyses indicated increased risk associated with increasing age, earlier 
age at onset of RA, disability, impaired ambulation, steroid use and thinness. 
There was a decreased risk associated with obesity and oestrogen use. Multivari-
ate analysis identified aging, impaired ambulation and thinness as independent 
risk factors. Lowthian and Calin (1985) reported the association between geode 
development and multiple fractures in RA. Verstraeten and Dequeker (1986) 
showed that vertebral and peripheral bone mass was significantly reduced in RA 
patients who develop fractures. Patients with RA had significantly reduced bone 
mass compared with normal controls, even in the absence of CS therapy. There 
were no significant differences in biochemical markers of bone turnover between 
RA groups. Konttinen et al (1988), in a review of the pathogenesis of the rheuma-
toid cervical spine, pointed out the importance of inflammation mediated osteo-
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paenia in the genesis of _vertebral subluxation of the dens in RA. This lesion is 
usually caused by a bilateral collapse of atlanto-axial facet joints, although col-
lapse of atlanto-occipital joints may also contribute to this end. The first stage of 
the pathological processes underlying this type of change involves ligamentous 
destruction, followed by diffuse loss of cartilage, erosions of facet joints progress-
ing centripetally, and the growth and advance of pannus as well as juxta-articular 
osteoporosis. 
Numerous epidemiologic studies have demonstrated a non-linear relationship 
between bone mass and fracture incidence (Cummings et al 1985; Melton and 
Riggs 1982). In an extensive review of the literature, Cummings (1985) concluded 
that there was insufficient objective evidence that patients with hip fractures are 
more osteopaenic. 
TREATMENT OF OSTEOPOROSIS. 
The pathogenesis of idiopathic OP is not clearly understood, nor is the defini-
tion of the disorder uniformly accepted. It is not surprising, therefore, that there 
is such controversy regarding the treatment of age-related bone loss (Milhaud et 
al 1983). The issue is further compounded in the patient with RA, particularly 
when the age-factor is not excluded. Some authorities have tried to standardise 
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for age after the menopause (Sambrook et al 1987; Reid et al 1986). However, in 
the individual subject, important factors may be responsible for the rapid bone 
losing state which are umelated to the amount of oestrogens present. A number 
of therapeutic approaches have been tried, with varying degrees of success. This 
variation is partly related to the heterogeneity of idiopathic OP. 
Calcium supplements are generally recommended at doses greater than 1.5 G 
daily (Keyler and Peterson 1985; Riis et al 1987). Vitamin D supplements are 
generally recommended where there is seasonal variation in the amount of sun-
light and sun exposure (Schnitzler and Solomon 1983; Tasi et al 1987). It is 
usually given together with calcium supplements. The use of 1,25 dihydroxy vit-
amin D is restricted to those individuals with evidence of decreased activation in 
a minority of patients with idiopathic OP (Johenssen et al 1982; Lindholm et al 
1977; Lund et al 1975). There is also some evidence that it may improve the 
myopathy associated with the disorder in some patients (Sorensen et al 1979). 
Fluoride is a potent stimulus to bone formation (Riggs et al 1982; Schnitzler et al 
1987). It has the severe drawback that it is unpalatable, but is probably the only 
significant bone forming agent available. The role of exercise has been clearly 
shown, but one needs to avoid the development of amenorrhea in some females. 
Inhibitors of bone resorption, such as the diphosphonates and calcitonin are cur-
rently experimental in the treatment of OP (Stevenson et al 1979). Coherence 
therapy combines the intermittent use of bone stimulation followed by inhibition 
followed by a period of resting. It may prove to be the superior approach to treat-
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ment (Aloia et al 1987). Vitamin C supplements are useful in some unusual cases 
of osteopaenia (Seftel et al 1966). 
There is a large body of evidence favoring the prophylactic use of oestrogens 
in the perimenopausal female (Adlin 1979; Nachtingall et al 1979; Nordin 1979). 
Although oestrogens do not generally increase bone mass, they do retard the rate 
of bone loss in the female predisposed to developing OP. Hormone replacement 
therapy (HRT) is now standard practice in several overseas countries (De Fazio 
et al 1985). Cigarettes interfere with the metabolism of oestrogens in this situ-
ation and should be avoided (Jensen et al 1985). 
Many of the above statement would apply equally to the menopausal patient 
with RA. However, they have usually been applied to those patients receiving CS 
therapy, so that these effects in RA patients receiving NSAID alone or together 
with DMA's is not known. When calcium supplements and vitamin D were used 
in patients with RA, no protective effect was shown (Dykman et al 1984; Bijlsma 
et al 1988). If vitamin D deficiency is clearly related to the pathogenesis (Mad-
dison and Bacon 1974; Ralston et al 1988), supplementation of the diet with vit-
amin D must clearly be effective. The effect of 1,25 dihydroxy vitamin D is prob-
ably better (Lund et al 1977). Recent evidence of improvement in some of the 
markers of disease activity in patients receiving oestrogen replacement (Bijlsma 
et al 1987), suggests that this group of hormones may be effective in this situation 
as well. These findings argue against the long-held belief that oestrogens are re-
sponsible for the female preponderance of this disorder. Another potentially use-
ful finding is that of a reduced level of DHEAA in patients with RA (Sambrook 
INTRODUCTION 144 
et al 1988; Spector et al 1988). Perhaps the answer to the treatment of OP in RA 
is a restoration of the premenopausal hormonal status. 
Many of the difficulties in evaluating the effects of therapy have been ham-
pered by poor reproducibility of the measurement techniques. Cohn (1982) re-
viewed the techniques for determining the efficacy of treatment of OP and con-
cluded that TBCa was the most accurate non-invasive measure of bone mass. 
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THE IDEAL STUDY. 
The review of the literature addressing the evaluation of MDB in RA, sug-
gests that a study which may contribute further to our understanding of the mech-
anisms involved in the causation of OP in RA would need to meet the following 
requirements: 
1) It would need to select patients who are not menopausal and could, 
therefore, be presumed to have normal ovarian function. These should 
include as many female patients with RA under the age of 45 years as 
possible. Males under 50 years of age should also be included for study. 
2) The study should be on an ambulant group of outpatients, so that all pa-
tients in Steinbrocker's (1949) functional classes 3 & 4 should be ex-
cluded. A measure of mobility or function would need to be selected to 
overcome the limitations of the ARA measure of function. Combining a 
mobility index with a functional test would probably suffice. 
3) A dynamometer should be used to evaluate grip strength as well as flex-
ion, extension, abduction and adduction of a single finger. These find-
ings could then be tested against bone mass values using the correspond-
ing single, and six metacarpal scores as a measure of bone mass. Correla-
tion coefficients would establish the relationship between strength and 
bone mass. 
4) The 7-day record to evaluate dietary intake, is highly suitable. 
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5) Patients who have either been on corticosteroids or are currently receiv-
ing this therapy should be included. A detailed drug history should be 
obtained and quantified as accurately as possible. 
6) Radiographic interpretations should be designed in such a way that the 
observer is not aware of the type of therapy being taken by the patient, 
so that objective evaluations may be achieved. The X-Rays should be 
graded according to the recommendations of Scott (1984) and Larsen 
and Dale (1977) for grading severity of radiological progression in RA 
7) Biochemical measurements of ionised calcium, inorganic phosphate, al-
kaline phosphatase, GLA, vitamin D metabolites, PTH, oestrogens and 
calcitonin may help in clearing some of the controversy. 
8) Bone mass should ideally be measured by radiogrammetry, photon ab-
sorptiometry, neutron activation analysis and WBR of calcium. The de-
velopment of an objective, quick, simple, accurate, reproducible com-
puter-assisted method of applying radiogrammetry principles would be a 
major advance in the study of bone mass at institutions where radiology 
is the only method of measurement. The various methods should then 
be correlated with each other. Correlations should be carried out be-
tween bone mass measurements and the other scores of radiological pro-
gression in RA. 
9) Controls should consist of two groups: one of normal age and sex 
matched subjects, and the other of age and sex matched patients attend-
ing outpatients for another chronic illness. Preferably, this second group 
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of controls should have a rheumatological disease, but they should also 
be ambulant. 
10) Statistical methods are very important in an analysis of this nature and 
univariate as well as multivariate analyses should be performed by 
trained statisticians. 
Strict principles such as these need to be applied to the design of protocols for research, 
so that meaningful conclusions can be drawn about pathogenetic mechanisms in the OP 
of RA. 
MATERIAL AND METHODS. 
The ideal study requires an ideal environment. The University of Cape Town 
(UCT), where this study was carried out, is reasonably equipped with the techniques 
for basic biochemical evaluations, but severely limited in facilities for the measure-
ment of bone mass by SP A, DP A, NAA, or WBR studies. It was hoped that attention 
to detail in performing the simplest of the available methods for measuring osteopo-
rosis would . compensate for these deficiencies. The methods for this study included 
detailed clinical examination, measurement of as many serum and urine variables as 
were possible in our laboratories, and radiological examination at three different 
sites of the skeleton. A personal computer-assisted alternative to the Vernier calipers 
in radiogrammetry measurements was assessed. It was hoped that the reproducibility 
of X-ray measurements in the hand would be improved with the use of a digitiser. 
This is vital, since serial studies are totally dependant on the repeatability, precision 
and sensitivity of the technique employed. 
The objectives of this study included the following: 
1. to define the factors involved in the pathogenesis of bone loss in RA; 
n. to improve the intra- and inter-observer reproducibility of radio-
grammetry measurements of metacarpal combined cortical width. 
The study was commenced after the protocol had been accepted by the Ethics 
and Research Committee at UCT. It was completed over twelve months from 1st 
April, 1985 to 31st March, 1986. 
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PATIENT SELECTION. 
The Rheumatic Diseases Unit (RDU) at UCT is the referral centre for patients 
with rheumatic diseases throughout the Western Cape. Two hospitals are involved 
with patient care, providing the unique availability of an acute and chronic hospital 
environment. Groote Schuur Hospital ( GSH) is the acute care centre with all the 
modern investigations easily available. The Princess Alice Orthopaedic Hospital 
(P AOH) is a much smaller centre with limited radiological facilities, but a highly 
sophisticated physiotherapy and occupational therapy department. These sources 
were ideally suited to the recruitment of volunteers and patients for study. Outpa-
tient followup facilities are available at both centres. 
SELECTION CRITERIA. 
A. Age - Males under 50 years; Females under 45 years. 
B. Function - ARA Functional Classes 1 and 2. 
C. Disease - Classical or Definite Adult RA 
D. Residence in the Cape Peninsula. 
E. Consent for study. 
EXCLUSION CRITERIA. 
A. Age. - Males over 50 years; Females over 45 years or early menopausal. 
B. Function - ARA functional classes 3 and 4. 
C. Disease - Less than 5 ARA Classification Criteria. 
D. Pregnancy. 
E. Residence outside the Cape Peninsula. 
F. Recent bedrest exceeding 14 days. 
G. Recent (previous 6 months) surgery of any nature. 
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SELECTION CRITERIA FOR CONTROLS. 
A. Normal, healthy volunteers. 
B. Age - Males under 50 years; Females under 45 years. 
C. Function - ARA Functional Classes 1 and 2. 
D. Residence in the Cape Peninsula. 
E. Consent for study. 
EXCLUSION CRITERIA FOR CONTROLS. 
A. Age. - Males over 50 years; Females over 45 years or early menopausal. 
B. Function - ARA functional classes 3 and 4. 
C. Disease - Any disease requiring regular medical therapy. 
D. Pregnancy. 
E. Residence outside the Cape Peninsula. 
ADDITIONAL CONTROLS. 
Patients with SLE meeting the selection and exclusion criteria were used as a 2nd 
group of controls, because : 
i) the disease is generally more common in young females; 
ii) they have multisystem manifestation of the disease; 
iii) they are generally mobile and less incapacitated than with RA; 
iv) corticosteroids are often used as an adjunct to therapy; 
v) the pathogenesis is likely to be closely related to that of RA; 
vi) they are easily accessible from the RDU Lupus Clinic of UCT; 
vii) they are often on multiple therapies simultaneously. 
viii) the hands are often involved and up to 5% may develop severe de-
formities (Alarcon-Segovia et al 1988). 
Informed consent was obtained from all subjects at the time of study. 
The protocol was approved by the Ethics and Research committee at UCT. 
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STUDY DESIGN. 
A detailed protocol was designed to record the relevant data on a computer. It 
was constructed in sections, aimed at capturing a wide range of data relating to: 
i) demography; 
ii) disease duration and criteria for diagnosis; 
iii) disease activity; 
iv) global functional assessment; 
v) mobility; 
vi) hand function; 
vii) hand strength; 
viii) movement at other joints; 
ix) treatment; 
x) biochemical changes of MBD; 
xi) serology and biochemical markers of RA activity; 
xii) dietary intake; 
xiii) nutritional status; 
xiv) X-rays at 3 skeletal sites; 
xiv) Genetic markers (HLA antigens). 
Details of the protocol are provided in Appendix A. 
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DEMOGRAPHY. 
AGE, RACE, SEX 
The date of birth, age, marital status, race and sex were recorded. Patients and 
controls were asked about their state of employment, work record, absence from 
work, time spent in the sun and also about a family history of arthritis. They were also 
questioned about smoking habits in the preceding 6 months, and a similar history of 
alcohol consumption was also obtained. A menstrual history was taken and informa-
tion about the use of the contraceptive pill was also elicited. 
DISEASE DURATION 
Age at onset of disease was recorded as the time at which the first acceptable 
symptoms of disease (RA, SLE), became manifest. Duration of disease was calcu-
lated in months. The criteria for the diagnosis of RA were recorded in the interview 
and the patient classified according to the ARA criteria into classical and definite 
RA groups (Ropes et al 1958). Previous surgical procedures were also recorded. Pa-
tients with SLE were classified according to the revised ARA criteria for classifica-
tion of SLE into definite or probable SLE (Tan et al 1982). 
DISEASE ACTIVITY. 
The patient was asked to grade the severity of his/her disease on a 10 cm. hori-
zontal visual analogue scale (SV AS). Pain was similarly graded by the patient 
(PV AS), as recommended by Huskisson (1974; 1982). The duration of morning stiff-
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ness was selected from a choice of 6 options, viz. less than 45 mins = O; 46 min - 90 
mins = 1; up to 2 hrs = 2; up to 3 hrs = 3; up to 4 hrs = 4; up to 6 hrs or more = 5. 
Hours to onset of fatigue was similarly selected from 5 options ranging from less than 
2 hrs = 1; to 8 hrs = 4. The presence or absence of night pain was recorded, as well 
as the patient's working capacity. 
The number of individual warm and swollen joints were counted and a Ritchie ar-
ticular index (RAI) (1968) was calculated. The author then recorded his global as-
sessment of the patient's disease activity, based on the clinical findings as nil, mild, 
moderate or severe. The Lansbury systemic index (1958) needed to be modified, 
since salicylates are no longer in use at our clinic. The index was calculated using the 
grip strength, duration of EMS, hours to onset of fatigue and ESR, scoring as defined 
by Lansbury et al (1958). 
PHYSICAL ACTIVITY. 
GLOBAL FUNCTION. 
Since there is no single, universal measure of functional disability in RA (Liang 
1981), the Keitel function test (KFf) (Keitel 1972), which relies on observed perfor-
mance, was performed in addition to the ARA functional classification (Steinbrocker 
et al 1949) and the UK classification of function (Joint Committee 1954). The Keitel 
Function Test (KFf) was selected because it is reasonably quick to administer, ex-
tremely reliable, very sensitive and highly reproducible (Eberl et al 1976). It involves 
observing the patient perform a series of movements, aimed at providing a global as-
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sessment of functional status. The components of the test are shown in table 2. These 
were all evaluated by a single observer. 
At the time of statistical analysis, the test was arbitrarily divided into 3 basic com-
ponents, namely hand and wrist, shoulder and lower limb. The hands feature most 
strongly, lower limbs slightly less and shoulders least in this test. It should be noted 
that the lowest possible total score is 4, due to items 6 and 7. The maximum score is 
100. The combined hand and wrist score can be obtained in less than one minute, 
compared with 12 minutes for the total score. The hand and wrist score will be 
referred to as the hand functional index (HFI). Table 2 outlines the complete test. 
The higher the score, the greater the disability. 
Table 2. Components of the Keitel Function Test. The test evaluates function in the 
hands, wrists, shoulders and lower limbs. It is conveniently divided into 3 major 
groups, where the hand and wrists are evaluated as a group. 
Test Items Grading Criteria 
Right Left 
1. Tip of thumb touches 
hypothenar of 5th 
0 0 Test performed 
fully and with 








Fully but with 
effort/or delay 
Tip of thumb 
touches 
proximal 
phalanx 3 and4 
Neither 
realised. 
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2. Bending of 2nd finger 0 0 Clutched 
normally 
1 1 Cannot be bent 
fully; tip 
reaches palm 
2 2 Fingertip does 
not reach palm 
3. 3rd finger As Above 
4. 4th finger As Above 
5. 5th finger As Above 
6. Forearm held horizontal 1 1 Test performed 
palmar surfaces fully and 
pressed together no delay. 
point upward. 2 2 Test performed 
fully with 
effort &/or delay 
3 3 Volar and 
dorsal flexion 
of wrist 45° 
7. Forearm held horizontal 1 1 Fully; no delay 
volar surfaces 2 2 Fully; with 
pressed together effort &/or 
point downward. delay 
3 3 palmar and 
ventral flexion 
of wrist 45° 
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8. Both backs of hands 0 0 Performed full 
simultaneously on the 1 1 Back of hands 
table; elbows held on table; 
rectangularly; ulnar margin cannot 
margin of hand lifted. lift 
2 2 Backs of hands 
not fully on 
table. 
9. Radial margins of hands 0 0 Performed full 
simultaneously 1 1 Planes of hand 
placed on table; thumb perpendicular; 
points downward before cannot be 
table edge; planes of inclined 
hand inclined inward; inward 
no lateral bending of 2 2 Planes of hand 
trunk. not vertical 
10. Both hands simultaneously 0 0 Normally 
on ipsilateral shoulder 1 1 Fingertips approach 
shoulder up 
to5 cm. 
2 2 Greater distance. 
11. Both hands simultaneously 0 0 Performed full 
behind the neck 1 1 Fully with 
(below ear level) effort &/or 
delay 
2 2 Fingertips 
touch neck 
3 3 Fngertips do 
not touch neck 
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12. Rising from resting 0 Quickly;hands 
position extended 
(examination couch). 1 Effort with 
hands extended 
2 Reinforcement of hands 
4 Extraneous assistance 
6 Impossible. 
13. Active spreading of 0 More than 50cm 
legs in resting position condylar 
distance 
1 More than 20 cm 
2 Less than 20 cm 
condylar distance. 
14. Rising from chair 0 Quickly; hands 
extended 




4 Extraneous assistance 
6 Impossible. 
15. Standing tip-toed 15 sec 0 Possible 15 sec 
support with one hand 
permitted 
1 Less than 15 sec 
2 Impossible 
16. Standing on heels 15 sec 0 Possible 15 sec 
Must stand straight 1 Less than 15 sec 
Support with one hand OK 2 Impossible 
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17. Knee-bending exercise 0 Normal test 
gluteal region almost 1 Partial test 
touches heels; support 2 Impossible 
with one hand permitted 
18. Standing on one leg 0 0 Possible 15 sec 
15 sec; support 1 1 Less than 15 sec 
with one hand permitted; 2 2 Impossible 
must stand straight. 
19. External rotation of hip 0 0 Normal test 
heel of test leg placed 
on supporting leg; 1 1 Angle of foot 
support with one hand axes 90° 
permitted; must stand 2 2 Angle of foot 
straight greater than 90° 
20. Plantar surface of foot 0 0 Normal test 
placed on chair; knee 
bent; patient stands 1 1 Leg lifted from 
very close to chair; floor 
support with one hand 2 2 Lifting leg 
permitted. impossible. 
21. Heel placed on chair; 0 0 Normal test 
knee extended; patient or delayed 
distance from chair lm 1 1 Leg lifted 
support with one hand from floor 
permitted. 2 2 Lifting leg impossible. 
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22. Walking 30m in hospital 0 No difficulty; 
corridor; standard standard time 
time of 20 sec 1 Visible 
difficulty;20sec 
2 25 sec 
3 30 sec 
4 40 sec 
5 Few steps with 
assistance 
6 Impossible 
23. Walking 10 steps upstairs; 0 No use of 
standard time of 7 sec rails; 7sec 
1 Up to 14sec with 
use of rails 
2 More than 14sec; 
some effort 
3 No steps. 
24. Walking 10 steps downstairs; 0 No use of 
standard time of 7 sec rails; 7sec 
1 Up to 14sec with 
use of rails 
2 More than 14sec; 
some effort 
3 No steps. 
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MOBILI1Y. 
Mobility was scored using a different functional assessment test (Badley et al 1984). 
The mobility score was derived from a disability questionnaire (DQ), which graded 
difficulties in performing activities of daily living. 
The method is based on the Stanford Health Assessment Questionnaire (HAQ) 
(Fries 1982) recommended by the WHO. 24 questions replaced the original 41 in the 
HAQ. This test allows scores to be obtained for mobility, bending down, dexterity, 
bending the arm and reaching up. The difficulty with which each of a series of tasks is 
performed was graded on a Guttman scale of 0-7, where O = no difficulties en-
countered and 7 = activity impossible. A total score of mobility could thus be ob-
tained from the responses to a series of simple questions. Table 3 shows the areas 
evaluated, and details of the questionnaire are included in appendix 1. 
Table 3. Questions pertaining to modified Stanford HAQ for evaluating global mobility in pa-
tients with RA. 
Functional Group. Constituent Activities. 
1. Mobility * Walk to toilet; 
* get on and off toilet; 
* get in and out of bed 
* turn side to side in bed 
* go up and down stairs; 
* get in and out of a bath 
2. Bending down * Put on shoes, tie laces; 
* pull on socks/stockings; 
* wash below waist and towel dry; 
* cut toe/finger nails. 
3. Dexterity * Unscrew lid from lin. jar 
* prepare vegetables; 
* carve meat;slice bread; 
* cut toe/finger nails. 
4. Bending arm * Drink from full cup or beaker; 
* shave/apply cosmetics; 
* wash face and neck and towel dry; 
* wash trunk and arms and towel dry. 
5. Reaching up * Clothes over head; 
* brush/comb hair; 
* wash hair; 
* put in electric plug at shoulder height; 
* peg out washing; 
* use shelves above shoulder height; 
* open/clean high window. 
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HAND FUNCTION. 
Hand function was further evaluated by an occupational therapist (OT), who re-
corded the ability of the patient to perform 4 standardised tests of hand function 
(Clawson et al, 1971), using the instruments depicted in Figure 1. 
Figure 1. Composite picture showing the instruments used by the occupational thera-
pist (OT) for evaluation of simple hand function. 
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These consisted of: 
i) the time taken to cut through a 1cm mould of putty, (the consistency of 
which was designed to maintain a constant firmness) (Fig 2); 
Figure 2. Knife and fork used to cut through a 1 cm thick mould of putty. The time 
taken to complete this task was recorded with a stopwatch. 
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ii) The time taken to button 3 buttonholes on a piece of material fixed to a 
board (Fig 3); 
Figure 3. The buttonhole test, measuring the time taken to do and undo 3 buttons. 
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iii) grip strength using a barometer with a medium-sized cuff, designed by Man-
nerfelt (Fig 4); and 
Figure 4. Mannerfelt instrument for testing grip strength. 3 sizes of bulb are 
available, of which the medium-sized was used for this study. Measured 
in mm Hg. 
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iv) three point pinch was measured as shown in figure 5. 
Three readings were obtained for each test and the average was used in the statis-
tical analysis. 
The mean of 3 readings was used because its numerous statistical advantages. The 
3 readings were compared with each other as a measure of reproducibility. 
Figure 5. Pinch grip measurement, using a guage designed by 
Manne,felt. Measurements are recorded in Kilo Pascals (Kp ). 
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VALIDATION. 
The scatter plots shown in figure 6a and b represents measurement of 3-point 
pinch by the OT, but similar correlation coefficients were obtained for the other 
measurements (grip strength, knife and fork and buttonhole test) done by the OT 




Figure 6a. Scatter plot showing the relationship between serial measurements of 
pinch g,ip. The figure shows the relationship between the 1st and 3rd attempt with 
the instnunent. 
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Figure 6b. Scatter plot showing the relationship between serial measurements of 
pinch grip. 17ie figure depicts the relationship between the 1st and 2nd attempt with 
the instnanent. 17ie mean of 3 readings was used in the analysis of the results. 
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Table 4 summarises the results for the various tests in the different groups tested. 
It is interesting to note that the correlations were better in the RA group (r > 0.9), 
particularly with the knife and fork test, suggesting a wider variation among the nor-
mal subjects. This was confirmed by the univariate sample distributions. 
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Table 4. Comparison of 3 readings from which the mean was calculated as a 
measure of hand function and grip strength. Measured by an occupational thera-
pist (OT). 
Test Group Correlation Coefficient 
Comparing Readings 
lvs2 lvs3 2vs3 
3-Point Pinch Normal 0.942 0.925 0.944 
RA 0.964 0.943 0.98 
Knife and Fork Normal 0.65 0.5 0.67 
RA 0.963 0.958 0.97 
Buttonhole Test Normal 0.801 0.824 0.77 
RA 0.887 0.909 0.91 
Grip Strength Normal 0.939 0.902 0.94 
RA 0.922 0.983 0.92 
These findings are important, since they mean that valid conclusions can be based 
on the readings obtained with this set of instruments. As it turns out, in this study, 
each of the 3 readings was valid and the measurements were reproducible for a single 
observer, with coefficients of correlation ranging from 0.77 to 0.98. The mean is, 
therefore, a good reflection of the measurement. 
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HAND STRENGTH. 
A dynamometer (Fig 7), was used to measure i) adduction, ii) abduction, iii) flex-
ion and iv) extension strength in the right middle finger, as well as v) torque strength 
in the right hand. 
Figure 7. 17ie dynamometer used for measuring force of finger flexion, exten-
sion, abduction and adduction. A separate component was used for 
measuring torque force in the right hand. The instrument was designed at 
the biomedical engi.neering department, UCT. 
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The instrument was designed by the Department of Biomedical Engineering 
(BME) at UCT. The base remains firm and the transducer causes the dynamometer 
to display the force as a measure of strength. The highest reading attained on each of 
3 attempts was recorded. 
Adduction and abduction were measured with the right arm in a comfortable po-
sition, wrist in a neutral position and fingers extended with the pal~ down. The 
middle finger applies pressure against a cushion attached to the transducer (Fig 8). 
Figure 8. Measurement of abduction and adduction in the right middle finger. Three 
readings were recorded. The transducer is turned in the opposite direction to 
measure adduction. 
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Flexion and extension were tested with the hand clutched prone, little finger 
against table, and pressure exerted against the cushion by the middle finger (Fig 9). 
The transducer can be detached and reversed for the measurement of flexion. 
Figure 9. Measurement of flexion and extension in the right middle finger. Three 
readings were recorded. The transducer is titmed in the opposite direction to 
measure flexion. 
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Torque was measured using the same instrument, except that a torquometer was 
designed for measurement of grip (Fig 10). A sponge cushion was glued to provide 
comfort and improved grip. 
Figure 10. Measurement of torque foce in the right hand. A sponge cushion 
was used to improve the comfort of grip. Three readings were recorded . 
• -.. 
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VALIDATION. 
Reproducibility of the dynamometer was shown by the comparison of 3 readings. 
The scatter plots depicted in figure lla + llb, show that the machine performed 
adequately between readings. The mean of these readings was used in comparisons 
between groups, in order to minimise errors due to reproducibility. The scatter plots 
show good precision with the instrument. 
Figure I la. Scatter plots showing the reproducibility of the dynamometer in measuring force in 
the finger. Only the abduction values are shown, but the technique was highly reproducible for a 
single observer measuring adduction as well. 
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Figure llb. Scatter plots showing the reproducibility of the dynamometer in measuring 
torque force in the hand. Only the RA values are shown, but similar findings were shown 
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Table Sa shows the coefficients of correlation for some of the readings.The table 
includes some of the tests of hand strength only, but similar results were obtained for 
the tests of adduction and extension strength in the right middle finger. These results 
show that the dynamometer was reproducible between readings. The results show 
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that the dynamometer measurements were more reproducible than the OT instru-
ments. 
Table Sa. Comparison of 3 readings of finger strength and hand torque strength 
using a dynamometer. The mean of 3 readings was used in all correlations invol-
ving hand strength. Some of the results ( abduction, flexion and torque) are shown 
in the 3 groups of subjects. 
Measure. Group Correlation Coefficient 
Comparing Readings 
lvs2 lvs3 
Abduction Normal 0.954 0.928 
RA 0.967 0.893 
Flexion Normal o.m 0.928 
RA 0.986 0.967 
SLE 0.934 0.913 
Torque Normal 0.957 0.925 
RA 0.977 0.951 










Since the study was confined to subjects with RA and SLE who were inde-
pendently mobile, the range of movement in the various joints was not recorded. The 
KFf and DQ are specifically designed for global assessment of function in RA. 
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DRUG THERAPY. 
NON-STEROIDALANTI-INFLAMMATORY DRUGS. 
Treatment was recorded as accurately as possible. Non- steroidal anti-inflamma-
tory drugs (NSAID's) are used routinely in the treatment of RA. These were often 
used in combination at our clinic. Use of these agents in the 12 months preceding the 
study was recorded. NSAID's have totally replaced aspirin in our clinic. The com-
monest agents used were diclophenac, indomethacin, naproxyn and piroxicam. Fre-
quent changes were sometimes indicated for side - effects or lack of effect. The dos-
ages and durations are, therefore, not absolutely accurate. 
DISEASE MODIFYING AGENTS. 
Disease modifying agents (DMA's) were recorded for their total duration, so that 
total doses up to the time of study could be calculated. If these agents were stopped, 
the reason for stopping was also recorded. Details were obtained for penicillamine, 
myocrisin, ridaura (Auranofin - oral gold), chloroquine, salazopyrine and immuno-
suppressive agents. Patients were often uncertain of dosage and duration, so their 
hospital records were analysed to make calculations more accurate. Despite this at-
tention to detail, some of the values obtained are at best an estimate of total therapy. 
Patients were not necessarily on these drugs at the time of study and the period for 
which they were discontinued was not recorded. 
CORTICOSTEROID THERAPY. 
Corticosteroid therapy was similarly recorded. Several routes of administration 
are applied in RA; intra-articular injection (IAI) is the commonest. Although it is 
generally accepted that insignificant amounts are absorbed systemically, there is 
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some evidence that frequent W's over a period of time may lead to adrenal sup-
pression. For this reason all forms of CS administration were recorded in detail. Hos-
pital records were again consulted when necessary, to improve and to check on the 
reliability of the calculations. Past and present usage was recorded. Cumulative dose 
was calculated as an approximation of total dose. The period for which CS therapy 
had been discontinued was not recorded. Patients with SLE usually used much 
higher doses of CS than those with RA, whose total dose was more difficult to ap-
proximate. RA patients currently receiving CS were compared with those not receiv-
ing CS at the time of study. SLE patients also took CS for longer periods as shown in 
Table Sb. 





Total 659 1569 
Mean 24 31 
Range 2-108 2-108 
ORAL CONTRACEPTIVES. 
The type of contraceptive used and the date of the last menstrual period were 
also recorded. Detailed menstrual and obstetric histories were not obtained. Females 
who had had a hysterectomy with oophorectomy and who were not receiving hor-
monal replacement therapy were excluded from the study. 
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LABORATORY INVESTIGATIONS. 
BIOCHEMISTRY OF METABOLIC BONE DISEASE. 
Biochemical tests of metabolic bone turnover were selected using the recommen-
dations of Nordin (1978), Jowsey (1975) and Aitken (1984c). Serum was separated 
for measurement of renal function, calcium, phosphorous, alkaline phosphatase 
(AP), ionised calcium, parathormone (PTH), albumen and uric acid. Liver enzymes 
such as gamma glutamyl transpeptidase (GGT), aspartate transaminase (AST) and 
alanine transaminase (ALT) were also measured. Haematological indices such as 
haemoglobin (Hb), ESR (Westergren), white cell count (WCC) and platelets (Plt) 
were also recorded. Calcium, phosphorous, albumen, urea, creatinine and enzymes 
were measured in the Department of Chemical Pathology using the Technicon 
SMAC 12 Autoanalyser. Haematological measurements were performed by the 
Haematology Department with the Coulter S-plus automated counter. 
Ionised calcium was measured in the renal laboratory, using the ICAI ionised cal-
cium analyser. CRP was also measured in the renal lab using rocket immunoelectro-
phoresis (mg/ml) [antibody from Hoechst]. Two 24 hr urine specimens were obtained 
for the measurement of urinary calcium and phosphorous excretion, as well as hy-
droxy-proline (OH-P). The patient was issued a set of instructions for the urine col-
lections and warned to avoid gelatin containing foods for the duration of the OH-P 
collection. Toluene (10ml) was added to the OH-P bottle, and HCL (10ml) was 
added to the calcium and phosphate specimens, as preservatives. Creatinine clear-
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ance was not calculated in the patients with RA, but was done on the patients with 
SLE. Urinary calcium and OH-praline was not assessed in the SLE subjects. 
Additional serum was stored at -70° for later analysis of thyroxine binding preal-
bumen (TBP) and retinal binding globulin (RBG). A limited number of these tests 
were performed on the normal controls, and the patients with SLE. 
Since PTH requires expensive kits for accurate results, this investigation was con-
fined to the group of patients with RA. Blood was collected in an EDTA tube and 
stored on ice. The N-terminal was measured in the renal laboratory, using a radioim-
munoassay. Local laboratory normals were used as reference values for comparison 
of the range of results. 
SEROLOGY. 
RA diagnosis was evaluated by the sheep cell agglutination test (SCAT; slide ag-
glutination technique: Rheumaton supplied by Wampole laboratories) and the Latex 
fixation test (slide agglutination technique: Ortho diagnostics). A latex titre of 1/40 or 
higher and a SCAT of 1/16 or higher were considered to be positive for our labora-
tory. Antinuclear factor (ANF) (Johnson and Holborow 1973) was measured by the 
indirect immunofluorescence technique. In the group of patients with SLE, addi-
tional samples were submitted for double stranded anti-DNA antibody activity 
(ADA) using the millipore filtration technique (Ginsberg and Keiser 1973). 
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DISEASEACTWITY. 
Disease activity was evaluated by measurements of C reactive protein ( CRP) 
(rocket electrophoresis), ESR (Westergren), sulphydryl (SH)-groups, retinal binding 
globulin (RBG), thyroxine binding prealbumen (TBP) and plasma viscosity ( capillary 
viscometer; cP). 
DIET AND NUTRITIONAL STATUS. 
DIET. 
All patients and controls completed a 7-day record of dietary intake. This was 
then analysed for food constituents and coded according to a computer program used 
by the Medical Research Council (MRC). This data was entered onto a computer 
and the mineral and food content calculated per 100 grams of foodstuff or fluid. 
NUTRITIONAL STATUS. 
Nutritional status was measured by several different anthropometric methods 
using body diameters (Willmore and Behnke 1970) skinfold thicknesses (Sloan 1967; 
1973), height and weight (body mass index). The height was measured without shoes 
and the patient was weighed with the minimum of clothing. The bi-acromial, bi-iliac, 
bi-trochanteric, bi-ankle and bi-wrist diameters were measured using a body calipers 
designed in the BME department at UCT. Subscapular, thigh, upper arm and ab-
dominal skinfold thickness was measured using a Harpenden caliper. The upper arm 
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diameter was measured using a tape measure.The anthropometric and skinfold 
measurements were performed by the research sister. 
The measurements were standardised according to the following landmarks and 
principles in all subjects:' 
i) Standing Height. The subject stands, head back, hands on hips and 
takes a deep breath at the time of measurement. Read to nearest cm. 
ii) Body Weight. The subject stands in the centre of the scale platform 
wearing only underwear and a light examination gown. 
iii) Bi-acromial Diameter. With the subject standing or sitting with arms 
hanging freely, record the distance between the most lateral projec-
tion of the biacromial processes. Record to the nearest mm. 
iv) Bi-iliac Diameter. Locate the crests of the ilium. Place the calipers on 
these sites and press firmly. Record to the nearest mm. 
v) Bi-trochanteric Diameter. Place the calipers over the most lateral pro-
jections of the trochanters. Press firmly. Record to the nearest mm. 
vi) Bi-ankle Diameter. Place one foot on a platform. Measure distance 
with the calipers placed at an angle of 450 and with the calipers on the 
widest point of the malleoli. Measure both ankles. Record to the near-
est mm. 
vii) Bi-wrist Diameter. Place calipers over styloid processes at their most 
lateral projection site. Measure both wrists. Record to the nearest mm. 
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viii) Chest Width. Take at end of expiration. Calipers must avoid the pecto-
ralis muscles and be placed in axillary region near the 2nd or 3rd rib. 
Pressure should be firm. Record to the nearest mm. 
ix) Chest Depth. Locate the end of the sternum and place the caliper tips 
on the sternum site and on the back near the spinal cord. Read at the 
end of expiration and record to the nearest mm. 
All Skinfolds were measured from the right side. Grasp the skin between the 
thumb and index finger. Grasp 2 skin thicknesses but avoid the muscle and fascia. 
Take all measurements in the vertical plane. 
i) Subscapular. Subject stands erect with shoulders relaxed and arms by 
the sides. The skinfold is raised with the thumb and forefinger of the 
left hand lateral to the inferior angle of the right scapula, the skinfold 
running downward and outward in the direction of the ribs. 
ii) Abdominal. Subject stands in normal erect posture. The skinfold is 
raised with the thumb and forefinger of the left hand in a position 1 - 2 
inches above the right anterior superior iliac spine so that the fold 
runs forward and slightly downward. 
iii) Triceps. Taken at the midposterior midpoint between the tip of the ac-
rornion and the tip of the olecranon with the arm hanging in an ex-
tended position. 
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All skinfold measurements taken 3 times, and the mean of the 3 readings was 
used in calculation of lean body mass (weight) by 3 different anthropometric tech-
niques (Sloan; Willmore-Behnke and body mass index). 
VALIDATION. 
The following scatter plots show the correlations between skinfold measure-
ments. The precision of the measurement was not influenced by the presence of dis-
ease, as shown in figure 12a and 12b respectively. 
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Figure 12a. Scatter plots showing the reprod11cibility of meas11ring skin/old thickness at the 
subscapular region in nonnal subjects. 
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Figure 12b. Scatter plots showing the reprod11cibility of measuring abdominal skin-
! old thickness in subjects with RA. The measurements were highly reproducible. 
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Table 6 summanses the coefficients of correlation between measurements of 
skinfold thickness for the 3 groups of subjects (RA, SLE, controls) at the different 
sites. The results show that repeated measurements at the same site were redundant 
(r> 0.9). 
Table 6. Skinfold measurements were used in calculating lean body mass (LEM). 
171e mean of 3 readings was used in the calculations of LEM. Reproducibility of 
the measurements is shown. 
Skinfold Group Correlation Coefficient 
Comparing Readings 
lvs2 lvs3 
Subscapular Normal 0.997 0.997 
SLE 0.997 0.998 
Triceps Normal 0.999 0.947 
SLE 0.998 0.916 
RA 0.997 0.938 
Abdominal Normal 0.999 0.998 









MATERIAL & METHODS 186 
The relevant values were substituted in the following formulae for the calculation 
of lean body mass (LBM): 
A. SLOAN: 
Xl = 1.1043 - (0.001327 X2) (0.001310 X3) I 
WHERE Xl = Density (G/ml) 
X2 = thigh skinfold (mm) and 









X Height (dm), 
AND 
X Height 0·7 x 0.263 
0.001835 x triceps SFf (mm) 
0.002779 x hip girth (in) 
+ 0.00549 x flexed biceps girth (in) 
0.0007167 x scapula SFf (mm). 
C. BODY MASS INDEX : 
BMI = Mass / Height 2 
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Biochemical assessment of nutritional status was based on measurement of serum 
albumen RBG and TBP measurements. 
RADIOLOGY AND RADIOGRAMMETRY. 
X-rays were standardised for the purpose of this study. These were performed at 
2 different centres. Three skeletal sites were selected for comparison with other pub-
lished series. The hands were radiographed at a tube distance of 100 cm, with expo-
sure time standardised as recommended by Dequeker (1976) and others (Barnett 
and Nordin 1960). A phantom phalanx embedded in wax was included on the picture 
for tests of reproducibility (Fig 13). 
Figure 13. Radiograph of the hands, showing the phantom embedded 
in a rectangle of wax. 171e phantom digit was used in the analysis of 
reproducibility of the technique. 
MATERIAL & METHODS 188 
The left hip was internally rotated to 15°, as recommended by Singh et al (1973). 
Finally, the lumbar spine was examined in a lateral view centered on the 3rd verte-
bra. 
These views allowed the measurement of the right 2nd metacarpal index as de-
scribed by Barnett and Nordin (1960), the 6 metacarpal index as described by Hors-
man et al (1975), the carpo- metacarpal ratio using the landmarks of Trentham and 
Masi (1976), the Singh index (1970; 1972; 1973) at the left hip, left femoral cortical 
thickness proximal to the lesser trochanter, the femoral index at the left hip by divi-
ding the cortical width by the narrowest width of the femoral neck (Fredensborg and 
Nilsson 1977), and the lumbar spine index according to the method of Saville (1967). 
Several modifications have been made to the basic formula proposed by Barnett and 
Nordin (1960), in an attempt to normalise for variations in body habitus and structure 
between individuals. These complex calculations depend on the basic measurements 
of the outer (TW) and inner (MW) diameters at the midshaft of the metacarpal. 
These diameters were used to calculate the combined cortical width ( CCW), which is 
the basis of the metacarpal bone mass calculations. 
In the application of the radiogrammetric method, the landmarks suggested by 
Barnett and Nordin (1960) and Dequeker (1976) were used (Fig 14). Horsman et al 
(1975), use slightly different landmarks, making comparisons of results difficult to in-
terpret. The Vernier caliper method, which has been extensively studied and vali-
dated, was not used in this study. 
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Figure 14. Diagramatic representation of landmarks used for measurements at th 
metacarpals. Combined cortical width (CCW) is calculated as the difference be-
tween total width (D) and medullary width (d) at the midshaft (L/2). 
In order to evaluate a newer, more reliable method for measurement of bone 
mass by radiogrammetry, the techniques of Evans (1978) and Horsman et al (1977), 
were modified for the interpretation of standard X-rays using a digitiser. In consult-
ation with the Department of Information Technology at the University of Cape 
Town, computer software was designed for use with a Houston Hipad digitiser inter-
faced with an IBM PC (Fig 15). 
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Figure 15. Houston Hipad Digitiser, showing grid markings as well as 
cursor for plotting co-ordinates. The cursor has ten times magnification 
and a cross in the centre, facilitating accurate measurement. 
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The computer programme written for this study was designed to calculate all the 
radiogrammetric measures of bone mass recommended by Aitken (1984a). The pro-
gramme was used to measure the inner (MW) {d}, and outer (TW) {D} diameters, 
after being directed to the midpoint of the metacarpal shaft (U2). The carpal length, 
femoral cortical width and narrowest diameter of the femoral neck trabeculations 
were also measured as recommended by the respective authors. The right wrist was 
graded for severity according to the modified Larsen index (1979). All measurements 
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for radiogrammetry were done on a standard antero-posterior radiograph of the 
hands at a tube distance of 100 cm. No magnification techniques were applied. 
Formulae were entered for the simultaneous calculation of the right 2nd meta-
carpal index, whole bone ash (WBA), density (WBD) and calcium content (WBCa), 
the 6 metacarpal indices (M6CA% and M6HS), carpo-metacarpal ratio (CMR) and 
femoral index (FI) (Figure 16). 
Figure 16. F onnulae for calculation of bone mass using measurements at the right 
2nd metacarpal. 
Area Index (Al) = 02-d2 = TW
2-MW2 
Metacarpal Index (Ml) 
02-d2 TW2-MW2 
:: = 
DL TWx L 
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Intra-observer reproducibility was tested by measuring the phantom digit 6 times 
on 6 randomly selected radiographs (Figure 13). The coefficient of variation ( cv) was 
calculated for 6 measurements as well as a single measurement. 
Table 7 shows that the readings were reproducible for a single observer. It would 
seem from the table that the margins of the metacarpal were more easily defined 
than those of the phantom used in this study. Our findings confirm earlier sugges-
tions (DeQueker 1976, Aitken 1984a) that medullary width (MW) shows the greatest 
variation in measurement. 
• 
Table 7. Intra - observer analysis of variance, using digitiser for measuring length, 
total width (TW) and medulla,y width (MW) at the midsltaft of tlte phantom used 
in this study, as well as the right 2nd metacarpal of 6 subjects. Measurements were 












Inter-observer reproducibility was evaluated for 5 different observers with varying 
experience with radiogrammetry. Observer 1 was familiar with the digitiser tech-
nique and was responsible for its development. Observer 2 was familiar with the Ver-
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nier caliper technique and had never previously used the digitiser. The remaining 3 
observers were not at all familiar with radiogrammetry or use of the digitiser. The re-
sults represent a single encounter with the digitiser by observers 2-5. 
Table 8 summarises the measurements for the 5 observers. Applying the method 
of Barnett (1969) we were able to show that the differences between the measure-
ments of the 5 observers was negligible. 
Table 8. Measurements of phantom by 5 different observers. Inter-observer differen-
ces were not statistically significant (p > 0.05). 
Measure Observer Reading-- Mean (SD) 
1 2 3 4 
Length 4.48 4.51 4.47 4.48 
(0.02) (0.05) (0.03) (0.04) 
TW(D) 1.15 1.09 1.10 1.08 
(0.02) (0.03) (0.02) (0.02) 
MW(d) 0.66 0.69 0.68 0.71 
(0.02) (0.02) (0.02) (0.02) 
ccw 0.49 0.44 0.42 0.37 










The inter-centre reproducibility was tested with the same phantom used at the 2 
centres where the patients were seen. Six measurements each on six X-rays from the 
respective centre were measured by one observer. The 36 measurements obtained 
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are shown in table 9. The paired t-test showed that there was no statistically signifi-
cant difference between measurements of the mould between centres (p > 0.05) for 
the diameters, even though the length was significantly different (p < 0.05). 
Table 9. Measurement of phantom at 2 different centres. Although the differences 
in length is statistically significant (P < 0.05), TW and MW were not significantly 
different. This suggests that inter-centre comparisons were valid. 
Mean Measure Centre 1 Centre 2 p value 
(SD) (SD) 
Length 4.493 4.426 
(0.027) (0.072) 0.001 
TW (D) 1.119 1.092 
(0.018) (0.031) NS 
MW (d) 0.604 0.607 
(0.025) (0.028) NS 
In order to further evaluate the error (particularly for longitudinal studies), 6 
controls and 10 patients with RA were X-rayed on 2 separate occasions, 1-4 weeks 
apart. The RA controls were recruited from the remission induction clinic at GSH, 
where patients were seen at regular intervals to monitor side-effects of therapy. They 
were selected because this is the group in whom one would expect disease modifying 
effects of therapy over a period of time. Randomisation was hopefully achieved by 
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studying the first 3 consecutive patients at the clinic over a month. Seven sets of 
radiographs were analysed (2 patients had only one set of X-Rays while 1 patient had 
had surgery to the MCP joints). The right 2nd metacarpal was measured 6 times on 
each set of X-Rays. 
In the control group, the metacarpal length was statistically significantly different 
in the 2 sets of radiographs. However, the cortical diameters at the midshaft were not 
significantly different on the 2 occasions. In the patients with RA, randomisation 
tests showed no significant differences in length, TW, MW or CCW in the 2 sets of 
radiographs. 
The results of the validation studies show that the measurements made with the 
instruments in this study were reliable. They show that the dynamometer is perhaps 
better than the cuff for measuring hand strength (see tables 5 and 6), supporting the 
suggestion by (De Choisy 1973). 
The digitiser is a marked improvement on the Vernier caliper technique, particu-
larly with respect to multiple observer analysis. The digitiser technique is ideally 
suited to multi-centre, multi-observer studies. This is particularly important to South 
Africa, where resources are limited and facilities sparsely distributed. 
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The 6 metacarpal bone mass was calculated from the formula provided by Aitken 
(1984a), depicted in figure 17. It is derived from the right 2nd metacarpal indices. 
Figure 17. F onnulae for calculating bone mass from measurements at the midshaft 
of 6 metacarpals. 
6MHS = 100 ((TWa-MWa] ~[TWb-MWb]+ ______ +[TWf-MWf]) 
TWa+TWb+TWc+TWd+TWe+TWf 
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The output of the data was in a computer format (ASCII), which allowed it to be 
read into a standard database management system ( eg CONDOR 3; DEASE 3). Se-
lected fields could then be subjected to graphical ( eg Lotus 123) and statistical ana-
lyses using the appropriate computer software. This method removed the errors in-
troduced while entering data for calculations when using the Vernier calipers. In this 
way the total error was likely to be reduced considerably. Details of the digitiser 
technique are provided in Appendix B. 
The authors of other studies do not indicate the amount of time spent in measur-
ing and subsequently calculating the indices, but the impression created is that the 
method is extremely time-consuming. It would seem that Horsman's method re-
quires at least 10 minutes of technical time, which does not include the time for mak-
ing the complex calculations (Aitken 1984a). The author was able to show that the di-
gitiser method is more accurate, reproducible and simple to administer. It was also 
found that, contrary to the suggestion (Horsman et al 1975), the 2nd metacarpal bone 
mass could be calculated in less than 1 minute, while the 6 metacarpal bone mass was 
calculated in less than 5 minutes. Records were available for comparison at different 
time of radiography. Therefore, time element was considerably reduced using the 
new technology. 
The sensitivity of the method would be illustrated by its ability to differentiate be-
tween the three groups in this study, using discriminant analysis. 
It was hoped that this modified method would be an improvement on the pre-
vious techniques (Barnett and Nordin 1960; Horsman et al 1977), especially with re-
spect to speed, precision and reproducibility. 
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The landmarks for measurement of carpal length were those of Trentham and 
Masi (1976). The femoral cortical and trabecular measurements were based on the 
recommendations of Fredensborg and Nilsson (1977). 
The Singh index was scored as suggested by Singh et al (1970; 1972; 1973). This 
was based on the trabecular pattern as depicted in Figure 18. 
Figure 18. Reference pattem at the left hip from which the Singh index was derived 
and graded according to the trabecular pattem. 
7 6 5 
4 3 2 1 
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The 3rd lumbar vertebra was also graded for trabecular porosity, using the 
method of Saville (1967). The following grades were recorded: 
0 = Normal bone density. 
1 = Minimal loss of density; end plates begin to stand out, giving a sten-
ciled effect. 
2 = Vertical striation is more obvious; end plates are thinner. 
3 = More severe loss of bone density than grade 2, end plates becoming 
less visible. 
4 = Ghost-like vertebral bodies. 
GENETICS. 
Alloantisera were obtained both locally and by international exchange for use in 
the standard microlymphocytotoxicity assay for HLA-typing (Terasaki et al 1974). 
180 antisera were used to type 17 A-locus, 31 B-locus and 8 C-locus antigens. The 
nylon wool technique was used to obtain the B lymphocyte fraction (Danilovs et al 
1980) and 95 antisera were used for the typing of 10 DR and 3 DQ locus antigens. 
STATISTICAL METHODS. 
The Institute of Medical Biostatistics, SAMRC was responsible for statistical ana-
lyses. Calculations were made using an IBM mainframe computer. A multitude of 
computer-based statistical methods were used in the final analysis of the data. These 
included univariate as well as multivariate techniques. The data was carefully 
scanned for data errors and true outlies (unexpected values). Sample distributions 
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were inspected for skewness, platykurtic or leptokurtic characteristics. Relationships 
between variables were investigated. In the case of nominal variables, contingency ta-
bles were used. In the case of continuous variables, Pearson and Spearman correla-
. tions were used. The Bonferroni technique (in Neter and Wasserman 1974) was ap-
plied when the 3 groups were being compared, as well as Duncan's multiple range 
test. Every large study of this nature, should aim at recommending a programme of 
data reduction for future researchers. A correlation matrix allows the researcher to 
reduce groups of variables to smaller sets without losing information. Tests such as 
the Keitel Functional Test and the mobility test measure a number of related vari-
ables. Also, radiogrammetry combines a series of variables of bone mass, which are 
not all necessary to draw meaningful conclusions. A series of correlation matrices 
were constructed with the goal of data reduction in mind, using Pearson and Spear-
man correlations. 
The correlation coefficients were applied to the concept of consensus analysis 
(Bull et al 1986), which is the mean of the correlation coefficients of a group of inde-
pendent variables. Calculations were done with Lotus 123. The spreadsheet was used 
in deriving histograms to illustrate important differences. Stepwise multiple regression 
and discriminant analyses were used where appropriate. Factor analysis (Gorsuch 
1974) was used to evaluate 27 variables representing disease activity, disability, bio-
chemical and radiological markers of OP. The measurements of finger strength were 
combined in a composite strength index. The tests of simple hand function were com-
bined in a composite hand index, in order to maximise the factor analysis of the 27 
variables. Further statistical techniques included the use of receiver operating charac-
teristic (ROC) curve analyses (Centor 1985) in evaluating the detectability of OP in 
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RA, as well as disease activity in RA, using clinical, laboratory and radiological vari-
ables. The IBM PC was used for this purpose, applying the spreadsheet of Centor 
(1985) in calculating the true positive ratio (TPR) and false positive ratio (FPR). The 
sample size per range of abnormality was derived with the CONDOR 3 database 
management system. 
In applying these techniques, the RA group was divided into 2 subgroups, based 
on the CA% below that of 90% of the normal control group ( < 10 percentile). ROC 
curves were derived for the :£ CCW, CCW, CA% and M6HS, comparing ranges for 
the normal control group and patients with RA In the RA group, the 2 subgroups 
were compared with the use of ROC curves for different measures of bone mass. The 
RA group was also subdivided into 2 groups based on the physician's assessment of 
disease activity. ROC curves were derived for clinical and laboratory variables in 
these groups. 
PRESENTATION OF THE THESIS. 
Several guidelines are available for the presentation of the thesis. Hawkins (1976) 
discusses a number of important features in a comprehensive outline of the prob-
lems. In this presentation, the results and discussion will be combined. This deviation 
from the conventional method was chosen in order to maintain continuity of thought. 
It was hoped that the reader would obtain a clearer understanding of the multifactor-
ial mechanisms of bone loss in rheumatoid arthritis. Caution was exercised in order 
to avoid the use of speculation in the presentation of the results. 
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Data was collected and stored on the IBM PC using the CONDOR 3 database 
management system. This was then transferred to the mainframe computer at the 
SAMRC for statistical analysis. The scatter plots were derived with the use of the 
Lotus 123 spreadsheet. ROC curves were constructed with Lotus 123 using the com-
puter programme reported by Centor (1985). The graphs were enhanced with the 
Lotus Freelance software. The manuscript was written with Microsoft WORD. Images 
were scanned with the DFI HS 2000 hand scanner. The final product was printed on 
the HP Laserjet II printer, using Ventura, the desktop publishing software for the 
IBMPC. 
RESULTS AND DISCUSSION. 
CLASSIFICATION CRITERIA OF DISEASE. 
CLASSIFICATION OF RHEUMATOID ARTHRITIS. 
Table 10 shows the prevalence of the criteria for classification of RA (ARA) 
(Ropes et al 1958). These compare with those of other series (Mitchell and Fries 
1982), suggesting that the patients with RA in this study were representative. Since 
most patients fulfilled more than 5 ARA criteria, it can be inf erred that very few pa-
tients required the more sophisticated diagnostic procedures, such as histology or sy-
novial aspiration, for classification. These findings concur with those of the ARA re-
vising committee (Arnett et al 1988) who have recently reduced the total number of 
criteria to 7. 
Table 10. Classification criteria for Rheumatoid Arthritis in 100 patients under 50 years of age. 
ARA Criterion 
Morning Stiffness 
Pain on motion of at least one joint 
Swelling in at least one joint 
Swelling in at least one other joint 
Positive Serology 
Symmetrical, Simultaneous joint disease 
Subcutaneous Nodules 
Poor Mucin Clot 
Characteristic Histology in 
Synovial Membrane 
Characteristic Histological 
changes in Nodules 
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The same table shows that all the patients in this study were considered to have 
radiological changes of RA (Ropes et al 1958) at the time they were seen for this 
study. The radiological assessment was performed by the same person who sub-
sequently performed bone mass measurements. The features in Mitchell's series 
were recorded at the time of presentation, while the present series includes patients 
with varying clinic follow-up. Patients with RA often develop further criteria as the 
disease progresses. This may explain some of the differences in the 2 groups of sub-
jects. 
Table 11 shows that 85% of the patients had classical RA. There were no patients 
with probable RA in this group of subjects. The revised criteria (1987) no longer dif-
ferentiate classical and definite groups. They also obviate the need for the long list of 
exclusions. Four criteria are now recommended for the diagnosis. 
Table 11. Summary of RA Classification according to ARA Criteria in JOO sub-
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CLASSIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS. 
Table 12 shows the criteria for classification of SLE (ARA), compared with 2 
other studies (Taylor and Stein 1986, Tan et al 1982). 
Table 12. Criteria for classification of SLE, comparing the present series of sub-
jects (72) with other reported studies. 
Present Taylor Tan 
Series & Stein et.al 
n=72 n=31 n = 177 
Criterion % % % 
Arthritis or Arthralgia 93 81 86 
Butterfly Rash 47 61 57 
DiscoidLE 15 19 18 
Photosensitivity 25 16 43 
Mucosal Ulcers 19 19 27 
Serositis 32 23 56 
CNS Lupus 21 13 20 
Renal Changes of SLE 42 71 51 
Positive ANF 99 96 99 
Haematological Abnormalities of SLE 74 61 59 
Positive ADA/ Sm/ WR 90 65 84 
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The antinuclear factor (ANF) was present in 99% of our patients with SLE. His-
tory of joint disease was the commonest clinical manifestation of the disease, con-
firming the findings of these workers. Immunological abnormalities were seen in 
90%. Auto-immune haemolytic anaemia, leucopaenia, lymphopaenia or thrombocy-
topaenia occurred at some stage of the disease in 74%, while the characteristic but-
terfly rash was seen in less than 50%. Urinary protein, casts, or biopsy evidence of 
renal disease was recorded in 42%. This is considerably less than in Taylor and 
Stein's (1986) series, which was confined to Blacks from Zimbabwe. Serositis was 
seen at some stage in approximately one-third of our patients with SLE (32% ). Dis-
coid LE and mucosa! ulcers were the least common clinical features in the present 
group. Approximately 1 in 5 patients had neurological features in the course of their 
illness. 
The table shows that the patients in this series were comparable with those seen 
in other parts of the world. There are minor differences in the distribution of individ-
ual criteria, but they need to be interpreted with respect to the actual classification of 
the disease, as shown in the table which follows. There is no relationship between the 
number of criteria at diagnosis and severity of disease. 
Table 13 shows that 3 of the patients in this series fulfilled less than 4 of the re-
vised ARA classification criteria for SLE (Tan et al 1982). They were included in the 
analysis of bone mass, since corticosteroid therapy had been commenced for the 
presumed diagnosis of SLE. 
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DEMOGRAPHY. 
AGEANDMENOPAUSALSTATUS. 
This is one of few studies of bone mass in RA, where the analysis has been con-
fined to an age-group where differences have generally been difficult to demonstrate 
with radiogrammetry (Saville and Kharmosh 1967). Causal relationships can be in-
ferred only when such stringency is applied to the selection of the study sample. 
The patients with RA were older, while the patients with SLE were younger than 
the controls, as shown in table 14. However, these differences were not statistically 
significant (p > 0.05). 
Table 14. The demographic features such as the mean, median and range of the 
subjects' ages is shown. All groups had a mean age less than 40 years. 
NORMAL RA SLE 
Number 100 100 72 
Mean 33.47 38.08 31.75 
Median 34 39 32 
Range (21- 50) (18 - 50) (19 - 45) 
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Each group of subjects had a mean age less than 40 years. Since RA is generally a 
disease of older females, it is not surprising that the mean age of the patients with 
RA was higher than that of the controls. Patients with SLE were younger than the 
controls, confirming the clinical impression that SLE is a disease of young females. 
Numerous epidemiological studies have shown that the physiological changes in 
bone mass are usually not detectable by radiogrammetry before the age of 45 years 
(Barnett and Nordin 1960; Meyers 1983; Solomon 1979). In addition, studies in pre-
menopausal subjects with RA have failed to show significant differences when com-
pared with premenopausal normal subjects (Saville and Kharmosh 1967). Therefore, 
any significant differences which may be demonstrated could be regarded to be due 
to some effect of the disease. Such differences may also be a reflection of the sensi-
tivity (precision) of the digitiser technique compared with the Vernier calipers. 
For this reason, the groups were only approximately matched for age. The mean 
age of the subjects with RA was not significantly different from that of the normal 
controls (Table 14 ), and a comparison between bone mass and age in the 3 groups 
showed that age did not contribute significantly to the differences in bone mass in 
this study. 
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RACEANDSEX 
Table 15 shows that the groups were adequately matched for race and sex, par-
ticularly in the Coloured group, who dominated in all 3 groups of subjects. The rea-
son for this is related largely to the fact that the RDU at GSH sees a greater propor-
tion of Coloured patients in comparison with other race groups, rather than a higher 
prevalence of RA in this ethnic group. 
Table 15. Frequency distribution of race and sex of the subjects under study. 
NORMAL RA SLE 
Number 100 100 72 
White Male 3 5 
White Female 27 16 5 
Coloured Male 24 16 4 
Coloured Female 45 48 56 
Indian Male 1 
Indian Female 1 2 2 
Black Male 3 
Black Female 10 4 
Overseas work (Mayor 1976) has shown that Negroes have a higher bone mass 
than age matched Whites. Solomon (1979), on the other hand, has shown that Blacks 
in Johannesburg (SA) have a lower bone mass than their White counterparts of com-
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parable age and sex. In a study of Coloureds in Rietpoort (RSA), no comparison was 
made with age - matched subjects of other race groups (Meyers 1983), but the fall in 
bone mass showed trends which were comparable with those of the Johannesburg 
study, as well as other studies in Caucasians. Wagener and Hough (1987) showed that 
Coloureds had lower bone mass than Whites, but the differences were not statisti-
cally significant (n = 582; n = 559). 
The present study was not aimed at comparing the race groups with respect to 
bone mass, and table 15 clearly shows that some groups were too small for statistical 
analysis. There is no evidence that the Cape Coloured is genetically predisposed to 
RA, SLE or osteoporosis. 
Figure 19 is a 3-dimensional histogram of the RA and normal control groups, 
showing the sex per study group (X-axis), racial distribution (Y-axis) and frequency 
(Z-axis) for the 2 groups. The age range is depicted by the height of each bar, as 
shown in the legend. The Coloureds, who formed the largest group, were comparable 
for age and sex distribution in the groups. The younger group of subjects with SLE is 
not shown. 
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Figure 19. Histograms showing the age, race and sex distribution of the groups 
under study. Coloured females predominated. 171e subjects with SLE are not 
shown (CM= Control Males; CF= Control Females; RAM= RA Males; RAF 
= RA Females). 
Age frequencies in RA and Normal young individuals 
CM CF RAM RAF 
Age group 
- 18-30 
~ 31 - 40 
[ill 41-·50 
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BONE MASS IN RA. 
METACARPAL RADIOGRAMMETRY. 
It can be seen from the review of the literature, that there are 2 major limitations 
of radiogrammetry. The first is due to the fact that the method only measures cortical 
bone, and the second is related to poor reproducibility. In order to overcome the first 
limitation, multiple areas were X-rayed. The preceding reliability studies showed 
that the digitiser technique used for the measurement of bone mass in this study was 
reproducible, overcoming the second limitation of the radiogrammetry method. 
The precision of the method needs to be tested by a longitudinal study in the 
same study group at a subsequent stage. However, if we assume that changes of bone 
mass in subjects below 45 years of age are generally small, a technique capable of de-
tecting significant differences between such age matched diseased and normal indi-
viduals would need to be highly sensitive and precise. Since our measurements were 
found to be reliable, valid conclusions can be drawn about bone mass changes in the 
study subjects with RA and these can be assumed to be due to the disease. 
The selection of subjects for study has also proved a limiting factor in the inter-
pretation of earlier reports of bone mass in RA. The most significant confounding 
factor is age, often associated with a change in sex hormonal status. These have been 
comprehensively a_ddressed in the introductory chapter. 
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There is controversy about the use of controls for comparative analyses. Some 
have suggested the the reference group for comparisons consist of young normal in-
dividuals (Barnett and Nordin 1960), while others have argued that the comparisons 
be made with age matched normal controls of all ages. Some of the studies in RA are 
summarised in Table 1 (pg 61). It can be seen that the subjects were generally of an 
elderly population (mean age > 50 years), making the interpretation of the results 
difficult to separate from age-related events. 
The literature is replete with studies showing that measurable bone loss begins 
after 45 years of age, irrespective of race (Exton-Smith et al 1969; Horsman et al 
1976; Solomon 1979; Wagener and Hough 1987). Postmenopausal females are 
known to show an accelerated loss, which is seen in males a decade or more later. 
Therefore, the subjects in this study represented a group of individuals in whom 
physiological bone loss is generally detected with great difficulty (Saville and Khar-
mosh 1967). The reasons for the careful selection of these subjects have been out-
lined. The review by Guyatt et al (1984), adequately summarises the defects in earlier 
studies of bone mass, particularly in corticosteroid treated patients. The criticisms 
apply to many of the studies of subjects with RA as well. 
Several calculations have been recommended for the determination of bone mass 
(fig 16; pg 191). Since the early studies of Barnett and Nordin (1960), workers such as 
Meema and Meema (1969), Dequeker (1972), Exton-Smith et al (1969a), Horsman 
and Simpson (1975), and Aitken (1984a) have addressed the limitations of the 
method and proposed modifications to overcome some of them. The calculations are 
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complex and there is no study in which all the various computations have been com-
pared with each other in the same individuals. 
Table 16 shows an unpaired comparison (t-test), taking into account unequal vari-
ances where necessary, between patients with RA and a group of normal controls. 
The table includes several of the different formulae which have been introduced by 
the various authorities for the purpose of normalisation of bone mass for body stat-
ure. The changes in the patients with SLE will be discussed separately, but reference 
will be made to the changes when related to possible pathophysiological mechanisms 
in the RA group. 
Table 16. Bone mass calculations in RA, using the standard techniques recom-
mended for nomia/isation of bone mass. 
Measurement Mean Mean p 
Control RA value 
(SD) (SD) 
AI 0.5893 0.5406 0.0027 
(0.089) (O.U7) 
MI 0.1077 0.0978 0.0002 
(0.014) (0.021) 
CA 0.4630 0.4247 0.0027 
(0.069) (0.099) 
CA% 85.1880 76.5957 0.0001 
(6.872) (10.14) 
CA/SA 0.0280 0.0252 0.0001 
(0.002) 0.003 
6MHS 62.5261 55.4786 0.0001 
(7.959) (8.733) 
6%CA 85.1085 79.0184 0.0001 
(5.711) (8.037) 
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The table shows that patients with RA have a significantly lower metacarpal bone 
mass than normal controls (p < 0.0001 ). The table also shows that in this group of pa-
tients, the differences remain significant at the most basic level of bone mass calcula-
tion (Barnett and Nordin 1960). However, the alternative hypothesis is strengthened 
by the corrections for body habitus, as is shown in the comparison of CA%, CNSA 
and M6HS, as suggested by Dequeker (1972), Exton-Smith et al (1969a) and Hors-
man and Simpson (1975), respectively. 
Since previous methods used the Vernier caliper to measure inner and outer 
diameters at the midshaft, it would seem that the method was not sensitive at detect-
ing small changes. The digitiser method overcomes a number of the limitations pre-
viously described and it is obviously more precise. In this study, 2nd metacarpal 
scores were comparable with 6 metacarpal scores in the RA patients. 
The various hand scores were correlated with each other using the Spearman 
rank correlation as a non-parametric test. The normal control group served as a basis 
for correlating different skeletal sites, as well as different calculations at the same 
skeletal site, in a non-pathological environment. Differences resulting from disease 
would change the basic correlations found in the control group. Table 17 shows the r 
value in the upper triangular matrix and the p value in the lower triangular matrix, 
for the control group. 
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Table 17. Speannan correlation of right second and six metacarpals in 98 nonnal 
control subjects. The r value is shown in the upper and p value in the lower trian-
gular matrix. Which 2nd metacarpal measure correlates best with the 6 metacar-
pal score? 
AI MI CA CA% CNSA M6HS M6CA 
AI 0.908 1.0 0.239 0.431 0.024 0.023 
MI 0.0001 0.908 0.193 0.99 0.153 0.156 
CA 0.0001 0.0001 0.024 0.431 0.024 0.023 
CA% NS NS NS 0.458 0.879 0.88 
CNSA 0.0001 0.0001 0.0001 0.0001 0.479 0.479 
M6HS NS NS NS 0.0001 0.0001 0.998 
M6CA NS NS NS 0.0001 0.0001 0.0001 
Table 17 shows that in normal subjects, measurements at the right 2nd metacar-
pal do not all correlate with those using 6 metacarpals of both hands. However, the 
CA% explained over 75% of the variation in M6HS and M6CA% (the square of r = 
0.88). The CNSA, on the other hand, showed significant correlations with all the 
other variables. This finding is in agreement with the suggestion by Exton-Smith et al 
(1969a), that it is the most representative measure of metacarpal bone mass using 
radiogrammetry. 
In addition, the table shows that in normal subjects, calculation of separate 6 
metacarpal hand scores is a redundant exercise (r = 0.998). These findings suggest 
that many of the recommendations previously suggested by other authors are, in-
deed, also pertinent to a young group of normal subjects. 
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Table 18 shows the same correlations in 97 young patients with RA. As in the 
previous table, the r value is depicted in the upper triangular matrix, while the p 
value is depicted in the lower triangular matrix. 
Table 18. Speannan co"elation of second and and six metacarpals in 96 patients 
with RA showing r value in upper and p value in lower triangular matrix. 
AI MI CA CA% CNSA M6HS M6CA 
AI 0.915 1.0 0.32 0.739 0.236 0.247 
MI 0.0001 0.915 0.534 0.99 0.441 0.448 
CA 0.0001 0.0001 0.325 0.739 0.236 0.247 
CA% 0.0011 0.0001 0.0011 0.663 0.896 0.899 
CNSA 0.0001 0.0001 0.0001 0.0001 0.553 0.567 
M6HS 0.0192 0.0001 0.0192 0.0001 0.0001 0.998 
M6CA 0.0144 0.0001 0.0144 0.0001 0.0001 0.0001 
Several differences become apparent on inspection of the table. The first obser-
vation is that CA is a linear function of AI. In addition, the correlations between the 
right 2nd metacarpal and 6 metacarpal scores are all significant (p < 0.02) in this 
group of patients with RA. The table also shows that the calculation of a host of 2nd 
metacarpal scores may be important. The variation in AI explained over 80% of the 
variation in MI (r = 0.92), and CA (r = 1). However, the variation in AI explained less 
than 10% of the variation in CA% (r = 0.325), M6HS (r = 0.236) and M6CA % 
(r= 0.247). The table shows that of the 2nd metacarpal scores, the CA% (r = 0.896) 
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best explains the variation in M6HS and M6CA %. Also, the effect of RA on bone 
mass is such that the calculation of CNSA does not appear to improve the sensitivity 
of the test relative to the CA%, even though the correlation with 6 metacarpal in-
dices is greater than with AI, CA or MI. 
The changes in correlations seen in the patients with RA confirm an osteopaenic 
process in the hands. Since the loss involves both hands equally (see later), no ad-
vantage is gained by repeating 6 measurements, except with respect to accuracy of 
measurements. This was borne out in the reliability studies discussed earlier, where it 
was shown that the accuracy of inner diameter measurement was considerably im-
proved by six measurements compared with a single measurement. Horsman and 
Simpson (1975), have suggested that the index derived by 6 metacarpals is as sensi-
tive as the bone mineral content (BMC) measured by single photon absorptiometry 
(SPA). 
Dequeker (1976) suggested that the differences must eventually be related to 
changes in periosteal (TW) and endosteal (MW) bone. Table 19 shows the rank 
correlations (Spearman) between these diameters and combined cortical width 
( CCW) of the right second metacarpal as well as the sum of the six cortical widths, 
and calculated bone mass for the control group. 
Table 19 shows that in normal subjects, CCW correlates significantly (p < 0.01) 
with the bone mass derived by CA, CA%, CNSA and M6HS. The outer diameter 
(TW) correlated significantly (p < 0.0001) with CA and M6HS, but the variation in 
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TW explained 23% of the variation in CA (r= 0.48) compared with 8% of the vari-
ation in M6HS (r = 0.28). 
Table 19. Comparison of co"elations of inner and outer diameters as well as 
combined cortical width of right 2nd metacarpal with bone mass in nonnal con-
trols. Also shown is the co"elation with the sum of the cortical widths of 6 meta-
carpals. The r value is depicted in the upper row and the p value in the lower row 
of the respective cross-co"elation. 
TW MW ccw I (CCW) 
CA (r) 0.49 0.25 0.27 0.45 
(p) 0.0001 0.02 0.013 0.0001 
CA% (r) -0.22 -0.71 0.61 0.65 
(p) 0.04 0.0001 0.0001 0.0001 
CA/SA (r) -0.12 -0.38 0.32 0.46 
(p) 0.09 0.0001 0.0002 0.0001 
M6HS (r) -0.28 -0.01 0.65 0.74 
(p) 0.005 0.0001 0.0001 0.0001 
The inner diameter (MW) correlated significantly (p < 0.0004) with CA%, 
CNSA and M6HS. The variation in MW explained 14% of the variation in CNSA 
(r = 0.38), compared with 48% of the variation in CA% (r = 0.69) and 69% of the 
variation in M6HS (r = 0.83). This shows that the inner diameter is the most signifi-
cant measurement for bone mass calculation in normal, young individuals. In addi-
tion, CCW is more important in the evaluation than either measurement alone. 
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Table 20 shows the rank correlations (Spearman) between the diameters and cor-
tical width of the right second metacarpal as well as the sum of the six cortical widths 
for the group of RA patients. Negative correlations in the table correspond to situ-
ations where MW has a greater influence on the normalisation process (see formulae 
in Fig 16). 
Table 20. Comparison of collelations of inner and outer diameters as well as cor-
tical width of right 2nd metacarpal, with bone mass in patients with RA. Also 
shown is the collelation with the sum of the cortical widths of 6 metacarpals. 
The r value is depicted in the upper row and the p value in the lower row of the 
respective cross- collelation. 
TW MW ccw I (CCW) 
CA (r) 0.52 0.02 0.44 0.63 
(p) 0.0001 NS 0.0001 0.0001 
CA% (r) -0.1 -0.69 -0.67 -0.79 
(p) NS 0.0001 0.0001 0.0001 
CA/SA (r) 0.11 -0.37 0.49 0.71 
(p) NS 0.0002 0.0001 0.0001 
M6HS (r) -0.2 -0.83 0.72 0.79 
(p) 0.044 0.0001 0.0001 0.0001 
It can be seen from table 20 that patients with RA exhibit a significant change in 
CCW. The variation in the sum of the cortical widths of 6 digits explained 40% of the 
variation in CA (r = 0.63). Variation in outer diameter (TW) explained 27% of the 
variation (r = 0.52) in CA, while variation in inner diameter (MW) hardly explained 
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any of the variation in CA (r = 0.02). Similar to the normal subjects, patients with RA 
showed the most significant correlations with the cortical width of the right 2nd 
metacarpal as well as the sum of the cortical widths of 6 metacarpals. 
In fact, the sum of the cortical widths explained 62% of the variation in M6HS 
(r= 0.79), compared with the cortical width of the right 2nd metacarpal, which ex-
plained only 52% of the variation in M6HS (r=0.72). Again, negative correlations 
are interpreted as being due to the influence of MW. In both groups of subjects, MW 
makes a greater contribution to bone mass calculation than TW. This table (Table 
20) confirms that metacarpal bone loss is significant in RA, and is largely related to 
loss of endosteal bone. However, cortical thinning at the metacarpals in RA is due to 
a combination of periosteal and endosteal resorption, although endosteal resorption 
predominates. This loss is similar to that seen in post-menopausal OP (Horsman et al 
1977). 
When the above tables are seen in conjunction, they highlight several features 
about the radiogrammetric detection of bone loss using metacarpal measurements. 
Although the statements would apply strictly to the patients under study, one might 
extrapolate to bone loss in other clinical situations, such as in post-menopausal OP, 
hyperparathyroidism, renal osteodystrophy, and osteomalacia, to name only a few. 
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The following points need to be emphasised, regarding the investigation of bone 
loss from hand X-rays in young patients with RA: 
1. TW plays a greater role than MW in determining CA (r = 0.5). However, the 
sum of multiple cortical widths is the most sensitive index of cortical area 
(CA). 
2. Calculation of the CA% amplifies the influence of MW (increased endosteal 
resorption) on the bone loss of Rheumatoid Arthritis. 
3. The sum of multiple cortical widths is a much stronger predictor of change 
in CNSA, a modification made to the basic formula, introduced for normali-
sation (standardisation). 
4. In RA, the 6 metacarpal hand score is virtually entirely predictable from the 
measurement of MW. This finding supports the suggestion that multiple 
measurements of the inner diameter improve the sensitivity of the radio-
grammetry technique. 
Muirden (1976) has suggested that the histological features of the bones in RA 
patients may resemble those seen in severe hyperparathyroidism and Paget's disease 
of bone. However, in those diseases the outer diameter is more significantly reduced, 
suggesting a discrepancy with our findings. Perhaps these discrepancies are due to 
differences between trabecular and cortical bone, since Muirden's report is based on 
biopsy changes at the iliac crest. 
Normal females had significantly lower values for inner diameter than normal 
males (p < 0.01), while the presence of disease reversed the difference considerably 
(p < 0.0001). In RA, the differences were not influenced by comparisons for gender. 
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The presence of disease had a greater effect on bone mass than the difference in gen-
der. 
Dequeker (1976), remarked that determinations of periosteal and endosteal 
changes over a period of time provides information on skeletal dynamics. The endos-
teal surface enlarges throughout life faster than the periosteal surface. Morgan et al 
(1967) found a poor correlation between cortical width and the width of the shaft in 
healthy individuals aged between 20 and 40 years. Dequeker (1972), found that corti-
cal area (D2 - d
2
) correlated best with outer diameter. This finding is confirmed 
above. 
In order to decide which of the 2nd metacarpal scores best represents the 6 meta-
carpal index, we performed consensus analysis (Bull et al 1986) using the correlation 
coefficients of the comparison between AI, MI, CA, CA%, CNSA, and M6HS. The 
results are depicted in the form of a histogram (Figure 20), showing that the CA% 
was the most suitable calculation of bone mass at the right 2nd metacarpal, closely 
representing the 6 metacarpal index. 
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Figure 20. Histogram showing the effect of consensus analysis. The consensus 
represents the mean of the r value of the comparison between the remaining 
variables and the 6 metacarpal hand score (M6HS ). 
CONSENSUS ANALYSIS - BONE MASS 
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Stepwise multiple regression analysis was used to determine which of the measures 
on X-ray best predicted the variation in CA%. The independent variables consisted 
of MW, TW and CCW at the midshaft of the right 2nd metacarpal, sum of inner and 
outer diameters of 6 metacarpals and sum of cortical thicknesses. Carpal length, 
CMR and Larsen index at the right wrist were included in the analysis. Both the RA 
group and the normal controls were evaluated. In the control subjects, the sum of 
inner diameters was able to predict 72% of the variation in CA%. Outer diameter at 
the 2nd metacarpal improved the predictive value to 80%, but none of the other vari-
ables were of any predictive value. In the RA group, on the other hand, 63% of the 
variation in CA% was predicted by the sum of the cortical thicknesses and the sum of 
inner diameters improved this to 83%. The other variables did not feature. This con-
firms the osteopaenic effects of RA. When the regression analysis was applied to 
CA% in SLE, the sum of inner diameters predicted 61 % of the variation in CA% 
while the sum of outer diameters increased the predictive value to 68%. These find-
ings suggest that the pathogenesis of bone loss in these 2 inflammatory diseases is 
significantly different. 
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WHOLE BONE PARAMETERS. 
Exton-Smith et al (1969a) showed that dry ash weight of bone correlates best with 
the cortical area. It can, therefore, be inferred that patients with RA have a signifi-
cant fall in the dry ash weight of bone. Aitken (1984a) has indicated that WBD, WBA 
and WBCa relate the physical and chemical properties of bone. Applying the knowl-
edge that the gravimetric density of bone is 2.0 G.mr1, these variables were calcu-
lated, using the measurements at the right 2nd metacarpal. Since these values are di-
rect multiples of the CA%, the differences and correlations can be expected to be 
identical to those seen when comparing the CA% with the other variables. These 
comparisons were, therefore, omitted in the present analysis. 
It is clear from table 21 that the bones of patients with RA had significantly lower 
chemical content than those of normal controls matched for age and sex. The find-
ings of this study are consistent with those of previous workers (McConkey 1965; Sa-
ville and Kharmosh 1967; Kennedy 1975), who have shown that bone mass is lower in 
patients with RA. However, this is the first study to demonstrate these differences in 
a group of premenopausal subjects under the age of 50 years by radiogrammetry, as 
discussed earlier. 
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Table 21. Whole bone density (WBD ), whole bone ash (WBA) and whole bone 























These results show that the patients with RA have accelerated OP as defined by 
Barnett and Nordin (1960). It becomes important to establish the pathogenesis of 
this bone loss. The further contributing factors which may have amplified this loss 
will be discussed later. 
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NUMERICAL DEFINITION OF OSTEOPOROSIS. 
The numerical definition of osteoporosis is based on the finding of a higher rate 
of fractures among subjects with metacarpal bone mass below the 10 th percentile of 
a normal control group. Table 22 shows that the prevalence depends on the ref-
erence bone mass for comparison as well as the measure of bone mass used. 
Table 22. Prevalence of Osteoporosis in RA using the Mean - JSD, Mean - 2SD 
and the 10 percentile value of the control subjects as the respective cut-off 
points. 
Measurement Prevalence of Osteopaenia 
Mean-1SD Mean-2SD 10 percentile 
CA 42.9% 17.3 % 33.7% 
CA% 53 % 30.6% 39% 
CA/SA 61.2% 37.8% 58.2% 
M6HS 45.9% 16.3% 32.7% 
M6CA 48 % 23.5% 33.7% 
It can be seen from table 22 that the CNSA was the most sensitive measurement 
of bone mass in RA, conflicting with our earlier observation that CA% is the most 
useful predictor of M6HS. If one accepts the fracture threshold as a bone mass less 
than 2SD below the normal mean, 37.8% of our patients could be expected to sustain 
a fracture if they should have a significant fall in the course of their disease. 
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HANDEDNESS AND BONE MASS. 
The following discussion will relate to the symmetry of changes in RA, and will 
also reflect the bone changes seen at other sites. In addition, the radiological features 
associated with RA will also be addressed in relation to the changes in metacarpal 
bone mass and the carpo-metacarpal ratio. 
Analysis showed that 98% of the normal controls were right handed while 10% of 
the patients with RA were left banded. The right 2nd metacarpal was selected to en-
able comparison with other studies (Barnett and Nordin 1960). It has been shown 
that involutional bone loss is symmetrical (Dequeker 1976). Similar studies in RA 
have been neglected. Therefore, the groups were compared using the diameters at 
the left 2nd metacarpal as well. There were no significant differences between the 2 
sides (p > 0.05). Similar comparisons using the other metacarpals on either side also 
showed symmetrical changes. This would suggest that the osteopaenia detected in 
this study was not due to the left-handedness of some of the subjects. 
The following scatter plots (Fig 21 - Fig 23) were constructed from the compari-
sons of the different measurements between right and left sides using the 2nd meta-
carpal of each hand. 
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Figure 21. Scatter plots showing the symmetry of changes in cortical thickness resulting 
from RA. The figure demonstrates that measurements of one hand closely reflect those 
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Scatter plots showing the symmetry of changes in total width resulting from 
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Figure 23. Scatter plots showing the symmetry of changes in medullary width resulting 
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These findings confirm the symmetry of radiological changes in the hands of pa-
tients with RA (Ropes et al 1958; Pitt 1986). The differences between the 2 sides 
were not statistically significant (p > 0.05). 
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RADIOLOGICAL CHANGES OF RA. 
These included an analysis of erosions, joint space narrowing (JSN), loss of allign-
ment and ankylosis. The methods used in this study have been reviewed. Difficulties 
related to reproducibility were not tested, but were overcome by confining the ana-
lysis to a single observer, who read all the X-rays. 
MODIFIED LARSEN INDEX AT RIGHT WRIST. 
The Larsen Index at the wrist has been modified (Larsen 1983), since it was first 
described (Larsen 1972). Several scoring methods have been described for measure-
ment of radiological changes in RA (Scott et al 1985, Larsen 1972, 1974, 1977, 1979). 
These have been shown to be reliable and reproducible (Sharp et al 1985). The 
changes in the wrists have been shown to correlate with changes in the periphery 
(Scott et al 1986), and for this reason the right wrist was the only area graded by the 
Larsen index (1977). 
The author scored the wrist according to the modified Larsen index (1983), recor-
ding the global impression of changes at the right wrist. These are shown in Table 23. 
The standard radiographs of Larsen were used for the evaluation. The intra-observer 
error was not studied. 
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Table 23. Modified Larsen index at the right wrist in 96 subjects with 
Classical or Definite RA. 
Larsen Grade Features Number 
1 JAOP 30 
2 JSN 10 
3 Erosions 21 
5 Ankylosis 37 
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It can be seen from table 23 that 37% of our patients had severe destructive dis-
ease ( erosions with ankylosis ). Thirty percent of the radiographs showed juxta-articu-
lar-osteoporosis (JAOP), while 10% showed joint space narrowing (JSN) as well 
(Larsen grade 1 & 2), giving a total of 58% with severe radiological change (grades 3-
5). This is an important point, since it shows that more than a third of this group of 
patients with RA had mild radiological disease, comprising the group in whom the 
Larsen index is least reproducible (De Carvalho 1981). This is the group in whom 
more reproducible radiological measures (such as radiogrammetry) might have a 
useful role in RA (Pullar and Capell 1985 and 1986). This is particularly significant 
with respect to longitudinal studies, where a change from one grade to another may 
be important in management (De Carvalho 1981). 
The correlation matrix depicted in table 24 shows that the modified Larsen index 
at the right wrist correlated significantly with the CA% as well as the 6 metacarpal 
hand scores (p < 0001). In fact, 20% of the variation in bone mass is explained by 
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variation in the Larsen index (r= 0.45; 0.43). This suggests that the 2 groups of vari-
ables ( disease severity and bone mass) are a reflection of a related pathogenetic 
mechanism. However, the correlation is far from perfect, suggesting that the basic 
mechanisms responsible for these changes are sufficiently different to be monitored 
separately. This finding needs to be interpreted with caution, since the the Larsen 
index represents a 5 point scale, whereas the bone mass represents a continuous vari-
able. The use of a rank correlation (non-parametric test; Spearman), makes the find-
ing statistically acceptable and important. As expected, patients with more severe 
Larsen grades at the wrist had a lower bone mass. 
Table 24. The modified Larsen index at the right wrist was co"e-
lated with the metacarpal bone mass, using a single metacarpal 
and the sum of six metacarpals. 171e r value is depicted in the 














Other studies have related bone mass changes in the metacarpals to erosive 
changes in the PIP and MCP joints, but not at the right wrist. One study (Castillo et al 
1965), showed that cystic bone changes were seen more commonly in males, who 
generally had a higher bone mass. Osteopaenia was more common in females, who 
generally had less severe changes and were thought to be less active, physically. How-
ever, no attempt was made to substantiate their claim by relating the changes to ac-
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tual differences in strength in the fingers and wrists. Another study (Reid et al 1988), 
showed good correlation between erosive change (at the PIP and MCP joints) and 
metacarpal bone loss. Trentham and Masi (1976) and Alarcon and Koopman (1985) 
compared the CMR to the Larsen index at the wrist, but not with metacarpal bone 
mass, so these results cannot be compared with the other reports. 
The Larsen index reflects a combination of bone loss and loss of cartilage. There 
is some suggestion that these processes occur independently of each other (Scott 
1985), so that both need to be measured separately. If metabolic processes control 
erosions, loss of bone mass may represent the earliest detectable stage of such a pro-
cess. This suggestion is confirmed by our finding of statistically significant negative 
correlations between the Larsen index at the right wrist and the CA% of the right 
2nd metacarpal. However, erosions are seen in the early stages at the margins of 
bone, yet our patients showed a more significant change in medullary width. It is 
possible that the correlation between Larsen index, erosions and outer diameter are 
more significant in comparisons at the respective sites, ie, MCP and PIP joints. These 
need to be evaluated in future studies. Radiogrammetry techniques for evaluating 
bone mass at the wrist have not been devised. 
In an attempt at further evaluating the relationship between the Larsen index at 
the wrist and metacarpal bone mass, pairwise comparisons were performed between 
the Larsen groups and between each Larsen grade and the normal controls, with re-
spect to medullary, total and combined cortical width at the right 2nd metacarpal; 
sum of 6 metacarpal diameters and cortical widths; CA% and M6HS (Table 25). The 
total width (right 2nd) was not significantly different across groups or in comparison 
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with the normal controls. Patients in the milder grade 1 had significantly smaller me-
dullary widths than those with a more severe grade 5. Only the patients with grade 5 
Larsen index had a significant increase in MW compared with the controls. The com-
bined cortical width (right 2nd) was significantly different between the groups. Only 
groups 2 and 5 were significantly different from the normal controls. Identical find-
ings were seen in the comparisons with the sum of 6 diameters. 
Table 25. Mean bone mass of various Larsen grades as well as normal controls. 
Comparisons were made between groups and against the nonnal control sub-
jects. 
Measure Larsen 1 2 3 5 Control 
TWo 0.34 0.37 0.36 0.42 0.32 
ccw 0.53 0.47 0.52 0.41 0.54 
CA% 81.57 76.27 78.54 71.55 85.15 
M6HS 59.96 55.87 57.91 50.36 62.46 
When the same groups were analysed with respect to metacarpal bone mass 
(CA%, M6HS), slightly different results were seen. Compared with the normal 
group, Larsen grades 2-4 had a significantly lower CA%, but only grade 4 had a lower 
M6HS. Grades 1 and 4, as well as grades 3 and 4 had significant differences in CA% 
andM6HS. 
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CARPO-METACARP AL RA TIO. 
The carpo-metacarpal ratio (CMR) has been recommended as a useful measure 
of severity in RA. Trentham and Masi (1976) showed that the ratio falls as a result of 
a shorter carpal length in patients with RA (n = 123). This fall in carpal length is 
probably due to a loss of cartilage between the carpal bones. Table 26 is a summary 
of the carpal length, metacarpal length and CMR in RA patients compared with nor-
mal controls. 


























The findings in this study confirm that the CMR is significantly reduced in RA 
The table also shows that cartilage loss is a significant component of the radiological 
change in RA. It can be seen from the table that the carpus is shorter in patients with 
RA. This is most likely due to the loss of joint space. The table also shows that the 
carpal length is the main determinant of the difference in the ratio between the 2 
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groups, although the metacarpal length was slightly increased in the RA group. The 
reason for the apparent differences in metacarpal length is surprising and difficult to 
explain adequately. It may have been due to difficulties in defining the ends of the 
bone in those patients with severe erosive change, or resorptive arthropathy (Mody 
and Meyers 1988). 
In the studies of Trentham and Masi (1976) and Alarcon and Koopman (1985), it 
was sho~ that the CMR was a useful monitor of disease progression in RA. They 
have also claimed it to be a more objective and reproducible measure than the Lar-
sen index. The mean ratio for our normal controls was comparable to that of Tren-
tham's control group. The patients in Alarcon's report had a mean CMR which was 
higher than that of our subjects. These 2 radiological methods measure similar 
events, since the variation in the Larsen index at the wrist explained 25% of the vari-
ation in CMR (r = 0.495;p < 0.0001), in the patients under study. 
The other studies have not measured bone mass, so that the relationship between 
the CMR, Larsen index at the right wrist and bone mass in the hands has not been 
previously explored. Table 27 shows these relationships. 
Table 27. Correlation matrix showing a comparison of the relationship between 
the Larsen index at the right wrist, CMR and metacarpal bone mass ( C4. % ). 
CMR Larsen CA% M6CA 
CMR 0.49 0.2 0.17 
Larsen 0.0001 -0.45 -0.43 
CA% 0.045 0.0001 0.9 
M6CA NS 0.0001 0.0001 
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The finding of a significant correlation between the Larsen index and the CMR 
has already been referred to above. There was no significant correlation between the 
CMR and the 6 metacarpal hand score (M6CA % ) (p > 0.05). The CA% just attained 
significance at the 5% level (p < 0.045), but explained only 4% of the variation in 
CMR. This is easy to understand, since the metacarpal indices reflect bone metabo-
lism and the CMR reflects both cartilage and bone metabolism. It is likely that the 
effect of RA at the wrist manifests cartilage loss to a greater extent than bone loss. 
Not surprisingly, there was a good correlation between carpal length and CMR 
(r= 0.88). It is also possible that the effects of the disease were disproportionately 
greater at the wrists than at the metacarpals (Sharp 1985). This is reflected in the sig-
nificant correlation between CMR and the modified Larsen at the right wrist. 
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FEMORAL CORTICAL WIDTH and FEMORAL INDEX. 
Two of the patients with RA had bilateral hip prostheses inserted for hip failure. 
Their measurements were excluded from the calculation of the mean and SD 
(n = 96). Table 28 shows the differences between the normal controls and the pa-
tients with RA. 





















The table shows that although the cortical width at the femur was significantly 
lower in patients with RA, the femoral index was not significantly different between 
the 2 groups. Fredensborg and Nilsson (1977), suggested that the index was a useful 
predictor of femoral neck fracture. This may be one reason why none of the patients 
in the present study demonstrated fractures of the femoral neck at the time of study. 
A longitudinal study is needed to evaluate this relationship more carefully. Perhaps 
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the patients with significantly reduced femoral bone mass are the ones who would 
fracture or experience complications from their prosthetic implants at a later stage in 
the disease. 
Patients with RA are known to be more susceptible to stress fracture (Fam et al 
1983). It has been suggested that this increased risk is related to bone loss in the 
femur. However, since the factors leading to fractures are not entirely understood 
(Cummings 1985; Cummings et al 1985), a prospective study would be required to as-
certain whether the fall in femoral cortical width plays a significant role in fracture 
incidence in RA. There is still controversy regarding the relationship between bone 
mass and femoral neck fracture in post-menopausal subjects (Cummings 1985). 
It has been suggested that the bone loss of RA is generalised (Kennedy et al 
1975). Therefore, the changes at the right second metacarpal, right wrist and both 
hands were compared with changes in bone mass at the left femur, using a correla-
tion matrix. 
The correlations in the normal controls were first tested to establish a baseline. 
The inner (MW) and outer (TW) diameters as well as the combined cortical width 
( CCW) at the right 2nd metacarpal, showed no significant correlations with femoral 
cortical width or the femoral index. The sum of these diameters in six metacarpals 
also failed to show any significant correlation. When bone mass (CA, CA%, CNSA, 
M6HS) in the hands was correlated with the femur, again no significant correlation 
could be demonstrated in these normal subjects. 
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In patients with RA, as shown in table 29, the femoral cortical width showed sig-
nificant correlations with TW and CCW at the right 2nd metacarpal, as well as the 
sum of the cortical widths of 6 metacarpals. However, the correlation with MW was 
not statistically significant. Since the inner diameter (MW) was the most significantly 
affected in the RA group, it is not surprising that a negative correlation existed be-
tween femoral width and medullary width. This suggests that an increase in medul-
lary width at the right 2nd metacarpal ( cortical thinning) is accompanied by a fall in 
femoral cortical width, lending support to the concept that generalised bone loss is 
seen in RA (Kennedy et al 1975). These findings suggest that the same mechanism 
causing periosteal resorption is responsible for femoral cortical resorption, but is dif-
ferent from that causing endosteal resorption in RA 
Table 29. Correlation matrix (Speamian) of metacarpal midshaft diameters 
and femoral cortical width measurements, showing r value in the upper and p 
value in the lower row, in patients with RA (n = 96). 
Metacarpal Femoral Femoral 
Measure Width Index 
TW (r) 0.24 0.21 
(p) 0.018 0.039 
MW (r) -0.03 -0.02 
(p) NS NS 
ccw (r) 0.2 0.2 
(p) 0.05 0.05 
I(CCW) (r) 0.22 0.2 
(p) 0.03 NS 
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The comparison with bone mass at the metacarpals and radiological changes at 
the right wrist are shown in table 30. Although the metacarpal bone mass calculations 
(CA%,CNSA,M6HS), showed no significant correlation with femoral bone mass in 
RA, the Larsen index at the right wrist showed significant correlation with the left 
femoral cortical width (p < 0.003). However, the variation in the Larsen index ex-
plained only 9% of the variation in femoral width (r = 0.29). The negative correlation 
confirms that the femoral width is significantly lower in patients with severe wrist dis-
ease. The femoral index, on the other hand, correlated less significantly with the Lar-
sen index (p > 0.05), and explained only 4% of the variation in the Larsen index 
(r= 0.2) at the right wrist. 
Table 30. Co"elation matrix of calculated metacarpal bone mass and femoral 
cortical width, showing r value in the upper and p value in the lower row, in pa-
tients with RA (11 = 96). 
Metacarpal Femoral Femoral 
Measure Width Index 
CA% (r) 0.16 0.01 
(p) NS NS 
CA/SA (r) 0.06 0.12 
(p) NS NS 
M6HS (r) 0.02 0.01 
(p) NS NS 
Larsen (r) -0.3 -0.1 
(p) 0.00 NS 
Carpal (r) 0.22 0.23 
Length (p) 0.02 0.02 
CMR (r) 0.01 0.08 
(p) NS NS 
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The carpal length correlated significantly with both the femoral cortical width 
and the femoral index. This finding supports our earlier suggestion that bone and 
cartilage loss occurs concurrently in RA An alternative explanation for these corre-
lations would be that severe disease in the wrists was a reflection of generalised se-
verity, resulting in reduced weight-bearing activities in such patients. 
The CMR, unlike the Larsen index or carpal length at the right wrist, showed no 
correlation with the femoral cortical width or femoral index (p > 0.05). The result 
shows that the generalised bone losing effect seen in these patients is reflected to 
some degree in the severity of the changes observed at the right wrist. Scott et al 
(1986), indicate that examination of the hands and wrists alone gives a good overall 
indication of both the extent of overall joint damage in any given time and the rate of 
progression of damage. The wrists are also often the most severely affected area in 
other series (Sharp 1985). Our findings support these suggestions. 
The practical implications of this finding are of potential importance in RA. They 
show that the Larsen index at the right wrist and metacarpal bone loss may be used to 
infer cortical changes further away in the skeleton, particularly the left femur. The 
implications regarding the prediction of femoral neck fractures and loosening of 
prostheses needs to be evaluated in longitudinal studies. 
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TRABECULAR BONE MASS MEASUREMENT. 
META CARP AL (JUXTA-ARTICULAR OP.) 
Juxta-articular osteoporosis (JAOP) is defined as the loss of bone adjacent to the 
joint capsule. The radius is considered to have trabecular bone at its proximal end at 
the carpus, and cortical bone more distally at the midshaft or one third up. This has 
been the basis of a number of SP A studies comparing cortical and trabecular changes 
(Dykman 1984), and probably applies to the metacarpal as well. The radiological de-
finition is largely subjective. Larsen et al (1977) regarded osteoporosis as the earliest 
change and used reference films in the assessment. They commented that compatible 
appearances may occur without arthritis in old age, Sudeck's atrophy, etc. The sub-
jective nature of such a method of diagnosis of osteoporosis in the hand was shown 
by De Carvalho (1981). In the present study, JAOP was regarded as that stage which 
was abnormal, but no erosions or JSN was present. It was thought to be present at 
the metacarpals in all the RA subjects (Table 4), but at the right wrist in only 30% 
(Table 23). 
There is no objective method of measuring JAOP radiologically. Horsman et al 
(1977) reported the use of a semi-automated computerised technique for 6 metacar-
pal bone mass measurement, but were unable to improve the observer error. Our 
study has shown that the metacarpal bone mass is highly reproducible using a di-
gitiser. A comparison between metacarpal diameters in normal controls and RA sub-
jects considered to have JAOP at the right wrist, as defined above, showed that CCW 
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was significantly lower in the group with JAOP. This suggests that bone mass in the 
patients with JAOP was significantly lower than in normal controls and that it can be 
objectively measured. One might infer from this that cortical and trabecular bone 
loss occurs concurrently in the hands of patients with RA. Since metacarpal bone 
mass measurement is objective and reproducible, it could serve as an important 
measure of disease status in patients with early disease. Digitised radiogrammetry 
may fulfill the need addressed by Pullar and Capell (1986). 
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FEMUR. 
THE SINGH INDEX 
The Singh index at the left femur has been shown to correlate with vertebral 
changes in patients with postmenopausal OP (Singh et al 1972). Surgery obviously 
produces changes in bone structure, so the patients with surgery to both hips were ex-
cluded. In the case of surgery to the left hip only, the right hip was used for measur-
ing the Singh index, as described earlier. The grades of porosity are shown in table 
31. This index in our patients was above the level which Singh associated with an in-
creased risk of spinal fractures, suggesting that none of the patients had detectable 
trabecular bone loss. The significance of this finding needs to be interpreted against 
the background that 30-50% of trabecular bone needs to be lost before it is detected 
visually. 
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The Singh index is not useful in patients with OA due to the severe changes from 
the disease (Dequeker 1983). In the current group of RA patients, this did not prove 
to be a major problem. This is likely to be due to our selection of ambulant patients, 
most of whom were unlikely to have major hip pathology. 
The correlation between CMR and the Singh index did not reach statistical signi-
ficance (p > 0.05). The Larsen index also showed no significant correlation with the 
Singh index of trabecular bone loss, suggesting that the metabolic effects on cortical 
bone are probably more significant in RA than on trabecular bone. However, since 
the responses of cortical bone cells are identical to those of trabecular bone cells in 
vitro (Kaplan 1987), these apparent differences are likely to be due to differences in 
the relative sensitivities of the measuring techniques used. 
LUMBAR VERTEBRA. 
VERTEBRAL INDEX. 
The vertebral index of Saville was also not significantly different in the groups, as 
shown in table 32. Again, the patients in this study were found to have an index which 
was above that associated with increased risk of spinal fractures. As discussed earlier 
with respect to the Singh index, these findings may reflect the insensitivity of the 
method rather than indicating differential rates of bone loss in trabecular and corti-
cal bone. However, the different metabolic rates in the 2 areas of bone may explain 
some of these findings. 
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Table 32. Vertebral index of Saville at L3 in 96 patients with RA, 72 with SLE 

















It has been previously shown that vertebral bone loss needs to exceed 30% before 
it is detectable on X-ray. In the absence of DPA, which is possibly the most sensitive 
method for detecting early vertebral loss, no further comments are possible regard-
ing changes in trabecular bone. 
Saville and Kharmosh (1967) showed that vertebral porosity increased as cortical 
thickness decreased. The correlations reached significance in patients over the age of 
50 years (n= 164). Hjelle et al (1970), measuring multiple sites such as the metacar-
pal, radius, femur and lumbar spine, found a decrease in bone mass at all sites except 
the vertebrae, in patients with RA. Although the femoral cortex was thinner than in 
age-matched normal controls, the difference was not statistically significant. Their 
study included subjects over 50 years of age (range 20-65; mean 47 years). They con-
cluded that weight-bearing and physical activity were important determinants of this 
difference, but did not quantitate the degree of physical activity in their patients or 
normal controls. 
Kennedy et al (1975), measured cortical thickness at the metacarpal, clavicle and 
femur. They found that the clavicular cortical thickness was lower in all age groups, 
RESULTS & DISCUSSION 250 
but that statistical significance was attained only in males between 55 and 65 years of 
age. They found a good correlation between metacarpal (MCI) and femoral cortical 
indices (FCI). The MCI and FCI were both lower than the clavicular cortical thick-
ness; this study confirming the suggestion by Saville and Kharmosh (1967), that age is 
an important factor in the genesis of bone loss in RA. Perhaps our finding of grade 3 
vertebral changes in 6 subjects each with RA and SLE is highly significant, particular-
ly if one considers the age group of the subjects. This group is too small for further 
statistical analysis. 
Studies after this period have used the more sophisticated techniques for 
measurement of bone mass (SP A, DP A, NAA). They are, therefore, not suitable for 
comparison with the findings in this thesis. In the present study, metacarpal bone 
mass did not correlate significantly with trabecular bone changes at the hip or the 
third lumbar vertebra. 
These later studies of trabecular bone using DPA (Sambrook et al (1987) have 
generally been marred by the lack of control for age and menopausal status. In the 
post-menopausal female with RA, disease does not seem to significantly influence 
the effects of age and the menopause on normal bone loss. Larger groups of pre-
menopausal subjects with RA need to be evaluated using DP A, in order for these re-
lationships to be more carefully analysed. Studies in RA using DP A must ultimately 
be related to metacarpal measurements, since the hand radiograph is probably the 
single, most useful investigation in the evaluation of patients with RA. Reid et al 
(1986) observe that the differences in TBCa measurements between RA subjects and 
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normal controls, matched for age and menopause, is largely due to the disproportion-
ate metacarpal loss associated with RA. 
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BONE LOSS IN SLE. 
This study was carried out at 2 different hospitals. Patients with SLE were seen 
regularly at the Lupus clinic at GSH. The normal controls and the patients with RA 
had their X-rays at PAOH. Since the major discussion revolves around the radiologi-
cal changes, it was important to establish that the methods were comparable in the 2 
centres. In order to test reproducibility, the phantom phalanx was included on most 
X-rays. The same mould was used at both institutions and comparisons were made 
between six X-rays from each centre. The analysis of variance showed that the dif-
ferences between the measurement of CCW at the 2 centres was not significant, as 
previously shown in Table 13. 
Involvement of the musculoskeletal system in SLE is one of the earliest and most 
frequent manifestation of the disease (Labowitz and Schumacher 1971). The degree 
of involvement may range from minor arthralgias or soft-tissue calcification to severe 
deforming arthritis (Alarcon-Segovia et al 1988) with multiple ruptured tendons 
(Cooney et al 1980). Although any joint can be involved, the knees, wrists and small 
joints of the hands are most common. Usually there is symmetrical involvement but 
up to 25% have asymmetrical disease. Deforming arthritis occurs in up to 30% of 
cases of SLE with arthritis, but hand deformities are rare and seen in 4-8% of pa-
tients (Bywaters 1975; Harvey et al 1954). Surprisingly, the development of these de-
formities most often occurs with little evidence of inflammation and may occur with 
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relatively little pam. This pattern of non-erosive, deforming disease has been 
referred to as Jaccoud's syndrome (Bywaters 1975). 
Sometimes, hook-like erosions of the metacarpal heads are seen late in the dis-
ease. Radiologic findings are usually few. There may be periarticular or diffuse OP. 
Soft-tissue swelling may be present, but typically there are no erosions, even when 
severe deformities are present (Weissman et al 1978). 
Despite these disabling effects of SLE and the increasing use of CS therapy for 
the control of this disease, systematic measurements of bone mass in SLE are lack-
ing. Textbooks (Dubois 1966; Schur 1983) contain empirical statements that OP is 
rare in SLE and usually associated with CS therapy. The need for objective evalu-
ation of bone mass in SLE becomes important with improved outcome of this disease 
(Studenski et al 1987), since more of these patients are likely to reach the meno-
pause. Avascular necrosis of the femoral head is seen in 7% (Kalla et al 1986) and 
Lindsay et al (1976) have shown the importance of bone mass measurement in pre-
dicting this complication in renal transplant subjects. 
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METACARPAL BONE MASS IN SLE. 
Pairwise comparisons between the normal controls and patients with SLE showed 
that these patients are also significantly osteopaenic, as shown in table 33. 
Table 33. Bone Mass in 72 patients with SLE, showing significant differences 
compared with nonnal controls. 
Measurement Mean Mean p value 
Control SLE 
(SD) (SD) 
ccw 0.59 0.552 0.01 
0.089 0.092 
AI 0.5893 0.5522 0.01 
0.089 0.092 
MI 0.1077 0.1062 NS 
0.014 0.012 
CA 0.4630 0.4339 0.01 
0.069 0.072 
CA% 85.1880 82.7149 0.04 
6.872 7.569 
CA/SA 0.0280 0.026 NS 
0.002 0.003 
6MHS 62.5261 61.411 NS 
7.959 7.828 
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The reason for introducing this second group of controls was to ensure that the 
differences found in the RA group were not necessarily due to a chronic disease. The 
degree of bone loss was much less than in patients with RA (see Table 16). Normali-
sation of bone mass removed the statistical significance of these differences. Since 
the CCW is significantly reduced in SLE, it needs to established whether the fall is 
due to periosteal or endosteal resorption (Dequeker 1972; Horsman et al 1977). 
When multiple groups are compared, the p value needs to be adjusted according-
ly. Duncan's multiple range test corrects for this Bonferroni effect. Table 34 was con-
structed by this statistical method, and showed that the two patient groups (RA,SLE) 
were similar with respect to CA, but they were significantly osteopaenic compared 
with the normal controls (p < 0.01). However, CA%, M6HS and M6CA% were simi-
lar between the normal controls and subjects with SLE, but the patients with RA had 
significantly lower values (p < 0.001 ). 
Table 34. Duncan's multiple range test for comparing 3 groups. The probability 
(p value) is appropriately adjusted for multivariate comparisons (Bonfe"oni ). 
The symbols (A, B, C) relate to significant differences between the means 
(p<0.05). 
Measure Control RA SLE 
I TW2 A A B 
I MW2 B A B 
I ccw2 A B B 
AI A B B 
MI A B C 
CA A B B 
CA% A B A 
CNSA A B C 
M6HS A B A 
M6CA A B A 
Carpus A B C 
CMR A B C 
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The area index (AI) was also comparable between the RA and SLE groups, but 
significantly lower than the normal controls (p < 0.01). The right 2nd metacarpal 
index (MI), was significantly different between the 3 groups (p < 0.001). The ratio of 
the cortical area to the surface area ( CNSA) was also significantly different between 
the 3 groups (p < 0.001). 
These findings show that, although RA and SLE both cause a fall in combined 
cortical width (CCW), the pathogenesis is different in the 2 diseases. Dequeker 
(1983) has shown that RA, similar to post-menopausal OP, causes an increase in 
MW. The fall in TW is usually a feature of diseases like hyper-parathyroidism and CS 
therapy. In the current study, PfH levels were not measured in the subjects with 
SLE. Ionised calcium Ca2+ levels were elevated in 49% of the RA group (normal 
PTH) and only 10% of the subjects with SLE. The mechanism of the elevated cal-
cium in RA is likely to be multi-factorial and will be discussed later. The significance 
of the marginally elevated Ca2+ in SLE is not known. 
When TW and MW are evaluated with regard to their respective contributions to 
cortical thinning in the 2 diseases, it can be seen from the box plots depicted in figure 
24 that SLE causes periosteal resorption while RA causes endosteal resorption. Both 
diseases are associated with significant cortical thinning. 






Figure 24. Box plots of the inner diameter (MW), outer diameter (TW) and combined corti-
cal width (CCW) in 3 groups of subjects. The box represents 75% of the readings and is 
divided at the mean, while the cross represents the median for that group. The lines com-
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Our findings suggest that the pathogenesis of bone loss (MBD) in SLE needs to 
be more carefully evaluated. Hyperparathyroidism is said to be uncommon in SLE, 
so it is possible that a PTH-like substance is responsible for the changes described. 
The small number of patients with elevated Ca2 + in this series mitigates against this 
mechanism. Perhaps IMO exerts its effects through IL-1 and other local mediators of 
bone resorption in this disease. These hypotheses need to be more carefully studied. 
There is experimental evidence that synovial cells from patients with these 2 diseases 
behave similarly in vitro (Seitz and Hunstein 1985). These findings become important 
in the light of the evidence that survival of these patients is considerably improved 
(Studenski et al 1987). 
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CARPO-METACARPAL RATIO. 
Table 35 shows that the CMR was also significantly reduced in patients with SLE. 
This is the first study where the ratio has been measured in SLE, so the significance 
of the changes is not clear. Although the arthritis of SLE is considered to be less 
severe than in RA (Cronin 1988), wrist involvement is probably a significant compo-
nent of the joint disease in SLE. This was corroborated by our finding that although 
93% of the SLE patients complained of joint symptoms, the Keitel score was much 
lower than in RA. In fact over 80% of the variation in total KFf could be explained 
by disease of the hands and wrists (see Table 49). 
Table 35. Comparison of carpal length, metacarpal length and CMR in SLE 
and nonnal controls. 
Measure SLE Control pvalue of 
Mean Mean Difference 
(SD) (SD) 
Carpal 3.17 3.44 0.0001 
Length (0.25) (0.26) 
Metacarpal 6.28 6.298 NS 
Length (0.43) (0.41) 
CMR 0.51 0.55 0.0001 
(0.04) (0.04) 
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Table 36 shows the comparison between CMR and metacarpal diameters. In the 
group with SLE, the CMR showed significant correlation with the MI at the right 2nd 
metacarpal (r = -0.3; p < 0.02), but not with any of the other bone mass calculations. 
However, the CMR showed significant correlations with TW and CCW at the right 
2nd metacarpal. 
Table 36. Relationships between carpo - metacarpal ratio (CMR) and metacar-
pal diameters in 98 nonnal controls, 72 patients with SLE and 96 patients with 
RA. 
Bone Mass CMR CMR CMR 
Measure. (Control) (SLE) (RA) 
MW2 (d) (r) 0.14 0.14 0.07 
(p) NS NS NS 
TW2 (D) (r) -0.02 0.26 0.19 
(p) NS 0.04 0.05 
TW2 -MW2 (r) -0.07 0.26 0.27 
(p) NS 0.04 0.009 
I (TW2-MW2) (r) -0.04 0.11 0.29 
(p) NS NS 0.004 
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The carpal length, on the other hand, showed significant correlation with all the 
metacarpal midshaft diameters in SLE (Table 37) (p < 0.001). Since the major con-
tribution to the change in CMR is due to a change in carpal length (Table 35), one 
might infer that bone and cartilage loss occur simultaneously in SLE. This would sup-
port the earlier suggestion that bone resorption in SLE is a manifestation of inflam-
mation. 
Table 37. Relationships between carpal length and metacarpal diameters in 96 
patients with RA, 72 with SLE and 98 nonnal controls. 
Bone Mass Carpal Carpal Carpal 
Measure. Length Length. Length 
(Control) (SLE) (RA) 
MW(d) (r) 0.28 0.38 -0.02 
(p) 0.01 0.003 NS 
TW(D) (r) 0.43 0.45 0.39 
(p) 0.0001 0.0003 0.0001 
TW2-MW2 (r) 0.41 0.36 0.49 
(p) 0.0001 0.005 0.0001 
I (TW2-MW2) (r) 0.53 0.39 0.54 
(p) 0.0001 0.001 0.0001 
In RA, where the destructive effect on the carpus is usually extensive, there was a 
significant correlation between carpal changes and endosteal resorption. It would 
seem that unrelated mechanisms govern the bone and cartilage loss seen in these 2 
diseases, since the cortical thinning in SLE was entirely due to periosteal bone loss. 
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Future analysis of these findings may confirm the close relationship between the 
chondrocyte, osteoclast and fibroblast, particularly in IMO. 
Table 38 shows the comparison of the correlation between carpal length and 
CMR, with metacarpal bone mass. It shows that in SLE (as in RA), bone and cartil-
age metabolism are affected to differing degrees. Although it is said that radiological 
changes in SLE are few, it would seem that the carpal length may have some value as 
a measure of radiological change in SLE. Osteopaenia is probably the result of the 
systemic nature of the disease and should be included among the systemic complica-
tions of SLE. 
Table 38. Comparison of the co"elation between metacarpal bone mass and 
carpo - metacarpal ratio in 72 patients with SLE, depicted in a standard co"ela-
tion matrix. 
Carpus CMR CA% M6CA 
Carpus 0.64 -0.27 -0.36 
CMR 0.0001 0.06 0.09 
CA% 0.04 NS 0.88 
M6CA 0.004 NS 0.0001 
It is clear from our findings that RA has a much more profound effect on the car-
pus than SLE. It would appear, therefore, that the mechanisms leading to loss of 
bone and cartilage are similar to, but less severe than, in patients with RA This is the 
first evidence of cartilage changes in SLE. The arthropathy of SLE is usually non-
erosive (Tan et al 1982), but ligamentous laxity is common. Jaccoud arthropathy is 
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well described in SLE (Bywaters 1975), and may be aggravated by hypermobility 
(Liote et al 1987). The mechanisms for subluxation and tendon rupture are not 
known, but it is possible that cartilage loss explains some of the ligamentous laxity 
seen clinically. 
FEMORAL CORTICAL WIDTH. 
The femoral cortical width in SLE was not significantly different from that 
measured in the normal controls. However, the outer diameter of the right 2nd meta-
carpal showed a significant correlation with femoral cortical width (r= 0.3; p < 0.02). 
The area index (r = 0.3; p < 0.02) and metacarpal index (MI) (r = 0.33; p < 0.008) also 
showed significant correlations with femoral width. Normalisation of bone mass 
(CA,CA%,CNSA,M6HS) reduced the correlation between these areas. The statisti-
cal significance of the correlation was considerably lower than in the RA group, indi-
cating that patients with SLE lose less femoral bone than patients with RA. However, 
these findings suggest that the bone loss in SLE is also generalised. 
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TRABECULAR BONE MASS. 
The Singh index and Saville index were not significantly different in the patients 
with SLE. compared with both the RA group and the normal controls. As in the case 
of patients with RA, these differences in metabolic events in trabecular and cortical 
bone may be due to several explanations. These could be due to effects of the dis-
ease, or may be a reflection of the sensitivity of the radiological method in detecting 
early trabecular changes. 
Osteoporosis has not been an area of systematic research in SLE. Textbooks gloss 
over it as an insignificant consequence, usually related to CS therapy. It is generally be-
lieved that vertebral fractures are uncommon; that the OP is mild and reversible. Our 
findings show that bone loss in SLE requires more carefuJ evaluation. The relationship 
with renal disease (2° hyperparathyroidism), inflammation mediated osteopaenia and 
CS therapy needs systematic evaluation. The mortality has improved over the years and 
many more subjects are likely to reach the menopause. The impact of OP in this disease 
is likely to gain prominence. There is a clear need for a search into the mechanisms of 
bone and cartilage loss in SLE. 
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FACTORS CONTRIBUTING TO OP IN RA. 
DEMOGRAPHY. 
RACE. 
The effects of race on bone mass are controversial. Reports from America have 
shown that bone mass in Blacks is significantly higher than in Whites in the USA 
(Garn 1967a & b; Mayor 1976). South African (SA) studies have shown the reverse; 
Whites in Johannesburg have a higher bone mass than Blacks of all ages (Solomon 
1979). In a study of Coloureds in Rietpoort (SA), no comparison was made with age-
matched subjects of other race groups (Meyers 1982), but the bone loss with age 
showed trends which were comparable with those of the subjects in the Johannes-
burg and overseas studies. 
Coloured females predominated the present study, most probably because the 
Cape has the largest population of Coloureds in the country. There is no evidence 
that Coloured females are genetically predisposed to the development of RA. The 
groups under study were matched with respect to the proportion of Coloured fe-
males (Table 15). This study was not aimed at showing differences between the vari-
ous racial groups, hence the smaller numbers of Black and White subjects. As a 
group, the two sets were found to be marginally comparable for race, sex and age, for 
meaningful conclusions to be drawn about differences in bone mass. 
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This study confirmed the need for normalisation of bone mass, as previously re-
ported (Dequeker 1976; Exton-Smith et al 1969a). The findings in Table 39 show that 
even in premenopausal subjects, the AI and CA are significantly different between 
the sexes. The results of normalisation techniques are shown in table 40. 
Table 39. Right'2nd metacarpal bone mass in males and females with RA, 
showing mean and result of comparison of the sexes in the various groups. 
Bone Sex Mean Mean p Value of Diff. 
Mass Control RA (M vs F) 
(SD) (SD) Control RA 
AI Male 0.6 0.64 
(0.09) (0.12) 
Female 0.57 0.51 
(0.08) (0.1) 0.0002 0.0001 
MI Male 0.11 0.1 
(0.008) (0.012) 
Female 0.11 0.09 
' (0.008) (0.014) NS NS 
CA Male 0.52 0.51 
(0.07) (0.09) 
Female 0.45 0.39 
(0.06) (0.08) 0.0002 0.0001 
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The statistical significance of the difference is diminished by normalisation tech-
niques (Table 40). 
Table 40. Effect of nonnalisation on differences in bone mass between 
males and females. 
Bone Sex Mean Mean p Value (M vs F) 
Mass Control RA Control RA 
(SD) (SD) 
CA% Male 83.56 77.06 
(7.95) (9.41) 
Female 85.71 76.44 
(6.48) (10.42) NS NS 
CNSA Male 0.027 0.026 
(0.001) (0.003) 
Female 0.027 0.024 
(0.002) (0.003) NS NS 
M6HS Male 59.66 54.3 
(7.97) (8.48) 
Female 63.44 55.86 
(7.82) (8.83) NS NS 
M6CA Male 82.55 78.15 
(3.1) (7.49) 
Female 84.41 79.3 
(6.16) (8.23) NS NS 
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The M6HS and M6CA were slightly higher for the females in both groups, but 
the differences were not statistically significant (p > 0.05). Similar findings were re-
ported by Wagener and Hough (1987), while others (Solomon 1979) found higher 
values for males of all ages. The group with SLE had too few males for a valid com-
parison between the sexes. It is known that patients with SLE are a highly selected 
group, since the disease has a predeliction for younger females. Coloured females 
predominated in this group as well, the mean age of the 72 subjects being 31.4 years. 
This is significantly lower than the RA group but not the normal controls. 
When an age and sex-matched comparison was done, the RA females (n = 73) 
and males ( n = 27) remained significantly different from the normal females ( n = 63) 
and males (n = 37; p < 0.001), irrespective of the radiogrammetric formula for bone 
mass calculation. However, when the females with SLE (n = 58) were compared with 
the normal females (n = 63), only the CA% showed a significant difference (p < 0.05). 
It would $eem, therefore, that age and gender do not make a significant contribu-
tion to metacarpal bone loss in RA. Perhaps other factors, such as disease activity 
(inflammation) and duration contribute to this loss to a greater extent. In post-meno-
pausal subjects with RA, Saville and Kharmosh (1967) showed that age contributed 
significantly to bone loss. This is not surprising, since the bone loss after the meno-
pause is multi-factorial and is likely to be aggravated by some of the effects of RA 
(Als et al 1985b ). 
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DURATION OF DISEASE. 
Duration of disease is generally calculated according to the time of the first ac-
ceptable symptoms of a disease. Studies in auto-immune diabetes mellitus, have 
shown that the immunological process is detectable some time before the onset of 
symptoms. There must also be a pre-clinical stage in the development of auto-im-
mune diseases such as RA and SLE. It is obvious that attempts at quantitating the 
duration of disease are often inaccurate, dependant largely on the ability of the pa-
tient to recall the exact date at onset of symptoms and patients generally have great 
difficulty in recalling such events with accuracy. 
Table 41 shows that patients with RA had a longer mean duration of disease than 
patients with SLE. This difference may be largely due to the fact that the RA patients 
were older at time of study. 
Table 41. Some demographic features in 72 patients with Systemic Lupus 




Age 38.2 31.8 yrs. 
(18-50) (17-45) 
Age at Onset 30 25 yrs. 
(17-49) (10-42) 
Duration of Disease 96 74 mths. 
(6-336) (3-408) 
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It has been suggested that the bone loss in RA occurs early in the course of the 
disease (Sambrook et al 1985b ). When the present RA group was subdivided at the 
median duration of disease (78 months), the group with duration less than the me-
dian (n=50) showed a significantly higher CNSA than the group with duration 
greater than the median (n = 48; p < 0.005). Sambrook et al (1985b ), showed that 
bone loss occurred within the first 3 years in their subjects with RA (n= 17). When 
the present group was subdivided at a duration of disease of 36 months, the CNSA 
and the M6HS were significantly higher in the group with duration less than 36 
months (n = 26). However, when the CNSA and M6HS of the patients whose disease 
had been present for less than 36 months were compared with those of the normal 
subjects, the difference was not statistically significant. Those with duration less than 
the median had significantly lower bone mass than the normal controls. 
This would suggest that bone loss in RA is progressive, and is significantly in-
fluenced by disease duration. In our patients with RA, bone loss became significant 
only after the disease had been present for more than 3 years. This is in contrast to 
the findings of Sambrook et al (1985b) and Als et al (1985b ). These findings also con-
tradict earlier suggestions that most of the bone loss in RA occurs early and reaches 
a plateau, since the loss in our patients was progressive after 3 years. Perhaps these 
differences are related to the differences in menopausal status of the patients from 
earlier studies. 
The patients with SLE showed no difference when subdivided at the median dur-
ation of disease of 54 months (n=30;p>0.0001). These differences may be related 
to the fact that disability in SLE is usually not as progressive as in RA. 
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The following line graphs (Fig 25a,25b, 25c) show the relationship between dis-
ease duration radiological changes at the metacarpal, wrist and femur. Figure 25a 
shows a significant downward trend (p < 0.05) in metacarpal bone loss. 
A similar downward trend is seen in the loss of carpal length (p < 0.0001) in pa-
tients with long-standing RA, as shown in figure 25b. The same relationship is shown 
with respect to the femoral cortical width (Figure 25c) [p < 0.0001]. 
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Figure 25a. Line graph showing that there was a significant downward trend in metacarpal 
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Figure 25b. Line graph showing that there was a significant downward trend in carpal length 
with increasing disease duration. 
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Figure 25c. Line graph showing that there was a significant downward trend in femoral corti-
cal width with prolonged disease. 
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SOCIAL IMPACT OF RHEUMATOID ARTHRITIS. 
RA is known to have far-reaching effects on the activities of daily living. It has 
been shown that the effects of disability erode the patients' personal relations as well 
as their work capacity (Brown et al 1987; Mody et al 1988). 
Table 42 shows a comparison of the RA group with the normal controls, showing 
the marital status and work capacity of the subjects under study. 





Single 27 24 
Married 57 68 
Divorced 15 7 
Widowed 1 1 
Employment 
Full Time 35 100 
Part Time 10 
Unemployed 55 
The control subjects were all employed at the time of study (for obvious reasons). 
It can be seen from table 42 that more than 50% of the patients with RA were unem-
ployed at the time of study. This is interesting, since the subjects were functionally in-
dependent (ARA FC 1 & 2). It is also interesting that twice as many RA patients 
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were divorced. Details of unemployment and reasons for divorce were not recorded 
in all cases. Some of the patients volunteered that reasons other than arthritis were 
responsible for the divorce or unemployment. This value is higher than the 40% of 
patients unemployed in a study by Brown et al (1987), who studied 254 patients of all 
ages with RA. However, the value is lower than the 76% of unemployed RA subjects 
reported by Mody et al (1988). The differences in these values may be related to in-
herent differences in the age-range and race of the subjects in the different studies. 
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DISEASE ACTIVITY. 
The role of disease activity in the genesis of the bone loss in RA is controversial. 
Some studies have shown no relationship between bone loss and disease activity 
(Virtama et al 1968, Reid et al 1982), while others (Steven et al 1982) have shown a 
significant relationship. Schorn (1983) showed that patients with RA receiving peni-
cillamine increased their bone mass over a 3 year period of therapy. Although this 
improvement could have been largely due to improved hand function, it is possible 
that the anti-rheumatic effects of penicillamine on the inflammatory load had a role 
in this improvement in bone mass. 
Table 43 summarises some of the clinical markers of disease activity in the sub-
jects under study. The ARA criteria for remission (Alarcon et al 1987), as well as 
components of systemic indices (l-,ansbury and Haut' 1958), were recorded in the sub-
jects under study. The features of active disease were divided according to the his-
tory, 'Physical examination and laboratory investigations. For the purpose of this dis-
cussion, functional assessment will be regarded as a separate evaluation. Various 
components are selected in developing a systemic index, which is based on a weighted 
evaluation of individual variables (Lansbury and Haut 1958; Mallya and Mace 1981; 
Bombardier and Tugwell 1982; Dixon and Wright 1986; Bull et al 1986). 
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Table 43. Features in the patient's history which indicate active disease. 
Measure % 
Pain VAS (PV AS) <5 69 
>5 31 
Severity VAS (SV AS) <5 72 
>5 28 
Night Pain 57 
Unable to Work Full Day 54 
Fatigue < 4HrsAwake 71 
Morning Stiffness > 45 min 55 
The clinical usefulness of many of these subjective variables is limited by the lack 
of objectivity and poor reproducibility (Wright et al 1985; Hart and Huskisson 1972). 
Dixon et al (1988) provide useful guidelines in choosing the best measurements for 
monitoring activity in RA, in the short-term. The visual analogue scales (VAS) show 
that more than two-thirds of the subjects in this study had pain (PV AS) and severity 
(SV AS) scores of less than 5 / 10. Fifty-seven percent had night pain. More than 50% 
felt they were unable to work an 8-hour day. Fatigue was a prominent feature in 
71 %, while 55% had significant early morning stiffness (EMS). 
Recent work has suggested that the patient's global evaluation be made a stand-
ard component of disease activity indices used in drug protocols (Meenan and Pincus 
1987; Kazis et al 1988). Our findings suggest that the patients base their evaluation 
on different variables compared with standard medical practice. Table 44 shows a 
comparison of the above variables, in a correlation matrix. All the variables showed 
significant correlations with each other (p < 0.01). 
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Table 44. Co"elation matrix of the comparison of features in the history, sug-
gestive of active disease. (Speamian co"elation showing r value in upper 
and p value in lower triangular matrix). 
SYAS PYAS Fatigue MS 
SYAS 0.57 -0.24 0.39 
PYAS 0.0001 -0.29 0.41 
Fatigue 0.02 0.003 -0.26 
MS 0.0001 0.0001 0.01 
The table shows that the patients' overall impression of the severity of disease 
was closely related to the perception of pain (r = 0.57), EMS (r = 0.39) and time to 
onset of fatigue (r=-0.24). Patients with active disease developed fatigue within 4 
hours of waking. It is interesting that the patients' evaluation of severity correlated 
significantly (p < 0.03) with all the other variables in this cluster, supporting our ear-
lier suggestion that it was a useful index of disease activity. 
The clinical measures of disease activity used in this study are summarised in 
table 45. These variables are also subject to significant observer differences (semi-
objective ). The findings in this study are based on the evaluation of a single observer, 
improving their objectivity (Kirwan et al 1983a & b; 1988). 
Table 45 shows that the subjects under study represented a heterogeneous group 
with respect to disease activity and severity. The physician's overall assessment of ac-
tivity is probably a reliable test of activity. It has been shown that therapeutic deci-
sions are largely based on such an assessment (Kirwan et al 1983a & b ). Forty-four 
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percent of the patients in this study were considered to have inactive disease, based 
on the physician's clinical evaluation. 
Table 45. Features found on clinical examination which are indicative of ac-
tive disease. 
No. of Warm Joints Mean 2.76 
Median 3 
Range (0 - 12) 
No. of Swollen Joints Mean 4.44 
Median 3 
Range (0 - 21) 
Ritchie Articular Index Mean 18.73 
Median 18 
Range (0 - 50) 
Physician Assessment Nil 44 
of Activity Mild 30 
Moderate 19 
Severe 7 
Modified Lansbury Mean 49.5 
Systemic Index Median 50 
(LSI) Range (12-107) 
The clinical markers of disease activity are compared with each other in the table 
46, which follows. The Ritchie articular index (RAJ) correlated significantly with all 
the other variables (p < 0.002). The physician's assessment of disease activity corre-
lated significantly with the number of swollen joints, the RAJ, and the number of 
warm joints (p < 0.004 ). The comparison of the correlation with the Lansbury sys-
temic index (LSI) confirms that the physician's assessment of the status of disease 
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was based on an objective evaluation of the features. Valid comparisons could, there-
fore, be made on an active and inactive group, based on the clinician's assessment. 
Table 46. Correlation matrix of the comparison of the clinical features of dis-
ease activity in RA, with each other. (Speannan correlation showing r value 
in upper and p value in lower triangular matrix. 
Physician Wann ·Swollen RAI LSI 
Physician 0.41 0.48 0.45 0.29 
Warm 0.0001 0.84 0.25 0.3 
Swollen 0.0001 0.0001 0.32 0.33 
RAI 0.0001 0.01 0.001 0.61 
LSI 0.004 0.003 0.001 0.0001 
Warmth and swelling of joints correlated very closely with each other. Warmth 
was evaluated subjectively, and the results with the use of thermography have been 
shown to be even more reproducible and accurate (Devereaux et al 1985). Table 46 
shows that the physician's overall impression of activity may have been influenced by 
the number of warm and swollen joints as well as the RAJ. The modified Lansbury 
systemic index (LSI) showed significant correlation with all the other measures of 
disease activity (p < 0.01). However, the RAJ explained the greatest proportion of the 
variation in the Lansbury index (r = 0.6), confirming its value as a simple test of dis-
ease activity in RA. 
The oblique principal component cluster analysis was used to establish the group-
ing of the clinical variables with respect to each other. The number of warm and 
swollen joints were separated as a cluster, while the RAJ was included with PV AS 
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and SV AS as a separate cluster. These clinical variables are compared with each 





Table 47. Comparison of the comlation of features in the history and physi-
cal examination in the patient with active RA (Speannan). 
Physician Warm Swollen RAI LSI 
(r) 0.157 0.323 0.34 0.259 0.44 
(p) NS 0.001 0.0006 0.01 0.0001 
(r) 0.192 0.27 0.207 0.402 0.468 
(p) NS 0.008 0.04 0.0001 0.0001 
(r) 0.11 -0.06 -0.04 -0.405 -0.59 
(p) NS NS NS 0.0001 0.0001 
(r) 0.389 0.16 0.239 0.419 0.493 
(p) 0.0001 NS 0.02 0.0001 0.0001 
It can be seen from table 4 7 that the RAI and the LSI correlated significantly with 
the more subjective measures of assessment of disease activity. The time to onset of 
fatigue, the duration of EMS and the PV AS were the most important subjective 
measures of disease activity in this group of patients, since they correlated more 
closely with the RAI and LSI. 
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changes are not significantly predicted by the clinical measures of disease activity in 
RA. It is clear from this that the clinical evaluation is a poor predictor of bone mass 
in RA. 
The total group was then subdivided into 2 groups based on the physician's as-
sessment of active disease. A discriminant analysis was performed using all the stand-
ard laboratory, radiological and dietary variables as well as SH groups, TBP, RBG 
and AlAT. The presence of night pain and hours to onset of fatigue were the.best 
clinical predictors of disease activity, with a sensitivity of 78% and a specificity of 
76%. However, the positive predictive value was only 58%, while the negative pre-
dictive value was much greater at 89%. This suggests that the absence of these 2 vari-
ables is predictive of inactive disease, while the presence does not necessarily imply 
active disease. None of the laboratory or radiological variables were significant pre-
dictors of disease activity. 
It was not surprising to find that the ESR, PV and CRP were unable to predict 
the physician's evaluation of active disease, since this was usually based on the clini-
cal evaluation only. In fact, none of the laboratory variables could significantly dis-
criminate the 2 groups. Among the dietary constituents, zinc content was a significant 
discriminant. When all the above groups of variables were combined, only 21 sub-
jects had all variables present for comparison. In this small number, the combination 
of dietary zinc content, night pain, fatigue and total width at the midshaft of the left 
2nd metacarpal were able to discriminate the 15 active and 6 inactive subjects with 
100% accuracy. 
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In the stepwise multiple regression analysis, where the physician's evaluation was 
the dependant variable, dietary constituents came through as remarkably significant 
predictors of active disease. When all the dietary variables were subjected to step-
wise regression analysis, combination of calcium content, 20-CF A precursors of ara-
chadonic acid and total phosphate content in the diet were able to predict up to 40% 
of the variation in disease activity. The femoral cortical width and white cell count in-
creased the predictability to over 60%. 
These findings are unusual and would be among the first to show this type of rela-
tionship, particularly with dietary components. Most other studies have concentrated 
on showing an improvement in laboratory variables of activity with fasting (Hafstrom 
et al, 1988). Our findings lend some credence to the age-old concept of dietary ef-
fects on RA. There is clearly a need for further evaluation of the relationship be-
tween dietary habits and activity of RA. A number of recent studies have looked at 
disease markers in response to fish-oil compounds (Kremer et al 1987; Panuch 1987; 
Belch et al 1988; Darlington 1988). They clearly seem to have a positive effect in re-
lieving symptoms, but they are unlikely to have disease-modifying properties. 
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FUNCTIONAL STATUS. 
The effects of immobilisation on bone mass are well known (Wright et al 1965; 
Kazarian et al 1969). Reference has been made to the difficulties in the measurement 
of physical activity. Functional tests, which are often used as a measure of disease ac-
tivity in RA (Steinbrocker et al 1949), are the only reasonable indirect measure of 
the patient's ability to perform activities of daily living (ADL). They do not include 
recreational capabilities, activity in sport, or many of the other simple activities re-
sponsible for the close inter-relationships between bone production and muscle ac-
tivity (Peacock and Francis 1983). Although it is known that physical activity is some-
times associated with increases in bone mass (Nilsson and Westlin 1971; Jones et al 
1977; Dalsky et al 1988), while immobilisation reduces bone mass (Wright et al 
1965), the quantity of physical activity/ inactivity which causes the critical imbalance 
between formation and resorption is not known. 
The earlier tests of function (Steinbrocker et al 1949), have remained in favour 
because of their simplicity. However, the simplicity limits their value in monitoring 
details of ADL, and reduces their usefulness in relating these with changes in bone 
mass. Grades 3 and 4 (ARA) are known to be associated with severe bone loss (Als 
et al 1985b ). It is particularly in the less disabled group that a global functional test is 
required for evaluating patients with RA. 
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The Keitel function test (KFf) is a useful test of global disability in patients with 
RA. Convery et al (1977) and others (Helewa et al 1982), have also reported global 
functional tests for RA, but these have not been carefully evaluated with respect to 
observer differences and are often time-consuming. Liang et al (1981), reviewed the 
objectivity and reproducibility of the more recent tests in patients with RA, and sug-
gested that the KFf fulfilled the requirements for a sensitive test of function. Badley 
et al (1984) have recommended 24 items of a Health Assessment Questionnaire 
(HAQ) as a measure of functional status in RA. The Stanford HAQ (Fries 1982) is 
also a marker of disease activity, as shown by Kirwan and Reeback (1986). 
ARA & UK FUNCTIONAL CLASSES. 
Table 48 shows the functional grades using the earliest classifications, the ARA 
(Steinbrocker et al 1949) and the UK (Joint Committee 1954). The difference in the 
2 methods is that the latter method attempts to increase the scale of measurement. 
Table 48. ARA and UK functional classification of activities of daily liv-
ing in 98 subjects with RA. 
n 
ARA Functional 1 22 
Class 2 76 
UK Functional 1 16 
Class 2 34 
3 48 
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The above table shows that the ARA and UK functional classifications are very 
similar. However, the UK method succeeds in spreading the distribution. The UK 
FC delineates a slightly less disabled group, which is not seen with the ARA FC. 
The inner diameter at the midshaft of all 6 metacarpals measured was significant-
ly different in the 2 ARA functional classes (p < 0.01 ). The M6HS (p < 0.01) and the 
M6CA % (p < 0.009) were also significantly different in the 2 groups. The outer 
diameter was not affected, nor was the combined cortical width at the right 2nd 
metacarpal. The sum of the combined cortical widths, however, was significantly dif-
ferent in the groups. 
The UK classification of function seemed to influence bone mass to a lesser ex-
tent, but the differences may be due to the smaller numbers in the respective groups. 
The combined cortical width at the right 2nd metacarpal was significantly different in 
the groups (p < 0.03). The sum of the cortical widths was also significantly different 
(p < 0.04 ). In addition, the CNSA was the only measure of bone mass which was sig-
nificantly different in the groups. The other measures of bone mass were not signifi-
cantly different between the groups. These findings need to be interpreted with cau-
tion, since 33% (UK FC) to 50% (ARA FC) of the variation in bone mass in these 
groups could be explained purely by chance. However, it does indicate that even rela-
tively minor disability could have a negative effect on bone mass. 
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KEITEL FUNCTION TEST. 
The Keitel Function Test (KFT) (Keitel et al 1972) was shown by a group of wor-
kers (Eberl et al 1976) to be more reproducible than the RAJ (Ritchie et al 1968). 
The strength of the RAJ as a clinical test of activity lies in its simplicity. Ritchie et al 
(1968), showed that it could be performed in 2-3 minutes. The KFT is carried out in 
12-15 minutes. For this reason, the KFT was arbitrarily divided according to groups 
of joints tested, in an effort to simplify the test. The test was analysed as a predictor 
of disease activity as well as bone mass. 
The hands, wrists, shoulders and lower limbs broadly represent the components 
of the KFT. It can be seen that the component areas are disproportionately repre-
sented in the total score. A standardised Keitel score was therefore derived for com-
parison with other activity indices (Lansbury and Haut 1958; Ritchie et al 1968). The 
hand and wrist will be considered jointly as the hand functional index (HFI). 
Table 49 shows that the patients with RA were considerably more disabled than 
those with SLE. The patient's with SLE had more extensive disease in the hands and 
wrists than in the shoulders or lower limbs. Both groups were significantly disabled 
compared with the normal controls. The articular disease in both these disorders was 
generalised (global). The patient's with SLE did not show significant disease of the 
shoulders (p > 0.05). 





Table 49. Total Keitel score (KFT) and components in RA compared with 
SLE. The nonnal controls had a Keitel score of 4, which is the minimum 
score attainable. The higher the score, the greater the disability. 
Mean Mean Range p value 
RA SLE RA SLE of difference 
(SD) (SD) 
27.21 12.89 4-42 4-36 0.0001 
(10.17) (9.27) 
2.13 0.04 0-10 0-1 0.0001 
(2.97) (0.2) 
8.7 1.72 0-36 0-22 0.0001 
(7.43) (3.49) 
38.04 14.65 4-86 4-39 0.0001 
(16.44) (10.65) 
The KFf evaluates the right and left limbs separately. The complete test evalu-
ates function in the interphalangeal, metacarpo-phalangeal, wrist, elbow, shoulder, 
hip, knee, ankle and metatarso-phalangeal joints. The comparison between the 2 
sides confirmed that symmetry was the rule. However, the ability to bring the tip of 
the thumb to the hypothenar was affected on the left in 52% compared with 40% on 
the right. The ability to place the hand on the right shoulder was affected in 44% 
compared with 37% on the left. Patients found it easier to place the hand behind the 
neck; 25% experiencing some difficulty. The 2 sides were equally affected in this ac-
tivity. In the group with SLE, patients found more difficulty bending the fingers of 
the left hand than the right. The left wrist was also more severely involved than the 
right. This asymmetry of involvement in the hands and wrists of patients with SLE 
has previously been reported in up to 25% of cases (Cronin 1988). 
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Thirty-eight percent (38%) of the RA patients had difficulty rising from bed, 
while 25% were unable to abduct the hips more than 50 cm apart. Less than 5% 
(4.17%) of the SLE group had difficulty with these activities. Twenty-three percent 
(23%) of the RA patients found difficulty rising from a chair, compared with 2.78% 
of the SLE patients. Thirty percent (30%) of the RA patients were unable to stand 
tip-toed for 15 seconds compared with 12.5% of the patients with SLE. Standing on 
the heels for 15 seconds was impossible for 26% of the RA group, but only 11.1 % of 
the SLE subjects. Knee-bending exercises were impossible in 28% of the RA group 
and 4% of the SLE group. 
The lower limb activities of individual joints showed symmetrical involvement of 
the hips in the RA group, while the left knee was more commonly involved. External 
rotation of the hip was symmetrically affected in 76% of the RA group. This is an un-
usual proportion, suggesting that the hip is commonly involved clinically in young pa-
tients with RA (mean < 40 years). This may also explain the significant femoral cor-
tical thinning seen in the RA group. It is also interesting that 30% of the patients 
with SLE experienced some difficulty in externally rotating either hip. This may have 
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The ability to walk 30 meters in 20 seconds was impaired in 54% of the patients 
with RA, compared with 6% of the patients with SLE. Forty-nine percent ( 49%) of 
RA subjects were unable to walk up 10 steps in 7 seconds, while 48% were unable to 
walk down 10 steps in that time. Only 6% of the SLE group had an impairment of 
these activities. 
It can be seen that for most of the functional components tested, approximately 
two-thirds of the RA group showed no difficulty. The alarmingly large number of pa-
tients with difficulty in rotating the hips, suggests that very few of the subjects were 
capable of strenuous recreational activities. Although no attempt was made to accur-
ately quantitate physical activity, it can be inferred that one-third (30%) of the pa-
tients with RA were severely disabled, compared with the normal controls. Patients 
with SLE were only slightly disabled. 
The KFf cannot be performed in less than 10 minutes, limiting its value in a busy 
clinic. The correlation matrix which follows, is based on an attempt at compartmen-
talising the test to make it more practical. The tests concerned with function in the 
hand and wrist (HFI) can be carried out in less than a minute, compared with 2-3 
minutes for the RAI. 
Table 50 shows that the components correlated significantly with the total Keitel 
score. The degree of correlation is related to the relative contribution to the score by 
the individual components. In RA, the HFI explained 76% of the variation in the 
total Keitel score (the square of r= 0.87). This means that the hand score could ade-
RESULTS & DISCUSSION 291 
quately replace the total score in the functional assessment of subjects with RA, as a 
global measure of disability. 
Table 50. Comparison of the correlation between the Keitel components and 
the total Keitel score in patients with RA. 
HFI SHOULDER LOWER LIMB KFf 
HFI 0.533 0.376 0.873 
SHOULDER 0.0001 0.428 0.675 
LOWER LIMB 0.0001 0.0001 0.743 
KFf 0.0001 0.0001 0.0001 
In patients with SLE, the hands and wrists explained over 90% of the variation in 
the total Keitel score. This means that these are the only areas which need to be 
evaluated to obtain a global measure of functional disability in SLE, as shown in 
table 51. 
Table 51. Comparison of the co"elation between the Keitel components and 
the total Keitel score in patients with SLE. 
HFI SHOULDER LOWER LIMB KFf 
HFI 0.152 0.348 0.95 
SHOULDER NS -0.026 0.136 
LOWER LIMB 0.003 NS 0.564 
KFf 0.0001 NS 0.0001 
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Functional impairment has potential as a marker of disease activity in RA, but 
has not previously been evaluated in this context. Bone mass is also closely related to 
functional impairment. Tables 52 and 53 aim to evaluate i) the role of functional im-
pairment in the genesis of bone loss in the metacarpals of patients with RA, and ii) 







Table 52. Comparison of the con-elation of the Keitel score and its compo-
nents with measures of bone mass in 98 patients with RA. 
HFI SHOULDER LOWER LIMB KFf 
(r) -0.204 -0.291 -0.326 -0.323 
(p) 0.04 0.004 0.001 0.001 
(r) -0.083 -0.141 -0.301 -0.124 
(p) NS NS NS NS 
(r) -0.237 -0.322 -0.337 -0.358 
(p) 0.02 0.001 0.0007 0.0003 
(r) -0.237 -0.324 -0.344 -0.359 
(p) 0.02 0.001 0.0005 0.0003 
(r) -0.09 -0.32 -0.281 -0.213 
(p) NS 0.001 0.005 0.04 
The above table shows that disability contributed significantly to the fall in bone 
mass in the patients with RA. However, CNSA was not dependant on the functional 
score, reaffirming its value as a measure of bone mass (Exton-Smith et al 1969a) in 
RA It is interesting that the total Keitel score explained a greater proportion of the 
variation in the metacarpal scores than the HFI. In fact, the HFI explained the smal-
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lest proportion of the variation in all the radiological assessments involving the meta-





Table 53. Comparison of the co1Telation of KFT and components with clini-
cal measures of disease activity in 100 subjects with RA. 
HFI SHOULDER LOWER LIMB KFf 
(r) 0.238 0.376 0.374 0.384 
(p) 0.02 0.0001 0.0001 0.0001 
(r) 0.05 0.154 0.346 0.223 
(p) NS NS 0.0005 0.03 
(r) -0.116 -0.066 -0.362 -0.248 
(p) NS NS 0.0003 0.01 
(r) 0.265 0.097 0.261 0.301 
(p) 0.008 NS 0.009 0.003 
Physician (r) 0.476 0.253 0.128 0.366 
(p) 0.0001 0.01 NS 0.0002 
Warm (r) 0.349 0.168 0.127 0.298 
(p) 0.0004 NS NS 0.003 
Swollen (r) 0.454 0.241 0.139 0.392 
(p) 0.0001 0.02 NS 0.0001 
RAI (r) 0.41 0.232 0.444 0.502 
(p) 0.0001 0.02 0.0001 0.0001 
LSI (r) 0.393 0.296 0.564 0.54 
(p) 0.0001 0.003 0.0001 0.0001 
Table 53 shows that the total KFf correlated significantly with all the currently 
used measures of disease activity. The RAJ and the LSI are commonly used in drug 
trials evaluating changes in disease activity (Rhind et al 1980). The KFf has not been 
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used in such studies, although a recent evaluation of auranofin ( oral gold) showed 
that the KFf is subject to changes by disease modifying drugs (Bombardier et al 
1987). In the present group, the KFf explained over 25% of the variation in both the 
RAJ and the modified LSI and correlated significantly (p < 0.0001) with these 2 vali-
dated tests of disease activity. Therefore, the KFf and its components would be a 
useful adjunct to the tests of disease activity in RA, but would not replace them 
(r< 0.9). 
The scatter plot shown in figure 26 depicts the relationship between the KFf and 
the RAJ. The KFf is probably a measure of disease activity, but the 2 tests are not 
mutually exclusive. 
Figure 26. Scatter plot showing the relationship between the KFT and RAJ in patients 
with Rheumatoid Arthritis. 
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The KFf and its components are more suitable tests of disease activity than the 
RAJ and LSI, since they correlated significantly with the radiological changes as well. 
The carpal length ( or carpo-metacarpal ratio) is considered a useful radiological test 
of activity in RA (Trentham and Masi 1976). The RAJ and LSI did not correlate sig-
nificantly with carpal length (p > 0.05), while the KFf did (p < 0.05). The components 
of the KFf also showed significant correlations with both radiological measures and 
disease activity measures, but explained only a small proportion of the variation in 
either group of variables. 
These findings suggest that the KFf is a useful overall test of disease activity in 
RA. It needs to be evaluated in longitudinal studies and may prove to be a valuable 
measure of activity and outcome, as shown recently by Bombardier et al (1987). 
DISABILITY QUESTIONNAIRE. 
The Stanford Health Assessment Questionnaire (HAQ) (Fries 1982) is a useful 
and reproducible method of evaluating function (Kirwan and Reeback 1986). Badley 
et al (1984) have adapted the test so that 24 of the most important components were 
selected. This disability questionnaire (DO) was recorded in the present group of pa-
tients with RA, in order to compare the method with the KFf, RAJ and LSI when 
used by a single observer. 
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The 24 components were grouped for 5 major aspects of mobility, using the 
Guttman scale of severity, as recommended by the World Health Organisation 
(WHO) (Badley et al 1984). 
Table 54 confirms that patients with RA were significantly less mobile than the 
patients with SLE. The normal subjects had a mobility score of zero. As with the 
KFf, the higher the score, the more disabled the subject. The differences between 
the groups remained significant even after correction for multiple comparisons, using 
Duncan's multiple range test. 
Twenty-one percent (21 % ) of the patients with RA experienced some difficulty 
walking to the toilet, compared with 15.28% of the patients with SLE (p > 0.05). 
Climbing on/off the toilet was a problem for 26% of the RA group, compared with 
5.5% of the SLE group (p < 0.0005). 







Table 54. Pairwise comparisons of the 5 categories of the disability question-
naire (DQ) between subjects with RA and SLE. Nomial subjects score "O" 
for this test. The higher the score, the greater the disability. 
Mean RA MeanSLE Range pvalue 
(SD) (SD) RA SLE 
6.87 3.76 0-24 0-23 0.0003 
(5.86) (4.72) 
6.52 2.31 0-28 0-22 0.0001 
(7.77) (4.16) 
13.74 6.58 0-35 0-31 0.0001 
(10.51) (8.12) 
3.09 0.63 0-17 0-10 0.0001 
(4.13) (1.72) 
14.38 4.69 0-49 0-32 0.0001 
(13.7) (7.68) 
44.6 17.97 0-135 0-98 0.0001 
(35.09) (20.23) 
Table 55 reaffirms the global effects of RA on the subjects under study, since the 
total mobility score (DQ) is suitably represented in the component scores (r = 0.82; 
0.83; 0.87; 0.69; 0.88). However, activities requiring the arm to be bent made the 
smallest contribution to the variation of the DQ. 







Table 55. Correlation matrix of the components of the DQ in patients with 
RA. (Speannan co"elation showing r value in upper and p value in lower 
triangular matrix.) 
MOBILITY BENDING DEXTERITY BENDARM REACH 
0.684 0.615 0.566 0.63 
0.0001 0.717 0.589 0.61 
0.0001 0.0001 0.592 0.68 
0.0001 0.0001 0.0001 0.51 
0.0001 0.0001 0.0001 0.0001 







Table 56 shows that the DQ and its components correlated significantly with the 
KFf and its components. It can also be seen from table 57, that the DQ and compo-
nents explained a greater proportion of the variation in RAI and LSI than did the 
KFf and components (Table 53). Therefore, the DQ could be regarded as a suitable 
test of disease activity in longitudinal studies of patients with RA, confirming the 






Table 56. Comparison of the DQ and its components with the KFT and 
components. 
MOBILITY BENDING DEXTERITY BEND ARM REACH 
(r) 0.35 0.35 0.28 0.36 0.24 
(p) 0.0004 0.0004 0.006 0.0003 0.02 
(r) 0.322 0.403 0.31 0.36 0.34 
(p) 0.001 0.0001 0.002 0.0002 0.01 
(r) 0.64 0.56 0.44 0.304 0.55 
(p) 0.0001 0.0001 0.0001 0.002 0.01 
(r) 0.56 0.54 0.41 0.41 0.46 















Table 57. Comparison of the DQ and its components with the Ritchie (RAJ) 
and Lansbury (LSI) indices. 
MOBILITY BENDING DEXTERITY BEND ARM REACH TOTAL 
0.547 0.47 0.54 0.44 0.46 0.6 
0.0001 0.0001 0.0001 0.0001 0.01 0.01 
0.549 0.53 0.46 0.37 0.55 0.61 
0.0001 0.0001 0.0001 0.0002 0.01 0.01 
However, comparisons with laboratory and radiological measures showed that 
the DQ and components did not correlate significantly with ESR, CRP, PV, metacar-
pal bone mass or carpal length (not shown). For this reason, it would seem that the 
KFf is a superior test of overall disease activity assessment in RA. The DQ has not 
been evaluated in drug trials of disease modifying drugs, but it is likely to change with 
improvement or worsening of disease. Its similarities with the Stanford HAQ sug-
gests that this is highly probable (Kirwan and Reeback 1986). 
The above tables show that patients with RA are severely disabled and incapaci-
tated by their disease. Lack of walking may have contributed to the differences in 
bone mass. 
It can be seen from table 58 that a wide range of disability is present in so-called 
mildly disabled subjects, judging by the KFf and DQ assessments of functional dis-
ability. The range of 5-86 (KFf) and 0-135 (DQ) is the same for the ARA and UK 
FC, confirming the insensitivity of these older tests in evaluating patients with poly-
articular diseases which affect predominantly smaller joints (Convery et al 1977). Our 
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findings suggest that objective measure of function may be a useful means of moni-
toring disease activity as well as outcome in RA. 
Table 58. ARA and UK functional classification of activities of daily living in 
98 subjects with RA, compared with co"esponding KFT and DQ scores. 
Considerable disability is present even though independence of activity is 
maintained. 
n Range of other Tests 
KFf HAQ 
ARA Functional 1 22 5-40 0-51 
Class 2 76 13-86 6-135 
UK Functional 1 16 5-40 0-51 
Class 2 34 6-64 0-99 
3 48 18-86 6-135 
DIFFICULTIES WITH THE SEXUAL ACT. 
The ease of sexual performance is a useful reflection of mobility (Cohen 1987). 
Although several factors control the sexual urge, performance is likely to be limited 
by severe disability. The patients with RA and SLE were questioned about sexual dif- · 
ficulties related to their arthritis. There are obvious problems in rating sexual diffi-
culty according to a Guttman scale, as was used for the responses to questions re-
garding mobility. Twenty-two percent (22%) of the RA patients had sexual difficul-
ties compared with 12.5% of the SLE patients (p < 0.05). Brown et al (1987) found 
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sexual problems in 71 % of 254 patients with a variety of rheumatic diseases, but their 
study was not confined to young subjects or FC 1 and 2. 
Comparison between the RAI, KFf, DQ, and difficulties in the sexual act are 
shown in table 59. It can be seen that the difficulty with sex was statistically signifi-
cantly related to both the markers of disease activity and measures of functional im-
pairment. However, if one considers that the question of sexual difficulties is a binary 
variable, at least 50% of the variation in the independent variable could be explained 
by chance. Since < 15% of the variation in the 3 variables was explained by the diffi-
culties in the sexual act, it is unlikely that the correlations were clinically significant. 
It is likely that the sexual disability was not solely due to lack of mobility or active dis-
ease, but that other, unrelated factors obviously influenced performance. Perhaps 
body image may have played a role in determining this reduced libido in both part-
ners. Although patients are generally reluctant to disclose personal matters of this 
nature, table 59 suggests that the responses of the patients were probably reliable. 
Table 59. Co"elation matrix showing difficulties with sexual activity as a mar-
ker of functional disability and disease activity in RA. 
SEX ACT KFf DO RAI 
SEX ACT 0.312 0.362 0.288 
KFf 0.002 0.568 0.504 
DO 0.0002 0.0001 0.609 
RAI 0.004 0.0001 0.0001 
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A comparison between the sexually active group and the inactive group using 
multiple comparisons (BMDP - 7D), showed that total mobility (p < 0.0001) and 
KFf (p < 0.0007) were significantly different between the groups, but the RAI was 
not significantly different (not shown). This suggests that sexual inactivity was less 
significantly related to pain or disease activity than to disability. 
The effect of sexual difficulties on bone mass measurements (t-tests ), are shown 
in table 60. The table shows that patients who expressed difficulty in performing sex-
ual activities had a significantly lower bone mass (CNSA; M6HS) than their sexually 
active counterparts. Since the hands are not specifically used in this activity, it is 
possible that the correlation is due to the generalised bone losing state in RA, which 
is most likely multi-factorial. The CMR was not significantly different in the 2 
groups, perhaps suggesting that disability rather than disease activity was responsible 
for these differences. 
Table 60. Comparison of bone mass in RA subjects who expressed difficulty 
with sexual activity compared with those who did not. 
Bone Mass Measurement. 
CA CNSA M6HS CMR 
Able 0.433 0.025 56.39 0.47 
Unable 0.395 0.023 52.12 0.46 
p value NS 0.05 0.006 NS 
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In order to further evaluate the basis of the bone loss due to sexual inactivity, a 
discriminant analysis was used to predict sexual disability, using age, duration of dis-
ease, DQ, total KFf, RAI, LSI, number of warm and swollen joints, pain VAS, CA% 
and M6HS as the independent variables. Total mobility was found to be the most sig-
nificant discriminant, with a sensitivity of 83% and specificity of 33%, further con-
firming that sexual inactivity was indirectly related to physical inactivity rather than 
disease activity. The positive predictive value was 71 %, while the negative predictive 
value was no better than chance at 50%. This suggests that factors not related to the 
DQ may have played a significant additional role in the sexual difficulties described 
by these patients. 
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SIMPLE HAND FUNCTION. 
Simple hand function was measured by an occupational therapist (OT), using 
tests recommended for evaluation following surgery (Clawson et al 1971). Four tests 
were used; testing the ability to use a knife and fork, doing up buttons, grip strength 
and power of pinch. These tests were performed in the patients with RA as well as 
the normal controls. The patients with SLE did not have these tests done, because 
the OT was stationed at one centre only. The results are summarised in the table 
which follows. 
Table 61 shows that simple hand function was significantly reduced in the patients 
with RA. It can be seen that the range of time taken using a knife and fork and to do 
up buttons was much higher in the patients with RA. This confirms that the group 
comprised of a heterogeneous population of disabled patients with RA. 
rable 61. Comparison of simple hand function between nonnal controls and patients 
vith RA, measured by the occupational therapist (OT). 
Test 















Mean p Value 
RA 
(SD) 
104.78 sec 0.0001 
(79.95) 




164.76 Kp 0.0001 
(94.69) 
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It can be seen from table 62 that bone loss in the hands of patients with RA was 
not related to the deterioration of the above-mentioned measures of hand function. 
The finding of a significant correlation with carpal length, however, is possibly a re-
flection of disease activity in the wrists, where function was probably inadequately as-
sessed by these tests. The fingers and wrist function as a unit when the hand is used 
for even the most mundane activities. 
Table 62. Comparison of the correlation between bone mass and simple hand function 
in patients with RA. 
CA% CNSA M6HS M6CA Carpal Length 
Knife & Fork (r) -0.06 -0.04 -0.21 -0.22 -0.23 
(p) NS NS NS 0.04 0.03 
Buttonhole (r) -0.14 -0.01 -0.25 -0.25 0.15 
(p) NS NS 0.02 0.02 NS 
Grip (r) 0.08 0.09 0.09 0.1 0.4 
(p) NS NS NS NS 0.0001 
Pinch (r) 0.07 0.04 0.09 0.09 0.29 
(p) NS NS NS NS 0.006 
Simple hand function did not contribute significantly to bone mass in the normal 
hand, either (not shown). However, activities requiring strength (grip strength and 
pinch force), have a positive influence on bone mass, particularly the M6HS, even 
though they did not reach statistical significance (p > 0.05). 
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Table 63 is a comparison of the correlation between the above tests of hand func-
tion and the diameters at the metacarpal midshafts. The sum of the cortical widths of 
6 metacarpals correlated significantly only with the grip strength (r = 0.35; p < 0.005) 
and pinch grip (r= 0.26;p < 0.04) in the normal controls. None of the other correla-
tions were statistically significant. 
Table 63. Comparison of the correlation between cortical thickness and simple hand 
function in nonnal controls. 
TW MW ccw I (CCW) CMR 
Knife&Fork (r) 0.12 -0.04 0.14 0.2 0.01 
(p) NS NS NS NS NS 
Buttonhole (r) 0.26 0.2 0.15 0.14 0.02 
(p) 0.04 NS NS NS NS 
Grip (r) 0.23 -0.03 0.22 0.35 0.1 
Strength (p) NS NS NS 0.005 NS 
Pinch (r) 0.07 0.02 0.12 0.26 0.05 
(p) NS NS NS 0.04 NS 
In the RA group, the time taken to do up buttons correlated significantly with all 
the metacarpal diameters. The correlation for MW (r = 0.35; p < 0.0006) was better 
than for TW (r=0.30; p<0.004). Grip strength and pinch force correlated signifi-
cantly with TW but not with MW (not shown). 
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HAND STRENGTH. 
Although it has been shown that bone mass is related to strength (Dickson et al 
1972; 1973), the relationship between functional impairment and strength in the 
hands is not known. One would expect that disabled hands would be weaker than 
normal. The five tests of strength measured with a dynamometer in the 3 groups of 
subjects are shown in table 64. 
Table 64. Tests of strength in the right middle finger and right hand. Nor-
ma/ controls, patients with RA and patients with SLE. 
MEASURE Mean Mean Mean 
Control RA SLE 
(SD) (SD) (SD) 
Flexion 20.23 9.5 13.57 
(8.11) (6.1) (4.85) 
Extension 3.33 1.85 2.25 
(1.35) (1.05) (1.05) 
Abduction 7.49 4.43 5.73 
(2.73) (2.72) (1.97) 
Adduction 6.09 2.9 3.5 
(3.39) (1.54) (1.97) 
Torque 55.35 26.55 36.28 
(18.46) (16.39) (11.49) 
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It can be seen from table 64 that the 3 groups under study were significantly dif-
ferent from each other, with respect to strength in the right hand. The patients with 
SLE formed an intermediate group of subjects. Extension of the right middle finger 
was the weakest movement in all 3 groups. The weakness seen in the RA group was 
possibly related to deformities leading to weaker grip, rather than an intrinsic weak-
ness of the muscle groups tested. 
Table 65 shows the comparison between simple hand function and hand strength 
in normal people. They seem to require no strength in doing mundane activities with 
the hand. Power of pinch was the only test which depended on strength in the middle 
finger. Grip was not dependant on strength, using the Mannerfelt apparatus. 
Table 65. Comparison of the comlation between hand strength and simple hand June-
tion in nonnal controls. 
FLEX EXTEND ABDUCT ADDUCT TORQUE 
Knife & Fork (r) 0.01 0.01 0.01 0.1 0.1 
(p) NS NS NS NS NS 
Buttonhole (r) 0.21 0.06 0.15 0.02 0.27 
(p) 0.07 NS NS NS 0.02 
Grip Strength (r) 0.16 0.12 0.22 0.11 0.26 
(p) NS NS 0.06 NS 0.03 
Pinch (r) 0.28 0.29 0.22 0.25 0.18 
(p) 0.02 0.01 0.07 0.03 NS 
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Table 66 shows that the situation is different in RA, in that the only function not 
requiring strength was the ability to do up buttons. 
Table 66. Comparison of the comlation between hand strength and simple hand June-
tion in patients with RA. 
FLEX EXTEND ABDUCT ADDUCT TORQUE 
Knife & Fork (r) -0.45 -0.1 -0.39 -0.39 -0.52 
(p) 0.0001 NS 0.0002 0.0002 0.0001 
Buttonhole (r) -0.19 -0.08 -0.1 -0.1 -0.17 
(p) NS NS NS NS NS 
Grip Strength (r) 0.57 0.46 0.54 0.49 0.65 
(p) 0.0001 0.0001 0.0001 0.0001 0.0001 
Pinch (r) 0.72 0.39 0.65 0.59 0.76 
(p) 0.0001 0.0002 0.0001 0.0001 0.0001 
Not surprisingly, extension of the middle finger seemed to make the least con-
tribution to these tests of function. Grip strength and power of pinch were signifi-
cantly correlated with hand strength in RA. It was surprising to find that weakness of 
extension explained over 20% of the variation in grip strength and pinch grip. It is 
clearly a sensitive index of overall strength in the hand. 
Table 67 shows the correlation between hand strength and global function in RA 
It is interesting that the HFI did not show any significant correlation with strength in 
the hand, apart from finger flexion (p < 0.04) and torque strength (p < 0.03). The 
KFT, on the other hand, correlated significantly with all the measures of hand and 
finger strength. Surprisingly, the DQ showed even more significant correlations with 
hand strength than the KFT (Table 67). The significant negative correlations with the 
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total KFf and total mobility tests, suggests that the patients with active disease had 
weaker hands. This is not surprising. The test of grip using the torquometer (Fig 10), 
was the most suitable test of hand function in patients with RA. This confirms the 
suggestion by De Choisy (1973) that this method be included in tests of therapeutic 
efficacy, since they found a significant correlation between torque strength and grip 
strength using a beaumanometer. 
Table 67. Comparison of the correlation between hand strength and global dysfunction 
(KFT, DQ) in RA. 
FLEX EXTEND ABDUCT ADDUCT TORQUE 
HFI (r) -0.41 -0.19 -0.13 -0.17 -0.23 
(p) 0.04 NS NS NS 0.03 
KFf (r) -0.38 -0.26 -0.3 -0.32 -0.36 
(p) 0.0001 0.01 0.003 0.001 0.0003 
DO (r) -0.46 -0.16 -0.44 -0.39 -0.52 
(p) 0.0001 NS 0.0001 0.0001 0.0001 
Dickson et al (1973), showed that function and bone mass, even in the normal 
hand, are related. They found that pinch force was significantly correlated with AI 
(area index), but flexion force was not. 
Table 68 shows the variation of bone mass with strength in the hand, in the con-
trols. All the tests of force correlated significantly with total width at the midshafts of 
6 metacarpals, but not with bone mass. However, torque strength and extension 
showed significant correlations with metacarpal bone mass, while finger flexion, ab-
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duction and adduction strength made no significant contribution to the variation in 
metacarpal bone mass. Less than 10% of the variation in bone mass could be pre-
dicted by the variation in torque strength, suggesting that its clinical usefulness in this 
regard was minimal. The significant relationship between hand strength and carpal 
length is interesting, but difficult to interpret. It probably indicates that hand strength 
is an important factor in the regulation of cartilage metabolism under normal cir-
cumstances. 
Table 68. Comparison of the co"elation between bone mass and strength in the hand, as 
measured with a dynamometer, in 96 nonnal controls. 
FLEX EXTEND ABDUCT ADDUCT TORQUE 
TW (r) 0.34 0.23 0.28 0.39 0.32 
(p) 0.002 0.03 0.008 0.0002 0.003 
CA% (r) 0.02 0.07 0.05 0.08 -0.24 
(p) NS NS NS NS 0.02 
CNSA (r) 0.11 0.10 0.13 0.08 0.03 
(p) NS NS NS NS NS 
M6HS (r) 0.04 -0.09 0.006 0.05 -0.28 
(p) NS NS NS NS 0.01 
M6CA (r) 0.05 0.23 0.02 -0.04 -0.29 
(p) NS 0.02 NS NS 0.006 
Carpal (r) 0.59 0.36 0.47 0.43 0.39 
Length (p) 0.0001 0.001 0.001 0.0001 0.001 
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Table 69 shows the variation of bone mass with strength in the hand, in patients 
with RA. Flexion force was not significantly correlated with bone mass in RA, con-
firming the findings Dickson et al (1973). However, they did not measure extension, 
abduction, adduction or torque strength. We measured all these variables in the nor-
mal control group as well as the patients with RA and SLE. These are summarised in 
the tables which follow. Differences in the patterns of correlation in the 3 groups 
could shed light on the pathogenesis of bone loss in RA. 
Table 69. Comparison of the correlation between bone mass and strength in the hand, as 
measured with a dynamometer, in 98 patients with RA. 
FLEX EXTEND ABDUCT ADDUCT TORQUE 
TW (r) 0.36 0.20 0.44 0.39 0.33 
(p) 0.0003 0.04 0.0001 0.0001 0.0001 
CA% (r) 0.05 0.26 0.005 0.002 0.005 
(p) NS 0.01 NS NS NS 
CA/SA (r) 0.11 0.41 0.13 0.08 0.03 
(p) NS 0.0001 NS NS NS 
M6HS (r) 0.04 0.23 0.006 0.05 -0.01 
(p) NS 0.03 NS NS NS 
M6CA (r) 0.05 0.23 0.02 -0.04 0.004 
(p) NS 0.02 NS NS NS 
Carpal (r) 0.36 0.26 0.33 0.45 0.33 
Length (p) 0.0004 0.01 0.001 0.0001 0.001 
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Table 69 shows that strength of finger flexion, abduction, adduction or hand 
torque did not contribute significantly to the variation in bone mass in patients with 
RA. However, extension of the middle finger (the weakest action), made a significant 
contribution to variations in bone mass (r= 0.4; p < 0.03). Extension of the right 
middle finger seems to be a useful marker of hand strength, even in RA. Similar to 
normal subjects, TW correlated significantly with all the measures of strength in the 
finger and hand. The carpal length correlated significantly with hand torque as well 
as finger strength ( all components). The variation in adduction of the middle finger 
explained up to 20% of the variation in carpal length (r = 0.45; p < 0.0001). This dif-
ference from the normal controls suggests that in RA, bone loss is related to changes 
in strength. However, other factors are more likely to be responsible for the metacar-
pal bone loss in RA, the likely culprits being the mediators of inflammation or some 
effect of the therapy of RA. 
In SLE (not shown), flexion force and torque correlated significantly with TW 
and MW in all the metacarpals. However, torque strength was the only variable 
which correlated significantly with CNSA (r = -0.38; p < 0.001) and the six metacar-
pal bone mass (r=-0.45;p < 0.0002). There was no significant correlation with CA or 
CA%. Carpal length correlated significantly only with torque strength (r = 0.38; 
p < 0.002). It is obvious that the bone resorptive effects in these 2 diseases are unlike-
ly to be due purely to changes in hand or finger strength. The negative correlation 
between bone mass and finger strength in SLE is interesting. Since this is the first 
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study of these relationships in SLE, the significance is not clear. It does, however, 
suggest that the genesis of metacarpal bone loss in these 2 diseases is very different. 
The findings in RA confirm the earlier suggestion (Dickson et al 1973) that flex-
ion force does not correlate with bone mass. In addition, total hand strength, as rep-
resented in the torque, did not contribute significantly to bone mass in RA, which is 
surprising. This supports the concept that bone loss in RA is likely to be due to a 
chemical rather than a mechanical effect of the disease. 
Stepwise discriminant analysis was used to establish the hand disability which was 
most useful in differentiating RA subjects from normals. This would be useful in ai-
ding the diagnosis in doubtful cases or in patients with ill-defined symmetrical poly-
arthritis. The measures of simple hand function as well as strength were used as the 
independent variables which would predict the disease group, comparing RA with 
the normal controls. Grip strength and time to do up buttonholes predicted RA with 
remarkable accuracy. Used in conjunction, these had a sensitivity of 97% and a speci-
ficity of 98%. Further discriminant analysis of these 2 variables showed that grip 
strength was the more sensitive (93%) and specific (97% ). The positive predictive 
value of 96% and negative predictive value of 95 % is remarkable. This finding has 
not been previously reported in RA and bears further evaluation in a prospective 
study with other rheumatic diseases. The test may be a useful addition to the revised 
ARA criteria for classification of RA (Arnett et al 1988) and SLE (Tan et al 1982). 
Unfortunately, the tests of simple hand function were not performed on the subjects 
with SLE, so that the discriminant value in these 2 rheumatic diseases could not be 
evaluated. 
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Table 70 shows a comparison of the 3 groups using Duncan's method. They were 
found to be significantly different from each other, even after correction of the p 
value for multiple comparisons (Bonferroni). In the table, the same letter implies 
that the means are not significantly different (p > 0.05). It can be seen that the pa-
tients with SLE were a distinct1y weaker group than the normal controls. However, 
patients with RA were significantly weaker than patients with SLE, except for adduc-
tion force in the middle finger of the right hand, which was equally weak in RA and 
SLE. 
Table 70. Duncan's Multiple Range Test comparing hand strength in 3 groups of young 
subjects, measured with a dynamometer. The symbols (A, B, C) imply significantly dif-
ferent mean values (p < 0.05). 
Measure Control RA SLE 
Abduction A B C 
Adduction A B B 
Flex.ion A B C 
Extension A B C 
Torque A B C 
Stepwise discriminant analysis using finger and hand force as the independent 
variables, was used to predict the underlying disease (SLE or RA : dependant vari-
able). Finger flexion was the most useful discriminant, with a sensitivity of 61 % and 
specificity of 71 %. The positive predictive value was 61 % while the negative predic-
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tive value was 71 %. It would seem from this analysis that the effects of arthritis in the 
hands has different sequelae with respect to hand strength in the 2 diseases. The pre-
dictive value of loss of finger flexion is statistically significant, but 30-40% of subjects 
would be at risk of being misclassified. 
The dynamometer has been shown to be a reproducible method of measuring 
hand function in RA (Helliwell et al 1987). Our findings support such a claim. 
RESULTS & DISCUSSION 317 
NUTRITIONAL STATUS AND DIET. 
NUTRITIONAL STATUS. 
Nutritional status was calculated by 4 methods. The reason for selecting 4 differ-
ent methods was to test whether skinfold thickness (SFT) is reduced in RA This 
would result in a discrepancy between Sloan's (1967) measure and that of Willmore 
and Behnke (1970). The calculation of BMI does not require either SFT or body 
diameters. 
Table 71 summarises the actual measurements. Pairwise comparisons using the 
T-test and the Bonferroni technique for multiple comparisons, showed that the pa-
tients with RA were not significantly different from the controls with respect to 
LBW. However, the patients with SLE were significantly leaner than the normal con-
trols and patients with RA, particularly with respect to body diameters. None of the 
patients under study were malnourished, defining ideal LBM as the range encompas-
sing 2 SD above and below the mean for the control group. 
Table 71. Lean body weight (LBW) of 89 nonnal controls, 87 subjects with RA and 67 
with SLE. 
Median Median Median 
Control RA SLE 
n= 89 78 67 
Sloan 1.097 1.098 1.098 
W-Bl 69.59 70.0 68.78 
W-B2 5.98 5.92 5.42 
BMI 22.99 22.49 17.14 
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Like bone mass, LBW is likely to be different due to the influence of race and 
gender. Duncan's multiple range test was used to compare the 3 groups with respect 
to the influence of race, gender and disease on the calculation of LBW. It was found 
that the LBW was comparable between the patients with RA and SLE and the nor-
mal controls. There was also no significant difference between Coloureds compared 
with the other race groups. However, males had a significantly higher LBW than fe-
males for all 4 calculations (p < 0.05). This was to be expected, so group comparisons 
were matched for gender. 
In order to select the most useful measure of lean body mass, the 4 methods were 
compared against each other. Table 72 shows that in the normal subjects, the meth-
ods correlated significantly (p < 0.001) with each other. However, W-B 2 compared 
better with Sloan's method than W-B 1, and the BMI showed an inverse correlation 
with the other tests, suggesting that the correlation was mainly due to the subject's 
height. This is difficult to explain. 
Table 72. Comparison of 4 calculations of bone mass using skin/old thickness and body 
diameters, in 89 nonnal controls. 17te co"elation matrix shows the rvalue in the upper 
and p value in the lower triangular matrix. 
SLOAN W-Bl W-B2 BMI 
SLOAN 0.379 0.535 -0.780 
W-Bl 0.0002 0.965 -0.410 
W-B2 0.0001 0.0001 -0.555 
BMI 0.0001 0.0001 0.0001 
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Table 73 shows that in patients with RA, on the other hand, the correlation be-
tween the anthropomorphic tests was more significant. In both groups, W-B 1 and 
W-B 2 were virtually replaceable (r=0.96; 0.95). The table shows that W-B 2 is a 
more sensitive measurement than W-B 1 in RA subjects. The BMI showed very weak 
correlations with the body diameters, but a very significant inverse correlation with 
skinfold thicknesses. The BMI is, therefore, a suitable test of nutritional status in RA. 
The correlation matrix shows that in RA, the tests are not mutually exclusive. 
Table 73. Comparison of 4 calculations of bone mass using skinfold thickness and 
body diameters, in 87 patients with RA. The co"elation matrix shows the r value in the 
upper and p value in the lower triangular matrix. 
SLOAN W-Bl W-B2 BMI 
SLOAN 0.449 0.553 -0.616 
W-Bl 0.0001 0.951 -0.174 
W-B2 0.0001 0.0001 -0.293 
BMI 0.0001 NS 0.01 
It can be seen from table 74 that in patients with SLE the correlation between 
Sloan's method and W-B 1 was not statistically significant. Also, W-B 2 seems to be 
the more sensitive measure of LBM in SLE. The BMI appears to be a simple 
measure of nutritional status in SLE as well. 
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Table 74. Comparison of calculations of bone mass using skinfold thickness and body 
diameters, in 67 patients with SLE. The co"elation matrix shows the r value in the 
upper and p value in the lower triangular matrix. 
SLOAN W-Bl W-B2 BMI 
SLOAN 0.19 0.23 -0.759 
W-Bl NS 0.94 -0.213 
W-B2 0.05 0.0001 -0.329 
BMI 0.0001 NS 0.007 
When the above tables are analysed in conjunction, it is clear that W-B 2 is the 
most sensitive measure of LBW which is likely to help differentiate the 3 groups on 
the basis of nutritional status. However, Sloan's calculation is less complicated than 
the Willmore-Behnke formula, giving it a small practical advantage. The BMI is the 
simplest measure of nutritional status. It is probably the most suitable test since it 
shows significance in all the groups tested, and it correlates significantly with Sloan's 
method. 
In the control group and patients with SLE, body diameters were found to corre-
late significantly with medullary and total width at the midshafts of all the metacar-
pals. Skinfold thicknesses did not show any significant correlations with metacarpal 
diameters. Furthermore, in the control group, BMI did not correlate with metacarpal 
diameters or metacarpal bone mass. Lean body mass calculated by the other 3 for-
mulae, correlated significantly with metacarpal diameters, but only LBWl and 
LBW2 correlated significantly with AI and CA. Carpal length correlated significantly 
with body diameters as well as skinfold thickness. The correlation with skinfold thick-
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ness was negative, which is difficult to explain adequately. These findings suggest a 
significant relationship between nutritional status, bone formation and cartilage for-
mation in health. 
In RA, similar correlations were seen. However, LBM calculated from SFf 
(Sloan) did not correlate significantly with metacarpal diameters or bone mass. None 
of the skinfolds showed any significant negative correlations with bone parameters. 
The BMI did not correlate significantly with the metacarpal diameters or metacarpal 
bone mass. The carpal length correlated significantly with body diameters, skinfold 
thicknesses and lean body mass, but not with BMI. This probably means that the 
bone loss in RA is not related to factors which influence nutrition. Cartilage loss re-
lates more significantly with disease activity than nutritional status in RA. 
In the control subjects, height correlated significantly with metacarpal diameters, 
AI and CA, but not with the other calculations of bone mass. In the patients with RA, 
both height and weight correlated significantly with metacarpal diameters, AI and 
CA. Abdominal SFf did not correlate significantly with any of the radiological vari-
ables. All the above correlation coefficients were higher for comparisons in the RA 
group, suggesting that the same processes which influence bone mass in this disease 
may also influence lean body mass, but to a lesser degree. 
McConkey et al (1965) found that older subjects receiving CS therapy had signifi-
cant relationships between bone mass and SFf. They proposed that both defects 
were due to the same factor inhibiting collagen metabolism. Schorn and Mowat 
(1977) showed that penicillamine therapy had no influence on wound healing and 
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improved metacarpal bone mass. Their findings disputed the suggestion of McCon-
key et al (1965). The SFf measurements in our study were at different sites from 
those reported in the above studies, so our results cannot be compared. Measure-
ments at the hands may be difficult due to soft-tissue swelling, while measurements 
at other sites may be influenced by loss of muscle bulk due to inactivity. Our findings 
suggest that thinning of the skinfolds is not a feature of RA in young subjects with 
metacarpal OP. 
In a recent study by Pitt et al (1986), SFf was measured histologically and radio-
logically in RA subjects. The study was confined to postmenopausal subjects. They 
found, surprisingly, that although the RA subjects had reduced skin collagen, skin 
thickness was increased compared with normal controls matched for age and meno-
pause. Our results cannot be compared with these results due to the differences in 
methodology. 
DIETARY RECORD. 
The 7-day dietary record allowed an analysis of the intake of various substances 
per 100G of food ingested. The calcium, phosphate, vitamin D, zinc, protein and 
total phosphate are likely to influence bone mass, so the analysis was restricted to 
these substances, and is shown in table 75. Recently, the 20-carbon fatty acids (20-
CF A), such as arachadonic acid, have been implicated in diseases like RA and SLE. 
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For this reason, the 20-CFA were analysed in the 3 groups. The statistical techniques 
compensate for sample size (type I error). 
Table 75. Chemical content per 100 Grams of food ingested by nonnal controls, patients 
with RA and SLE. 
Chemical Mean Mean Mean 
Compound Control SLE RA 
(SD) (SD) (SD) 
n=44 n=37 n=16 
Protein 131.31 59.66 179.08 
(162.6) (18.96) (185.85) 
Calcium 915.15 424.54 1390.7 
(1111.8) (193.87) (1844.13) 
Phosphate 1749.07 819.71 2596.91 
(2055.6) (294.35) (2911.66) 
Zinc 18.71 8.51 24.52 
(22.13) (3.11) (25.43) 
Vit.D 2.38 1.22 4.66 
(3.18) (0.78) (7.44) 
TotalPhos 1.51 0.95 2.80 
(2.32) (0.65) (4.13) 
20-CFA 0.30 0.12 0.37 
(0.37) (0.06) (0.43) 
The above dietary constituents were compared between the RA group and the 
controls, as well as groups matched for race and sex (not shown). There were signifi-
cant racial differences (p < 0.05) and males had a higher intake of all components 
(p < 0.1) The protein content (p < 0.03) and phosphate content (p < 0.02) were signi-
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ficantly higher in the RA group. Vitamin D intake was also significantly higher in the 
RA group. The other dietary components were not significantly different between 
the 2 groups. Since the bone mass in RA was significantly lower than that of the con-
trols, it would seem unlikely that dietary habits significantly influenced metacarpal 
bone mass in these subjects. The other compounds were not significantly different in 
the 2 groups. No attempt was made to quantify dietary supplements. None of the sub-
jects in this study was receiving vitamin D supplements at the time of the study. 
The adequate intake of calcium and vitamin D, and the adequate sunlight in SA 
would suggest that OM was an unlikely cause of the osteopaenia in this group of sub-
jects with RA. However, bone biopsy and vitamin D measurements in the serum 
were not carried out, so that OM was not conclusively excluded. OM is a recognised 
complication in some patients with RA (Ralston et al 1988). OM was also reported in 
11 % of elderly subjects thought to have OP (Schnitzler and Solomon 1983). 
A comparison of the correlation between the various dietary compounds and the 
components of bone mass (TW, MW and CCW), confirmed the lack of any associ-
ation. In the control group, protein, phosphate, zinc, folate and 20-CF A content 
showed a significant correlation with metacarpal lengths, but not with cortical widths. 
These correlations were absent in the RA group, suggesting that the effects of the 
disease override this potential dietary influence on bone metabolism. It would be in-
teresting to evaluate the comparisons in patients with idiopathic post-menopausal 
OP, where dietary factors have been postulated in the pathogenesis (Richman et al 
1979). We did not evaluate the relationships with vitamin C, which is a known factor 
in some patients with OP (Seftel et al 1966). 
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BIOCHEMISTRY. 
Numerous biochemical variables were measured in the course of this study. 
These were directed towards an analysis of metabolic bone loss (serum and urine cal-
cium and phosphorous,serum alkaline phosphatase, serum ionised calcium and PTH, 
urinary OH-Proline), nutritional status (serum albumen, cholesterol, retinol binding 
protein and thyroxine binding prealbumen), and disease activity (ESR, CRP, plasma 
viscosity, SH-groups, alpha-1-anti-trypsin). There is considerable overlap in these 
tests (Mbuyi et al 1982; Helliwell et al 1984b ), but they will be separately grouped for 
the sake of convenience. SI units were used in the laboratory. 
DISEASE ACTIVITY. 
Several workers have compared radiological changes with laboratory changes in 
RA. With respect to the Larsen index, it has been shown that there is no correlation 
between improvement in laboratory variables and improvement in erosive change. 
Very few workers have related changes to bone mass, and the results are controver-
sial (Reid et al 1982; Hancock et al 1978). 
The erythrocyte sedimentation rate (ESR) (Westergren), C reactive protein 
(CRP) (mg/ml) and plasma viscosity (PV) (cP) are established laboratory markers of 
disease activity in RA. Other tests include the measurement of SH-groups (Lorber et 
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al 1964; Grimaldi 1980; Hall et al 1982), alpha-1-anti-trypsin, haemoglobin (Hb) and 
circulating immune complexes (CIC) (Forster and McConkey 1986). Retinal binding 
globulin (RBG) and thyroxine binding prealbumen (TBP) are markers of nutritional 
status in RA, but they may be elevated as an expression of the acute phase response 
(Helliwell 1984 ). 
Some of these biochemical markers of disease activity are shown in table 76. The 
table shows that the RBG was not significantly different from that of the normal con-
trols, but TBP and SH groups were both significantly higher in the RA group. This is 
surprising, since SH levels usually fall during active inflammation (Hall et al 1982). 
Table 76. Laboratory markers of disease activity i11 patie11ts with RA. 
Test 11 Mean Median Range 
ESR 95 46.05 40 1-150 Illlll/Hr 
CRP 80 2.68 1.9 0-11.5 mg/ml 
PV 98 1.99 1.99 1.39-3.03 cP 
AlAT 94 2.76 2.64 0.53-5.84 mg 
SH 88 401.4 394 172-671 mg 
TBPA 94 44.8 41 4-375 mg 
RBG 70 43.57 46 8-88 mg 
The ESR, CRP and PV, the standard tests of disease activity in RA, showed signi-
ficant correlations with each other (p < 0.0001) [not shown]. However, the tests were 
not mutually exclusive, since the predictive value was less than 90% (r< 0.9) (not 
shown). Because there is some controversy about the value of the latter group of 
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tests (SH groups, RBG, TBP) in assessing disease activity in RA, we compared the 
correlation of these tests with the ESR, PV and CRP. 
Table 77 demonstrates that the SH groups showed a significant negative correla-
tion with ESR (p < 0.002; r= -0.3), confirming the findings of Hall et al (1982) but not 
with PV or CRP. TBP and RBG showed no correlations with these tests. AlAT, 
however, showed significant correlations with all 3 tests of activity. These findings 
show that AlAT may be a useful additional biochemical marker of disease activity in 
RA. Sulphydryl groups, RBG and TBP probably add little to the assessment of dis-
ease activity in RA. Despite recent criticisms (Chlud 1986), our findings confirm the 
value of the ESR as the standard against which newer tests should be evaluated. Bull 
et al (1986) also showed the importance of the ESR and PV in the laboratory evalu-
ation of active RA. 
Table 77. Correlation table comparing different biochemical 
tests of disease activity in RA. 
ESR PV CRP 
SH (r) -0.31 -0.004 0.107 
(p) 0.002 NS NS 
TBPA (r) 0.081 0.061 0.138 
(p) NS NS NS 
RBG (r) -0.139 -0.024 -0.033 
(p) NS NS NS 
AlAT (r) 0.324 0.289 0.361 
(p) 0.001 0.004 0.0003 
RESULTS & DISCUSSION 328 
Earlier, we showed that the physician's evaluation of disease activity was an ac-
ceptable representation of clinical variables generally in use. In order to examine the 
relationship between laboratory variables and the physicians' impression, pairwise 
comparisons were performed between the 2 groups (active vs inactive) for ESR, CRP, 
PV, SH-groups, TBP, RBG and AlAT. Each group was simultaneously compared 
with the normal controls for the latter 4 variables. The only variables which were sig-
nificantly different between the active and inactive groups were the AlAT and TBP 
(not shown). However, the SH-groups, TBP and AlATwere significantly different in 
the active group compared with the normal control values, but not in the inactive 
group. 
Discriminant analysis showed that none of the laboratory variables were able to 
adequately differentiate the 2 groups due to the wide overlap of positive tests in pa-
tients with clinically inactive disease. 
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METABOLIC BONE DISEASE. 
A wide range of tests in the urine and serum were used to study the biochemical 
effects of bone loss in RA. These are summarised in table 78. 
Table 78. Biochemical tests of bone metabolism in patients with RA. 
Test Number Mean RA Normal 
RA Range Range 
Total Calcium 97 2.36 2.13-2.77 2.1-2.6 (mmoles) 
Inorganic Phosphate 96 1.08 0.7 -1.57 0.8-1.4 (mmoles) 
Ionised Calcium 72 1.19 1.1-1.7 1.1-1.2 (mmoles) 
Urinary Calcium 90 1.76 0.1-10.8 1-5 (mmoles/1) 
Urinary Phosphate 89 15.85 3.4-55.0 <35 (mmoles/1) 
Urinary OH-Praline 93 204 41-999 (110-330) (mg/1) 
PlasmaPTH 100 2.17 0-22.0 (0-10) (pmol/1) 
Alkaline P04 96 95.8 2-253 (30-115) (IU) 
Table 78 shows that the range of biochemical readings in the patients with RA 
was higher than expected. The change must be due to abnormalities resulting from 
disease or related factors. Caution needs to be exercised in the interpretation of 
these changes. Although they may reflect metabolic bone events, they may also be re-
lated to disease activity (Mbuyi et al 1982). Table 79 shows the proportion of results 
which were abnormal in the patients with RA. 
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Table 79. Proportion of patients with RA whose biochemical tests 
were outside the upper limit of nonnal. 
Test % Abnormal 
Total Calcium 3 
Inorganic Phosphate 3 
Ionised Calcium 49 
Urinary Calcium 1 
Urinary Phosphate 2 
Urinary OH-Proline 10 
Plasma PTH 1 
Alkaline P04 25 
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It can be seen from table 79 that less than 5% of subjects with RA developed signifi-
cant abnormalities in total calcium, inorganic phosphate, urinary calcium and phos-
phorous, and plasma PTH. Elevated urinary OH-Praline levels are often regarded as 
a sign of bone resorption (Sambrook et al 1985a). However, it is possible that the 
elevation is due to active RA rather than an indication of bone resorption (Mbuyi et 
al 1982), particularly in view of the normal PTH, serum and urinary calcium and 
phosphorous seen in the subjects under study. The finding of an elevated ionised cal-
cium in 49% is difficult to explain. It could have resulted in a suppression of PTH se-
cretion. These findings confirm those of Kennedy et al (1979), but differ from those 
of Scott et al (1981) and Verstraeten and Dequeker (1986), who found low and nor-
mal levels respectively. 
The fact that a greater proportion of subjects had elevations of AP than OH-P sug-
gests that subjects with RA have excessive bone formation, probably as a reparative 
response to the chemically mediated resorption. However, AP may also be elevated 
in the acute phase response, making the interpretation difficult. The fact that GGT 
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levels were not simultaneously elevated suggests that the AP originated in bone 
rather than liver. Osteocalcin levels were not measured in this study, but have been 
found to be elevated by some workers, who have proposed that the OP in RA is cer-
tainly not due to a defect in bone formation (Gevers et al 1986). 
Kennedy et al (1976) proposed that bone resorptive activity in RA is increased due 
to a resorption stimulating factor, which causes an elevation in Ca
2+. Our finding of 
increased ionised calcium with normal PTH lends support to this concept. Table 80 
compares the correlation of ionised calcium and PTH, with bone mass measure-
ments. 
Table 80. Comparison of the correlation of ionised calcium, urinary 
OH-Praline and senun PTH with metacarpal bone mass in RA. 
Ionised OH Serum 
Calcium Proline PTH 
CA% (r) 0.17 0.10 -0.25 
(p) NS NS 0.01 
CNSA (r) 0.1 0.10 -0.2 
(p) NS NS 0.05 
M6HS (r) 0.24 0.06 -0.23 
(p) 0.02 NS 0.02 
M6CA (r) 0.24 0.06 -0.24 
(p) 0.02 NS 0.01 
Carpal (r) -0.1 0.01 -0.18 
Length (p) NS NS NS 
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It can be seen from the table that ionised calcium was positively correlated with 
the 6 metacarpal bone mass but not the right 2nd metacarpal bone mass. These posi-
tive correlations would imply that bone is not the source of the ionised calcium. This 
effect was associated with a significant negative correlation with medullary width, 
probably suggesting that at least some of the Ca
2+ was from resorbing bone. PTH, 
on the other hand, had a negative effect on 2nd metacarpal and 6 metacarpal bone 
mass. The mechanism of the resorption is not clear, since there was no significant 
correlation with total width or medullary width at the midpoint of the metacarpals. 
Urinary OH-proline, phosphate and calcium excretion did not correlate significantly 
with bone mass or the determinants of cortical thickness. These findings need to be 
interpreted against the background that bone mass changes reflect the result of dis-
ease over time while the blood results are a single measure at the time of study. Per-
haps the elevated levels of ionised Ca
2+ reflect some defect in transcellular trans-
port of calcium in RA osteoblasts. Reith (1983) has demonstrated the complexity of 
this process under normal circumstances. Wouters et al (1985) proposed a possible 
relationship with rapidly destructive polyarthritis in a patient with adult onset Still's 
disease who became hypercalcaemic. 
Stepwise multiple discriminant analysis was used to evaluate the predictive value 
of the above biochemical markers with respect to bone mass. CA% was the depend-
ant variable for this analysis. Ionised calcium was the only significant predictor, but 
the predictive value was only marginally better than chance at 6%. The other bio-
chemical markers were unable to significantly differentiate the osteopaenic group, as 
defined by a bone mass below the 10 percentile value of the normal control group. 
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It has been suggested that the ionised calcium may be a marker of disease activity 
in RA (Kennedy et al 1979). The levels showed no significant correlations with ESR, 
CRP or PV in our group of RA patients. We confirmed an earlier finding (Scott et al 
1981) of a significant correlation between ionised calcium and total calcium levels 
(r= 0.4;p < 0.0001). However, while total calcium was elevated in only 3%, Ca
2+ was 
elevated in 49%. This suggests that in our subjects with RA, Ca
2+ was a more sensi-
tive marker of metabolic events. Scott et al (1981) reported that RA is associated 
with hypocalcaemia, which is difficult to explain. 
Urinary OH-praline correlated significantly with urinary calcium and phosphate, 
but not with serum PTH levels. This could imply that urinary OH-P was elevated as 
an acute phase response. Alkaline phosphatase levels correlated significantly 
(p<0.01) with the ESR (r=0.32), CRP (r=0.25) and the PV (r=0.35), confirming 
our earlier suggestion that the serum AP in RA may be an expression of the acute 
phase response. There was also a significant correlation between AP, total calcium 
and inorganic phosphate (p < 0.01). These findings are difficult to interpret adequ-
ately, but probably reflect that the biochemical changes are related to disease activity 
rather than bone kinetics. Our findings confirm the suggestion by Mbuyi et al (1982) 
that caution is needed in interpreting the changes in markers of metabolic bone dis-
ease in RA. 
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NUTRITIONAL STATUS. 
Serum albumen is regarded as the most useful lab test of nutritional status (An-
derson and Wochos 1982). Levels may also be reduced as a result of the negative 
acute phase response. The RBG has been used in nutritional evaluation of RA, but 
there has been some suggestion that it may actually be a marker of disease activity. 
The TBP has similar problems (Helliwell et al 1984). Table 77 showed that both (the 
RBG and TBP) showed no significant correlation with clinical variables such as the 
number of swollen joints and Ritchie index, or laboratory markers such as ESR, PV 
or CRP ( table 77). It is likely that they were a measure of nutritional status instead. 
Albumin, on the other hand, showed a significant negative correlation with ESR and 
PV, but not CRP. It therefore, tends to behave as a negative acute phase reactant in 
RA, and is therefore an unsuitable measure of nutritional status in this disease. 
Table 81 shows the biochemical measures of nutritional status in SLE. Compari-
son with the results in RA (Table 76) shows that there are differences in the 2 
groups, but only the IBP levels were significantly higher in the RA group 
(p < 0.0001). 
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Table 81. Biochemical tests of nutritional status in patients with SLE. 
Test n=71 Mean Median Range 
RBG 55.79 55 18-108 
TBPA 37.38 37 7- 75 
Serum Albumen 38.9 34.2 21-47 
S-H Groups 391.03 378 205- 691 
A comparison of the correlation between these 2 lab tests (TEPA and RBG) and 
nutritional status using the 4 anthropomorphic methods in this study showed a signi-
ficant correlation between the method of Sloan and TEP (p<0.03; r=-0.24) (not 
shown). The negative correlation is difficult to explain, implying that well nourished 
subjects have lower TEP levels. Further work is needed to clarify the significance of 
this finding. Our results do not compare favorably with those of Helliwell et al (1984a 
& b ), who suggested that RA patients were significantly malnourished. 
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TREATMENT OF THE UNDERLYING DISEASE. 
Almost all (96%) of the subjects in this study received regular NSAI drugs. Table 
82 provides a breakdown of the type of therapy being used by the patients at the time 
of study. 39% of the RA group had received a disease modifying agent (DMA) at 
some stage of the disease. The patients with SLE required NSAI drugs less often 
( 41 % ) and 18% of this group required Chloroquine Phosphate. Corticosteroid ther-
apy was used at some stage of the disease in up to 28% of the patients with RA, com-
pared with 69% of the SLE subjects. 13% of the RA subjects and 38% of the SLE 
subjects were receiving CS therapy at the time of study. 
Table 82. Drng therapy in RA and SLE. A number of different non-ste-
roidal anti-inflammatory drngs (NSAJD) and disease modifying 
agents (DMA) were used. In the SLE subjects, Chloroquine was the 
only DMA in use. 
Medication RA SLE 
It 100 72 
NSAID 94% 41% 
SAARD 39% 18% 
Prednisone Past 28% 69% 
Present 13% 38% 
RES UL TS & DISCUSSION 337 
NON STEROIDALANTI INFLAMMATORIES (NSAID). 
Table 83 summarises the different NSAI drugs used in the treatment of the pa-
tients with RA The mean and range are dependant on the dose and duration of ther-
apy. These were not analysed any further, since changes were frequent and equival-
ent doses varied tremendously. 
Table 83. Non-Steroidal Anti-inflammatory drug (NSAID) therapy in RA. 
Drug Number Mean Dose 
Dose Range 
Indocid 65 27,0CJ9 mg. (2100-67200) 
Voltaren 68 33,446mg. (2100-50400) 
Naprosyn 25 165,760 mg. (14000-336000) 
Feldene 27 3,090 mg. (560-6720) 
Other 20 75,250mg. (11200-268800) 
Table 83 shows that diclofenac (Voltaren) was the commonest agent, often used 
in combination with indomethacin (Indocid). The preference for Diclofenac (Vol-
taren) reflects the bias of the clinician. The physicians at this clinic seemed to favour 
the use of oral diclofenac combined with rectal indomethacin. 
The effects of NSAID on bone mass were not evaluated. However, recent evi-
dence has shown that indocid and aspirin can inhibit osteoblast activity (Khokher and 
Dandona 1988). The osteopaenia of RA could be due to a reduced rate of formation, 
although studies of osteocalcin (Gevers et al 1986) mitigate against this possibility. It 
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is conceivable that the hypercalcaemia in RA is related to reduced incorporation of 
calcium into bone, due to an inhibitory effect of NSAID. However, the prevalence of 
hypercalcaemia was 49%, while 94% of the RA subjects were using NSAID regular-
ly. 
DISEASE MODIFYING AGENTS (DMA). 
The disease modifying agents (OMA) listed in table 84 were those most widely 
used in the RA subjects under study. As with the NSAID, equivalent doses of these 
drugs vary, so a comparative study using total dose at time of study was not possible 
for these agents. Penicillamine and myocrisin are the oldest DMA's in use, so it is not 
surprising that these drugs were used more commonly. The frequency of use of a par-
ticular agent reflects the bias at this clinic for Gold and Penicillamine. 
Table 84. Disease modifying agents (DMA) used in subjects with Rheumatoid Arthritis. 
Drug Number Mean Range 
Penicillamine 25 163,968 mg. (12600-1008000) 
Myocrisin 24 1,334mg. (200-4800) 
Ridaura 13 3,980 mg. (336-10080) 
Chloroquine 13 400,077 mg. (14000-2555000) 
Salazopyrine 14 402,000 mg. (56000-1344000) 
RES UL TS & DISCUSSION 339 
The mean duration of therapy with DMA's is shown in table 85. The period var-
ied between 7 months and 5 years ( mean 57 months). The tolerance was greatest 
with chloroquine, which was used longest. Reasons for stopping therapy with 
myocrisin or penicillamine ranged from skin rashes through blood dyscrasias, pro-
teinuria and lack of efficacy. Skin rashes were the commonest side effect. 
Table 85. Comparison of the duration of disease modifying agent (DMA) usage in pa-
tients with RA. 
Drug Mean Range 
Penicillamine 16 mths. (3 - 60) 
Myocrisin 20 mths (1- 96) 
Ridaura 23 mths (2- 60) 
Chloroquine 57mths (2 - 365) 
Salazopyrine 7mths (1- 24) 
The effects of DMA's on bone mass were also evaluated (not shown). A compari-
son of the correlation between type of therapy and bone mass was performed for all 5 
agents. This showed that there was no correlation between 2nd metacarpal bone 
mass and total dose of drug used, except for penicillamine. In addition, the total dose 
(p < 0.0001; r=-0.4) and duration of penicillamine therapy (p < 0.0001; r=-0.36) 
correlated significantly with femoral cortical width. The negative correlation was un-
expected and may indicate that penicillamine has a negative effect on femoral corti-
cal collagen metabolism. Another possible explanation for this may be that the peni-
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cillamine group had greater impairment of lower limb function. Penicillamine was 
also negatively correlated with carpal length, supporting the suggestion that these pa-
tients had severe disease. When the bone mass of treated subjects was compared with 
those of untreated subjects, there were no significant differences. The possibility of a 
type I error cannot be excluded with the small numbers of treated subjects. The posi-
tive correlation with metacarpal bone mass supports the findings of Schorn (1983). 
The total dose of ridaura correlated significantly with the 6 metacarpal bone mass 
(p < 0.05; r=-0.2) and medullary width of the right 2nd metacarpal, but not with 2nd 
metacarpal bone mass. The negative correlation probably implies more severe dis-
ease in the ridaura group. Chloroquine therapy showed a significant correlation with 
carpal length (p < 0.0003) and CMR (p < 0.0007), but not with bone mass. Total 
width in the metacarpals correlated significantly with chloroquine usage. Salazo-
pyrine therapy did not correlate with bone mass or carpal length. However, there was 
a significant correlation with the length of all the metacarpals. Since these results are 
based on use of these drugs at any stage of the disease, one is unable to comment fur-
ther on their effects on skeletal dynamics. 
Significant correlations were also observed with the raw measurements of cortical 
thickness. Penicillamine therapy was significantly inversely correlated with inner 
diameter at the midshaft (r=-0.23). The possible reasons for this apparent paradox 
have been alluded to above, with respect to femoral cortical width. The work of 
Schorn and Mowat (1977) showed that this relationship with penicillamine therapy is 
unlikely to be due to the interference with collagen metabolism associated with the 
use of this drug. However, the effects of penicillamine on bone are not known. 
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Stepwise multiple regression analysis was applied to the evaluation of the clinical, la-
boratory, radiological and nutritional variables which might help in predicting the 
use of DMA therapy. In the analysis of penicillamine, the femoral cortical width was 
the best discriminant overall (r2 = 0.16), while the CMR was the next best radiologi-
cal discriminant (r2 = 0.04 ). This supports the concept that penicillamine use is in-
fluenced by radiological severity. Duration of disease was the only significant dis-
criminant of myocrisin therapy (r2 = 0.10). This suggests either a trend to later use of 
myocrisin therapy or that patients tolerated it better. With respect to ridaura, the 
ESR was the most useful laboratory discriminant (r
2 = 0.11 ), while the CMR com-
bined with CA% was the best radiological discriminant (r2 = 0.10). The treated pa-
tients had more severe radiological changes. The use of chloroquine could be pre-
dicted by a number of laboratory tests. However, age at onset of disease was the 
most significant predictor (r2 = 0.08), while the addition of ESR and RBG increased 
the predictive value to 20% (r2 = 0.20). Carpal length was a significant predictor 
(r2 = 0.16) and when combined with the femoral cortical width, X-Rays could predict 
over 20% of the variation in chloroquine usage. These findings suggest that DMA 
were generally reserved for the more severe cases. Similar studies are not available 
for comparison. Varying sample size may have had a role in some of the differences 
observed. 
Dietary constituents were not generally useful predictors of the drug used, except in 
the case of chloroquine. Arachidonic acid fatty acid precursors (C-20 FA) in the diet 
had a significant predictive value of 16%. In fact, the combination with zinc, fibre 
and polyunsaturated fats gave a predictive value of 30%. These interesting findings 
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need to be explored further and may provide some important clues about the rela-
tionship between diet and disease activity in RA. 
While none of the laboratory and radiological variables were of any predictive value 
in discriminating patients using salazopyrine, the dietary analysis proved very interes-
ting. Folate content was able to predict 30% of the variation in the use of this drug. 
Together with polyunsaturated fats and calcium in the diet, over 40% of the vari-
ation in the use of salazopyrine could be predicted on a dietary analysis alone. This is 
the first such report and the implications are not clear. It is likely that the doctors 
using this drug were careful in warning their patients about increasing their intake of 
folate. The clinical variables were unable to significantly predict any of the treatment 
groups. These findings suggest that the use of DMA's at the clinic was probably 
based on a rational evaluation of clinical, laboratory and X-Ray features of the dis-
ease. 
CORTICOSTEROID THERAPY. 
The effect of corticosteroid therapy on bone is controversial (Guyatt et al 1984). 
Most studies are flawed by the overlap with menopausal subjects, making it difficult 
to remove the confounding effect of this important variable ( Guyatt et al 1984 ). 
Some reports suggest that the effect is confined to trabecular bone, sparing the corti-
cal bone of the metacarpals and femoral neck (Dykman et al 1985). It is not at all 
clear why this selective attack on trabecular bone should occur, since osteoblasts and 
osteoclasts from these areas have similar in vitro responses to biochemical stimuli. 
One possible explanation for these apparent differences could be the relative insensi-
tivity of the Vernier caliper technique of radiogrammetry. Studies with SP A 
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measurement of bone mass have shown differences between treated and untreated 
subjects (Dykman et al 1985), offering the DM/MM ratio as a measure of this effect 
of CS therapy. Studies have also shown that a fluorinated form of prednisone (Defla-
zacort), causes less bone loss than prednisone (Gennari et al 1984; Balsan et al 1987). 
Our data on CS therapy was analysed within each disease group (treated vs un-
treated) as well as across the groups (RA vs SLE). Table 6 showed that the patients 
with SLE required CS therapy for longer periods than those with RA. This is not sur-
prising if one considers the nature of the respective diseases. Patients in the treated 
group received CS at some stage of their disease. They were not necessarily receiv-
ing CS at the time of study, and no record was kept of the period that steroids were 
discontinued prior to study. 
Table 86 shows the amount of CS required by the 2 groups of patients. It is clear that 
CS requirements in SLE were considerably greater than in RA. The groups under 
study serve as a useful basis for comparing the effects of high-dose CS therapy (SLE) 
with low-dose therapy (RA), on metacarpal bone mass. 
Table 86. Comparison of the total dose of colticosteroids used 























5 - 60mg. 
1,092,840 mg. 
21,856 mg. 
2520 - 75600 
RESULTS & DISCUSSION 344 
The comparison of metacarpal bone mass in the 2 groups showed that patients with 
SLE had a higher metacarpal bone mass than patients with RA, despite the greater 
requirements for CS therapy. The differences found between treated and untreated 
subjects in either group, are shown in Table 87. The SLE subjects who were un-
treated formed too small a sample so the results need to be viewed with caution. 
Table 87. Bone mass in patients with RA and SLE based on prior use of 
CS therapy. Comparison of the total dose of corticosteroids used by pa-
tients with RA and SLE. 
SLE p RA 
CS(44) No CS(15) CS(27) No CS(71) 
TW 0.81 0.81 NS 0.86 0.85 
MW 0.31 0.29 NS 0.41 0.37 
ccw 0.51 0.52 NS 0.45 0.49 
CA% 82.98 82.77 NS 74.07 77.56 







A correlation matrix showed that the 6 metacarpal index just reached significance 
when compared with the total dose of CS therapy (p < 0.05; r= -0.2). No correlation 
was found with daily dose or duration of therapy. The Larsen index at the right wrist 
also correlated significantly with the total dose of CS (p < 0.02; r= 0.25), suggesting 
that in RA, it was the patients with more severe disease who required such therapy. 
These effects on bone and cartilage are more likely to be due to disease activity than 
CS therapy. 
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A comparison of the correlation between bone mass and CS use showed that in SLE, 
the daily dose of CS was significantly correlated with 2nd metacarpal CCT (p < 0.06). 
In the patients with RA, these drugs had a significant negative effect on metacarpal 
length (p < 0.05). However, the correlation with TW, MW, CCT or M6HS was not 
statistically significant. MW was the only variable which reached a significant correla-
tion with daily dose, duration and total CS dose (0.05 > p < 0.1). These findings sup-
port the earlier suggestion that these effects on bone metabolism are more likely to 
be a reflection of disease than a direct effect of CS therapy. 
It is clear, therefore, that metacarpal osteopaenia in RA is a reflection of the disease 
process rather than the effect of therapy. This would support the suggestion by 
Byron and Kirwan (1986) that it is essential to evaluate the disease modifying effects 
of low-dose CS therapy. It is also possible that the use of this agent together with 
DMA may be better than either agent alone. There are likely to be reports of such 
combination therapy in the future. 
Bijlsma et al (1986; 1988), have shown that the effects of methyl prednisolone pulse 
therapy are significantly different from those of regular CS therapy. These relation-
ships need to be more carefully evaluated in young subjects with RA, particularly 
with respect to trabecular bone mass. None of the RA patients under study had re-
ceived high-dose methyl prednisolone pulse therapy in the course of their disease. 
The relationship between bone mass and CS therapy could be the subject of a separ-
ate thesis. 
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SMOKING AND ALCOHOL CONSUMPTION. 
Table 88 shows the number of smokers in the 3 groups of subjects studied. The 
numbers of smokers was too small for statistical analysis. The same was found for al-
cohol consumption. No statistically significant differences were demonstrated be-
tween the groups, controlling for the Type I error. The numbers of smokers and drin-
kers are surprisingly low in all the groups studied. The reasons for this are not clear, 
but may be related to the fact that many of the subjects were female. The relation-
ship with caffeine intake was not evaluated in this study. 
Table 88. Number of patients who smoked cigarettes or con-
sumed alcohol among the 3 groups of subjects under study. 
Study Group Smokers Non - Smokers 
Controls 8 92 
Lupus 13 59 
Rheumatoid 12 88 
Drinkers Non - Drinkers 
Controls 6 94 
Lupus 2 70 
Rheumatoid 7 93 
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GENETICS. 
The genetics of RA are not clearly understood. Studies in families suggest a hered-
itary tendency of auto-immune diseases in relatives of patients with the disease. 
However, twin studies have failed to show a simple Mendelian form of inheritance. 
Recent work has shown an association with the HLA (human leucocyte antigen) 
locus of the short arm of chromosome 6. HLA-DR4 is the antigen most strongly im-
plicated. There is some suggestion that DR4 codes for seropositivity. Other evidence 
suggests that the gene codes for severity of disease (Gran et al 1984). 
The analysis of our HLA data was confined to the Coloured group, since these were 
the largest in number. 16 A loci, 24 B loci, 7 C loci and 10 DR loci were tested. The 
Fisher exact t-tests were applied to the analysis. HLA Al showed a significant associ-
ation with RA in the Coloured group (p < 0.03; corrected p = 0.06) with a relative 
risk (rr) of 2.3. None of the B or C loci showed a significant association with RA. 
None of the patients in this series possessed HLA-B27, in contrast with recent over-
seas reports (Khan et al 1987; Dahlqvist 1986). HLA DR4, on the other hand, 
showed a very significant association with RA ( corrected p < 0.0002). The relative 
risk of RA in DR4 positive Coloureds was 3.3. This corresponds with a Canadian re-
port in Caucasians (Gladman and Anhorn 1986). 
Stepwise discriminant analysis was applied to the prediction of CA%, using the HLA 
data. The only significant predictor of OP was HLA-A2. The sensitivity was 69.4% 
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and the specificity 54.8%. The DR antigens were not predictive at all. Although 
HLA-A2 has been implicated in RA (Tiwari and Terasaki 1985), it is conceivable 
that the presence of HLA-A2 may be an independent risk factor in the development 
of OP. Studies in postmenopausal OP do not support any HLA association with 
I 
bone loss (Dequeker, personal communication), but our findings suggest that fur-
ther studies are needed. It is conceivable that the uncoupling of resorption and for-
mation may be related to a gene-specific defect in bone cells coding for collagen syn-
thesis (Prockop 1988; Shapiro and Rowe 1984 ). 
The relationships between HLA antigens and RA has also been studied with respect 
to disease severity and toxic reactions to therapy (Moens et al 1987). When the total 
group was divided according to DR4 status, we found that Whites who had DR4 had 
more active disease than those who did not, based on the clinical and laboratory 
evaluation. These differences were not seen in the Coloureds. 
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SEROLOGICAL STATUS. 
Some workers have suggested that seronegative RA may be a different disease 
with a more favorable outcome. Numerous problems relate to the definition of sero-
positivity, as outlined by Gran and Husby (1987). Many of the patients included in 
the present study had been attending the arthritis clinic for some time before this re-
search was undertaken. Since changes in sero-reactivity may be associated with DMA 
therapy, there was no point in dividing the total group according to seropositivity. In 
fact, our laboratory has a positive titre of 40 using the Latex test for RF, so that there 
is a further reason for not engaging in this artificial exercise. The 1987 revised ARA 
criteria (Arnett et al 1988) do not specify a titre for seropositivity. Although studies 
of prognosis suggest that seropositivity and subcutaneous nodules signal a worse 
prognosis, there is no evidence that disease activity is related to the degree of sero-
positivity at a particular moment in time, even though titre of RF may feature in 
multivariate analysis. 
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PREVALENCE OF OP IN RA. 
There is no consensus regarding the definition of osteoporosis. Confining the de-
finition to subjects who have evidence of vertebral fracture runs the risk of late diag-
nosis and poor response to therapy. The numerical definition of osteopaenia is arbi-
trary, and varies with the method· of bone mass calculation. This is confirmed in table 
89. We divided the group according to Nordin's suggestion that subjects whose bone 
mass is below 2SD from the normal mean are more susceptible to the complications 
of OP (fracture threshold). 
Table 89. Prevalence of osteopaenia using the JO percentile of the control subjects as the 
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It is possible to construct a normogram for metacarpal bone mass, using the re-
sults obtained in the normal controls, as shown in Figure 27. The graph has been con-
structed to represent the ascending order of bone mass according to percentiles. The 
25 th percentile has been used as the lower limit for this relationship. 
Figure 27. Nonnogram for metacarpal bone mass derived from measurements in 
healthy young subjects aged between 18 and 50 years. 
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Patients at risk of fracture usually have bone mass below the 25 th percentile. 
Figure 28 shows the values for the RA subjects superimposed on the normogram in 
ascending order. There is a distinct group of RA subjects with osteopaenia. 
Figure 28. Metacarpal bone mass in rheumatoid subjects, superimposed on the 
nonnogram. There is a distinct group of RA subjects who are relatively osteo-
paenic. Subjects whose bone mass is below 25% of the nomial control value 
are at high risk for fractures. 









Using this information, 2 groups were defined each for CA% and M6HS accord-
ing to the 25 th percentile of the normal controls. 
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These were then compared with respect to clinical markers of disease activity, as 
well as age and disease duration (DOD), as outlined in figure 29. 
Figure 29. Schematic representation of the steps used in comparing 2 groups of 
RA subjects divided according to the 10th percentile of the nonnal control 
value. Clinical, laboratory and radiological variables were evaluated in stepwise 
multiple regression and discriminant analyses. 
OP 
OSTEOPOROSIS IN RA 
PREDICTING BONE MASS 
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The demographic features for the 2 groups are shown in figure 30. Osteopaenic 
subjects were comparable to non-osteopaenic subjects with respect to age, race and 
sex. 
Figure 30. Histogram showing some of the demographic features in the group of 
patients with RA, comparing osteopaenic and non-osteopaenic subgroups, using 
a 3-dimensional model (M = Male; F =Female). 
Three-dimensional representation of 
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Patients who were osteopaenic had their disease for a significantly longer period 
of time, and were clinically distinguishable from their normopaenic counterparts by a 
significantly higher Keitel score. The results are shown in table 90. Comparison of 
the cortical thicknesses showed that the medullary diameter ( endosteal resorption) 
explained the greatest degree of the variation in bone mass (CA%) in the groups. 
Table 90. Clinical, laboratory and radiological variables which help to predict combined 
cortical width ( CCW) in Rheumatoid Arthritis, using stepwise multiple regression ana-
lysis. 
Predictor Partial% Total% 
CLINICAL 
1. Biacromial Diameter 21.69 
2. Duration of Disease 7.92 29.61 
3. Extension 3.71 33.32 
LABORATORY 
1.DOD 11.64 
2.TBG 7 18.64 
RADIOLOGICAL 
1. Carpal Length 13.02 
2.CMR 11.62 24'.64 
These findings confirmed those of the discriminant analysis, which showed low 
sensitivity and specificity for the clinical and laboratory variables (Table 91). When 
all the variables were included in the discriminant analysis, the sum of medullary 
widths was the most powerful predictor of OP in RA. 
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Table 91. Discriminant analysis for classifying subjects with RA into 2 groups based on 



















The sensitivity of digitised radiogrammetry in the diagnosis of OP in RA was 
tested by stepwise discriminant comparison between the RA group and normal con-
trols. The metacarpal diameters of the right 2nd as well as the sum of 6 metacarpals 
were the independent variables, while the underlying diagnosis was the dependant 
variable. The sum of CCW of 6 metacarpals was the best discriminator, with a sensi-
tivity of 61 % and a specificity of 68%. The positive predictive value was 66% and the 
negative predictive value was 63%. This means that the technique is confidently able 
to detect up to two-thirds of osteopaenic patients. This is far superior to the eyeball-
ing technique, which has an unacceptable false positive and false negative rate (Po-
grund et al 1981). These results, when incorporated in Bayes' theorem (Ott et al 
1983; Fletcher et al 1982; Lequesne 1988), show a prevalence of osteopaenia in RA 
of 55%, not too dissimilar from our prevalence of 58% using CNSA. 
In SLE, TW was the most significant discriminant, with a sensitivity of 64% and 
specificity of 48%. The positive predictive value was 58%, while the negative predic-
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tive value was 57%. This is not surprising, since the genesis of the bone loss in the 2 
diseases is obviously different. 
If one confined the discriminant analysis to the comparison between the RA OP 
group (as defined earlier) and the normal controls, the combined effect of the sum of 
TW and the sum of CCW of the 6 metacarpals showed a sensitivity of 75% and a spe-
cificity of 91 %. The positive and negative predictive value was 81 %, so that only 20% 
of such patients might be misclassified. Clearly, the digitised technique appears to be 
ideal for quantitating bone mass in patients who have radiologically obvious cortical 
thinning, as well as those patients with RA who do not have evidence of erosive dis-
ease at presentation. This latter group is particularly important, since studies with the 
use of MRI have shown erosions when JAOP is the only radiological feature present 
(Gilkeson et al 1988). Similar discrepancies with regard to erosions have been shown 
with the use of microfocal radiography (Buckland-Wright 1983a & b ). 
Its value in the serial evaluation of patients with RA receiving DMA's needs to be 
studied in a prospective, randomised, controlled fashion. The method shows poten-
tial for application in RA, meeting several of the requirements proposed by Pullar 
and Capell (1985; 1986). 
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DETECTABILITY OF OP - ROC ANALYSIS. 
Although stepwise multiple regression analysis and stepwise discriminant analysis 
are useful in evaluating relationships between independent variables, they offer little 
information regarding the likelihood of detecting an abnormality (detectability). Re-
ceiving operator characteristic (ROC) curves have proved to be a useful adjunct to 
clinical radiology (Centor 1985a & b). The development of a Visicalc programme 
(Centor 1985a) for use on the personal computer (PC) makes this a user friendly de-
vice in statistics. The meaning of the area under the ROC curve is explained by Han-
ley and Mc Neil (1982). The technique has not previously been applied to the evalu-
ation of OP in RA. In the first instance, ROC curves were used to determine the 
most useful radiogrammetry measurement for detecting RA 
Figure 31 shows that the I CCW was very effective in detecting OP in RA. Al-
though the true positive ratio (TPR) and false positive ratio (FPR) do not reach 1.0, 
l 
the area under the ROC curve is statistically very significant. The lower FPR suggests 
that wrong diagnoses would be made less frequently using this radiological tech-
nique. It also confirms that the I CCW was an important measure of metacarpal OP. 










Figure 31. Receiving operator characteristic (ROC) analysis of factors which may 
be useful in detecting osteoporosis. The l CCW was the most useful variable in 
detecting OP at the inetacarpals. 171e TPR and FPR are less than 1.0, but the 
area under the ROC curve is statistically significant (p < 0.05). 
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ROC CURVE - DETECTING OP IN RA 




In the 2nd part of the analysis, the markers of disease activity based on the discrimi-
nant and regression analyses were tested for their ability to detect OP in patients 
with RA. A complete evaluation of all the variables is beyond the scope of this thesis. 
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Figure 32 shows the ROC curve derived from a comparison between OP and 
non-OP subjects with RA. The area under the ROC curve is far less than in the ear-
lier curve. The reason for this is probably due to the wide overlap in metacarpal bone 
mass in the 2 groups of patients with RA. Although duration of disease and PV 
showed a significant ability in detecting osteopaenia, measurement of the combined 
cortical widths of 6 metacarpals was clearly the superior test in a dichotomised deci-
sion making process. This lends further support to the earlier suggestion that bone 









Figure 32. Receiving operator characteristic (ROC) analysis of factors which may 
be useful in detecting osteoporosis in RA. The duration of disease and the plas-
ma viscosity were the most important detem1inants of the osteopaenia in RA sub-
jects whose bone mass was less than the JO percentile for matched nomial sub-
jects. The TPR and FPR are less than 1.0, but the area under the ROC curve is 
statistically significant (p < 0.05). 
0 
ROC CURVE - DETECTING OP IN RA 
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DETECTABILITY OF DISEASE ACTIVITY IN RA. 
Consensus analysis (Bull et al 1986) was used in the evaluation of the various 
clinical, laboratory and radiological variables which help to assess inflammatory ac-
tivity of RA. The RAJ and KFf were the basis for comparison. However, the DQ and 
HFI were also used in determining a consensus correlation coefficient (Bull et al, 
1986). These 4 clinical variables were correlated with the other clinical variables, the 
ESR, CRP, PV and radiological variables (CA%, Larsen index and CMR at the right 
wrist). The consensus analysis for the more important variables is depicted in the his-
togram shown in figure 33. 
Figure 33. Histogram showing the effects of consensus analysis on the compari-
son between the RAJ and the KFT as measures of disease activity. The consen-
sus was derived from the RAJ, KFT, HF! and DQ. Comparisons were made 
with the LSI, ESR, PV and Larsen index at the right wrist. 11te KFT is superior 
to the RAJ as a measure of disease activity in this group of young subjects. 














LSI ESR PV LARSEN 
t?2Zl RAI ~ CONSENSUS t!ZZI KFT f.'.::x'.J CONSENSUS 
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With respect to the LSI, the RAI and KFf compared similarly. In the case of the 
ESR and PV, the correlation with KFf was considerably better than the consensus, 
while the correlation with RAI was less than the consensus. The most significant 
finding was the marked difference in the correlation with the Larsen index at the 
right wrist. The KFf was superior to the RAI in these relationships. 
In addition, the concept of the ROC curve was applied to the detectability of dis-
ease activity using clinical and laboratory variables. This has not been previously re-
ported in RA. Figure 34 shows that the RAI had the greatest area under the curve, 
followed by the KFf and finally the PV. It is interesting that ESR, CRP, CA%, 
M6HS and carpal length had no significant area under the ROC curve. 
Figure 34. Receiving operator characteristic (ROC) analysis of factors which may 
be useful in detecting disease activity in RA. Other clinical, laboratory and radio-
logical variables did not have a significant area under the ROC curve. The KFT 
performed better than the RAJ in this test of detectability. 
ROC ANALYSIS - DISEASE ACTIVITY 
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It is clear from these findings that the clinical evaluation is a good reflection of la-
boratory and radiological features in the majority of patients, particularly if this is 
based on the KFf. 
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PATHOGENESIS OF BONE LOSS IN RA. 
The pathogenesis of bone loss in RA is not known. Several different statistical 
techniques were used to determine the possible causes of bone loss in this group of 
subjects with RA 
STEPWISE MULTIPLE REGRESSION ANALYSIS. 
The stepwise multiple regression analysis for CA% provided a number of predic-
tors of bone mass. The independent variables tested included all the clinical, labora-
tory and radiological investigations outlined in the protocol. These were used to pre-
dict CA% and combined cortical width ( CCW) as separate dependant variables for 
analysis. The predictive values of the tests for CCW are shown in table 90. The step-
wise multiple regression analysis for CA% showed that measurement of cortical 
width at the right 2nd metacarpal could predict up to 45% of the variation in bone 
mass. 
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DISCRIMINANT ANALYSIS. 
These same variables were then applied in a discriminant analysis to obtain the 
sensitivity and specificity of the individual tests, as shown in table 91. 
The analysis showed that radiology is absolutely essential in the evaluation of OP 
in RA. Furthermore, it can be seen that an accurate assessment of OP can be 
achieved only by careful measurement of the total width and medullary width at the 
midshaft of 6 metacarpals. We did not analyse the calculation of bone mass using 3 
(Reid; personal communication) or 4 metacarpals (Virtama et al 1968). Table 91 
shows that digitised measurements were very effective in discriminating the osteo-
paenic RA subjects. 
Not surprisingly, radiogrammetry was the most sensitive and specific method of 
detecting OP in RA. The sum of TW and MW of 6 metacarpals had a specificity of 
90% and a sensitivity of 85%. When one analysed the clinical, laboratory and radio-
logical variables as a group, the sum of the MW and CCW of 6 metacarpals proved to 
be the most sensitive and specific predictors of OP in RA. These findings suggest that 
radiology is absolutely essential in the diagnosis of OP in RA. Little inference can be 
drawn regarding the presence of OP based on clinical, anthropomorphic or labora-
tory measures in these patients. 
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Table 92 shows the differences between the osteopaenic and non-osteopaenic 
groups with respect to the important variables identified by the stepwise regression 
analysis. 
Table 92. Comparison of osteopaenic and non-osteopaenic subjects with RA, showing 
the differences between some of the clinical markers of disease activity in RA. 
OP Non-OP p value 
Age 39.46 ?,6.27 NS 
DOD 124.8 72.48 0.0001 
RAI 19.32 17.71 NS 
KFf 40.88 33.62 0.05 
LSI 48.72 48.44 NS 
DO 46.09 40.64 0.05 
Swollen 5 4 NS 
It is clear that the stepwise multiple regression and discriminant analyses did not 
provide conclusive information regarding pathogenesis of the reduced bone mass 
seen in RA 
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FACTOR ANALYSIS. 
The application of factor analysis (Gorsuch 1974; Green 1978) is useful in further 
elucidating possible mechanisms of disease. For the sake of convenience, only 27 
variables were evaluated with the use of factor analysis. These represented disease 
activity, disability, laboratory and radiological markers of bone metabolism. The 
technique isolated 10 factors consisting of a number of variables, shown in Figure 35. 
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Figure 35. Results of factor analysis, using 27 variables selected to represent features of dis-
ease activity, functional disability, nutritional status, measures of bone mass and metabo-
lic bone disease. 
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Careful examination of the individual factors provides useful information for 
speculating about the cause of OP in RA. Each factor shows the variables relative to 
the load within that factor (!actor loading). 
Factor 1 shows that serum PTH and duration of EMS were significantly associ-
ated with metacarpal cortical thinning. It shows also that femoral cortical width 
(FCW) is reduced similarly to the metacarpal cortical width. It would seem from this 
that PTH plays a significant role in the genesis of OP in RA. The fact that duration of 
EMS is included in this factor probably reflects the effect of disease activity on PTH 
metabolism (bone mass). It is interesting that the laboratory measurements of PTH 
revealed values within the normal range for most subjects. Perhaps the effect is due 
to a PTH-like substance, as suggested by Kennedy et al (1976). 
Factor 2 shows that the KFf and DQ behave as disease activity markers rather 
than pure measures of disability. In addition, it would seem that measurement of 
metacarpal bone mass is a useful radiological measure of disease activity in RA. The 
variables in this factor show that OP is an effect of the inflammatory process, suppor-
ting the suggestions that circulating or locally produced substances are responsible 
for the relative bone deficiency in RA. 
Factor 3 shows that the PV AS and SV AS are useful markers of disease activity. In 
addition, alkaline phosphatase elevation is likely to be a manifestation of the acute 
phase response. The ANF titre may reflect active disease. This factor shows that the 
use of CS therapy was generally confined to patients with active disease at the time of 
study. The potential effects of CS on bone metabolism are likely to be indirectly re-
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lated to the osteopaenic effects of active disease rather than a direct effect of CS on 
bone. 
Factor 4 is difficult to interpret with confidence. It would appear that changes in 
strength of the fingers and hand are associated with loss of cartilage (at the wrist) as 
well as loss of cortical bone (at the femur). This osteopaenic effect may be reflected 
to some extent in the level of serum calcium. 
Factor 5 consists of variables generally associated with active disease. The fact 
that total calcium is included in this factor supports the view that bone deficiency in 
RA is a systemic feature of the underlying disease. 
Factor 6 shows that ionised calcium and OH-proline (markers of bone resorp-
tion) probably reflect endosteal resorption at the metacarpals in RA. The inclusion 
of DQ in this factor is likely to be due to its value in assessing active disease. This 
finding is in support of the recent report (Wolfe et al 1988) that the Stanford HAQ 
could be used to grade disease activity in RA. 
The variables included in factor 7 add further support to the role of inflammation 
in mediating the osteopaenia of RA It is interesting to see that the test of simple 
hand function are also useful in evaluating disease activity. 
Factor 8 shows that thigh SFf is significantly associated with femoral cortical 
thinning. This could imply that the systemic mediator of the bone deficiency state in 
RA has a comparable effect on skin collagen, as postulated by Mc Conkey et al 
(1965). The significance of alkaline phosphatase in this factor is not clear. It seems to 
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behave as an acute phase reactant in RA, so that one might interpret this as further 
evidence for the role of inflammation as a cause of the OP in RA Osteocalcin levels 
are probably better than alkaline phosphatase (Tanaka et al 1988). 
Factor 9 shows that CS usage is generally associated with femoral cortical thin-
ning, which is most likely mediated by a PTH-like substance. The presence of al-
kaline phosphatase in this factor is probably reflecting the earlier suggestion (!actor 
3) that CS therapy is generally confined to patients with active disease. It is interes-
ting to speculate that this factor supports a bone-depleting effect of CS therapy (inhi-
biting formation and stimulating resorption), but it is more likely that disease activity 
is the dominant factor unifying these variables. 
Analysis of /actor 10 shows that the disease was more active in patients who had 
long-standing disease. The effect of duration is likely to be cumulative. Bone loss in 
RA is likely to be due to prolonged exposure to a PTH-like substance. Evidence 
from the literature (Gowen et al 1988) suggests that this substance is likely to be re-
lated to either IL-1, tumour necrosis factor (TNF) or other, yet unknown, stimulant 
of bone loss in RA. 
The above analysis shows convincingly that metacarpal osteopaenia in RA is due to 




1. Rheumatoid Arthritis causes osteoporosis and the effect is worst at the 
metacarpals. DP A measurements of vertebral BMD are needed in young 
RA subjects to determine the extent of the generalised OP. 
2. The metacarpal bone mass can be objectively measured by digitised radio-
grammetry. The correlations with erosion scores and CMR suggests that it 
may be useful in the progressive evaluation of radiological change in RA. 
3. The lack of a universal definition of osteoporosis results in conflicting data 
on prevalence. The prevalence of 55% in this study is higher than other re-
ported series. This difference may be due to the improved precision of the 
digitiser technique. 
4. Osteoporosis at the metacarpals cannot be detected early without careful 
measurements of the diameters at the midshafts of 6 metacarpals. 
5. CA% is the most suitable single measure of metacarpal bone mass in RA. 
6. The prevalence of hypercalcaemia is close to 50% in young adults with RA. 
Total calcium is not a good enough measure of this increase, which is not 
associated with increased levels of PTH. The mechanism of the hypercal-
caemia was not clarified by this study. The source of the ionised calcium was 
likely to be from resorbed bone, but other explanations need to be con-
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sidered. It is possible that the inflammatory process interferes with the de-
position of calcium into bone from the effects of the disease either on cellu-
lar membrane transport or incorporation into proteins. Another possible 
source may have been the inadvertent ingestion of milk or other dairy pro-
ducts prior to drawing blood for analysis. Further research using in-vitro 
studies of serum and bone from young patients with RA are needed to clar-
ify these osteopaenic effects of the disease. 
7. Simple hand function is significantly impaired in RA, but this does not seem 
to have any significant role in the genesis of metacarpal osteopaenia. The 
effect on bone mass is mediated through inflammation, which is suitably 
represented in the loss of hand function. 
8. In contrast, loss of hand strength as a result of arthritis contributed signifi-
cantly to the loss of metacarpal bone in RA. It was also associated with loss 
of bone in the femur as well as loss of cartilage at the wrist. These findings 
confirm the important relationship between muscular activities and bone 
and cartilage metabolism. The lack of an association between the HFI and 
metacarpal bone mass suggests that systemic factors are more likely to be 
responsible for the osteopaenia. 
9. Young patients with RA are generally well nourished. Generalised thinning 
of the skin did not accompany the generalised OP seen in our young sub-
jects with the disease. Malnutrition was an unlikely cause of the OP seen in 
these subjects. Thigh SFT was associated with active disease in the factor 
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analysis, suggesting that the mediators of inflammation may have a common 
effect on bone and skin collagen synthesis. 
10. Dietary factors did not appear to play a role in the development of OP in 
RA. In fact, RA patients had better dietary habits than the normal controls 
and patients with SLE in this study. However, dietary factors seemed to be 
important in the inflammatory process and need to be more carefully stu-
died from that point of view. Some interesting relationships were observed 
between dietary habits and DMA usage. These need to be looked at more 
critically in future research. 
11. Biochemical markers of bone turnover were generally unhelpful in the 
evaluation of OP in RA subjects who were osteopaenic. Contradictory 
changes were found in the markers of bone formation and resorption. The 
acute phase proteins were able to explain a significant proportion of the 
variation in alkaline phosphatase and ionised ca2+ but not OH-praline. 
This suggests that the pathogenesis was probably related to a combination 
of increased resorption and decreased formation. Ionised calcium was a 
more sensitive index of osteopaenia than total serum calcium. 
12. Corticosteroid therapy was associated with metacarpal osteopaenia. How-
ever, patients with active disease were more likely to receive CS therapy. 
Therefore, it is not certain whether the CS or the disease activity was the 
overriding factor in this bone loss. Patients with SLE used bigger doses for 
longer periods than patients with RA, but their metacarpal bone mass was 
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higher than that of the RA subjects. The findings showed that the systemic 
factor in RA was not significantly modified by the administration of CS. 
13. NSAID's and DMA's did not contribute significantly to metacarpal osteo-
paenia. The lower bone mass in patients receiving DMA's was more likely 
to be a manifestation of more severe disease than a direct effect of these 
drugs on bone metabolism. Prospective studies are needed to evaluate the 
effects of DMA's in retarding bone loss. In the light of the recent evidence 
suggesting an inhibitory effect of NSAID's on bone formation, future 
studies should evaluate a group of RA subjects not receiving NSAID. 
14. The finding of an increased prevalence of HLA A2 in this group of subjects 
could be the potential genetic link with OP. This is an interesting area for 
future research. 
15. Disability and disease activity seemed to have a synergistic effect on bone 
loss in RA. However, disease activity is much more important than dis-
ability in the genesis of the OP in RA. Although longer disease duration 
contributed significantly to bone loss in RA, the mechanism was not due to 
progressive disability as suggested in previous studies (Als et al 1985), but 
more likely due to the prolonged effects of inflammatory mediators on bone 
metabolism. 
CONCLUSION 376 
16. The clinical measures of disease activity correlated more significantly with 
radiological changes of RA, than did the laboratory investigations. These 
findings support those of other studies and confirm the importance of care-
ful clinical examination in the assess_ment of disease activity in RA. 
17. Objective functional evaluation by detailed techniques such as the Keitel 
function test and modified HAQ (DQ) may be a more useful and reproduc-
ible measure of active disease than the conventional measures such as the 
Ritchie index or Lansbury systemic index. 
18. Bone mass can be significantly predicted by anthropomorphic and clinical 
measurements. However, the predictive value is far less than that of careful 
measurement of metacarpal cortical width using a digitiser. 
19. Generalised OP is a feature of SLE. The bone loss at the femur may predis-
pose to the development of avascular necrosis of the femoral head in the 
small proportion of subjects in whom this is not associated with CS usage. 
This is an exciting area for research in the future. 
20. There are several differences in the mechanism of metacarpal osteopaenia 
in RA and SLE. This study confirmed that the metacarpal bone loss in RA 
is predominantly endosteal, similar to idiopathic OP. In SLE, however, re-
sorption is primarily periosteal. This similarity with hyperparathyroidism 
needs to be explored, since elevations in PTH levels have not been reported 
in SLE. It seems that the metabolic effects of SLE on bone are under-esti-
mated, but may be important in the light of improved survival. 
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SHORTCOMINGS. 
1. Cross-sectional studies of this nature do not allow one to extrapolate longi-
tudinally regarding the effects of bone loss in RA. However, the lack of pre-
vious evidence of OP in young subjects with RA required a careful cross-
sectional analysis in order to establish this finding. 
2. A prospective evaluation is required to clarify the relationship with com-
monly used drugs such as DMA's and CS. Such an analysis would be more 
valuable if it incorporated the findings of bone biopsy in patients requiring 
surgical therapy. 
3. It is impossible to remove the effects of NSAID in this evaluation, since 
90% of the subjects had been using the agents for at least 6 months prior to 
the investigation. Future research on bone metabolism will have to evaluate 
a group of RA subjects not receiving these agents. Perhaps such patients 
may be obtained from the private sector, but it seems unlikely that patients 
attending specialist Rheumatology units would fulfill this criterion. 
4. Bone biopsies were not performed in any of the subjects. This is a vital com-
ponent of the evaluation of bone metabolism and should be a pre-requisite 
for future studies in RA. 
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5. In-vitro effects of the serum of hypercalcaemic subjects was not evaluated. 
Future researchers should be advised about providing for this possibility if 
the facilities are available. 
6. Measurement of osteocalcin levels was not included in the protocol due to 
technical reasons. However, it seems that this substance is a better reflec-
tion of bone metabolism than alkaline phosphatase in RA, so that future re-
search should endeavour to include this measurement in the overall evalu-
ation. 
7. The effects of sex-steroids in these pre-menopausal subjects was not stu-
died. There is a paucity of information regarding the effects in young sub-
jects with RA and there is clearly a need for a careful analysis of their 
possible effects on bone metabolism in premenopausal patients with RA. 
8. Patients with resorptive arthropathy due to RA reflect the severe end of the 
spectrum of metabolic bone disease in RA. They need to be carefully stu-
died as a group, particularly with respect the imbalance between formation 
and resorption. 
9. This study did not evaluate the bone loss of systemic lupus erythematosus in 
any great detail. There is a dire need for detailed assessment of the pa-
thogenesis of osteopaenia in SLE, particularly in view of the improved sur-
vival and use of corticosteroids in postmenopausal females. 
This study has shown that RA causes generalised osteopaenia. The systemic na-
ture of the process is significantly represented at the metacarpal midshaft. The 
metacarpal bone mass can be objectively and reproducibly measured with the use 
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of a computer-assisted digitising technique. Cortical thinning is due to endosteal 
bone loss. Local, mechanical factors seem less important than systemic, inflamma-
tory mediators. Diet and nutritional status do not contribute to the osteopaenic 
process. Drug therapy has no influence on the process and corticosteroids do not 
worsen this effect. The objective measurement of metacarpal bone mass could 
potentially be a useful radiological measure of the effects of RA on bone and 
joints, as shown by the significant correlations with the Larsen index and carpo-
metacarpal ratio. Biochemical markers of bone metabolism are poor predictors of 
the changes observed. Further research should be directed at illucidating the ef-
fects of the disease on osteoblast and osteoclast activity, using in-vitro studies as 
well as bone biopsy. 
Figure 36 summarises the hypothesis which emanates from the analysis of the 
data. Disease activity is central to the development of osteopaenia in RA. All the 
other factors seem much less important, and probably mediate their effect on bone 
during active disease. 
Patients with active disease are more disabled, but not to the extent where local 
immobilisation affects bone metabolism. The effect of prolonged disease is one of cu-
mulative inte,f erence with bone metabolism. Disease modifying agents are important 
in modifying disease activity and are usually given to patients with unremitting disease. 
Their effects on disease activity may have a modifying effect on bone metabolism. Nu-
tritional status is influenced by the presence of active disease, but does not have a di-
rect influence on bone mass. Dietary factors may aggravate disease activity and could 
influence bone mass indirectly. NSAID are used routinely in the management of pa-
tients with RA. Although no significant relationship was shown from the analysis, re-
cent evidence regarding their inhibitory effect on bone formation in vitro suggests that 
they may have a direct effect on bone cells. Corticosteroid therapy is generally reserved 
for patients with active disease and the effects on bone seem to be predominantly due 
to the systemic effects of the disease rather than the drug. Their effect on bone is prob-
ably mediated through a combination of PTH-stimulated bone resorption as well as 
inhibition of osteoblast activity. Total calcium and ionised Ca
2+ reflect these metabo-
lic bone events. This group of patients did not have any significant increase in PTH le-
vels. 
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APPENDIX A. 
RHEUMATIC DISEASES UNIT. 












Race. Sex .. 
Do you work? 
l=S; 2=M; J=D 
1-8 
l=FT; 2=PT; 3= Nil. 
Does anyone in your f amity have arthritis? 
l=Y; 2=N; J=D (Don't know) 
How much time do you spend in the sun? 
1=1 Hr; 2=2Hrs; 3=4Hrs; 4=6Hrs; 5=8Hr; 
HLA 
Associated Diseases. 
0 = Nil; 1 = HIT; 2 = DIM; 3 = Epilepsy; 4 = Other. 
























Age at onset of RA. 





Other joint swelling. 





Poor Mucin Clot. 
Synovial Histology. 
Nodule Histology. 
X-RAY Changes of RA. 
ARA Classification. I= C; 2 = D; 3 = P 























DISEASE ACTMTY DATA 
How do you grade the severity of your disease ? 
0-----------------5-----------------10 
How much pain do you have at present ? 
0-----------------5------------------10 
Functional Class (ARA) 
Functional Class (U.K) 
Do you have pain at night ? 
Do you manage a full working day ? 
No. of wann joints. 
Duration of MS. 1=2; 2=3; 3=4; 4=5Hr. 
0 = <45min. 
How soon after waking do you feel tired ? 
1 = Hrs; 1 = 2Hrs; 2 = 4Hrs; 3 = 6Hrs; 4 = 8Hrs. 
No. of swollen joints. 
Articular Index (Ritchie). 
Keitel Functional Score. 
Clinical Disease Activity Grade. 

















APPENDIX A A-4 
Card No. M 1. 







Plasma Viscosity. N47. 
Albumen. N48. 
Serum Calcium. N49. 
Serum Phosphorous. NSO. 
Alkaline Phosphatase. N 51. 
Gamma ·G-T. N52. 
Haemoglobin. N53. 
Alpha- JA-T N54. 
SH-Groups. N55. 
Retinol-Binding Globulin. N56. 









Bi-Acromial Diameter --.-- -.-- --.--














Subscap. Skin Fold Thickness 
Thigh S.F. T. -- -- -- --
Upper Ann S.F. T. -- -- -- -
Upper Ann Diameter --.-- --.-- --.--



























Sernm VitD (Reserve) 
Thyroxine Binding Globulin 


















MOBILITY ASSESSMENT (DQ) 
A: Mobility. 
Can you walk to toilet 1 = Y,· 2 = N 
Can you climb on/off the toilet 
Can you climb in/out of bed 
Can you walk up/down stairs 
Can you climb in/out of a bath 
Can you tum in bed 
B: Bending Down. 
Can you put on shoes/tie laces 
Can you pull on socks/tights 
Can you wash below the waist 
Can you cut your toe/finger nails 
Are you able to have sex 
C: Dexterity. 
Can you unscrew jar lids 
Can you prepare vegetables 
Can you carve meat 
Can you slice bread 























MOBILITY ASSESSMENT II. 
D: Bending Arm. 
Can you drink from a full cup 
Can you shave/apply cosmetics 
Can you wash face/neck towel dry 
Can you wash trnnk/anns towel dry 
E: Reaching Up. 
Can you wear clothes over your head 
Can you brush/comb your hair 
Can you wash your hair 
Can you put a plug in at shoulder ht. 
Can you peg out washing 
Can you use shelves above shoulder ht. 
Can you open/clean high windows 
TOTAL= 
0 No difficulties encountered. 
1 Difficulties encountered. 
2 = Abnonnal peifonnance. 
3 = Aids were required 
4 = Aids with a helping hand. 
5 = Personal assistance. 
6 = Personal help + aid. 



















KEITEL FUNCTION TEST. (K) 
1. Tip of thumb touches hypothenar. 
0 = Fully,no delay; 1 = fully,delay + effort; 
2 = Tip of thumb PIP 3/4; 3 = unable. R + L 
2.Bending of 2nd finger. 
O=nonnal clutch;] =abnonnal,tip reaches palm; 
2 = tip does not reach palm. R + L 
3.Bending of 3rd finger. 
(0-2) As Above. 
4.Bending of 4th finger. 
(0-2) As Above. 
5.Bending of 5th finger. 
(0-2) As Above. 
6.Foreanns horizontal,palms together, 
tips upward. 
1 = Fully,no delay; 2 = fully,delay + effort; 
3 = volar + dorsal flexion = 450 R + L 
7.Foreanns horizontal, back of hands together. 
. (1-3) As Above. 
8.Both dorsum on table,ulnarend lifted. 
0 =Fully; 1 = back of hands lie fully,margin 























KEITEL II (K) 
9.Radial margin of hands 
simultaneously on table. 
0 = Fully; 1 = planes of hands perpendicular,cannot 
be inclined inwards,· 2 = planes of hands not vertical. 
JO.Both hands simult on ipsilateral shoulder. 
0 = Nom1al; 1 = fingertips up to 5cm 
from shoulder; 
2 = greater distance. 
11.Both hands simult behind neck. 
(below ear level). 
0 = Fully,no delay; 1 = fully,effort + delay; 
2 = fingertips touch neck; 3 = no tips reach neck. 
12.Rising from lying position. (Examination bed.) 
0 = Quickly hands extended; 1 = Effort hailds extended; 
2 = Reinforcements; 4 = Extraneous assistance;6 = Impossible. 
13Active spreading of legs in bed. 
0 = 50 cm condylar distance; 1 = 20cm condylar distance; 
2 = 20-50 cm condylar distance. 
14.Risingfrom chair. 

















JS.Standing tip-toed for 15 secs. 
0 = 15 secs; 1 = secs; 2 = Impossible. 




heel to gluteal region. 
0 = Nonna/; 1 = Partial; 2 = Impossible. 
JS.Standing on one leg for 15 secs. 
(support pennitted.) 
0 = 15 secs; 1 = secs; 2 = Impossible. 
19.futemal rotation hip,· 
heel on supporting leg. 
0 = Fully; 1 = L of foot axes = 9()°; 
2 = L of foot axes < 9a°. 
20.Plantar surface on chair;knee bent. 
0 = Fully ?delayed; 1 = Leg lifted from floor; 

















21.Heel on chair: lm : knee extended. 
As Above. 
22. Walk 30m in standard time of 20 secs. 
0 = No difficulty; 1 = Visible difficulty; 
2 = 25 secs; 3 = 30 secs; 4 = 40 secs; 
5 = Few steps; 6 = Impossible. 
23. Walk JO steps upstairs; standard time 7 secs. 
0 = No railing std. time; 
1 = Up to 14 secs + rails; 
2 = 14 secs + some effort; 3 = No steps. 
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Card No. M 1. 
Study No. M2. 
FUNCTIONAL ASSESSMENT 
Knee Pain 
(0-3) = Severe-Nil S 138. L 138 
Function (0-3) S 139. L 139 
Motion (0-4) = Nil-Full S 140. L 140 
Total Score S 141 L 141 
Hip Pain 
(0-6) S 142. L 142 
Function (0-6) " S 158. L 158 
Total Score I 12 S 143. L 143 
Finger 
Abduction Strength - .-- --.- --.-- S 144. 
Adduction Strength --.-- --.-- --.-- S 145. 
Flexion Strength --.-- -.- --.-- S 150. 
Extension Strength --.-- --.-- --.-- S 151. 
Torque Strength --.-- --.-- --.-- S 161. 
Hand: 
Knife & Fork Test --.-- -.- --.-- S 146. 
Button - Hole Test --.-- --.-- --.-- S 147. 
Grip Strength - .-- --.-- --.-- S 148. 
3 - Point Pinch -- -- -- -- -- -- S 149. . . . 
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Card No. M 1. 
Study No. M2. 
DRUG HISTORY (Past Year) 
NSAID 
Indocid l=Y; O=N T 161. 
Dose T 162. 
Duration T 163. 
Total Dose T 164. 
Voltaren l=Y; O=N T 165. 
Dose T 166. 
Duration T167. 
Total Dose T 168. 
Naprosyn l=Y; O=N T 169. 
Dose T 170. 
Duration T 171. 
Total Dose T 172. 
Feldene l=Y,· O=N T173. 
Dose T174. 
Duration T175. 
Total Dose T176. 
OtherNSAID l=Y,· O=N T177. 
Dose T 178. 
Duration T 179. 
Total Dose T 180. 
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Card No. M 1. 
Study No. M 2. 
DRUG HISTORY (Past Year) 
DISEASE MODIFYING AGENT 
Penicil/amine l=Y; O=N T 181. 
Dose T182. 
Duration T183. 
Total Dose T184. 
Myocrisin l=Y; O=N T 185. 
Dose T 186. 
Duration T 187. 
Total Dose Tl88. 
Ridaura l=Y; O=N T 189. 
Dose T 190. 
Duration T 191. 
Total Dose T 192. 
Chloroquine l=Y; O=N T 193. 
Dose T 194. 
Duration T 195. 
Total Dose T 196. 
Salazopyrine l=Y; O=N T 197. 
Dose T198. 
Duration T199. 
Total Dose T200. 
OESTROGEN REPLACEMENT 
l=Y; O=N T201. 
Dose T202. 
Duration T203. 
Total Dose T204. 
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Card No. M 1. 





When was your last menstrual period? T250. 
STEROIDS 
Oral l=Y; O=N U208. 
Dose U209. 
Duration U210. 
Total Dose U211. 
Articular l=Y; O=N U212. 
Number U213. 
Period U214. 
Effect G/B/N U215. 
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The program has been designed for measurements of metacarpal bone mass. It 
has been customised for the systemic recording of inner and outer diameters at the 
midshaft of six digits of the left and right hand respectively. Additional options exist 
for measurement of the carpo-metacarpal ratio as well as femoral cortical width and 
femoral index at the left hip. A separate program is included for testing reproduci-
bility. 
HARDWARE REQUIREMENTS. 
1. IBM PC/ XT / AT. 
2. 256 KB Memory. 
3. Serial Adapter addressed to COM 1. 
4. Monochrome ar Color Adapter. 
5. Houston Instruments HIP AD or similar Digitiser. 
6. DOS Version 2.0 or greater. 
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Figure 37 shows the digitiser interfaced with the IBM PC. The apparatus is con-
nected via a RS 232 serial port. 
Figure 37. Houston Hipad digitiser interfaced with the IBM PC, connected 
via a serial port. The digitiser rests on a portable X-Ray viewing box as a 
light source. 
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OPERATION. 
The method of operation is demonstrated in Figure 38. The following set of in-
structions provides a detailed outline of the steps involved in digitised radio-
grammetry. 
Figure 38. Demonstration of operation of digitiser. 17te length is plotted fol-
lowed by sequential measurement of outer and inner diameters of metacar-
pal cortical bone. 
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1. Ensure that the machine is set up with the digitiser connected to the serial port 
(COM 1). 
2. Boot the computer. 
3. At the DOS prompt, enter RGRAM. 
4. Key in the patient's name, folder number, study code, age, race and sex (defined 
by a numeric code combining both variables). The date is also entered. 
5. Indicate if you wish to measure the right 2nd metacarpal alone, or the sum of six 
metacarpals. 
6. If the six metacarpal hand score is to be measured, load the X-Ray of left hand 
first, with the thumb on the left of the digitiser grid. 
7. Plot the base, then the tip of the 2nd metacarpal of the left hand, as directed on 
the computer screen, using the landmarks shown in the picture. 
8. A continuous bleep will sound at this point, with a message to move the cursor to 
the midpoint (pre-defined). As soon as the midpoint is reached, the bleeper stops. 
Plot the left and right margins for the outer diameter, followed by the margins of the 
inner diameter, at the midpoint. 
ENSURE THAT THE X-RAY DOES NOT MOVE AFfER THE BASE 
AND TIP HA VE BEEN DIGITISED. 
9. Indicate if you are satisfied with the measurement. If the response is affirmative, 
a message will appear to indicate that the next metacarpal should be digitised. 
10. Follow these steps until the 2nd, 3rd and 4th metacarpals of the left hand have 
been measured. 
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11. You will then be directed to load the X-Ray of the right hand. 
ENSURE THAT THE THUMB IS ON THE LEFT OF THE DIGITISER 
GRID. 
12. Repeat steps 7 to 10 for the right hand. 
13. You will then be directed to plot the carpal length of the right hand. 
14. The next step is to load the X-Ray of the left hip. 
15. Plot the margins of the femoral cortical width, just proximal to the lesser tro-
chanter. 
16. Plot the margins of the trabecular width, 1 cm proximal to the lesser trochanter. 
This measurement needs to be repeated three times, the largest of the values being 
used in calculating the femoral index. 
17. Insert a comment, e.g. Larsen index at the right wrist. One byte is allowed, so 
you should establish a numeric code which describes the comment. 
18. Space is allocated for 2 further comments, e.g. the serial X-Rays for that individ-
ual may be number_ed in chronological order. The 3rd comment may be reserved for 
any further special comments, e.g. type of therapy (again coded numerically). 
19. You will then be requested to indicate if the procedure should be continued or 
terminated. If you decide to continue, you will be asked to indicate if the X-Rays 
which are to follow belong to the same patient or not. If not, the name, folder num-
ber, etc. would need to be typed in, as above. If the X-Rays belong to the same pa-
tient, only the new date of the X-Ray would need to be entered ( dd/rnm/yy). 
20. Repeat steps 7-18 as above. 
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21. At the DOS prompt, rename the default file (XXXX.DGT) to a name of your 
choice. If the name is not changed, subsequent records would be added to the orig-
inal file, in the order in which they have been entered. The records exist as an ASCII 
(SDF Format) file, which can be read into a database management system such as 
CONDOR 3, DBASE III or DBASE III +, provided the fields have been defined for 
length of metacarpal, the diameters (TW, MW), combined cortical width (TW -
MW), the squares of the diameters (TW2, MW2) as well as the difference of the 
squares of the diameters (TW2 - MW2) (i.e. 7 values per metacarpal). Additional 
fields should be provided for recording the bone mass at the right 2nd metacarpal as 
well as six metacarpals, using the formulae provided in the Appendix. 
These calculations are done automatically. A total of 75 fields need to be defined 
per record, with 2 decimal places for all measured and calculated values (see 
example form for CONDOR 3). 
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REPRODUCIBILITY. 
A separate program has been included for testing reproducibility of measure-
ments. It differs from the main program only in the nature of the output file which 
records the length, outer and inner diameter of the metacarpal. The program is de-
signed to record a set of six measurements ( either a reference metacarpal or cadaver 
digit included in the X-Ray picture can be used for testing reproducibility). 
TEST OF REPRODUCIBILITY. 
1. Ensure that the machine is set up with the digitiser connected to the serial port 
(COM 1). 
2. Boot the computer. 
3. At the DOS prompt, enter . 
4. Key in the patient's name, folder number, study code, age, race and sex. The date 
is also entered. 
5 Plot the base, then the tip of the metacarpal. 
ENSURE THAT THE X-RAY DOES NOT MOVE AFTER THE BASE AND TIP 
HA VE BEEN DIGITISED. 
6. A continuous bleep is then sounded, with a message to move the cursor to the 
midpoint (pre-defined). As soon as the midpoint is reached, the bleeper stops. Plot 
the left and right margins for the outer diameter, followed by the margins of the 
inner diameter, at the midpoint. 
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7. Repeat steps 4 - 6 for six measurements. 
8. You will then be requested to indicate if the procedure should be continued or 
terminated. If you decide to continue, you will be asked to indicate if the X-Rays 
which are to follow belong to the same patient or not. If not, the name, folder num-
ber, etc. would need to be typed in, as above. If the X-Rays belong to the same pa-
tient, only the new date of the X-Ray would need to be entered ( dd/mm/yy). 
9. At the DOS prompt, rename the default file {XXXX.TST) to a name of your 
choice. If the name is not changed, subsequent records would be added to the orig-
inal file, in the order in which they had been entered. The records exist as an ASCII 
(SDF format) file, which can be read into a database management system such as 
CONDOR 3, DEASE III or DEASE III +, provided the fields have been defined 
for length and the diameters (TW, MW). A total of 24 fields per record. 
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HOUSTON INSTRUMENTS HIPAD DIGITISER MUST BE SETUP 
AS FOLLOWS:. 
1. SERIAL ASCII MODE. 
2. 4800 BAUD. 
3. FIXED ORIGIN. 
NB!DIGITISER MUST BE SET TO STREAM MODE !. 
3 1 AUG 1989 
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EVALUATION OF OP IN RA. 
Hospital No. [M3] Study No. [A3] _R.S [Mllj _Age [MS]_ [Hosp.No.] 
[DATE] __ _ 
DETAILED RADIOGRAMMETRY (X) 
[XA] __ Length Digi.t A [X262}__ [X263] __ TWa & MWa 
[X264]__ [X265] __ TWa - MWa & TWa * TWa [X266]__ [X267] __ MWa * 
MWa & 265 - 266 
[XB] __ Length Digi.t B [X268]__ [X269] __ TWb & MWb 
[X270]__ [X271] __ TWb - MWb & TWb * TWb [X272]__ [X273] __ MWb * 
MWb & 271 - 272 
[XC] __ Length Digit C. [X274]__ [X275] __ TWc & MWc 
[X276]__ [X277] __ TWc - MWc & TWc * TWc [X278]__ [X279] __ MWc * 
MWc & 277 - 278 
[XD] __ Length Digit D. [X280}__ [X281] __ TWd & MWd 
[X282]__ [X283] __ TWd - MWd & TWd * TWd [X284]__ [X285] __ MWd * 
MWd & 283 - 284 
[XE] __ Length Digit E. [X286]__ [X287] __ TWe & MWe 
[X288]__ [X289] __ TWe - MWe & TWe * TWe [X290]__ [X291 ] __ MWe * 
TWe & 289 - 290 
[XF] __ Length Digit F. [X292]__ [X293] __ TWJ & MWf 
[X294]__ [X295] __ TWf-MWf & TWJ* TWJ [X296]__ [X297] __ MWJ* 




298/299 = M6HS [X301]__ 267+73+79+85+91+97 
[X303]__ 301 I 302 = M6CA% 
[XIO] __ 288/286 [Xllj __ XlO*lOO [X12] __ 291*100 
[X13] __ 291/XE*286 [X14] __ 291/XE*4*286 
[WBD J __ X12*2 [WBA] ___ X12* 1150 [WBCa] ___ X12*450 
[XS]__ Carpal Length [X6] __ Carpo/Metacarpal Ratio 
[XO] __ Fem.Cortical Width [XI] __ Femoral Neck Index. 
[X2] _ Singh Index [X3] _ Spinal Index [X7] _ Larsen Index. [X8] _Record No. [X9]_ {Zl]_ 
TrabecularWidth [Fllj_ [FI2]_ [FI3]_ 
